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SUMMARY 
It is well established that elevated plasma cholesterol is a major risk factor for 
atherosclerosis, the cause of cardiovascular disease (CVD), which is most often 
manifested as coronary artery disease (CAD) and myocardial infarction (MI). The 
identification through GWAS of genes associated with lipids and CVD has only to a 
minor extent explained the genetic architecture of CVD and dyslipidemias. In an 
effort to identify genes affecting cholesterol regulation, an RNAi-based functional 
profiling of GWAS-derived loci, which were associated with lipid traits, CAD and/or 
MI was previously performed in our lab (Blattmann et al. 2013). This study resulted 
in the identification of 55 genes that had an effect on LDL internalization and/ or 
cellular cholesterol levels.  However, most of the screen hits did not have a strong 
effect, suggesting that the combinatorial -rather than the individual- function of 
these genes might regulate cholesterol homeostasis and subsequently CVD. This 
reasoning is supported by the fact that CVD is a complex disease, which is assumed 
to arise from the synergistic effect of genes. 
In the present study, a combinatorial RNAi screen was performed in order to identify 
interactions between genes identified in the aforementioned study, after 
juxtaposing them with the results of an Exome Chip of more than 70,000 individuals, 
genotyped for lipid traits (LDL, HDL, TG, TC) (Peloso et al. 2014). For this purpose, the 
effect on LDL uptake of all pairwise combinations between 30 candidate genes was 
tested, and 21 pairs were confirmed as genetic interactors. A gene interaction model 
network was constructed, based on the results of the screen, connecting known 
cholesterol regulators, as well as genes without a previously reported lipid-
regulatory function. Secondary screens were performed to measure the effect of the 
gene interactions on LDLR mRNA and protein, as well as on SREBF1 and SREBF2 
mRNA levels. The results from secondary experiments provided further valuable 
information for the mechanistic interpretation of the interactions. The one occurring 
between LDLR, which encodes for the receptor of LDL and HAVCR1, which encodes 
for a membrane receptor for hepatitis A virus was followed up. Furthermore, 
hypotheses were generated for the sub-network of LDLR-MLXIPL-HAVCR1 on the 
mechanism of interaction influencing cholesterol homeostasis. Hypotheses were 
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made also for a few other interesting interactions, which correlated with cellular 
LDLR mRNA and/or protein levels, as well as with SREBF mRNA levels. For HAVCR1, 
mutation screening was performed, whereby the overexpression of 18 out of 19 
mutations had a significant inhibitory effect on LDL uptake, further supporting a so 
far undescribed role for HAVCR1 in cholesterol endocytosis. In parallel, in 
collaboration with Heiko Runz (Merck Research Laboratories), all lead SNPs of the 
genes tested with co-RNAi were examined for co-occurrence and SNP-SNP 
interactions in a cohort of more than 4000 individuals (Muntendam et al. 2010). 
With this analysis, an additive effect was demonstrated for three pairs of SNPs that 
corresponded to gene interactions identified with the co-RNAi screen (LPL+CELSR2, 
APOB+HMGCR, LDLR+NCAN).  
In summary, the study in hand identified combinatorial effects of genes on 
cholesterol homeostasis, through systematic identification of genetic interactions 
between GWAS-derived genes. Altogether, this research demonstrates the potential 
of the scalable strategy employed using quantitative cell-based assays, to uncover 
the genetic networks underlying common disorders and diseases. Further 
characterization of these networks would lead to a better understanding of CVD 
inheritance and provide valuable insight for the generation of novel treatments.  
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ZUSAMMENFASSUNG 
Es ist gut bekannt, dass erhöhte Plasma-Cholesterinspiegel ein wichtiger Risikofaktor 
für Atherosklerose sind, die Ursache für Herz-Kreislauf (HKL)-Erkrankungen, die sich 
am häufigsten als koronare Herzkrankheit (KHK) und Myokardinfarkt (MI) 
manifestieren. Die Identifizierung durch genomweite Assoziationstudien (GWAS) von 
Genen, die mit Lipiden und HKL assoziert sind, hat nur in geringem Masse die 
genetische Architektur von gemeinsamen Erkrankungen wie HKL und Dyslipidämien 
erklärt. In einer Bemühung, Gene zu identifizieren, die die Cholesterin Regulation 
beeinflüssen, wurde zuvor in unserem Labor eine RNA-Interferenz-basierte 
funktionelle Profilerstellung von GWAS-abgeleiteten Genorten, die verbunden mit 
Lipidmerkmalen, KHK und/ oder MI geworden sind, durchgeführt (Blattmann et al. 
2013). Diese Studie führte zur Identifizierung von 55 Genen, die einem Einfluss auf 
die LDL-Cholesterin Internalisierung und/ oder den zellulären Cholesterinspiegel 
hatten. Allerdings hatte für die Mehrheit der RNAi-Screen Treffer eine 
Unterdrückung ihrer Expression keinen starken Einfluss auf die Endozytose von LDL, 
was darauf hindeutet, dass die kombinatorischen -und nicht die individuelle 
Wirkung- dieser Genen die Cholesterin-Homöostase und infolgedessen KHK 
regulieren könnte. Diese Argumentation wird durch die Tatsache unterstützt, dass 
HKL eine komplexe Erkrankung ist, die aus Wechselwirkungen zwischen Genen 
entsteht.  
In der vorliegenden Studie wurde ein kombinatorischer RNAi-Screen durchgeführt, 
um die genetischen Wechselwirkungen zwischen den in der obigen Studie 
identifizierten Genen aufzudecken, nachdem sie mit den Ergebnissen eines Exome-
Chips von mehr als 70,000 Individuen (Peloso et al. 2014), die für Lipidmerkmalen 
(LDL, HDL, TG, Gesamtcholesterin) genotypisiert waren, verglichen wurden. Zu 
diesem Zweck wurde die Wirkung auf die LDL-Cholesterin Aufnahme aller gepaarten 
Kombinationen zwischen 30 Kandidatengenen getestet, und 21 Paaren als 
͞Interaktoren͟ wurden bestätigt. Es wurde ein Gen-Interaktionsmodell Netzwerk auf 
der Basis der gefundenen genetischen Wechselwirkungen aufgebaut, wobei sowohl 
bekannte Cholesterolregler als auch Gene ohne eine zuvor berichtete 
Lipidregulationsfunktion verknüpft wurden. Folgeuntersuchungen wurden 
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durchgeführt, um die Wirkung der ko-RNAi-Screen Treffer auf LDLR mRNA und 
Protein Niveaus sowie auf SREBF1 und SREBF2 mRNA Niveaus zu messen. Die 
Ergebnisse aus diesen Folgeuntersuchungen lieferten weitere wertvolle 
Informationen für die mechanistische Interpretation der Wechselwirkungen. Die 
Interaktion zwischen LDLR, das für den Rezeptor von LDL kodiert, und HAVCR1, das 
für einen Membranrezeptor für Hepatitis-A-Virus kodiert, wurde mehr im Detail 
untersucht. Ausserdem wurden Hypothesen für das Subnetz von LDLR-MLXIPL-
HAVCR1 auf dem Mechanismus der Interaktion, die Cholesterin-Homöostase 
beeinflussen, erzeugt. Hypothesen wurden auch für einige andere interessante 
Interaktionen aufgestellt, die in Wechselbeziehung mit zellulären LDLR mRNA und 
/oder Protein Niveaus, oder mit SREBF mRNA Niveaus waren. Für das Gen HAVCR1, 
konnte bei der Überexpression von 18 aus 19 Mutationen, die in Patienten 
vorkommen, eine signifikante Hemmwirkung auf die LDL-Aufnahme beweist werden, 
was die wichtige Rolle des HAVCR1 Gens bei der Cholesterol-Endozytose weiter 
zeigte. Parallel dazu wurden in Zusammenarbeit mit Heiko Runz (Merck Forschung 
Labore, Boston USA) alle führenden SNPs der bei ko-RNAi getesteten Genen auf 
gemeinsames Auftreten und SNP-SNP-Wechselwirkungen in einer Kohorte von mehr 
als 4000 Personen (Muntendam et al. 2010) getestet. Unter Verwendung dieser 
Analyse konnte ein additive Effekt bei drei Paaren von SNPs nachgewiesen werden, 
die den Gen-Wechselwirkungen, die beim ko-RNAi Screening identifiziert wurden, 
entsprachen (LPL + CELSR2, APOB + HMGCR, LDLR + NCAN). 
Zusammenfassend hat die vorliegende Studie funktionellen Verbindungen zwischen 
bisher nicht verwandten Genen erstellt, die eine kombinatorische Wirkung auf die 
Cholesterin Homöostase nachweisen. Insgesamt zeigt die Studie das Potenzial dieser 
erweiterbaren Strategie zur systematischen Identifizierung von genetischen 
Wechselwirkungen zwischen GWAS-abgeleiteten Genen mit quantitativen 
zellbasierten Assays, um die genetischen Netzwerke, die Häufige Erkrankungen und 
Krankheiten zugrunde liegen, aufzudecken. Eine weitere Characterisierung dieser 
Netzwerke würde zu einem besseren Verständnis der HKL-Vererbung führen und 
einem wertvollen Einblick in die Entstehung neuartigen Behandlungen liefern. 
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1 INTRODUCTION 
 
The present PhD Thesis endeavors to shed light on the genetic interactions that 
regulate cholesterol homeostasis in human, and are thus causally associated with 
the development of cardiovascular diseases (CVDs). With an aim to demonstrating 
the role of genes and their variants in CVD, this introduction starts with a general 
overview of disease genetics (1.1), which is followed by a more focused description 
of the genetics and pathophysiology of CVD (1.2). The causative link between 
cholesterol and CVD is explained (1.2.2) and the mechanisms of cholesterol 
regulation are illustrated thereafter (1.3). Given that the study in hand focuses on 
the role of genetic interactions in CVD, which is a complex disease, the association 
between genetic interactions and complex diseases is analyzed (1.4). In the last 
section of the introduction, the theoretical framework is provided for the 
approaches utilized in this study in order to screen for gene-gene interactions, 
through combinatorial perturbations of gene function with RNAi (1.5).  
 
1.1 INVESTIGATING DISEASE GENETICS 
As the potential to control infectious and nutritional diseases in developed countries 
increases, it becomes evident that genetic diseases are a major cause of disability, 
mortality and morbidity. Understanding the genetic basis of hereditary diseases is 
challenging, due to the diversity of the human genome, as well as the multiple 
genetic causative elements that might contribute to disease risk. The sequencing of 
the complete human genome (International Human Genome Sequencing 
Consortium 2004), together with a comprehensive description of common human 
genetic variation (The 1000 Genomes Project Consortium 2015) provided us with a 
plethora of genetic information, that is critical for the identification of disease-
causing genes. 
 
1.1.1 INHERITANCE OF DISEASE GENETICS 
Genetic disorders arise from the malfunction of genes, most often caused by 
mutations. Genetic diseases caused by mutations in a single gene or locus are 
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described as ͞monogenic͟ or ͞Mendelian͟. Examples of such single-gene diseases 
are Huntington’s disease and cystic fibrosis. However, a plethora of genetic disorders 
are caused by mutations in more than one gene and their inheritance cannot be 
explained by simple Mendelian theory; therefore, they are described as ͞non-
Mendelian͟ or ͞polygenic͟. The concept of ͞polygenic͟ inheritance was introduced 
as early as 1918 by R. Fisher, who analyzed the causes of human variability using 
mathematics to combine Mendelian genetics with natural selection. Fisher 
demonstrated that the individual phenotype of quantitative traits can be produced 
by the combined action of many different genes (Fisher 1918). Many diseases have 
been shown to have a complex, polygenic inheritance pattern. Common diseases, 
such as Alzheimer’s and Parkinson’s (Singleton and Hardy 2016), schizophrenia 
(Sawa and Snyder 2002), type 2 diabetes (Flannick and Florez 2016) and 
cardiovascular disease (Kathiresan and Srivastava 2012) are named ͞common 
complex diseases͟, because they can be caused by interplay between many genes as 
well as between genes and environment. In order to investigate the causality of 
genetic diseases, one needs to delve into the genetic variation and acquire a 
thorough understanding of its contribution to the observed phenotype.  
 
1.1.2 GENETIC VARIATION 
The human genome is unique; this means that any two persons share 99.5% identity 
in their genomic sequences. Nonetheless, there are millions of differences among 
the 3.2 billion base pairs, which create the variation among individuals and may 
account for susceptibility to disease. Remarkably, the 1000 Genomes Project, in 
which 2,504 individuals from 26 human populations were sequenced, demonstrated 
that "a typical genome differs from the reference human genome at 4.1 million to 
5.0 million sites … affeĐting 20 million bases of sequence" (The 1000 Genomes 
Project Consortium 2015). The vast majority of the variants are single-nucleotide 
polymorphisms (SNPs), namely substitutions of a single nucleotide at a particular site 
in the DNA sequence. The bulk of SNPs (~ 90%) are common SNPs, namely they have 
a minor allele frequency, MAF (MAF; the frequency at which the less frequent allele 
appears in a population) of ш5%. Throughout the twenty-three chromosome pairs 
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there are roughly 11 million common SNPs. The remaining (~10%) SNPs are rare 
SNPs, namely they have a MAF less than 1%.  
Common SNPs tend to be older than rare SNPs, which are recently derived alleles in 
the human population (Kruglyak and Nickerson 2001). In principle, these sequence 
variations have arisen from single historical mutation events, and are therefore 
associated with neighboring variants that were present in the ancestral chromosome 
on which the mutation occurred (Kruglyak and Nickerson 2001). Hence, a specific 
group of SNP alleles are found on a single chromosome that commonly segregate 
together, forming the so-called ͞haplotype blocks͟ or ͞haploblocks͟. The closest the 
distance between two SNPs on a chromosome, the higher the chance that they are 
inherited together, due to decreased recombination likelihood between them; this is 
described as ͞linkage disequilibrium͟ (LD). Within each haploblock, a SNP in high LD 
with the other alleles, termed ͞tag SNP͟ represents the region and can be used to 
identify the whole haplotype. It has been proved that genotyping a set of carefully 
selected ͞tag SNPs͟ is sufficient to uncover most of the genetic variation (The 
International HapMap Consortium 2003). This was confirmed by the International 
HapMap Project, which genotyped 3.1 million SNPs, in an effort to create a 
haplotype map of the human genome (The International HapMap Consortium 2007). 
Sequence data collected by the project demonstrated that SNPs are typically 
perfectly correlated with flanking SNPs and haplotypes; SNPs that show a strong 
correlation with other SNPs are termed ͞proxies͟ (The International HapMap 
Consortium 2005). Thus, when two SNPs are perfectly correlated (r2=1.0, r2; 
correlation coefficient), testing one of the two SNPs is sufficient to extract 
information for the effect of the other one.   
 
1.1.3 DISCOVERING DISEASE-ASSOCIATED VARIANTS 
The pinpointing of causal genes and variants in order to uncover the genetic 
architecture of hereditary traits and diseases is done with genetic mapping 
(Altshuler, Daly, and Lander 2009). Genetic mapping is a powerful approach through 
which the relative position of causal genes on a chromosome can be determined, 
based on their inheritance pattern. In order to produce a genetic map, DNA has to 
be isolated from tissue or blood samples collected from patients, often members of 
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the same family in which a certain disease ͞runs͟. Characteristic DNA patterns that 
are observed uniquely in affected individuals, called ͞markers͟ are useful to locate 
and identify the causal gene(s), based on LD.    
 
1.1.3.1 LINKAGE STUDIES FOR MENDELIAN DISORDERS 
The simplest form of genetic mapping, described as ͞genome-wide linkage analysis͟, 
or simply ͞linkage analysis͟ was proposed in 1980, and represented the first 
approach to connect DNA sequence polymorphisms with Mendelian traits (Botstein 
et al. 1980). Linkage analysis has been used to investigate the inheritance of rare 
Mendelian diseases within families with many affected individuals, as the 
segregation of the disease phenotype is a prerequisite for linkage mapping (Botstein 
and Risch 2003). In linkage studies, a disease-associated chromosomal region (locus) 
is identified, by discovering the alleles- ͞markers͟ that segregate (are linked) with 
the disease, and are therefore assumed to neighbor with the disease-causing gene(s) 
(Mayeux 2005). Once the candidate locus is defined, the likelihood that the genetic 
marker and the disease gene are linked is statistically estimated, based on the 
genetic recombination frequencies generated by meiotic cross-over. In order to 
further narrow down the genomic region, where the disease gene must reside, LD is 
often used in a method termed ͞linkage disequilibrium mapping͟ or ͞LD mapping͟ 
(Botstein and Risch 2003). Thereafter, a strategy referred to as ͞positional cloning͟ is 
used to identify the causal mutation(s) and define its functional role in the 
pathogenesis of the disease (Puliti et al. 2007).     
Classical linkage analysis and positional cloning have been successful in the 
identification of rare genetic mutations causing Mendelian traits and diseases, as 
well as Mendelian subtypes of common diseases. These methods failed, however, to 
unveil the causal genes in common forms of complex diseases.  
 
1.1.3.2 GENOME-WIDE ASSOCIATION STUDIES FOR COMPLEX DISEASES 
An alternative to family-based linkage study for the genetic mapping of complex 
diseases is the population-based ͞genetic association study͟. The basic idea behind 
genetic association studies is to correlate genetic variants with a trait or disease, by 
comparing SNP frequencies between a sample of cases and a sample of control 
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individuals. The measure of association between each individual SNP and the disease 
is given by the odds ratio (OR), which reflects the probability of disease occurrence 
divided by the probability of non-occurrence, compared between cases and controls. 
In a ͞genome-wide association study͟ (GWAS), also known as ͞whole-genome 
association study͟ (WGAS), a genome-wide set of SNPs is examined in a large 
population (hundreds or thousands) of both affected and non-affected individuals, 
to detect any existing association(s) with a trait or disease (see Fig. 1). Owing to LD, 
which is widespread in the genome, a set of tag SNPs is sufficient to be genotyped, 
as it can capture most of the allelic variation in their region.  
GWA studies of common variants (with a MAFш5%), also known as ͞common-variant 
association studies͟, CVAS, were based on the common disease-common variant 
(CDCV) hypothesis. The CDCV hypothesis postulates that susceptibility to common 
diseases is often attributable to a small number of common polymorphisms with low 
penetrance, namely at each disease-associated locus there is only one or a few 
predisposing alleles (Reich and Lander 2001; Schork et al. 2010) (see Fig. 2). Because 
of strong associations among SNPs, only a set of the best tag SNPs need to be 
genotyped in a GWAS to predict the remaining associated SNPs (see 1.1.2). The 
selection of SNPs is done based on LD patterns among them, making use of the 
HapMap that was built for this purpose; to facilitate the identification of common 
causal variants (The International HapMap Consortium 2005). 
The first GWAS was published in 2005 and investigated age-related macular 
degeneration (Haines et al. 2005). Up to this point (03/2017), 2785 GWA studies 
have been published and 32284 unique SNP-trait associations have been identified 
(http://www.ebi.ac.uk/gwas/). GWA studies have been quite successful in identifying 
associations between common SNPs and disease traits. However, the majority of 
SNPs identified have a low effect size (strength of association) on the traits with 
which they are associated (Manolio 2009; Wang et al. 2005). To date, GWA studies 
have identified hundreds of genetic variants associated with complex human 
diseases, but most variants identified confer relatively small effects in risk (odds ratio 
(OR); 1.2-1.5), and explain only a small proportion of the population variance in 
liability to disease (typically 0.2-0.5%) (see Tbl. 1). Even in aggregate, all the risk SNPs 
identified so far for any complex disease explain 5-10% of variance, when the overall 
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heritability of these diseases is 40-80% (Manolio 2009; Zeggini and Morris 2010). 
Thus, there is a large proportion of the heritable component of complex diseases 
that remains unidentified, which is described as ͞missing heritability͟ (Maher 2008; 
Manolio 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Genome-Wide Association Study (GWAS) 
In a typical GWA study, individuals genotyped for SNPs are divided in cases and controls. The strength 
of association between each SNP and disease is calculated based on the prevalence of the SNP in the 
two populations. In the example shown here, SNP1 is associated with the disease with P value of 
1x10
-12
. The plot shows the P values for all the SNPs genotyped, located in different chromosomes.   
(Reproduced with permission from Manolio NEJM 2010, Copyright Massachusetts Medical Society) 
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1.1.3.3 THE ISSUE OF MISSING HERITABILITY 
The issue of missing heritability has been heavily discussed and many explanations 
for this have been suggested. One possible explanation is that only a small portion of 
the causal common variants have been identified so far, and the missing heritability 
is hidden within the ones that still need to be found -as many as 30% of existing 
common variants might remain undetected (Manolio 2009; Wang et al. 2005). A 
second explanation takes into account the rare variants (MAF<5%), which are 
assumed to have a larger effect than the common ones, but fail to be detected by 
GWASs due to their poor representation in genotyping arrays (Pritchard 2001) (see 
Fig. 2). Moreover, a probable cause for the small effect sizes observed so far is that 
the potential causal variants within each gene have been incompletely examined. 
That is to say, genes identified as having common associated variants could as well 
harbor rare variants with larger effects. This is implied by the identification of high-
frequency lipid-associated variants in genes such as LDLR and PCSK9 that also carry 
low-frequency variants causing Mendelian dyslipidemias (Cohen et al. 2005; 
Kathiresan et al. 2008; Manolio 2009). Structural variants have also been suggested 
to account for missing heritability, as a special case of rare variants, based on 
findings for schizophrenia, autism, epilepsy and mental retardation (Cirulli and 
Goldstein 2010). Epigenetic effects such as genomic imprinting and parent-of-origin 
effects, that is sex-specific associations between variants in parents and risks in 
offspring, have also been implicated (Eichler 2010). Last but not least, gene-gene and 
gene-environment interactions, which cannot be captured by GWA studies, are 
believed to be the explanation for the missing inherited risk (Manolio 2009; 
McCarthy and Hirschhorn 2008).  
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Figure 2. Feasibility of identifying genetic variants by risk allele frequency and strength of genetic 
effect (odds ratio) 
Variants of low minor allele frequency (MAF), roughly 0.5%чMAFчϱ%, oƌ ƌaƌe ;MAF<Ϭ.ϱ%Ϳ aƌe Ŷot 
frequent enough to be captured by GWA genotyping arrays, and usually do not carry large effect sizes 
to be detected by linkage analysis. Low frequency variants could however have considerable effect 
sizes (increasing disease risk two-to threefold) and could considerably contribute to missing 
heritability. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature, Manolio et al., copyright 2009)  
 
 
 
 
 
 
 
 
 
 
 
Table 1. Estimates of heritability and number of loci for several complex traits 
For very few common diseases, such as age-related macular degeneration, a small number of 
common variants of large effect explain a substantial proportion of heritability. For most common 
diseases however, the proportion of heritability explained is minor, despite a much larger number of 
identified variants. 
(Reprinted by permission from Macmillan Publishers Ltd: Nature, Manolio et al., copyright 2009)  
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1.1.3.4 EXOME SEQUENCING STUDIES FOR COMPLEX DISEASES 
The extreme alternative to CDCV is the ͞heterogeneity hypothesis͟, also known as 
the ͞multiple rare-variant hypothesis͟ or ͞common disease, rare variant (CDRV) 
hypothesis͟. The CDRV hypothesis postulates that disease risk is attributed to 
multiple low-frequency variations (MAF<5%) at different loci, each with relatively 
high penetrance (Pritchard 2001; Schork et al. 2010; Smith and Lusis 2002). The 
argument for an important role of rare variants is that purifying selection purges 
deleterious alleles strongly predisposing to disease, which are thus kept at low 
frequencies (Goldstein et al. 2013; Pritchard 2001; Zuk et al. 2014). In order to 
sufficiently test the CDRV hypothesis against the CDCV hypothesis for any disease, 
the first step is to identify rare variations among affected individuals. This can be 
only achieved through DNA sequencing, and consitutes the target of ͞rare-variant 
association studies͟, often called ͞exome sequencing͟ studies.  
Rare-variant association studies (RVAS), relative to common-variant association 
studies, test for association of rare variants with a trait or disease. RVAS, like GWAS 
require very large sample sizes. Unlike GWAS, wherein all individuals are genotyped, 
RVAS involve sequencing of all individuals, which may or may not be followed by 
genotyping. A key difference between RVAS and CVAS is that most RVAS have 
focused on the coding part of the genome -the exome, which constitutes only about 
1.5% of the genome. This way the sequencing cost can be lowered for a large sample 
of patients, because less sequencing is required per individual. Another difference is 
that because the MAF of rare variants does not allow for association tests, RVAS test 
combined sets of rare variants instead of individual variants, in order to reach 
sufficient statistical power (Kiezun et al. 2013). In RVA studies, variants identified by 
aligning sequence reads to the reference genome, are annotated using probabilistic 
tools for their predicted functional effects (Do, Kathiresan, and Abecasis 2012).  
Exome sequencing has been so far useful in studies of Mendelian disorders and is 
very promising for the study of complex traits. Ideally, exome sequencing can be 
employed to design association studies that will study both common and rare 
variants, as the genetic etiology of complex diseases is believed to involve both 
components. Noteworthy, the prevailing view for the allelic architecture of complex 
diseases falls between the two extreme theories that were aforedescribed -the CDCV 
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and the CDRV (Hall, Moore, and Ritchie 2016; Wang et al. 2005). Namely, there is 
evidence that both low- and high-frequency alleles account for disease risk.   
 
1.1.3.5 EQTL STUDIES FOR COMPLEX DISEASES 
GWASs together with exome sequencing studies have brought to light a vast 
collection of genomic loci and variants -both common and rare- associated with 
common complex diseases. The challenge however is to acquire a mechanistic 
understanding of how these loci and variants affect diseases. Interestingly, it has 
been observed that most variants identified by GWASs reside in non-coding genomic 
regions, which suggests that they might exert their effect rather indirectly, through 
regulation of gene expression (Albert and Kruglyak 2015). A particular class of 
variants, named ͞expression quantitative trait loci (eQTLs)͟, includes genomic 
regions harboring variants that influence gene expression. Mapping of eQTLs is 
based on association analyses comparing the expression levels of genes between 
two sets of individuals, who have been grouped based on which allele of the variant 
under study they carry. eQTLs may exert their effect to a gene located either in a 
close distance (in-cis eQTLs) or far away (in-trans eQTLs) from them. Notably, it has 
been demonstrated that heritable gene expression regulation is at large due to 
variants functioning from a distance (Grundberg et al. 2012). This means that a SNP 
discovered within the defined region of a specific gene might have a functional role 
for a different gene, instead for the gene to which it territorially belongs. eQTL 
studies have been proven valuable in providing insight into the function and the 
causality of variants associated to complex traits and diseases.  
A notable example is a SNP (rs12740374) at the 1p13 locus, which (locus) was 
reported by GWASs as associated with serum low-density lipoprotein cholesterol 
(LDL-c) and myocardial infarction (Samani et al. 2007). This SNP, which resides at the 
3’ untranslated region (3’ UTR) of CELSR2 gene, was shown to be part of a binding 
site for a transcription factor named C/EBP which regulates the transcription of 
SORT1 gene (Linsel-Nitschke, Samani, and Schunkert 2010; Musunuru et al. 2011). 
Binding of C/EBP at the site of that SNP results to elevated expression of sortilin 1, 
which in turn leads to reduced LDL-c levels and subsequently to a lower risk for 
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myocardial infarction (MI), which is a cardiovascular event (see 1.2.2) (Kathiresan et 
al. 2009; Strong et al. 2012).  
 
1.2 CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is a leading health problem in the developed countries 
of the world, as well as many of the developing countries. CVD has been the leading 
cause of mortality since 1921, according to data from the Centers for Disease Control 
and Prevention  (CDC) (https://www.cdc.gov/nchs/fastats/heart-disease.htm). 
According to CDC, an estimated 17.5 million people deceased from CVD in 2012, 
representing 31% of global deaths. Moreover, in the United States alone more than 
80 million individuals are affected by the disease.  
Cardiovascular disease comprises a number of conditions, ranging from myocardial 
infarction (MI) to congenital heart disease, most of which are heritable (Kathiresan 
and Srivastava 2012).  
  
1.2.1 GENETIC ARCHITECTURE OF CARDIOVASCULAR DISEASE  
Some forms of CVD, such as familial hypercholesterolemia (FH) follow a Mendelian 
inheritance pattern, in which case a single causal gene has a large effect on the 
observed phenotype. In such subtypes of the disease, direct sequencing and family-
based linkage analysis have proved successful in the identification of the causal 
genes. In the example of familial hypercholesterolemia, M. Lehrman from the 
laboratory of M. Brown and J. Goldstein identified the causative deletion in the gene 
of low-density lipoprotein receptor (LDLR) by directly sequencing the gene in an FH 
patient (Lehrman 1985).  
However, most forms of CVD, such as MI or plasma lipid concentrations exhibit 
complex inheritance, suggesting the combined contribution of multiple genes and 
non-genetic factors to the disease. Complex forms of CVD are investigated with 
genetic association studies, which have focused until recently on common variants. 
The combination of GWAS with re-sequencing of selected genes has led to the 
conclusion that the genetic architecture of complex CVD traits is a mosaic of 
common variants with a small effect, rare variants with a large effect and 
environmental factors (Kathiresan and Srivastava 2012). A mosaic model hypothesis 
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for cardiovascular traits is reinforced by the strong overlap between genes identified 
with GWAS and those identified earlier by familial linkage analysis (Kathiresan and 
Srivastava 2012). In addition, it is believed that interactions among genetic and non-
genetic factors shape the complex, multifactorial CVDs (Farhan and Hegele 2013).  
In particular, complex CVDs are assumed to result from multiple inherited DNA 
variants, each of which has a small effect on disease risk, but which cumulatively 
could play a substantial role (Farhan and Hegele 2013; Lanktree and Hegele 2009). In 
the case of CAD, rare variants in at least nine genes have been identified by 
sequencing studies, which contribute to disease risk (Khera and Kathiresan 2017) 
(see Tbl. 2). In addition, GWA studies have identified 202 independent variants in 
109 loci as associated with disease risk. All the identified variants together explain 
28% of the total estimated heritability of CAD, leaving the remaining, so-called 
͞missing heritability͟ unexplained (McPherson and Tybjaerg-Hansen 2016). As was 
already mentioned (see 1.1.3.2.1), one explanation for the ͞missing heritability͟ of 
CVD and other complex diseases is believed to lie within interactions among 
causative genes and their polymorphisms (Lanktree and Hegele 2009). That is to say, 
the genetic architecture of CAD is assumed to result from the combined action of 
alleles in many genes (Badano and Katsanis 2002). The reason why the studies 
conducted so far have not been able to address the matter of ͞missing heritability͟ 
of CVD is because they examined the effect of genetic factors in isolation, not 
allowing for potential interactions with other genetic factors (Cordell 2009). 
 
1.2.2 PATHOGENESIS OF CARDIOVASCULAR DISEASE 
The most commonly observed form of CVD is coronary artery disease (CAD), which 
affects the coronary arteries of the heart. The process underlying CAD, known as 
atherosclerosis, starts with the accumulation of lipoproteins in the inner walls of 
blood arteries, as a consequence of elevated LDL-cholesterol (LDL-c) levels in the 
bloodstream (Lusis 2012). Large arteries are bound on their luminal side by an 
endothelium, which insulates the vessel wall from the blood. The accumulation of 
plasma lipoproteins -particularly low-density lipoprotein (LDL)- at the sub-
endothelial region results to an inflammatory response, which involves the 
recruitment of monocyte-derived macrophages and lymphocytes. The macrophages 
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take up lipoproteins to form the cholesterol-engorged ͞foam cells͟, some of which 
eventually die resulting to a lipid-rich necrotic core. The accumulation of cholesterol, 
cellular debris and smooth muscle cells that migrate to the region results in the 
formation of an atherosclerotic plaque, which decreases the blood flow to the heart 
(see Fig. 3). This condition is described as CAD, with its most common manifestation 
being myocardial infarction (MI), which results from the rapture of the plaque, and 
leads to the formation of a thrombus that blocks the blood flow to the heart (Lusis 
2012). Respectively, when a cerebral artery becomes occluded by a thrombus, the 
blood flow to the brain is inhibited and this causes an ischemic stroke.  
Many genetic risk factors have been identified by epidemiological studies for 
atherosclerosis development, including elevated levels of low-density (LDL) and very-
low-density lipoprotein (VLDL), low levels of high-density lipoprotein (HDL), high 
levels of lipoprotein a, family history, obesity, hypertension and diabetes. 
Environmental factors such as smoking, high-fat diet and lack of exercise may also 
contribute to the disease. However, elevated serum cholesterol levels are probably 
the only risk factor that is sufficient to cause atherosclerosis (Glass and Witztum 
2001).  
Blood cholesterol levels, particularly those of LDL-c, have long been associated with 
a risk for CAD (D’Agostino et al. 2008; Keys 1966), and the work of Brown and 
Goldstein established a causal relationship between them (Brown and Goldstein 
1974, 1986; Goldstein and Brown 1977). The effect of a class of cholesterol-lowering 
drugs named ͞statins͟ on cardiovascular mortality reduction in patients with 
hypercholesterolemia is a confirmation that high cholesterol is causally related to 
CVD (Gould et al. 1998).  
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Table 2. Summary of results from gene sequencing studies for CAD 
Damaging mutations in at least nine genes have been robustly associated with risk of coronary artery 
disease; in each case, identified genes disrupt pathways related to low-density lipoprotein (LDL) 
cholesterol, triglyceride-rich lipoproteins or lipoprotein (a) metabolism. Pharmacological therapies are 
in current use or development to mimic the protective variants for five of the six genes in which 
inhibition of the related protein would be predicted to reduce risk. 
(Adapted by permission from Macmillan Publishers Ltd: Nature Rev. Genet., Genetics of coronary artery disease: discovery, 
biology and clinical translation, Khera and Kathiresan, copyright 2017) 
 
 
Figure 3. The process of atherosclerotic plaque development 
Low-density lipoprotein (LDL) enters the arterial endothelium and induces an inflammatory reaction, 
which attracts monocytes and macrophages. Foam cells (lipid-loaded macrophages) accumulate and 
smooth muscle cells proliferate, which results to the plaque formation. Many foam cells and muscle 
cells die through apoptosis, making the plaque vulnerable. Plaque rupture causes formation of a 
thrombus, which can occlude the vessel.   
(Adapted by permission from Macmillan Publishers Ltd: Nature Watkins and Farrall, copyright 2006 and reprinted from Trends 
Genet. 28 (6): 267-275, Genetics of atherosclerosis, Lusis, copyright 2012, with permission from Elsevier.) 
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1.3 CHOLESTEROL HOMEOSTASIS 
Cholesterol is an essential component of mammalian cells, as it imparts special 
biophysical properties to their membranes, which can thus maintain their stability 
and durability. Furthermore, cholesterol partakes in the compartmentalization of 
cells, as it contributes to the creation of a semi-permeable barrier between 
specialized functional spaces (Ikonen 2008). Moreover, it participates in intracellular 
transport, cell signaling and -specifically in neurons- nerve conduction. Additionally, 
cholesterol is a precursor molecule for the biosynthesis of steroid and sex hormones, 
as well as vitamin D (Harvey and Ferrier 2011). Both dietary intake and biosynthesis 
constitute cholesterol sources for the body and tissues. In order to maintain 
cholesterol in the blood at the right level, and avoid atherosclerosis and CVD, the 
biosynthesis and metabolism of cholesterol are tightly regulated both in the body 
and in the cells. 
 
1.3.1 REGULATION OF CHOLESTEROL IN THE BODY 
Because cholesterol is not soluble, it is carried by several lipoprotein particles, which 
are classified according to their density into five groups. These classes from least 
dense to most dense are chylomicrons, very low-density- (VLDL), intermediate-
density- (IDL), low-density- (LDL) and high-density- (HDL) lipoproteins, with LDL being 
the most prevalent. The role of lipoproteins is to transfer lipids through the 
extracellular fluid and serum to the different tissues of the body. Liver plays a central 
role in cholesterol metabolism in human, by maintaining cholesterol balance in the 
body and keeping LDL cholesterol levels steady in the plasma. To begin with, dietary 
cholesterol, which is initially absorbed by enterocytes of the small intestine, is 
subsequently delivered to the liver within chylomicrons, which consist of cholesterol 
and triglycerides. Moreover, the liver itself synthesizes cholesterol, which it then 
secretes in the form of VLDL. As much as 70% of VLDL that is produced by the liver is 
reabsorbed by it, while the remaining 30% is converted to LDL and cleared by 
extrahepatic tissues. Additionally, the liver absorbs cholesterol that is produced by 
the extrahepatic tissues in the form of HDL (see Fig. 4). It has been demonstrated 
that under normal dietary conditions the extrahepatic tissues are responsible for 
>80% of total sterol synthesis (Dietschy, Turley, and Spady 1993).  
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Whereas in a fetus or a child, there needs to be a net accumulation of cholesterol 
required for growth, in adults the amount of cholesterol that is both synthesized and 
absorbed must equal the amount of cholesterol that is excreted (plus minor 
quantities used for the skin or hormone synthesis) (Dietschy et al. 1993). The hepatic 
parenchyma cells have a key role in cholesterol excretion, by secreting sterols into 
the bile, in the form of bile acid, which is then disposed of with the feces (Dietschy et 
al. 1993). 
Cells of hepatic and peripheral tissues have a central role in regulating the circulating 
cholesterol levels, by taking up LDL. The mechanism of LDL uptake from cells via 
binding to its receptor on the plasma membrane, LDL receptor (LDLR), significantly 
contributes to the clearance of LDL-cholesterol from the bloodstream (Brown and 
Goldstein 1986). This is evidenced by the fact that in absence of functional LDL 
receptors, LDL is massively accumulated, as was demonstrated in patients with the 
homozygous form of FH (Goldstein and Brown 1977). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cholesterol metabolism in the body. 
Dietary cholesterol is initially absorbed by intestine, and subsequently delivered to the liver within 
chylomicrons. The liver synthesizes cholesterol, which it then secretes in the form of VLDL. 30% of 
VLDL that is produced by the liver is converted to LDL and cleared by extrahepatic tissues. 
Additionally, the liver absorbs cholesterol that is produced by the extrahepatic tissues in the form of 
HDL. 
(Adapted by permission from Macmillan Publishers Ltd: Nature Calkin and Tontonoz, copyright 2012.) 
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1.3.2 REGULATION OF CHOLESTEROL INSIDE THE CELL 
Within the cell, cholesterol is distributed unevenly among membranes, with a higher 
concentration being that of the plasma membrane, where it consists 20-25% of total 
lipids. In addition, cholesterol is ample in the endocytic recycling compartment and 
the Golgi complex (Ikonen 2008).  Cholesterol sources for the cell consist of the 
following three major pathways; cholesterol synthesis from acetyl-coenzyme A 
(acetyl-coA), receptor-mediated LDL-cholesterol uptake, as well as hydrolysis of 
cholesterol esters stored inside lipid droplets and fatty acids.  
 
1.3.2.1 CHOLESTEROL BIOSYNTHESIS 
Cholesterol biosynthesis is adaptable to the changing needs of the body for tissue 
growth and membrane remodeling. Moreover, de novo cholesterol biosynthesis is 
decreased when cholesterol intake increases. Importantly, the total sterol 
requirements of the body can be met by biosynthesis alone, even in total absence of 
dietary cholesterol (Dietschy et al. 1993).  
All nucleated cells can synthesize cholesterol through the mevalonate pathway. The 
initial steps in the pathway result to the conversion of acetyl CoA to 3-hydroxy-3-
methylglutaryl-coA (HMG-CoA), which is then converted to mevalonate by HMG-CoA 
reductase (HMG-CoAR or HMGCR) (Russell 1992) (see Fig. 5).  
 
 
 
 
 
Figure 5. Cholesterol biosynthetic pathway 
Shown are the basic steps in the cholesterol 
biosynthetic pathway from acetyl-coA and 
acetoacetyl-coA. 
(Adapted by permission from Macmillan Publishers Ltd: 
Nature Rev. Karasinska and Hayden, copyright 2011) 
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HMGCR is regulated through a negative feedback loop mediated by sterols and other 
mevalonate metabolites and is considered to be the rate-limiting enzyme in the 
cholesterol biosynthetic pathway (Brown and Goldstein 1980). Importantly, HMGCR 
constitutes the target of statins, a class of cholesterol-lowering drugs that inhibit the 
enzyme by binding to its catalytic domain and thus blocking access of the natural 
substrate HMGCoA (Gelissen and McLachlan 2014).  
Cholesterol synthesis is primarily controlled at the level of HMGCR, both 
transcriptionally and post-transcriptionally. The transcription of HMGCR is regulated 
by a class of transcription factors named ͞sterol regulatory element-binding 
proteins͟ (SREBPs) (Ikonen 2008). An additional level of regulation is achieved with 
the degradation of HMGCR, which is mediated by lanosterol, a cholesterol precursor. 
Lanosterol post-transcriptionally regulates HMGCR, by mediating its binding to INSIG 
(insulin-induced gene protein) in the ER, which triggers its ubiquitination and 
subsequently its degradation (Song, Javitt, and DeBose-Boyd 2005). 
 
1.3.2.2 THE SCAP-SREBP AND THE LXR PATHWAY 
The transcriptional regulation of cholesterol homeostasis is mediated by two main 
nuclear receptor systems; the first system comprises the aforementioned sterol 
regulatory element-binding proteins (SREBPs) while the second one consists of the 
liver X receptors (LXRs). The SREBP system induces the transcription of genes related 
to cholesterol synthesis (Goldstein, DeBose-Boyd, and Brown 2006), whereas the LXR 
system suppresses LDL-cholesterol uptake and promotes reverse cholesterol 
transport, namely cholesterol clearance from peripheral cells and excretion of bile 
acid (Zelcer 2009).  
The regulation of cholesterol homeostasis by SREBP was elucidated by Brown and 
Goldstein and has been since extensively studied. Under conditions of ample sterol 
in the cytosol, SREBP is bound with high affinity to the chaperone SREBP cleavage-
activating protein (SCAP), and the SCAP/SREBP complex is retained in the 
endoplasmic reticulum (ER) by the ER-anchor-protein; INSIG. Conversely, a decrease 
in cellular cholesterol level induces conformational changes to SCAP, which is then 
released from INSIG, thus allowing the SCAP/SREBP complex to be transported 
within COPII-coated vesicles to the Golgi, where SREBP undergoes proteolytic 
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processing (Goldstein et al. 2006). The cleavage product is a soluble fragment of 
SREBP, which enters the nucleus and binds to promoters containing the sterol 
regulatory element 1 (SRE-1) sequence, whereby it acts as mature transcription 
factor. SRE-1 is contained in genes involved in lipid biosynthesis and uptake, such as 
HMGCR and LDLR, and binding of SREBP to it leads to the upregulation of their 
expression and subsequently to increased cholesterol biosynthesis (Brown and 
Goldstein 1997; Ikonen 2008) (see Fig. 6).  
In humans, the SREBP family consists of three members; SREBP1 has two isoforms, 
SREBP-1a and SREBP-1c, which are encoded from a single gene with alternative 
splicing, whereas SREBP2 is encoded by a separate gene.  SREBP-1a promotes the 
synthesis of cholesterol and fatty acids, while SREBP2 activates the LDLR gene and 
enzymes of cholesterol biosynthesis (Goldstein and Brown 2015). SREBP-1c activates 
the synthesis of fatty acids, therefore its role in cholesterol regulation is not so 
relevant (Shimano et al. 1997).  
 
 
Figure 6. The SCAP-SREBP system 
When cholesterol levels are high, SREBP is bound to SCAP, and the SREBP/SCAP complex is retained in 
the ER by INSIG. A decrease in cholesterol levels induces the release SCAP/SREBP from INSIG, allowing 
the complex to be transported to the Golgi, where SREBP undergoes proteolytic processing. The 
cleavage product is a soluble fragment of SREBP, which enters the nucleus and binds to promoters 
containing the sterol regulatory element 1 (SRE-1), whereby it acts as transcription factor for 
cholesterol regulating genes such as HMGCR and LDLR, and increases cholesterol biosynthesis. 
(Adapted by permission from Macmillan Publishers Ltd: Nature Rev. Karasinska and Hayden, copyright 2011.) 
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Upon increase of intracellular cholesterol levels, the LXR pathway is also activated. 
This results to transcriptional induction of IDOL (Inducible degrader of LDLR)/MYLIP, 
an E3-ubiquitin ligase, that causes ubiquitylation of LDLR, which is thus targeted for 
lysosomal degradation (Nelson et al. 2015; Zelcer 2009). Subsequently, the amount 
of LDLRs on the membrane is reduced and the LDL uptake is inhibited. Therefore, the 
LXR/IDOL/LDLR axis serves as a complementary pathway to the INSIG/SCAP/SREBP 
pathway for regulation of cholesterol uptake. 
 
1.3.2.3 CHOLESTEROL UPTAKE 
Cholesterol is taken up by cells in the form of LDL, via a receptor-mediated pathway. 
LDL receptors (LDLRs) reside at clathrin-coated pits on the cell membrane, where 
they are anchored with their transmembrane domain (Brown, Herz, and Goldstein 
1997; Goldstein et al. 1985). LDLRs bind particles that contain APOB or APOE 
apoproteins, such as chylomicrons, VLDL and LDL. When LDLRs bind to their ligand, 
LDL, the coated pits invaginate into the cell and pinch off the membrane to form 
clathrin-coated vesicles. After discarding their clathrin coats, the vesicles typically 
fuse to an early endosome, wherein LDL is released from its receptor. Subsequently, 
LDL is carried to lysosomes, where cholesterol esters are hydrolysed by acid lipase to 
release free cholesterol, while LDLR recycles back to the membrane (Lagor and Millar 
2010) (see Fig. 7).  
The cholesterol that is released from the endolysosomal system undergoes 
trafficking to other compartments, such as the plasma membrane, ER, recycling 
endosomes and mitochondria. Release of cholesterol from the late endosomes and 
lysosomes is strongly dependent on the NPC (Niemann-Pick type C) proteins; NPC1 
and NPC2. Loss-of-function mutations in either of the two proteins results in a 
severe childhood lysosomal storage disease, named Niemann Pick type C (NPC). This 
disease is characterized by the accumulation of unesterified cholesterol and 
glycosphingolipids in the late endosomes and lysosomes (Blanchette-Mackie 2000; 
Ribeiro et al. 2001). 
The LDLR which is released from the late endolysosomal compartment can 
alternatively be bound by PCSK9 (proprotein convertase subtilisin/kexin type 9), a 
protease that targets the receptor for degradation in the lysosomes. The function of 
  21 
PCSK9 inhibits the recycling of LDLR from endosomes to the cell surface, leading to 
reduction of the amount of LDLRs available to internalize LDL, which causes an 
increase of LDL-cholesterol in the circulation (Lagor and Millar 2010). For this reason, 
PCSK9 has been the target of new cholesterol-lowering therapies that are based on 
its inhibition. Importantly, clinical trials with monoclonal antibodies against PCSK9 
have demonstrated that PCSK9 inhibition can lower LDL-cholesterol levels by 60%-
70% when administered either as monotherapy, or in combination with statins 
(Lepor and Kereiakes 2015). In accordance with its role in cholesterol metabolism, 
PCSK9 expression is also regulated by SREBP, through an SRE binding site on the 
promoter of PCSK9 gene (Lagor and Millar 2010). 
Efficient internalization of LDLR in the liver requires the protein ARH (autosomal 
recessive hypercholesterolemia), also known as LDLRAP1 (LDLR adaptor protein 1), 
that binds to the cytoplasmic tail of LDLR (Lagor and Millar 2010). ARH was initially 
discovered in patients with homozygous ARH deficiency, which show a markedly 
decrease in LDL clearance from plasma (Lagor and Millar 2010). Last but not least, 
another adaptor protein, important for LDLR internalization is DAB2 (disabled 
homolog 2), which catalyzes the efficient clustering of LDLR into coated pits. DAB2, 
like LDLRAP1, mediates its effect via binding to the cytoplasmic tail of LDLR. In the 
absence of DAB2, LDLRAP1 can mediate the endocytosis of LDLR, only when AP-2 
(Adaptor Protein complex 2) is present. DAB2 on the other hand can function 
independently of ARH and AP-2 (Maurer and Cooper 2006). 
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Figure 7. Cholesterol uptake 
LDL-cholesterol is taken up from LDLR on clathrin-coated pits, which pinch off the membrane to form 
clathrin-coated vesicles. LDL is discharged from its receptor, LDLR, in endosomes, and cholesterol 
esters are hydrolyzed in lysosomes to release free cholesterol. LDLR is recycled from endosomes back 
to the plasma membrane. 
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1.3.2.4 CHOLESTEROL STORAGE 
When intracellular cholesterol levels exceed the capacity of cellular membrane to 
incorporate sterols, cholesterol is either released from the cells or stored for future 
use. Excess free cholesterol in the cytosol is esterified by the enzyme acyl-coA: 
cholesterol acyltransferase-1 (ACAT-1), and cholesterol esters are stored within lipid 
droplets in the cytoplasm (Glass and Witztum 2001). Respectively, in peripheral cells 
excess cholesterol is converted to cholesterol esters by lecithin-cholesterol 
acyltransferase (LCAT). If needed, cholesterol esters within lipid droplets can in turn 
be hydrolyzed by hormone-sensitive lipase, to release free cholesterol (Glass and 
Witztum 2001). Cells rich in lipid droplets are mature adipocytes, as well as foam 
cells; the macrophages that engorge massive amounts of LDL-cholesterol during the 
atherosclerotic plaque development.  
 
1.3.2.5 CHOLESTEROL REMOVAL 
Cholesterol removal from macrophages is crucial for the prevention of 
atherosclerosis development. Macrophages secrete cholesterol in the form of HDL, 
which returns to the liver through reverse cholesterol transport and can from there 
be secreted to the bile. Essential regulators of cholesterol efflux are the ABC 
transporters. In particular, ABC transporter A1 (ABCA1) is the key regulator of HDL 
particle formation and secretion, and thus of maintenance of plasma HDL levels 
(Favari et al. 2015). ABCA1 binds the apoprotein APOA1 of HDL and facilitates 
cholesterol removal from late endosomes, in cooperation with the second ABC 
transporter, ABC transporter G1, (ABCG1). Hepatocytes internalize HDL through 
binding to the scavenger receptor SR-BI (Favari et al. 2015).  
In enterocytes the main cholesterol transporter is ABCG5/G8, which mediates 
cholesterol efflux from the cells to the gut lumen. Hepatocytes on the other side 
secrete cholesterol and triglycerides in VLDL, the assembly of which is mediated by 
MTP (microsomal triglyceride transfer protein). The VLDL particles are carried within 
COPII-coated vesicles from the ER to the Golgi, where they are further lipidated 
before secretion (Ikonen 2008). 
Endosomal cholesterol trafficking is additionally regulated by several Rab GTPases, 
including Rab8, Rab11, Rab7 and Rab9. Rab7 and Rab9 are involved in the removal of 
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cholesterol from late endosomes and lysosomes, whereas Rab8 and Rab11 function 
in recycling endosomes, and promote cholesterol efflux (Ikonen 2008). 
 
1.3.3 GENETICS OF CHOLESTEROL REGULATION 
So far, a large number of genes have been involved in cholesterol homeostasis and 
disorders in lipoprotein metabolism, which lead to the development of various 
diseases that are highly heritable. Numerous monogenic, mendelian disorders have 
been described which are caused by mutations in one of the genes regulating 
cholesterol synthesis, uptake, or efflux. The prototypic example is the 
aforementioned familial hypercholesterolemia (FH), also known as autosomal 
dominant hypercholesterolemia, which is mostly due to mutations in LDLR (Brown 
and Goldstein 1986). Additionally, mutations in two more genes - PCSK9 and APOB - 
were shown to be causally related with FH (Abifadel et al. 2003; Soria et al. 1989). 
The case of autosomal recessive hypercholesterolemia (ARH), which is caused by 
mutations in the LDLRAP1/ARH gene was also previously described (Garcia 2001). 
Furthermore, autosomal recessive Niemann-Pick type C disease is caused by 
mutations in NPC genes, as was already mentioned. Mutations in ABCG5 or ABCG8 
cause sitosterolemia, a disorder whereby there is excessive accumulation of plant 
sterols (phytosterols) in tendons and arteries (Patel et al. 1998). Some additional 
examples of monogenic lipid disorders are shown in Table 3. 
Despite the fact that various Mendelian lipoprotein disorders have been elucidated 
for each of the three lipoprotein traits -LDL, HDL and triglycerides- only a small 
proportion of the overall heritability of serum lipoprotein and lipid concentrations 
can be explained by them. Since the levels of plasma lipids follow a normal 
distribution in the general population, their inheritance pattern is believed to follow 
a rather polygenic model (Pirucello and Kathiresan 2010).  
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Gene Protein Locus Associated traits Lipid disorder 
ABCA1 ATP-binding cassette 
transporter (ABC) A1 
9q31.1 Low HDL-C  Tangier disease 
ABCG5 ATP-binding cassette 
transporters (ABC) G5 
2p21 High LDL-C Sitosterolemia 
ABCG8 ATP-binding cassette 
transporters (ABC) G8 
2p21 High LDL-C Sitosterolemia 
APOA1 Apolipoprotein A1 11q23 Low HDL-C ApoA-I deficiency 
APOA5 Apolipoprotein A5 11q23 High VLDL, 
high chylomicrons 
ApoA-V deficiency 
APOB Apolipoprotein B 2p24 Low LDL-C 
High LDL-C 
Familial hypobetalipoproteinemia 
Familial defective ApoB-100 
APOC2 Apolipoprotein C2 19q13 High chylomicrons Familial ApoC-II deficiency 
APOE Apolipoprotein E 19q13 High VLDL, 
high chylomicrons 
Familial dysbetalipoproteinemia 
CETP Cholesterol ester 
transfer protein 
16q13 High HDL-C Cholesteryl ester transfer protein 
deficiency 
LCAT Lecithin:cholesterol 
transfer protein 
16q22 Low HDL-C Lecithin-cholesterol acyltransferase 
deficiency 
(fish-eye disease) 
LDLR LDL receptor 19p13 High LDL-C Familial hypercholesterolemia 
LDLRAP1/ 
ARH 
LDL receptor associated 
protein 1 
1p36 High LDL-C Autosomal recessive 
hypercholesterolemia 
LIPA Lysosomal acid lipase 10q23.31 Normal lipid levels Wolman syndrome, cholesteryl 
ester storage disease 
LIPC Hepatic lipase 15q22 High VLDL 
remnants 
Familial hepatic lipase deficiency 
LMF1 Lipase maturation 
factor 1 
16p13 High triglycerides Combined lipase deficiency 
LPL Lipoprotein lipase 8p21 High chylomicrons Lipoprotein lipase deficiency 
MTTP Microsomal triglyceride 
transfer protein 
4q24 Low LDL-C 
 
Abetalipoproteinemia 
PCSK9 Proprotein 
subtilisin/kexin 9 
1p32 Low LDL-C 
High LDL-C 
PCSK9 deficiency 
Autosomal-dominant 
hypercholesterolemia 
SAR1B Saccharomyces 
cerevisiae homolog 1B 
5q31.1 Low chylomicrons Chylomicron retention disease 
 
Table 3. Genes implicated in monogenic lipid disorders 
Shown are the single gene causes for some primary dyslipidemias and their lipid phenotypes. 
(Adapted from Teslovich 2010 and Kuivenhoven and Hegele 2014.) 
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1.4 GENETIC INTERACTIONS IN COMPLEX DISEASES 
The identification through GWASs of genes associated with lipid traits and lipid-
based disorders, has solved only a small part of the inheritance puzzle of such 
disorders, like dyslipidemia and CAD. The complete picture of the genetic 
architecture of these complex diseases still remains to be uncovered. Considering 
that complex diseases such as CAD are assumed to result from the combined action 
of alleles in many genes, interactions between the multiple identified genes should 
be examined (Badano and Katsanis 2002; Farhan and Hegele 2013; Lanktree and 
Hegele 2009). It is anticipated that detecting interactions between loci will both 
elucidate the biological and biochemical pathways that underlie complex traits and 
diseases, and contribute to a better understanding of the ͞missing heritability͟ (see 
1.1.3.2.1).  
Interestingly, it has been suggested that most of the genetic variants that contribute 
to the heritable phenotypic variation of complex diseases might have already been 
discovered, however the heritability explained by them was underestimated by not 
accounting for interactions among them. This hypothesis is evidenced by the 
example of Crohn’s disease; the risk loci that have been identified so far by GWASs 
explain only 21.5% of the estimated heritability of the disease. However, if potential 
genetic interactions between the identified variants are accounted for, that is if non-
additivity of effects is also considered, the explained heritability reaches 84% 
(Baryshnikova et al. 2013; Zuk et al. 2012). 
 
1.4.1 GENETIC INTERACTIONS IN CORONARY ARTERY DISEASE 
Regarding CAD, the total of 202 variants that have been so far identified with GWASs 
explain only 28% of the total estimated heritability, while the remaining ͞missing 
heritability͟ is believed to be lurking within interactions among polymorphisms of 
causative genes (Badano and Katsanis 2002; Lanktree and Hegele 2009; McPherson 
and Tybjaerg-Hansen 2016), as was aforementioned (see 1.1.3.2.1).  
It is worth mentioning the following two examples of replicated gene-gene 
interactions in CAD, which were identified in candidate gene studies of common 
SNPs. The first example is the interaction between polymorphisms in the renin-
angiotensin system and CAD. More specifically, an interaction between a variant in 
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the ACE (angiotensin I converting enzyme) gene and a variant in the AGTR1 
(angiotensin II type 1 receptor) gene was detected, that increases the risk for 
myocardial infarction (Kardia et al. 2006; Tsai et al. 2007). The second example is the 
interaction between LPL (lipoprotein lipase) gene and the εϰ allele of APOE 
(apolipoprotein E) gene that significantly increased the risk for a combined 
hypertriglyceridemia and hyperapobetalipoproteinemia ͞hyperTG/hyperapoB͟ 
phenotype, which is associated with elevated CAD risk (Perron et al. 2007). These 
two genes had also been demonstrated earlier to interact in HDL concentration 
levels (Corella et al. 2002). The above examples strongly support that genetic 
interactions should be taken into account when assessing the CAD risk. 
 
1.4.2 THE CONCEPT OF STATISTICAL INTERACTION  
The interaction between genes is termed ͞epistasis͟. The concept of epistasis was 
first invented by W. Bateson in 1909, to describe the deviations between the 
segregation ratios that were predicted based on a mendelian, single-gene 
inheritance model and the observed phenotypic outcomes (Phillips 1998). R. Fisher 
introduced ͞statistical epistasis͟ in 1918, in which the effect on a quantitative 
phenotype of two alleles at different loci deviates from additivity in a statistical 
model (Cordell 2002; Fisher 1918). In the case of complex quantitative traits, 
statistical epistasis refers to interaction between two or more loci resulting in a 
phenotype that cannot be predicted by simply adding the single-locus effects 
(Carlborg and Haley 2004) (see Fig. 8). Although epistasis was originally described by 
Fisher as a divergence from an additive model of gene action, population geneticists 
later on used a multiplicative model instead. Depending on the nature of the trait 
under investigation, either of two models -additive or multiplicative- is used 
nowadays to measure epistasis.  
Most commonly, statistical interaction is described as departure from a linear 
(regression) model that describes the relationship between two (or more) predictor 
variables and a phenotypic outcome variable (Cordell 2009). Linear regression is a 
statistical approach based on the least squares method, commonly used for 
modeling quantitative traits, as well as for detecting gene-gene interactions in such 
traits. In particular, a linear model relating two non-interacting predictor variables 
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(X1, X2) to an outcome variable (Y) would look like Y=β0+β1Χ1+β2Χ2+ε, where β0 is the 
iŶteƌĐept, β1 aŶd β2 are the slope or ƌegƌessioŶ ĐoeffiĐieŶts, aŶd ε is the unexplained 
error of the model. On the other hand, if the two predictor variables (X1, X2) were 
interacting, the interaction term β3Χ1Χ2 would be added to the linear model, which in 
this case would look like Y=β0+β1Χ1+β2Χ2+β3Χ1Χ2+ε. Thus, the inclusion of the product 
term β3Χ1Χ2 to the linear model is used to measure deviations from additivity 
(Gilbert-Diamond and Moore 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Graphical representation of genetic interaction inference from a measurable phenotype 
The wild-type phenotype is defined as 1.0. The phenotypes of two mutants are 0.7 (single mutant A) 
and 0.5 (single mutant B). The expected phenotype of the AB double mutant based on an additive 
model would therefore be 1.2. Deviations from expectation are considered as interactions (synergistic 
phenotype).   
(Adapted from Dixon et al., Annu. Rev. Genet. 2009) 
 
1.4.3 CLASSIFICATION OF GENETIC INTERACTIONS  
Based on the definition of epistasis, a genetic interaction is measured as the degree 
to which the resulting phenotype deviates from the additive (or multiplicative, 
depending on the trait under study) expectation. Namely, an additive phenotype is 
considered as a sign of absence of genetic interaction. Along these lines, genetic 
interactions can be classified as positive or alleviating, when the resulting phenotype 
is less severe than expected, and as negative or aggravating, when it is stronger than 
expected (Baryshnikova et al. 2013). Both positive and negative genetic interactions 
are considered synergistic, that is when the phenotype resulting from the 
combination of two variants differs from the expected phenotype of the individual 
variants (Phillips 2008).  
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When studying genetic interactions in double mutants (or double knockouts/ 
knockdowns), the aforedescribed classification into epistatic, suppressive or 
synergistic can be adopted. Specifically, a double mutant phenotype is considered 
epistatic when it resembles one of the single mutants, while the suppressive 
phenotype resembles the wild-type condition rather than any of the single mutants. 
Furthermore, a phenotype is described as synergistic, when the joint effect of two 
mutations is either stronger or milder than their individual effects (Pérez-Pérez, 
Candela, and Micol 2009).  
Classifying genetic interactions into categories can yield important information 
concerning the biological pathways in which the genes are taking part.  In particular, 
assumptions can be made concerning whether the interacting genes function in the 
same pathway or in parallel and convergent pathways. In addition, the pathway 
order may be defined in the case the interacting genes function in the same 
pathway, that is if one gene operates upstream or downstream of the other gene. 
More specifically, considering two single mutants (A and B) and their combined 
double mutant (AB), an epistatic interaction resembling one mutant (A) could 
suggest that gene A operates upstream of gene B within a pathway. Similarly, a 
synergistic interaction resulting to a phenotype stronger or milder than that of the 
double mutant (AB) would suggest that the two genes (A and B) operate either in 
successive steps of the same pathway, or in parallel pathways that converge at the 
same node of a network (Markowetz and Boutros 2015; Pérez-Pérez et al. 2009) (see 
Fig. 9).  
 
Figure 9. Models for synergistic genetic interactions. 
The use of hypomorphic alleles for studying genetic interactions can yield synergistic phenotypes 
when the two genes (A, B) act in a linear pathway or in two parallel and convergent pathways. 
(Reprinted from Trends Genet. 25 (8): 368-76, Pérez-Pérez et al., Copyright 2009, with permission from Elsevier) 
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1.4.4 THE RELATIONSHIP BETWEEN GENETIC AND PHYSICAL INTERACTIONS  
The presence of statistical interaction between two genes does not necessarily 
reflect a direct physical interaction between the two gene products. In fact, only 
0.9% of genetic interactions connect proteins that also physically interact, whereas 
only 10%-20% of interacting protein pairs are encoded by genes that genetically 
interact (Baryshnikova et al. 2013; Costanzo et al. 2010). This low overlap between 
genetic and physical interactions is in agreement with the notion that genetic 
interactions represent a broad spectrum of functional relationships between genes. 
More often than encoding for physically interacting products, interacting genes may 
encode proteins that participate in the same regulatory -signaling, transcription 
factor, metabolic, developmental or epigenetic- network.  
 
1.4.5 SNP-SNP INTERACTIONS 
With a view to shedding light upon the genetic component of complex diseases, the 
combined effect of SNPs needs to be taken into account, rather than the individual 
effects of SNPs. For this purpose, interactions occurring between SNPs can be tested 
on GWAS data, applying more complex statistical analysis, such as logic or logistic 
regression models. 
Interestingly, SNP-SNP interactions have been shown to explain the genetics of some 
forms of cancer and Crohn’s disease (Dinu et al. 2012; Lin et al. 2013; Onay et al. 
2006). Moreover, multiple independent SNPs within a single locus were shown to be 
associated with lipid traits (HDL, LDL, TG, TC) or CAD, doubling the heritability 
proportion explained for lipid traits (Tada et al. 2014). 
In order to discover strongly interacting SNPs, the whole range of potential SNP-SNP 
interactions need to be tested. Again in this case, the complexity of analysis of 
higher order interactions limits the search for SNP interactions to pairwise testing for 
the time being. However, epistasis effects are difficult to detect for complex 
diseases, even with pairwise testing of interactions between genetic variants.  This is 
because large sample sizes are required in order to gain sufficient statistical power 
to detect complex and potentially subtle epistatic effects (Lucas et al. 2012; 
Musameh et al. 2015). Despite the limitations inherent in SNP interaction testing, 
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studying the co-occurrence of SNPs in patients versus control individuals is 
considered promising for predicting susceptibility to diseases. 
 
1.4.6 INDIVIDUALIZED MEDICINE: FROM PERSONAL GENOMES TO INTERACTOMES 
The complete set of interactions between genes and their products is called the 
͞interactome͟, as an analogy to the genome, proteome and metabolome 
terminology (Cusick et al. 2005). Following the completion of the human genome 
sequencing, efforts are currently being made towards the construction of a map of 
the human interactome network (Human Interactome Project) (Rolland et al. 2014; 
Rual, Venkatesan, and Hao 2005). Based on the fact that every individual carries a 
distinct set of genetic variants, which shape its personal genome, transcriptome, 
proteome and metabolome, it is expected that individual interactomes will be 
present as well (Zhang, Kuivenhoven, and Groen 2015).  
Interactome mapping can be a great benefit for the field of pharmacogenomics, 
which studies the role of genome in drug response. In cardiovascular disease, 
currently prescribed medication such as statins has been demonstrated to exert 
differential effects in patients, depending on the genetic variants they carry 
(Musunuru 2015). Interactions between these genetic variants are believed to have 
a substantial impact on the response to medication. Therefore they need to be 
elucidated, in order to identify the correct dosage for best efficacy, as well as to 
prevent adverse effects. Thus the current challenge for personalized medicine is the 
understanding of human interactome, in order to determine the optimal therapy for 
the disease for each individual patient.  
 
1.5 MAPPING GENETIC INTERACTIONS 
Identification of genetic interactions by genetic interaction mapping involves the 
simultaneous perturbation of two -or more- genes, and assessment of the resulting 
phenotype in comparison to the one resulting from single perturbation. Genetic 
interaction mapping methods, which attempt to understand gene function starting 
with genes of interest and examining the phenotypic consequences of an induced 
genetic change -mutation, knockout or knockdown- are defined as ͞reverse 
genetics͟. These methods constitute the opposite of ͞forward genetics͟ methods, 
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whereby gene function is studied starting from the phenotypes of interest and 
subsequently identifying mutants that are responsible for this phenotype (Beltrao, 
Cagney, and Krogan 2010; Nijman 2011).  
Mapping genetic interactions underlying quantitative traits has been performed 
using different model systems, from unicellular organisms such as yeast 
(Saccharomyces) and bacteria (Escherichia coli), to multicellular ones such as worm 
(Caenorhabditis elegans) and fly (Drosophila). More recently, genetic interaction 
studies were carried out using mammalian cells (e.g. mouse and human).  
Drosophila has been employed as a model organism to study epistasis since the 
1960s by Dobzhansky, Rendel and others. Dobzhansky observed that the 
combination of certain chromosomes led to synthetic semilethality, that is a slight 
reduction of viability, which is due to epistatic interactions among genetic variants 
(Dobzhansky 1965; Spassky, Dobzhansky, and Anderson 1965). The existence of 
genome-wide deletion libraries in yeast since 2001 (Giaever et al. 2002) made S. 
cerevisiae a convenient model system to study genetic interactions, mainly focusing 
on synthetic lethality or synthetic sickness (Boone, Bussey, and Andrews 2007). 
Synthetic lethality and synthetic sickness, in which the joint effect of mutations in 
two genes is cell death or reduced fitness, respectively, are particularly informative 
phenotypes, as they can uncover members of the same essential biological pathways 
(Nijman 2011). These fitness readouts were used in S. cerevisiae to perform a global 
mapping of its interaction network by applying synthetic genetic array (SGA) 
analysis, an approach to systematically generate and isolate double mutant strains 
(Tong 2004).  
Whereas in yeast comprehensive deletion libraries have made it possible to screen 
for genetic interactions in a systematic, high-throughput way, by completely 
discarding the product of the genes under study (͞knockout͟), such approaches are 
not feasible for more complex organisms. The reason for this is mainly a scaling 
issue; whilst in S. cerevisiae there are approximately 6,000 genes, D. melanogaster 
genome contains around 17,000 genes and both C. elegans and human have around 
21,000 genes, which would lead to a huge number of combinations. Therefore, an 
approach that takes advantage of RNA interference (RNAi) has been used in 
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multicellular organisms, examining the effect of the reduction of gene products 
(knockdowns rather than knockouts). 
 
1.5.1  RNA INTERFERENCE 
The mechanism of RNAi is based on the enzymatic cleavage of long double-stranded 
RNAs into short 21-nucleotide long RNAs, named ͞short interfering RNAs͟ (siRNAs). 
Following the ͞dicing͟, the siRNA triggers the destruction of the homologous mRNA, 
which results in the so-called ͞silencing͟ of the gene, namely the inhibition of its 
expression. Thus, the function of a gene can be studied by observing the phenotype 
resulting from its RNAi-induced silencing.   
In contrast to gene knockouts, as in the case of deletion libraries in yeast, whereby a 
gene product is completely abolished, RNAi-mediated gene knockdowns frequently 
reduce protein levels only up to a certain extent. The incomplete knockdown of a 
gene, which is termed DAmP (Decreased Abundance by mRNA Perturbation), 
generates a partial phenotype (hypomorph) that would not be observed upon gene 
knockout. Importantly, partial gene product depletion generated by RNAi can be 
informative for genetic interactions. This is suggested by studies performed in yeast, 
in which the use of hypomorphic (DAmP) alleles revealed biologically meaningful 
genetic interactions (Roguev et al. 2013; Schuldiner et al. 2005). Moreover, 
phenotypes generated by RNAi-induced incomplete gene knockdowns very closely 
resemble those in patients carrying partial loss-of-function (hypomorphic) 
mutations.  
The construction of siRNA libraries for model organisms such as Drosophila and C. 
elegans, as well as for mammalian cells, in combination with a recent advance in 
high-throughput screening technologies has enabled the appliance of RNAi for 
genetic interaction mapping.  
 
1.5.2 HIGH-THROUGHPUT SCREENING USING RNAI 
Importantly, a microscopy platform was established at the European Molecular 
Biology Laboratory (EMBL) for high-throughput RNAi screens using fluorescence-
based imaging assays in cells (Pepperkok and Ellenberg 2006). This platform was 
based on the development of an RNAi-based reverse transfection protocol on pre-
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spotted microarrays of 384 samples, using mammalian tissue culture cells (Erfle et al. 
2007, 2008). The aforementioned platform has already been used in genome-wide 
RNAi screens studying cell division (Neumann et al. 2011), signal transduction 
(Ritzerfeld et al. 2011) and secretion (Simpson et al. 2012). In addition, the above 
platform has been used in targeted RNAi screens studying cholesterol regulation 
(Bartz et al. 2009; Blattmann et al. 2013). 
 
1.5.3 HIGH-CONTENT GENETIC INTERACTION SCREENING USING CO-RNAI 
To identify genetic interactions using RNAi, multiple genes are targeted by siRNAs 
simultaneously, in an approach described as ͞combinatorial RNAi͟ (co-RNAi). 
Combinatorial RNAi was first used to study genetic interactions in C. elegans (Lehner, 
Tischler, and Fraser 2006; Tischler et al. 2006) and Drosophila (Billmann et al. 2016; 
Horn et al. 2011), while more recently it was employed for genetic interaction 
mapping in human cells (Laufer et al. 2013). Over the last decade, the technology of 
combinatorial RNAi has been employed for mapping genetic interactions in 
mammalian cells in a systematic, automated, large-scale manner (Barr and Bakal 
2015; Bassik et al. 2013; Kampmann, Bassik, and Weissman 2013; Laufer et al. 2013; 
Roguev et al. 2013; Wang et al. 2014). High-throughput gene-gene interaction 
screens are performed using 96- or 384-well plates and microarrays, robotics, as well 
as automated imaging and image analysis.  
For the time being, gene-gene interaction testing has been limited to pairwise, due 
to the complexity of statistical analysis required for higher-order interactions, 
although interactions among a number of genes may account for an observed 
phenotype. Specifically, pairwise RNAi-mediated perturbations of gene function 
(͞double knockdowns͟) have been employed in studies of genetic interactions (GIs) 
(Barr and Bakal 2015; Bassik et al. 2013; Billmann et al. 2016; Horn et al. 2011; Laufer 
et al. 2013; Roguev et al. 2013; Wang et al. 2014). Such reports have demonstrated 
the potential of this approach to reveal novel genetic interactions, discover protein 
complexes, functional modules and pathways, and to infer gene function.   
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1.5.4 MAPPING GIS IN CHOLESTEROL HOMEOSTASIS WITH CO-RNAI 
In our laboratory, an RNAi-based functional profiling of GWAS-derived loci, 
associated with lipid traits, CAD and/or MI was previously performed. This work was 
aimed towards gaining a mechanistic understanding of how the loci identified affect 
cholesterol regulation (Blattmann et al. 2013). The study resulted in the 
identification of 55 genes that had an effect on LDL internalization and/ or cellular 
cholesterol levels.  
However, most of the screen ͞hits͟ did not have a strong effect on cholesterol 
regulation. This suggests that the combinatorial -rather than the individual- function 
of genes might regulate cholesterol homeostasis. The complexity of cholesterol 
regulation is in agreement with the complexity of CVD, for which dysregulated 
cholesterol is a major risk factor. Keeping all the above in mind, we decided to 
perform a co-RNAi-based interaction screen, in order to explore possible interactions 
between the genes identified in the aforementioned study. 
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2 AIMS OF THE STUDY 
The pathogenesis of coronary artery disease (CAD), the most common form of 
cardiovascular disease (CVD), results from elevated levels of LDL-cholesterol in the 
bloodstream, a consequence of defective cholesterol-regulatory mechanism in the 
cells. CAD is a complex disease, believed to result from multiple combinations of 
gene-gene interactions. Therefore, multiple inherited DNA variants are assumed to 
contribute to CAD risk, each of which has a small individual effect on disease risk. 
The study of Blattmann et al. identified a number of disease-regulated genes with an 
effect on cholesterol regulation, most of which however did not have a strong 
individual effect. The question that arises therefrom is if and how these cholesterol-
regulating genes interact with each other, in order to collectively control cholesterol 
homeostasis. Furthermore, it is interesting to discover how these genetic 
interactions may contribute to disease risk. 
 
To address these questions, the aims of the present study were the following: 
i. to screen for and identify gene-gene interactions among cholesterol 
regulators 
ii. to reveal how these gene-gene interactions contribute to cellular 
cholesterol homeostasis and  
iii. to define how these gene-gene interactions are linked to CVD. 
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3 RESULTS 
 
The work described here is divided into three parts. In the first part (3.1), the 
combinatorial RNA interference (co-RNAi) approach is described that was used to 
identify gene-gene interactions with an effect on LDL endocytosis. After establishing 
the high-throughput microscopy-based approach (3.1.1) and determining the 
optimal siRNA concentrations (3.1.2), candidate genes were selected (3.1.3), as well 
as the corresponding siRNAs (3.1.4) for the screen. The results of the co-RNAi screen 
are described (3.1.5) and the gene interactions identified are shown (3.1.6). With a 
number of secondary experiments (3.1.7) the identified gene interactions were 
validated (3.1.8). The validated gene interactions were clustered and finally used to 
construct a model network (3.1.9). Some of these interactions were followed up 
(3.1.10). In the second part, the effect of mutations of one prominent screen 
interactor on LDL uptake was studied (3.2). In the third and last part, the co-
occurrence of SNPs of the candidate genes tested in the co-RNAi screen was 
examined in a cohort of >4,000 individuals (3.3).    
3.1 COMBINATORIAL RNAI SCREEN  
3.1.1 ESTABLISHMENT OF A HIGH-THROUGHPUT MICROSCOPY-BASED APPROACH TO 
SYSTEMATICALLY IDENTIFY GENE INTERACTIONS AFFECTING CHOLESTEROL 
HOMEOSTASIS 
 
With a view to defining gene networks underlying cellular cholesterol homeostasis, I 
performed pairwise double knockdowns in vitro between 30 disease-associated 
genes, by reverse transfecting HeLa Kyoto cells on siRNA-spotted arrays (LabTeks), as 
described (see 7.1.2.2.1) (Erfle et al. 2007, 2008). For the analysis of knockdown 
effects, I used a cell-based assay, previously established in the lab to measure the 
effect of the gene knockdowns on cholesterol regulation (Bartz et al. 2009). This is a 
quantitative LDL-uptake assay, which measures the ability of tissue culture cells to 
endocytose fluorescently (DiI) labeled LDL (see 7.1.5.1). Uptake of fluorescently 
labeled LDL from the siRNA-transfected cells was determined using high-content 
automated microscopy (see 7.4.1.2.1) (Bartz et al. 2009; Erfle et al. 2007). The 
experimental workflow is illustrated in Figure 10. 
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Figure 10. The experimental workflow followed in the high-throughput screening for cholesterol 
interactors 
a. For the co-RNAi interaction screen, cell microarrays (LabTeks) were printed with 2 siRNAs per spot, 
and afterwards HeLa Kyoto cells were seeded on the spotted LabTeks. After a 48-hour knockdown, 
the LDL-uptake assay was performed in the LabTeks, and images of the transfected cells were 
acquired in a widefield microscope in a high-throughput manner. Finally, the images were analysed 
using image analysis softwares (FiJi-ImageJ and CellProfiler). b. Shown are representative images of 
LDL-uptake assay: cells transfected with negative control siRNA show a normal uptake of fluorescently 
labeled LDL (top image), whereas cells transfected with siRNA targeting the LDL receptor show a 
significant decrease in fluorescence signal of endocytosed LDL (bottom image) (scalebar=10 μm). 
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3.1.2 DETERMINING THE OPTIMAL SIRNA CONCENTRATION FOR THE DOUBLE KNOCKDOWNS 
In order to determine the optimal siRNA concentration for the double knockdowns 
on LabTeks, two conditions were examined in a pilot experiment. For this purpose, 
single knockdowns as well as double knockdown of LDLR and DAB2 were performed 
on spotted LabTeks, using either 30pmol or 15pmol total siRNA (per well of a 384-
low-volume-plate used for the spotting of the LabTek, see (Erfle et al. 2007)). NEG9 
was used as negative control siRNA and INCENP as transfection control siRNA (see 
also section 7.1.2.2.1.1). The selection of the two target genes, LDLR and DAB2, was 
based on the inclusion of one gene with strong knockdown effect and one with mild 
knockdown effect. LDLR is the key regulator of LDL internalization, therefore its 
knockdown leads to drastic impairment of LDL endocytosis, whereas DAB2 has an 
auxiliary role in LDL internalization (Chetrit, Ziv, and Ehrlich 2009; Maurer and 
Cooper 2006; Mishra et al. 2002), thus its individual knockdown has no significant 
effect on LDL internalization (Eden et al. 2007; Wei, Hemani, and Haley 2014). The 
transfection control siRNA targets INCENP; Inner Centromere Protein, which is 
necessary for chromosome segregation during mitosis, and therefore its knockdown 
results in multi-nucleated cells and it has been previously used in siRNA screens 
(Erfle et al. 2007). 
The knockdown effect on LDL internalization was evaluated using the LDL-uptake 
assay (for details see 7.1.6.1). The transfection efficiency in the two conditions was 
also evaluated by quantifying the number of cells showing the characteristic INCENP 
phenotype, upon knockdown with INCENP. 
Although there was not significant difference between the two conditions on LDL 
uptake (see Fig. 11), the INCENP phenotype (see Fig. 12) was more penetrant with 
the higher siRNA concentration: 16% of the cells showed the phenotype with 15pmol 
siRNA versus 59% with 30pmol. Therefore, the higher siRNA concentration (30 pmol) 
was selected for the co-RNAi screen, in order to achieve robust knockdowns.  
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Figure 11. Results of the experiment for siRNA concentration optimization for double knockdowns 
Shown in this graph are the effects of knockdowns on LDL uptake, using either 15pmol (3+3uM) or 30 
pmol (6+6uM) total siRNA. The mean fluorescent intensities of endocytosed DiI-LDL are normalized to 
the negative control siRNA; NEG9. Error bars represent the standard deviation (n=8). 
 
 
 
 
 
 
Figure 12. Cells showing the characteristic INCENP phenotype 
Shown are cells transfected with either 30 pmol (A) or 15 pmol (B) siRNA targeting the Inner 
Centromere Protein (INCENP) gene. Knockdowns of this gene results in mitotic arrest, strange nuclear 
shape, binuclear cells or polylobed nuclei, due to spindle assembly defects (Neumann et al. 2011).  
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3.1.3 CANDIDATE GENE SELECTION STRATEGY AND RATIONALE 
Thirty candidate genes were selected for combinatorial RNAi screening (Figure 3.2); 
all of them were identified by GWAS as associated with blood lipid levels, coronary 
artery disease (CAD), and/or myocardial infarction (MI) (Tbl. S3). Of these, 28 genes 
were previously shown to affect low-density lipoprotein (LDL) internalization and/or 
cellular levels of free cholesterol in Blattmann et al. (Blattmann et al. 2013). It should 
be noted that the genes tested in the aforementioned study originate from GWA 
studies, which are only powered to detect common variants-SNPs with a minor allele 
frequency (MAF)>5%. In order to more efficiently address the missing heritability 
problem that was described previously (see also section 1.1.3.2.1), genes with rare 
variants associated to lipid traits were also included in the screen. Besides, the 
inclusion of the total of 55 ͞hits͟ of the Blattmann et al. study in the combinatorial 
RNAi screen would end up in 3025 (55x55) combinations, without taking into 
account the controls. Therefore, a filtering of these hits had to be done. For these 
reasons, the results of the Blattmann et al. study were filtered by comparing them 
with those of an Exome Chip for lipid traits (Peloso et al. 2014) (see Tbls. S1 and S2). 
This approach narrowed down the candidate gene number to 30 and the pairwise 
combinations to 900. A relatively small gene combination set was preferable in order 
to perform the experiments in many replicates, which led to more reliable data.  
The Blattmann et al. study utilized RNAi in an effort to complement GWAS data with 
functional information. Until 2009 when the aforementioned study started, 22 
GWAS had been published analyzing association with serum lipid traits or 
cardiovascular disease. For the Blattmann et al. study, 56 from the 64 identified loci 
were selected, and 133 genes that represented these 56 loci were analyzed for a role 
in cholesterol regulation. This study led to the identification of 55 genes with a 
functional effect on LDL uptake and/ or cellular free cholesterol levels.  
In the second study that was utilized for the candidate gene selection, a total of 
approximately 70,000 individuals were genotyped for LDL, HDL, triglycerides (TG) 
and total cholesterol (TC) traits. The genotyping was performed with an Illumina 
HumanExome genotyping array (͞the Exome Array͟ or ͞Exome Chip͟) built with 
variants discovered upon exome-sequencing of ~12,000 individuals  (Tbl. S1, Single-
variant-based analyses performed by Anirruddh Patel and other, Kathiresan lab, 
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Massachusetts General Hospital, Boston). This study revealed 165 ͞hits͟-genes with 
variants significantly associated with lipid traits. A large part of this study has been 
subsequently published (Peloso et al. 2014).  
The ͞hits͟ from the two aforementioned studies were juxtaposed (Tbl. S2), and the 
21 overlapping genes were selected (APOB, APOE, BAZ1B, BCAM, BCL7B, CBLC, 
CELSR2, HAVCR1, HMGCR, LDLR, LPL, MLXIPL, MYBPHL, NCAN, PCSK9, PVRL2, SIK3, 
TM6SF2, TMEM57, TOMM40 and ZNF259). Additionally, to the candidate gene set a 
few genes were added that did not overlap between the two studies, as they were 
considered significant. First, seven genes from the hits of Blattmann et al., that did 
not overlap with the Exome Chip hits were selected, for the reasons listed below. 
Five of these genes -CXCL12, SORT1, FAM174A, WDR12 and SEZ6L- were the 
strongest hits in Blattmann et al. (Blattmann et al. 2013). LDLRAP1/ARH gene was 
included as it has a well-described role in LDLR endocytosis, and its mutations are 
responsible for autosomal recessive hypercholesterolemia. 
 
Figure 13. Final selection of 30 candidate genes for the interaction screen. 
In total, 30 genes were selected to be tested for gene-gene interactions with co-RNAi. Of those 30 
genes, 21 overlapped between the Blattmann et al. study and the Exome chip (green), seven were 
additionally selected from the Blattmann et al. (blue), and two were selected from the Exome Chip 
(yellow). 
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PAFAH1B1 was selected as it may have a significant role in cholesterol regulation, 
based on a number of unpublished experiments by Blattmann et al. Secondly, two 
genes that were hits in the Exome Chip but were not analyzed in Blattmann et al. 
were selected; of these, MYLIP/IDOL has a well-described role in endocytosis and 
degradation of LDLR (Zelcer 2009), and PAFAH1B2 encodes a subunit of the 
PAFAH1B complex that is formed together with PAFAH1B1, which was shown to 
affect LDL internalization and/or cellular levels of free cholesterol (Blattmann et al. 
2013). So, the final selection consisted of 30 candidate genes (see Fig. 13 and Tbl. 
S4). The reported function of the candidate genes, as well as their link -if existing- to 
cholesterol regulation or lipid homeostasis are shown in Tbl. S5. 
 
3.1.4 SIRNA SELECTION 
The combinatorial RNAi screen contained 30 siRNAs each targeting the one of the 
selected genes, as well as two negative control siRNAs, one positive control siRNA 
for Filipin assay and one transfection control siRNA. 
In my screen, gene knockdowns were performed using only one Silencer Select 
siRNA per gene. For the 28 genes that were previously analyzed in Blattmann et al. 
(Blattmann et al. 2013), siRNAs were selected from this study. In Blattmann et al., 
three-five independent siRNAs were tested per gene. For my screen, I chose the 
siRNA that had the strongest effect on either of the two assays performed (LDL-
uptake assay preferred over Filipin assay). For the two genes that were not analyzed 
in Blattmann et al. (MYLIP, PAFAH1B1), the Silencer Select siRNAs that targeted most 
gene transcripts were selected. The siRNAs used and the selection criteria are shown 
in detail in Tbl. S6.  
All siRNA sequences were mapped to the human reference genome GRCh37 
(Ensembl 75) using the in-house software tool Bluegecko (J.K. Hériché, unpublished). 
With this tool the number of targeted protein-coding transcripts was evaluated and 
unspecific siRNAs that target other human mRNAs were identified. Moreover, the 
siRNAs were evaluated for mismatches to the reference sequence of the respective 
target gene or for targeting transcripts not anymore considered as protein coding. 
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3.1.5 RESULTS OF THE COMBINATORIAL RNAI SCREEN 
Using the selected siRNAs, the double knockdowns were performed on HeLa Kyoto 
cells for all the combinations between the 30 candidate genes on spotted LabTeks, 
as described (for details see 7.1.2.2.1.2). The LDL-uptake assay was performed to 
measure the effect of the combined knockdowns on LDL internalization and the fixed 
cells were imaged using a widefield Olympus Scan^R microscope (see also 7.1.5.1 
and 7.1.4.2). Internalized DiI-LDL intensity was measured in at least 6 biological 
replicas (after excluding those which did not pass quality control) per spotted array, 
acquiring one image per spot.   
All images from the screen were analyzed performing automated image analysis 
with a Cellprofiler pipeline, in which DiI-LDL fluorescence signal was quantified 
within intracellular areas-͞dots͟ (for details see 7.4.1.2.1). From each cell, the 
following parameters were measured: 
(i) total intensity above local background within all dots in one cell (͞integrated 
intensity͟),  
(ii) mean intensity above local background within these dots per cell (͞mean 
intensity͟),  
(iii) number of dots per cell and 
(iv) mean area covered by dots per cell. 
The total intensity corresponded to the total uptake of LDL, while the mean intensity 
was assumed to correspond to LDL concentration within the segmented structures.  
 
3.1.5.1 PRIMARY ANALYSIS; CONTROL-BASED NORMALIZATION 
The readout chosen for quantifying the knockdown effect and afterwards for 
defining the interactions was the mean total fluorescence intensity of internalized 
DiI-LDL per cell, per image. A robust Z score was calculated by normalizing the total 
intensity of a treatment to the controls of the identical plate;  ݎ𝑜ܾݑݏݐ𝑍ݏܿ𝑜ݎ𝑒 = ௧௥௘𝑎௧௘ௗ−௠௘ௗ𝑖𝑎௡ሺ𝐶௧௥௟௦ሻ௠𝑎ௗሺ𝐶௧௥௟௦ሻ   
(Birmingham et al. 2009; Malo et al. 2006). Thus, a positive robust Z-score meant 
enhancement of LDL uptake, whereas negative meant inhibition. The robust Z-score 
was calculated using a self-written R-script (for details see 7.4.2.1). Within this R-
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script, a median robust z score per treatment was calculated for each treatment, by 
taking the median of robust z scores of same treatments across different biological 
replicates.  
The analysis of the screen resulted to both predicted, as well as unpredicted 
outcomes. For instance, LDLR knockdown had a negative effect on LDL uptake in 
combination with most other genes, which was expected considering that in absence 
of LDL receptors on the plasma membrane LDL uptake is significantly hindered. 
Interestingly, however, LDLR double knockdown with HMGCR or PVRL2 did not have 
a strong effect on LDL uptake. In these two cases, the effect of LDLR knockdown on 
LDL uptake seemed to be counteracted by the co-knockdown of the second gene. A 
heatmap representation of the screen results can be seen in Figure 14. 
 
Figure 14. Heatmap matrix representation of the combined effects of double knockdowns on DiI-
LDL uptake. The colours represent effect size on the linear scale:  positive effects are in magenta and 
negative in green. The readout is the median robust Z score of internalized DiI-LDL intensity per 
treatment; robust Z score=(treated-median(controls))/mad(controls). Numeric data are shown in Tbl. 
S19. 
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3.1.5.2 ALTERNATIVE ANALYSIS; SAMPLE-BASED NORMALIZATION 
In an alternative analysis the robust Z score was calculated by normalizing the total 
intensity of a treatment to all the treatments of the identical plate (Birmingham et 
al. 2009; Malo et al. 2006). The transfection controls (Incenp) and the positive 
controls (Npc1, Ldlr) were excluded from the normalization.  ݎ𝑜ܾݑݏݐ𝑍ݏܿ𝑜ݎ𝑒 = ௧௥௘𝑎௧௘ௗ−௠௘ௗ𝑖𝑎௡ሺ𝑎௟௟ሻ௠𝑎ௗሺ𝑎௟௟ሻ .  
The robust Z score was calculated using a self-written R-script (for details see 
7.4.2.2). Within this R-script, a median robust z score per treatment was calculated 
for each treatment, by taking the median of robust z scores of same treatments 
across different biological replicates. 
This analysis approach is based on the assumption that most of the treatments do 
not display biological effect in the analyzed assay. A heatmap representation of the 
screen results can be seen in Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Heatmap matrix representation of the combined effects of double knockdowns on DiI-
LDL uptake, calculated with the alternative approach. The colours represent effect size on the linear 
scale:  positive effects are in magenta and negative in green. The readout is the median robust Z score 
of internalized DiI-LDL intensity per treatment; robust Z score=(treated-median(all))/mad(all). 
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3.1.6 DEFINING GENE-GENE INTERACTIONS AMONG THE RESULTS OF THE SCREEN 
3.1.6.1 PRIMARY APPROACH; CONTROL-BASED ANALYSIS 
To test for gene-gene interactions among the results of the combinatorial RNAi 
screen, the effect on LDL uptake of the combined transfection with two siRNAs 
targeting two different genes A and B was compared to the additive effect of the 
two single transfections. In single transfections the respective siRNAs were co-
transfected together with the negative control siRNA. For this, a multiple linear 
regression model was applied to analyze the screen data using an R-script that was 
written with the help of Bernd Klaus from the Huber Group at EMBL (for details see 
7.4.3). Thereby, the additive effect of two single knockdowns A and B 
{(GeneA+control)+(GeneB+control)} was compared to the respective double 
knockdown effect (GeneA+GeneB). Thus, a double knockdown phenotype was 
considered indicative of a genetic interaction when it deviated from the additive 
effect of the individual knockdowns. 
This analysis was based on Fisher’s definition of gene interaction -termed ͞epistasis͟; 
͞Epistasis is a deviation from the additivity in the effect of alleles at different genetic 
loci with respect to their contribution to a quantitative phenotype͟ (Fisher 1918) 
(see also section 1.4.2). In the regression model used, the interaction effect of two 
genes was calculated from the difference between the additive effect of the two 
single knockdowns and that of the double knockdown (Axelsson et al. 2011; Horn et 
al. 2011). Finally, a p-value was calculated from the t-value of the regression model 
and the p-value was adjusted for multiple comparisons using the false discovery rate 
(fdr) method (Benjamini and Hochberg 1995). The significance threshold for gene 
interactions was set at pValuefdr<10
-2.  
With this analysis, 35 gene interactions were identified. The identified interactions 
and their interaction effect and significance (p-value) are shown in Tbl. 4 and Fig. 16.  
 
 
 
 
 
 
  48 
 
Gene1 Gene2 robustZscore Interaction Value pVal (fdr) 
1 PAFAH1B1 TOMM40 0.89 2.29 6.54E-05 
2 APOB HMGCR 2.80 2.18 4.05E-03 
3 SORT1 TOMM40 0.77 1.84 3.90E-03 
4 PAFAH1B1 SIK3 1.62 1.79 2.52E-03 
5 PCSK9 TMEM57 1.46 1.76 2.37E-03 
6 MYLIP SEZ6L 2.18 1.75 2.22E-03 
7 HMGCR PAFAH1B1 1.45 1.74 6.59E-03 
8 CELSR2 SIK3 2.30 1.60 8.09E-03 
9 MYBPHL SIK3 2.17 1.59 6.59E-03 
10 PVRL2 SORT1 1.36 1.54 5.88E-03 
11 LDLR PVRL2 0.08 1.48 4.23E-03 
12 LDLR NCAN -1.86 -1.28 7.64E-03 
13 APOE MLXIPL 0.35 -1.40 7.25E-03 
14 HAVCR1 MYLIP -0.13 -1.40 5.60E-03 
15 CELSR2 LPL -1.40 -1.43 7.53E-03 
16 LDLR MLXIPL -2.03 -1.49 2.97E-03 
17 BCAM HAVCR1 -0.51 -1.56 2.97E-03 
18 NCAN TOMM40 -1.40 -1.56 7.17E-03 
19 NCAN SEZ6L -0.59 -1.60 5.54E-03 
20 HAVCR1 ZNF259 -1.01 -1.62 3.23E-03 
21 LDLRAP1 SORT1 -1.11 -1.65 2.57E-03 
22 LDLRAP1 LPL -0.81 -1.68 3.69E-04 
23 HAVCR1 LPL -1.65 -1.75 4.01E-04 
24 CXCL12 PAFAH1B1 -2.17 -1.78 3.69E-04 
25 HAVCR1 TMEM57 -0.96 -1.82 4.62E-04 
26 BCAM LDLRAP1 -0.40 -1.83 3.58E-04 
27 LDLR LDLRAP1 -2.44 -1.86 9.34E-05 
28 HAVCR1 SEZ6L -1.19 -1.91 3.39E-04 
29 HAVCR1 LDLRAP1 -0.56 -2.16 1.03E-05 
30 HAVCR1 NCAN -0.51 -2.19 2.18E-05 
31 LDLRAP1 SEZ6L -1.46 -2.20 1.60E-05 
32 HAVCR1 SORT1 -2.09 -2.24 9.34E-05 
33 HAVCR1 MLXIPL -0.63 -2.31 1.03E-05 
34 MLXIPL SEZ6L -0.91 -2.40 2.18E-05 
35 MLXIPL TOMM40 -2.14 -2.67 1.03E-05 
 
Table 4. Hits of the combinatorial RNAi screen 
The 35 gene pairs that were identified as interacting in the combinatorial RNAi screen. The statistical 
significance threshold was set at p-value (fdr)<10^-2. Shown are the median robustZscores, the 
interaction effects calculated with the linear regression model, as well as the p-values after fdr 
correction for each gene pair. 
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Figure 16. Hits of the combinatorial RNAi screen 
The 35 gene pairs that were identified as interacting from the combinatorial RNAi screen. The 
statistical significance threshold was set at p-value (fdr)<10^-2. The Y axis shows the estimated 
interaction effect of the robust linear model. 
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3.1.6.2 ALTERNATIVE APPROACH; SAMPLE-BASED ANALYSIS 
In an alternative statistical analysis to test for gene-gene interactions among the 
results of the combinatorial RNAi screen, the double knockdown effect 
(GeneA+GeneB) was compared to the additive effect of two single knockdowns A and 
B {(GeneA+any)+(GeneB+any)}, in which case as single knockdown I considered the 
combination of the respective gene with any other gene.  
This analysis was based on the observation that the knockdown effect of an siRNA 
was sometimes milder when it was co-transfected with a second siRNA, as 
compared to when transfected alone or with negative control siRNA. Therefore, it 
was considered as more ͞fair͟ to compare double knockdowns (GeneA+GeneB) with 
double knockdowns (GeneA+any) or (GeneB+any), instead of comparing with ͞single͟ 
knockdowns (GeneA+control) or (GeneB+control), assuming that the control siRNA 
has no effect. 
With this analysis, seven gene-gene interactions were identified at pValuefdr<5x10
-2; 
(MYLIP+SEZ6L), (PAFAH1B1+TOMM40), (SORT1+TOMM40), (LDLR+PVRL2), 
(APOE+CXCL12), (CXCL12+PAFAH1B1), (MLXIPL+TOMM40), and only two at 
pValuefdr<10
-2; (MYLIP+SEZ6L), (PAFAH1B1+TOMM40). 
The identified interactions and the interaction effect and significance of the 
interaction (p-value) are shown in Figure 17. 
 
 Gene1 Gene2 Interaction Value pVal (fdr) 
1 APOE CXCL12 1.01 3.90E-02 
2 CXCL12 PAFAH1B1 -1.13 1.84E-02 
3 LDLR PVRL2 1.10 2.27E-02 
4 MLXIPL TOMM40 -1.25 2.80E-02 
5 MYLIP SEZ6L 1.83 8.09E-05 
6 PAFAH1B1 TOMM40 1.40 6.63E-03 
7 SORT1 TOMM40 1.36 2.27E-02 
 
 
 
 
 
 
Figure 17. The seven gene pairs were identified as interacting in the combinatorial RNAi screen 
(alternative analysis).  
The statistical significance threshold was set at p-value (fdr)<10
-2
. Shown in the table are the 
interaction effects calculated with the linear regression model, as well as the p-values after fdr 
correction for each gene interaction. The Y axis of the figure shows the estimated interaction effect of 
the robust linear model. 
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3.1.6.3 OVERLAP OF HITS BETWEEN TWO ANALYSES 
At pValue(fdr)< 10-2 , the hits that were identified in the two analysis overlapped 
100%. At pValue(fdr)< 5x10-2, seven hits were identified with the second analysis, 
that also overlapped 100% with the (99) hits that were identified at the same 
threshold with the first analysis (not shown here). 
 
3.1.7 SECONDARY EXPERIMENTS 
3.1.7.1 REPLICATION AND VALIDATION OF SCREEN RESULTS 
In order to perform a number of secondary experiments that could not be done with 
the microarrays, the 35 double knockdowns that emerged as screen hits (primary 
analysis) were repeated in a larger format using liquid-phase forward transfection 
(for details see section 7.1.2.1). The purpose of doing this was to measure the 
knockdown efficiency of the siRNAs used, as well as to determine if these double 
knockdowns had an effect on LDLR mRNA and/or protein levels, and most 
importantly to validate the hits with a different method. To this end, the single 
knockdowns (GeneA+control) for each interacting gene as well as the double 
knockdowns (GeneA+GeneB) were performed, and the same analysis was conducted 
as for the screen (for details see sections 3.1.4 and 3.1.5). 
Liquid phase transfections resulted in more penetrant and stronger phenotypes. 
Thus adjustment of the siRNA concentrations was necessary to mimic the 
experimental setup of the screen (see Fig. S1).  
Of the 32 screen hits, 20 were validated with liquid-phase transfection. These 20 hits 
had a statistically significant interaction effect, which was similarly up- or down- 
regulating as in the screen. One more interaction (LDLR+HAVCR1) that had not 
reached statistical significance in the screen, but seemed interesting to us (see 
section 3.3) was independently confirmed. The 21 interactions that were confirmed 
with liquid-phase transfection are shown in Tbl. 5 and Fig. 18 (see also Fig. S2). The 
siRNA amounts and knockdown efficiencies for the single and double knockdowns 
are shown in Tbls. S7 and S8, respectively, and the siRNA amounts used for double 
knockdowns in the validation experiments are shown in Tbl. S9. The results of the 
validation experiments are shown on Tbl. S20. 
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Table 5. Validated gene interactions. 
21 gene interactions were validated with liquid-phase transfection. Shown are the interaction effects 
of the forward transfection experiments, as well as the fdr-corrected p-values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Validated gene interactions. 
21 gene interactions were validated with liquid-phase transfection. The y-axis represents the 
interaction effects of the forward transfection experiments. 
  Treatment Robust Z score Interaction value  pVal (fdr) 
1 LDLR+ NCAN -1.23 -2.22 2.20E-11 
2 CXCL12+ PAFAH1B1  1.32 -1.92 9.84 E-13 
3 NCAN + SEZ6L -0.08 -1.56 7.94 E-12 
4 NCAN + TOMM40  -1.49 -1.34 1.75E-08 
5 HAVCR1 + MLXIPL -0.12 -1.20 2.06 E-05 
6 LDLRAP1 + SORT1 -1.09 -1.04 6.78E-09 
7 LDLR + LDLRAP1 -2.49 -0.92 2.36E-10 
8 CELSR2 + LPL  -0.11 -0.86 8.7 E-05 
9 MLXIPL + TOMM40  -1.94 -0.85 3.82 E-08 
10 LDLR + MLXIPL -2.26 -0.78 4.19E-11 
11 HAVCR1+ SEZ6L -0.67 -0.77 2.9 E-04 
12 HAVCR1 + LDLRAP1 0.39 -0.73 5.40E-03 
13 BCAM + LDLRAP1 -0.05 -0.70 5.20E-03 
14 HAVCR1 + SORT1 -0.63 -0.58 1.98E-03 
15 BCAM + HAVCR1  -0.51 -0.54 6.23E-02 
16 MYBPHL + SIK3 2.30 0.96 7.91E-03 
17 APOB + HMGCR 3.33 0.97 1.53E-03 
18 SORT1 + TOMM40  -2.48 1.77 0.00E00 
19 PAFAH1B1+ SIK3 3.30 2.44 8.37E-12 
20 PCSK9 + TMEM57  3.21 2.44 3.74E-11 
21 HAVCR1+LDLR -2.24 -1.24 
 
1.81E-10 
  53 
3.1.7.2 RELATING PHENOTYPIC EFFECT TO GENE EXPRESSION 
3.1.7.2.1 EVALUATING GENE EXPRESSION  
The use of a primary-tumor derived cell line, such as HeLa Kyoto, for RNAi screening 
raises the concern if the genes targeted are expressed and if their expression levels 
are reduced through RNAi. To address this question, HeLa Kyoto transcriptome RNA-
sequencing data from the Simpson et al. secretion screen (Landry et al. 2013; 
Simpson et al. 2012) were explored, to assess if the genes tested with the co-RNAi 
screen are expressed in HeLa Kyoto cells. Moreover, qRT-PCR experiments were 
performed for 22 of the 30 genes screened with co-RNAi, and CT values from qRT-
PCR were juxtaposed to RNA-Seq coverage values, considering that both 
measurements reflect the mRNA level. The correlation between the two methods 
was strong (R=-0.63, p-value= 0.008354) (see Fig. 19). 
 
  
 
Figure 19. Correlation of RNA-Seq with qRT-PCR gene expression experiments 
Both qRT-PCR and RNA-Seq experiments were utilized to quantify the mRNA levels of genes in HeLa 
Kyoto cells, by measuring the threshold cycle (Ct) or the coverage (cov), respectively. For 17 of 23 
genes, for which Ct of qRT-PCR was below 29, RNA-Seq detected the mRNA and the knockdown could 
be measured with qRT-PCR. The correlation between the two methods was strong (Pearson’s 
correlation coefficient R= -0.63, p-value: 0.008354) (n.d.: not detected). 
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qRT-PCR (Ct) 
Gene  RNA-seq  
(cov) 
qRT-PCR  
(CT) 
knockdown 
detectable 
GAPDH 2627.17 14.0 + 
TOMM40 142.26 19.0 + 
BCL7B 52.53 21.2 + 
PAFAH1B1 39.47 20.2 + 
PCSK9 34.98 19.5 + 
LDLR 32.38 20.5 + 
CELSR2 30.49 22.3 + 
PVRL2 21.55 21.4 + 
LDLRAP1 18.33 23.1 + 
SIK3 16.34 23.9 + 
LPL 15.78 21.4 + 
TMEM57 15.16 22.1 + 
HMGCR 12.18 20.3 + 
SORT1 10.31 22.5 + 
MLXIPL 5.85 24.8 + 
BCAM 3.57 27.3 + 
APOE 1.16 28.9 - 
APOB n.d. 36.0 - 
CXCL12 n.d. 36.2 - 
HAVCR1 n.d. 33.2 - 
MYBPHL n.d. 32.9 - 
NCAN n.d. 33.2 - 
SEZ6L n.d. 33.1 - 
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In agreement with the RNA-Seq data, gene knockdown could only be measured with 
qRT-PCR in genes with CT <29 and that were detected with RNA-Seq. Out of 30 genes 
tested in the co-RNAi screen, 22 (73%) were detectable with RNA-Seq in the 
transcriptome of HeLa Kyoto cells. However, some of the genes that scored as 
interactors in the co-RNAi screen were neither detected by RNA-seq, nor by qRT-
PCR.  
With a view to investigating if the protein expression of such genes, that were not  
detectable at mRNA level, could be observed, the Confetti online resource of HeLa  
proteome (https://proteomics.swmed.edu/confetti/) was employed. This is a map of 
the HeLa proteome that was generated by digesting the HeLa lysate with a 
multiprotease approach, and subsequently analyzing the lysate digest with mass 
spectrometry (Guo et al. 2014). This approach led to the identification of more than 
7,500 proteins. 
Out of the 30 genes tested in the co-RNAi screen, 21 (70%) were detected in the 
proteome, according to the Confetti map. Noteworthy one gene that was not 
detected by RNA-seq and its knockdown could not be detected with qRT-PCR 
(APOB), as well as one gene that was detected by RNA-Seq, but its knockdown could 
not be detected (APOE), were detected in the proteome. Moreover, one gene that 
was detected with RNA-Seq and its knockdown could be measured, was not 
detected at the proteome level (MLXIPL). The correlation between the protein levels 
from Confetti and the mRNA levels from RNA-Seq was strong (R=0.72, p-value= 
0.001055), but the correlation between the protein levels and the mRNA levels from 
qRT-PCR was weak (R= 0.327208) (see Fig. 20).  
Both the transcriptome and the proteome resources were useful to provide a priori 
knowledge concerning gene expression levels at the mRNA and protein level in HeLa 
cells. However, neither of them was utilized with the aim to preclude genes from the 
co-RNAi screen. As was explained before, the expression of genes undetected by 
RNA-seq or proteomics might be lower than the detection threshold of these 
techniques. 
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Figure 20. Correlation of RNA-Seq and qRT-PCR gene expression experiments with protein 
expression 
For 17 out of 23 genes, for which the Ct of qRT-PCR was below 29, the protein was detected with the 
Confetti approach. Noteworthy one gene (MLXIPL) with Ct below 29 (Ct=24.8) the protein was not 
detected. The correlation between RNA-Seq and protein measurements was strong (Pearson’s 
correlation coefficient R=0.72, p-value=0.001055), but the correlation between qRT-PCR and protein 
values was weak (Pearson’s correlation coefficient R=0.327208). 
 
 
 
 
 
 
 
 
 
 
 
Gene  RNA-seq (cov) qRT-PCR (CT) Confetti (cov) 
GAPDH 2627.17 14 99.7 
TOMM40 142.26 19 96.12 
BCL7B 52.53 21.2 38.12 
PAFAH1B1 39.47 20.2 75.12 
PCSK9 34.98 19.5 20.52 
LDLR 32.38 20.5 19.42 
CELSR2 30.49 22.3 1.03 
PVRL2 21.55 21.4 39.22 
LDLRAP1 18.33 23.1 26.62 
SIK3 16.34 23.9 11.01 
LPL 15.78 21.4 28.21 
TMEM57 15.16 22.1 14.46 
HMGCR 12.18 20.3 2.48 
SORT1 10.31 22.5 39.71 
MLXIPL 5.85 24.8 n.d. 
BCAM 3.57 27.3 40.92 
APOE 1.16 28.9 9.15 
APOB n.d. 36 5.28 
CXCL12 n.d. 36.2 n.d. 
HAVCR1 n.d. 33.2 n.d. 
MYBPHL n.d. 32.9 n.d. 
NCAN n.d. 33.2 n.d. 
SEZ6L n.d. 33.1 n.d. 
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3.1.7.2.2 ASSESSING KNOCKDOWN EFFICIENCY 
In an attempt to correlate the observed effect in the cellular assay with the RNAi-
mediated knockdown efficiency, RT-qPCR was utilized to quantify the mRNA levels in 
the cell lysate of the cells transfected with siRNA targeting the genes under study. In 
detail, knockdowns for all the 19 validated interactors of the screen were performed. 
For six (APOB, CXCL12, HAVCR1, MYBPHL, NCAN, SEZ6L) of the 19 genes tested, 
mRNA levels were too low to be detected and therefore knockdown could not be 
assessed. For the remaining 13 genes, the average knockdown was 80%. For 11 of 
the 13 genes, the knockdown ranged between 67% and 97%, while for the other 2 
genes (MLXIPL, TMEM57) the knockdown ranged between 35% and 45% (see Tbl. 6).  
The anti-correlation of the knockdown levels with the functional effects observed 
was moderate (Pearson’s correlation coefficient R= -0.42). For instance, strong 
phenotypic effects were observed for genes with a mild knockdown (<45%), such as 
MLXIPL and TMEM57. Similarly, very mild phenotypic effects were observed for 
genes with a strong knockdown (>95%), such as PAFAH1B1 and BCAM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Correlation of the gene knockdown with the functional effects on LDL uptake  
The gene knockdown efficiencies are calculated after normalization to the GAPDH. The effect on LDL 
uptake shown is the median robust Z score of endocytosed DiI-LDL. The correlation of the gene 
knockdown levels with the functional effects was moderate (Pearson’s correlation coefficient R= -
0.42). 
 
 
 
 
siRNA treatment % gene kd effect on LDL uptake 
BCAM + control 95.7 -0.16 
CELSR2 + control 85.0 0.84 
HMGCR + control 67.4 1.70 
LDLR + control 76.8 -1.43 
LDLRAP1 + control 92.9 1.11 
LPL + control 96.7 -0.67 
MLXIPL + control 35.6 0.89 
PAFAH1B1 + control 95.3 0.37 
PCSK9 + control 85.1 0.70 
SIK3 + control 78.9 0.39 
SORT1 + control 93.9 -0.56 
TMEM57 + control 44.8 1.01 
TOMM40 + control 88.6 -1.51 
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3.1.7.3 EFFECT OF GENE INTERACTIONS ON LDLR MRNA AND PROTEIN LEVEL 
Next, I asked whether the effects of the identified gene interactions on LDL-uptake 
are due to alterations of the LDLR expression at the transcriptional and/ or post-
transcriptional level. Given the fact that LDLR is the key regulator of LDL endocytosis, 
an increase in LDLR expression should lead to increased LDL uptake and vice versa. In 
order to address this question, LDLR mRNA and protein levels upon knockdowns 
were assessed for the validated hits of the screen. Altogether, 20 double 
knockdowns for the interacting gene pairs as well as the corresponding single 
knockdowns were performed, and their effect on LDLR mRNA and protein levels was 
measured using qRT-PCR and Western blotting, respectively (Figures 21 and 23).  
 
Figure 21. Effect of gene interactions on LDLR mRNA levels  
Shown are mRNA levels of LDLR in HeLa Kyoto cells after 48 h knockdown of the identified interacting 
genes, transfected alone (siRNAA+control siRNA) or in combination (siRNAA+siRNAB), after 
normalization to the control siRNA. The LDLR levels were normalized to the housekeeping gene 
GAPDH. The error bars represent the standard error of the mean (n=4, statistical significance 
compared to the control in two-sided Student´s t-test is indicated; *P<0.1; **P<0.01; ***P<0.001).  
(A-D) The siRNA concentrations used are shown in Tbl. S10 and numeric data in Tbl. S13. 
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A significant decrease in LDLR mRNA levels was observed upon the single knockdown 
of LDLR (at different siRNA concentrations), as well as for the double knockdowns 
LDLR+HAVCR1, LDLR+MLXIPL, LDLR+NCAN and NCAN+TOMM40. 
 
In order to identify which of the 20 validated gene interactions are reflected on LDLR 
mRNA level, the additive effect of two single knockdowns was compared to the 
combined knockdown effect, by fitting a linear regression model (see section 7.4.7), 
as was done in the analysis of the co-RNAi screen. The interaction effect was 
calculated, and the threshold for the p-value was set at pVal<10-1. With this analysis, 
five gene pairs (HAVCR1+LDLR, LDLR+MLXIPL, HAVCR1+SEZ6L, NCAN+TOMM40, 
LDLR+NCAN) were identified as interacting at the level of LDLR mRNA expression 
(see Fig. 22). The results of the linear regression analysis are shown in Tbl. S16. 
 
 
Figure 22. Gene interactions affecting LDLR mRNA levels. 
Shown are the 5 gene pairs that were identified as interacting at the level of LDLR mRNA, by 
comparing the additive effect of the two single knockdowns to the effect of the double knockdown, 
using a linear regression model. For each gene pair, the mean (log2-transformed) fold change of 
mRNA of the control, the two single knockdowns as well as the double knockdown are shown. The 
LDLR levels were normalized to the housekeeping gene GAPDH. The error bars represent the standard 
error of the mean (n=4). The siRNA concentrations used are shown in Tbl. S10 and numeric data in 
Tbl. S11. 
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Figure 23. Effect of gene interactions on LDLR protein level. 
LDLR protein levels in HeLa Kyoto cells were measured by Western blot upon 48 h knockdown 
following starvation of the cells (see section 7.1.6). The identified interacting genes were either 
transfected alone (siRNAA+control siRNA) or in combination (siRNAA+siRNAB). LDLR was normalized to 
the housekeeping gene a-tubulin, after normalization of both to the control siRNA. Shown are results 
from three biological replicates. Arrows denote siRNAs that significantly (*<0.01; **<0.001, 
***<0.0001) altered LDLR protein levels. Bands from lysates wherefrom no reliable results could be 
obtained were crossed out and excluded from the analysis. The siRNA concentrations used are shown 
in Tbl. S10 and numeric data in Tbl. S13. 
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A significant decrease in LDLR protein levels was observed upon single knockdown of 
LDLR, TOMM40, SEZ6L, SORT1 and BCAM, as well as for the double knockdowns 
LDLRAP1+BCAM, LDLRAP1+SORT1, HAVCR1+SORT1, HAVCR1+SEZ6L, SORT1+ 
TOMM40, MLXIPL+TOMM40, LDLR+LDLRAP1, LDLR+MLXIPL, CXCL12+PAFAH1B1, 
NCAN+LDLR, NCAN+TOMM40. 
In order to identify which of the 20 validated gene interactions are reflected on LDLR 
protein level, the additive effect of two single knockdowns was compared to the 
combined knockdown effect, by fitting a linear regression model, as before (see 
section 7.4.7). The interaction effect was calculated, and the threshold for the p-
value was set at pVal<10-1. With this analysis, five gene pairs (LDLR+LDLRAP1, 
MLXIPL+TOMM40, BCAM+LDLRAP1, HAVCR1+LDLR, and CXCL12+PAFAH1B1,) were 
identified as interacting at the level of LDLR protein expression (see Fig. 24). The 
results of the linear regression analysis are shown in Tbl. S16. 
 
 
 
Figure 24. Gene interactions affecting LDLR protein levels. 
Shown are the five gene pairs that were identified as interacting at the level of LDLR protein, by 
comparing the additive effect of the two single knockdowns to that of the double knockdown, using a 
linear regression model. For each gene pair, the median LDLR after normalization to a-tubulin is 
shown for the control siRNA, the two single knockdowns and the double knockdown. The error bars 
represent the standard error of the mean (SEM). The siRNA concentrations used are shown in Tbl. S10 
and numeric data in Tbl. S12. 
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3.1.7.4 EFFECT OF KNOCKDOWNS ON SREBF MRNA LEVEL 
As was described (see section 1.3.2.2), LDLR expression is regulated by the SREBF 
transcription factors, in particular SREBF-1a and SREBF-2. In order to determine if the 
effect of the identified gene interactions on LDL uptake was due to an effect on the 
expression of SREBF-1a and/or SREBF-2, the mRNA levels of both genes upon 
knockdowns were assessed for the validated hits of the screen. Namely, 20 double 
knockdowns for the interacting gene pairs as well as the corresponding single 
knockdowns were performed, and their potential effect on SREBF mRNA levels was 
measured using qRT-PCR. 
A significant decrease in SREBF1 levels was observed upon single knockdown of 
BCAM, as well as double knockdowns MYBPHL+SIK3 and PAFAH1B1+SIK3 (Fig. 25). 
Regarding SREBF2, a significant decrease in mRNA levels was observed upon single 
knockdown of BCAM, as well as double knockdowns SORT1+TOMM40, 
NCAN+TOMM40, MYBPHL+SIK3, PAFAH1B1+SIK3, HAVCR1+MLXIPL, 
HAVCR1+LDLRAP1 and BCAM+LDLRAP1 (see Fig. 25). 
In order to identify which of the 20 validated gene interactions are reflected on the 
SREBF1 and/or SREBF2 mRNA level, the additive effect of two single knockdowns 
was compared to the combined knockdown effect, by fitting a linear regression 
model (see section 7.4.7). The interaction effect was calculated, and the threshold 
for the p-value was set at pVal<10-1. With this analysis, four gene pairs were 
identified to interact at the SREBF1 mRNA level; SORT1+LDLRAP1, PCSK9+TMEM57, 
HAVCR1+SORT1 and CELSR2+LPL (see Fig. 26, for numerical data see Tbl. S17). At the 
mRNA level of SREBF2, eight interactions were identified; PCSK9+TMEM57, 
LDLRAP1+SORT1, NCAN+TOMM40, LDLR+NCAN, LDLR+LDLRAP1, SORT1+TOMM40, 
MYBPHL+SIK3 and LDLR+MLXIPL (see Fig. 27, Tbl. S17).  
 
Figure 25. Effect of gene interactions on SREBF1 and SREBF2 levels 
Shown are mRNA levels of SREBF1 (blue) and SREBF2 (red) in HeLa Kyoto cells after 48 h knockdown 
of the identified interacting genes, transfected alone (siRNAA+control siRNA) or in combination 
(siRNAA+siRNAB), after normalization to the control siRNA. The LDLR levels were normalized to the 
housekeeping gene GAPDH. The error bars represent the SEM (n=3, statistical significance compared 
to control in two-sided Student´s t-test is indicated; *P<0.1; **P<0.01; ***P<0.001).  (A-D) The siRNA 
concentrations used are shown in Tbl. S10 and numeric data in Tbl. S15. 
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Figure 26. Gene interactions affecting SREBF1 mRNA levels. 
Shown are the four gene pairs that were identified as interacting at the level of SREBF1 mRNA, by 
comparing the additive effect of the two single knockdowns to the effect of the double knockdown, 
using a linear regression model. For each gene pair, the mean (log2-transformed) fold change of 
mRNA of the control, the two single knockdowns as well as the double knockdown are shown. The 
SREBF1 levels were normalized to the housekeeping gene GAPDH. The error bars represent the 
standard error of the mean (n=4). The siRNA concentrations used are shown in Tbl. S10 and numeric 
data in Tbl. S.14 
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Figure 27. Gene interactions affecting SREBF2 mRNA levels. 
Shown are the eight gene pairs that were identified as interacting at the level of SREBF2 mRNA, by 
comparing the additive effect of the two single knockdowns to the effect of the double knockdown, 
using a linear regression model. For each gene pair, the mean (log2-transformed) fold change of 
mRNA of the control, the two single knockdowns as well as the double knockdown are shown. The 
SREBF1 levels were normalized to the housekeeping gene GAPDH. The error bars represent the 
standard error of the mean (n=4). The siRNA concentrations used are shown in Tbl. S10 and numeric 
data in Tbl. S.14. 
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For 21 gene pairs in total, quantitative data for LDL uptake, LDLR mRNA and protein 
levels, as well as SREBF1 and SREBF2 mRNA levels are available. The most interesting 
gene pairs from this analysis are provided in Tbl. 7 (all results are available in Tbl. 
S18). The findings of these experiments were more complicated as it would have 
been expected. For example, PCSK9+TMEM57 double knockdown resulted in 
increased SREBF1 mRNA but decreased SREBF2 mRNA. Another unexpected example 
is LDLR+NCAN, which decreased LDL uptake and LDLR mRNA levels, but also 
decreased SREBF2 mRNA, while the contrary would be expected. The same was true 
for NCAN+TOMM40.  
 
 
Table 7. Combined results from secondary experiments and co-RNAi for 10 selected gene pairs. 
Shown is the effect on LDL uptake, LDLR mRNA and protein, as well as SREBF1 and SREBF2 mRNA, upon double knockdowns of 
the genes which were identified by the screen as interacting. Interaction effects are highlighted with pink (increased) or green 
(decreased). 
 
  
  
LDL 
uptake 
LDLR mRNA LDLR protein SREBF1 
mRNA 
SREBF2 
mRNA 
  
  
Treatment Robust Z 
score 
log2 (fold 
change) 
log2(LDLR/a-
tubulin) 
log2 (fold 
change) 
log2 (fold 
change) 
correlation anti-correlation 
1 LDLR+ NCAN -1.23 -1.88 -3.91 -0.63 -0.25 LDL-LDLR mRNA-SREBF2 mRNA   
2 NCAN + TOMM40  -1.49 -1.27 -1.10 -0.88 -1.10 LDL-LDLR mRNA-SREBF2 mRNA   
3 LDLRAP1 + SORT1 -1.09 -0.06 -1.45 -0.89 -0.20 LDL-SREBF1 mRNA -SREBF2 mRNA   
4 LDLR + LDLRAP1 -2.49 -2.04 -3.91 -0.55 0.43 LDL-LDLR protein LDL-SREBF2 mRNA 
5 MLXIPL + TOMM40  -1.94 -0.81 -1.45 -1.69 -1.57 LDL-LDLR protein   
6 LDLR + MLXIPL -2.26 -2.60 -2.32 -0.42 0.21 LDL-LDLR mRNA LDL-SREBF2 mRNA 
7 MYBPHL + SIK3 2.30 0.59 -0.10 -0.51 -1.01   LDL-SREBF2 mRNA 
8 SORT1 + TOMM40  -2.48 -1.21 -2.10 -0.89 -0.61 LDL-SREBF2 mRNA   
9 PCSK9 + TMEM57  3.21 0.24 -0.15 0.21 -0.28 LDL-SREBF1 mRNA LDL-SREBF2 mRNA 
10 HAVCR1+LDLR -2.24 -1.29 -3.91 -0.08 -0.42 LDL-LDLR mRNA-LDLR protein   
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3.1.8 CLUSTERING OF INTERACTIONS 
In an effort to allocate the genes identified as interactors from the co-RNAi screen onto 
genetic pathways and networks controlling LDL-cholesterol regulation, the 21 validated 
GIs from the RNAi screen were classified into 3 gene-gene interaction categories; 
suppression, epistasis and synergy. The classification was done according to the 
definitions for these classes, which are quoted here from Perez et al. (Pérez-Pérez et al. 
2009):  
(i) Suppression; ͞when the double knockdown is closer to the wild-type condition than 
either of the single knockdowns͟ 
(ii) Epistasis; ͞when the double knockdown resembles the phenotype of one of the 
singles, but not the other͟ 
(iii) Synergy; ͞when the joint contribution to the phenotype made by both knockdowns 
is greater than the sum of their individual effects͟. The three interaction classes are 
shown in Fig. 28. 
Out of 21 GIs, 10 were classified as ͞synergistic͟, 8 as ͞epistatic͟ and 3 as ͞suppressive͟ 
(see Tbl. 8).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Classification of gene interactions.  
Shown is the classification into the 3 described genetic interaction classes, of the 21 gene-gene 
interactions identified from the RNAi screen that were validated. 
Suppression Epistasis Synergy 
HAVCR1 + MLXIPL NCAN + SEZ6L CXCL12+ PAFAH1B1  
CELSR2 + LPL  NCAN + TOMM40  HAVCR1 + LDLRAP1 
BCAM + LDLRAP1 LDLRAP1 + SORT1 HAVCR1 + SORT1 
  LDLR + LDLRAP1 BCAM + HAVCR1  
  MLXIPL + TOMM40  LDLR+ NCAN 
  LDLR + MLXIPL MYBPHL + SIK3 
  HAVCR1+ SEZ6L PAFAH1B1+ SIK3 
  SORT1 + TOMM40  PCSK9 + TMEM57  
  HAVCR1+LDLR 
    BCAM + HAVCR1  
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Figure 28. The three gene interaction classes identified in the co-RNAi screen. 
Shown are representative examples of two interacting genes, for each of three identified classes of 
gene-gene interactions. The boxplots show the median intensity of internalized DiI-LDL, normalized to 
the control, for the two single knockdowns (transfected together with the control siRNA), as well as 
for the double knockdown, for each pair of genes. 
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3.1.9 GENE-GENE INTERACTION MODEL NETWORK CONSTRUCTION  
With an aim to reveal potential functional relationships among the interacting genes 
identified with co-RNAi, a gene interaction network was constructed based on the 21 
validated gene interactions identified. These interactions were overlapped with 
known interactions from the STRING, among all 30 genes tested in the co-RNAi 
screen (see Fig. 29). Out of the 30 genes tested, 24 genes were taking part in 
interactions, while six did not interact with any other gene. Out of the 24 interacting 
genes, 17 genes were connected into a main network  (APOB, APOE, BCAM, CELSR2, 
HAVCR1, HMGCR, LDLR, LDLRAP1, LPL, MLXIPL, MYLIP, NCAN, PCSK9, SEZ6L, SORT1, 
TMEM57 and TOMM40), five other genes were connected into a smaller network 
(CXCL12, MYBPHL, PAFAH1B1, PAFAH1B2 and SIK3), and two other genes were only 
connected with each other (WDR12 and ZNF259).   
 
  
Figure 29. Model network of gene-gene interactions affecting LDL uptake. 
In this network that was constructed using STRING, all the 30 genes tested in the co-RNAi screen are 
shown. All pairwise measurements between the 30 depicted genes have been tested, and interacting 
genes are depicted as connected with a dark blue line. The light blue and pink lines represent known 
interactions, whereas the black lines represent gene co-expression.  
 
  69 
3.1.10 NETWORK ANALYSIS 
In order to investigate the genetic interaction network that was constructed based 
on data from co-RNAi experiments, the large network was sub-divided into smaller 
sub-networks, such as the ͞triangles͟, that can be observed, which can then be 
further investigated. One such triangle is the network of LDLR, HAVCR1 and MLXIPL 
(see Fig. 30). Within this sub-network, each gene interacts with the two other genes.  
 
 
 
 
 
 
 
Figure 30. A sub-network of the GI model network.  
LDLR, MLXIPL and HAVCR1 were shown to interact with each other in regulating LDL-uptake, 
therefore form a gene-interaction network that can be further investigated.  
 
In this network, the knockdown of both MLXIPL and HAVCR1 are potentiating the 
negative effect of LDLR knockdown on LDL uptake, upon co-depletion. On the other 
hand, the co-depletion of HAVCR1 and MLXIPL is reversing the positive effects of the 
two single knockdowns, leading to a down-regulation of LDL uptake. With these 
results in mind, I turned into the literature in order to construct hypotheses on how 
these 3 genes might interact in order to regulate the endocytosis of LDL. LDLR is a 
well-described gene that encodes for the receptor of LDL, and is responsible for its 
endocytosis, as was already described (see section 1.3.2.3). HAVCR1 encodes a 
phosphatidylserine (PtdSer) receptor, which binds with its extracellular 
immunoglobulin variable domain (IgV domain) to PtdSer on the viral envelope of 
Hepatitis A virus and other viruses (s.a. EBOV), mediating their internalization. 
Moreover, it was shown that HAVCR1 can bind and internalize both oxidized and 
native LDL (Ichimura et al. 2008). Based on the above, I hypothesized that HAVCR1 
might act as an alternative receptor for LDL, with lower affinity for LDL than LDLR, or 
alternatively might act as a chaperone for LDLR, thus promoting LDL uptake. MLXIPL, 
also known as CHREBP (Carbohydrate Response Element Binding Protein), encodes a 
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glucose-sensitive transcription factor that has been involved in lipogenesis (Cha and 
Repa 2007; Stoeckman, Ma, and Towle 2004). I hypothesized that MLXIPL might be 
involved in the transcriptional regulation of LDLR and/ or HAVCR1. 
With a view to investigating these hypotheses, I performed some follow-up 
experiments for LDLR and HAVCR1. 
 
3.2 CELL-BIOLOGICAL CHARACTERIZATION OF SELECTED SCREEN HITS 
3.2.1 HAVCR1 KNOCKDOWN DOES NOT DECREASE LDL BINDING 
First, in order to investigate the hypothesis that HAVCR1 might act as an alternative 
receptor for LDL, I asked if the depletion of HAVCR1 had an effect on the binding of 
LDL on the plasma membrane, and if its combined knockdown together with LDLR 
could potentiate the down-regulating effect of LDLR knockdown on LDL binding. To 
answer these questions, I depleted HAVCR1 and LDLR alone and in combination, 
using RNAi, and performed the LDL-binding assay (for details see section 7.1.5.2). 
The knockdown of HAVCR1 alone resulted to a significant increase on LDL binding, as 
compared to the control siRNA (TTEST; p=0.004199), whereas the combined 
knockdown of LDLR and HAVCR1 had no significant difference from the single 
knockdown of LDLR on LDL binding (see Fig. 31). 
 
3.2.2 HAVCR1 OVEREXPRESSION DOES NOT RESCUE THE EFFECT OF LDLR KNOCKDOWN ON 
LDL UPTAKE 
Next, I asked if HAVCR1 could function as a receptor for LDL upon depletion of LDLR. 
To test if HAVCR1 could rescue the effect of LDLR knockdown, LDLR was depleted 
using RNAi, and GFP-tagged HAVCR1 was overexpressed and the effect on LDL 
uptake was measured. The overexpression of HAVCR1 in cells that had been 
depleted of LDLR could not rescue the effect of LDLR knockdown (see Fig. 32). 
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Figure 31. The effect of single and double knockdowns of LDLR and HAVCR1 on LDL binding and 
quantification. 
LDLR knockdown significantly decreased LDL binding, whereas HAVCR1 slightly increased LDL binding. 
The combined knockdown of LDLR and HAVCR1 did not potentiate the effect of LDLR knockdown on 
LDL binding (scalebar=10 μm). 
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Figure 32. Rescue of LDLR knockdown with HAVCR1 overexpression. 
HeLa Kyoto cells transfected with control siRNA or siRNA targeting LDLR, and with either GFP-GFP 
plasmid or HAVCR1-GFP. The LDL-uptake assay was performed to assess the ability of HAVCR1 to 
rescue the effect of LDLR knockdown on LDL uptake. (a) Representative cells for LDL-uptake assay (b) 
Quantification of the mean membrane-bound DiI-LDL, normalized to the control cells (scalebar=10 
μm).  
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3.3 HAVCR1-RARE VARIANTS OVEREXPRESSION EFFECT ON LDL UPTAKE 
3.3.1 VARIANT SELECTION 
As a first step in investigating the role of rare variants of our interacting genes in 
CVD, I turned to one of the most prominent interactors of the screen, HAVCR1. As I 
hypothesize that HAVCR1 may play an important role in lipid regulation, I 
investigated the effect of a number of mutations of this gene on LDL uptake. For this 
purpose, 19 variants were extracted from the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/), from the NHLBI Exome Sequencing Project 
(ESP). Of those 19 variants, 15 were rare (MAF<5%). 
In general, ESP samples were selected to contain controls, the extremes of specific 
traits (LDL and blood pressure), and specific diseases (s.a. early onset MI and early 
onset stroke). The group includes some of the largest well-phenotyped populations 
in the United States, representing more than 200,000 individuals altogether from 
studies, such as the Framingham Heart Study (FHS), the Atherosclerosis Risk in 
Communities (ARIC), and the Multi-Ethnic Study of Atherosclerosis (MESA).  
14 of these 19 variants were predicted to have a possibly damaging or probably 
damaging effect on protein function, 4 were predicted benign, and 1 had unknown 
effect, according to PolyPhen-2 (Polymorphism Phenotyping v2) 
(http://genetics.bwh.harvard.edu/pph2/) (see Tbl. 9). 
The 19 variants were cloned into GFP expressing vector and expressed in HeLa Kyoto 
cells for 24 hours. The effect of the variants’ overexpression on LDL uptake was 
measured. 
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Table 9. The 19 HAVCR1 variants extracted from the Exome Variant Server.  
The rs (reference SNP cluster ID) number, the aminoacid substitution, the coded allele and the 
PolyPhen-2 prediction for each variant are shown. 
 
 
 
3.4 RESULTS OF LDL UPTAKE ASSAY UPON OVEREXPRESSION OF HAVCR1 MUTATIONS  
18 out of 19 variants had a significant inhibitory effect on LDL uptake upon 
overexpression (see Fig. 33 and Fig. 34). Interestingly, 4 variants that were predicted 
as benign by Polyphen-2 (188, 190, 191 and 230) had a significant inhibitory effect as 
well, while a variant that was predicted as probably damaging (186) had no 
significant effect. 
 
 
 
 
 
rs ID AA change Alleles MAF PolyPhen2 Prediction 
rs368474218 W47R t139c 0.0244 probably damaging 
rs373839023 V69I g205a 0.0081 probably damaging 
rs370454823 V69G t206g 0.0081 probably damaging 
rs56084311 D99H g295c 0.8518 probably damaging 
rs199849162 S100G a298g 0.0241 possibly damaging 
rs370980439 R110C c328t 0.0081 probably damaging 
rs377678930 N114S a341g 0.0082 probably damaging 
rs373938216 V138I g412a 0.0078 possibly damaging 
rs199816459 T149A a445g 0.0078 possibly damaging 
rs200642665 V156I g446a 0.4005 benign 
rs61734035 T174M c521t 1.3038 probably damaging 
rs1553316 L179P t536c 14.6004 benign 
rs12522248 T207A a619g 24.6885 benign 
rs369956191 E223stop g667t 0.0081 unknown 
rs200392856 D264N g790a 0.0084 possibly damaging 
rs376460912 Y297C a890g 0.0083 probably damaging 
rs370221161 K317E a949g 0.0082 probably damaging 
rs373996191 A343E c1028a 0.0084 possibly damaging 
rs141023871 M158T t473c 42.7464 benign 
  75 
 
Figure 33. Effect of overexpression of GFP-tagged HAVCR1 variants in HeLa Kyoto cells.  
The y-axis shows the fluorescence DiI-LDL intensity normalized to GFP vector-transfected cells. Blue: 
extracellular, pink: transmembrane, yellow: cytoplasmic (n.s.: not significant, * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001). 
 
Figure 34. The effect of overexpression of wtHAVCR1-GFP and one tagged mutant on LDL uptake. 
The first row shows cells transfected with GFP-vector without the protein. The second row shows cells 
transfected with the wild type HAVCR1 protein, and the third row shows cells transfected with one of 
the variants (K317E) that had a strong downregulating effect on LDL uptake. 
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3.5 SNP CO-OCCURRENCE DETECTION 
For each of the genes in the GI network there have been found in GWA studies a 
number of SNPs associated with lipid traits and CVD. An interesting question that 
would give further insight into the molecular basis of CVD is: do SNPs of interacting 
genes co-occur? More precisely, can we detect SNPs from two or more interacting 
genes occuring in the same patient? Clinical data pointing to this direction will 
further support the in vitro results. 
In order to address this question, the lead SNPs for each of the 30 genes that were 
tested in the co-RNAi screen were extracted from the PhenoScanner of the 
University of Cambridge (http://www.phenoscanner.medschl.cam.ac.uk/ 
phenoscanner); a database holding publicly available results from large-scale genetic 
association studies. I noticed that the most significant lipid SNPs for the genes tested 
in the co-RNAi screen came from the Global Lipids Genomics consortium (Willer et 
al. 2013), the largest meta-GWAS study published to date. For comparisons, I 
decided to extract p-values from the same source. Therefore for lipid traits (LDL, 
HDL, TG, Tc) p-values for SNPs were only extracted from the above study, whereas 
for CAD, CHD and MI p-values were extracted from other studies in the 
PhenoScanner. 
The total 144 lead SNPs extracted (Tbl. S21) are located on 14 genomic loci, where 
28 of the 30 genes that were screened in this work here are mapped (APOB, APOE, 
BAZ1B, BCAM, BCL7B, CBLC, CELSR2, HAVCR1, HMGCR, LDLR, LDLRAP1, LPL, MLXIPL, 
MYBPHL, MYLIP, NCAN, PCSK9, PVRL2, SIK3, SORT1, TM6SF2, TMEM57, TOMM40, 
ZNF259). For two genes (PAFAH1B2, SEZ6L), SNPs have not yet reached statistical 
significance in GWAS.  
The identified SNPs were tested for SNP-SNP interactions in a cohort of 4893 
individuals from the Bioimage study, in collaboration with Heiko Runz (Merck 
Research Laboratories, US).  
The Bioimage study is a multi-ethnic, observational study of the characteristics of 
subclinical atherosclerosis and cardiovascular disease, in a population of 7,300 US 
adults (55-80 years at baseline) at risk for, but without clinical cardiovascular disease 
(Muntendam et al. 2010). This study used measurements from imaging methods 
(including MRI for carotid and aortic plaques, coronary CT angiography, and PET/CT 
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for carotid and aortic inflammation), circulating biomarkers (s.a. blood lipids) and 
risk factors that predict progression to CVD (Natarajan et al. 2015). 
Of the 144 SNPs that were extracted from the PhenoScanner, 70 were present on 
the Illumina Exome Array that was used for the genotyping in the Bioimage study 
(Muntendam et al. 2010), while 47 were not present on the Exome Chip but had 
proxies that were present on it, and 27 were neither present nor had proxies on the 
Exome Chip. 
For the (70) SNPs that were present on the exome chip, as well as for the proxies of 
those not present (7 after removal of the identical ones), single-variant LDL 
association test was performed by Gulum Kosova, based on the allele-frequency of 
the LDL-raising allele in the Bioimage study. In order to test for pairwise SNP-SNP 
interactions, the following 4 models were tested against the null hypothesis model; 
model 1: ͞snp1 only͟:  Y = β0 + β1*snp1 
model 2: ͞snp2 only͟ : Y = β0 + β2*snp2 
model 3: ͞additive͟ : Y = β0 + β1*snp1 + β2*snp2 
model 4: ͞interaction͟: Y = β0 + β1*snp1 + β2*snp2 +β3*snp1*snp2, 
to determine which model best explains the LDL phenotype. 
The individual lipid phenotypes were provided in residuals, that is blood lipid 
phenotypes (LDL, HDL, TG), adjusted for covariates (s.a. age, BMI, alcohol intake, 
smoking, lipid-lowering treatment status) using linear regression models. Based on 
the individual lipid phenotypes, the number of individuals, as well as the mean 
residual LDL value was calculated for individuals carrying 0, 1, 2, 3 or 4 LDL-raising 
alleles (sum of snp1 and snp2 LDL-raising alleles).  
With this analysis, none of the SNP pairs reached statistical significance for the 
͞interaction͟ model. However, 36 SNP pairs reached statistical significance for the 
͞additive͟ model (see Tbl. S22). Moreover, for these 36 pairs of SNPs it was shown 
that the LDL residuals increased with the number of LDL-increasing alleles. Namely, if 
one carries 3 or 4 risk alleles, one has higher chance of having high LDL blood levels, 
and as a consequence, higher risk for cardiovascular disease. 
Interestingly, 3 pairs of SNPs (LPL + CELSR2, APOB + HMGCR, LDLR+NCAN) that were 
identified with this analysis to fit in the ͞additive͟ model correspond to genes that 
were identified as interactors for LDL-uptake in my co-RNAi screen (see Fig. 35). 
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Figure 35. SNP co-occurrence effect on lipid levels for the 3 SNP pairs from Bioimage cohort that 
correspond to gene interactions from my co-RNAi screen 
(A) The lipid levels (HDL, LDL, TG) in individuals where both SNPs are present (2 SNPs) versus 
individuals carrying 1 of the two SNPs (1 SNP) or no SNP for the three SNP pairs that were identified 
as having an additive effect in the Bioimage cohort and were interactors in my co-RNAi screen. (B) The 
lipid levels (residuals) for HDL, LDL and TG (y axis) are plotted against the total number of LDL-
increasing alleles (x axis), in cases of SNP co-occurence (2, 3 or 4 risk alleles) and non co-occurence (0 
or 1 risk alleles), for the three SNP pairs that correspond to genes that interacted on LDL uptake in my 
co-RNAi screen. The gene mapped closest to each SNP is shown above the SNP ID. 
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For these three SNP pairs, I extracted from the Bioimage cohort data the lipid levels 
for the individuals for which a pair of SNPs co-occurred, and compared the average 
to that of the individuals for which they did not co-occur (Figure A). For all three 
pairs, LDL levels increased in the case of co-occurrence. In addition, for CELSR2+LPL 
also HDL and TG increased. Furthermore, I checked the relationship between the 
total number of risk alleles and the lipid levels (Figure B), in individuals with 2, 3 or 4 
risk alleles (SNP co-occurence), and with 0 or 1 risk alleles (no SNP co-occurrence). 
For 2 out of 3 SNP pairs, the LDL levels increased proportionally to the number of risk 
alleles, whereas for 1 pair (APOB+HMGCR) LDL increased only in the case of 4 risk 
alleles. For CELSR2+LPL, also the TG increased proportionally to the risk alleles.  
 
I then performed the same analysis for those interactors of my co-RNAi screen, 
which are mapped close to SNPs that were present on the Exome Chip, or had 
proxies that were present on it (PCSK9+TMEM57, LDLR+MLXIPL, LDLR+HAVCR1, 
MLXIPL+HAVCR1), as well as for the triplet LDLR+MLXIPL+HAVCR1. For the three 
pairs LDLR+MLXIPL, LDLR+HAVCR1, MLXIPL+HAVCR1, as well as for the triplet 
LDLR+MLXIPL+HAVCR1, the LDL levels increased proportionally to the number of risk 
alleles. Specifically for LDLR+HAVCR1, LDL levels rised from negative residual values 
to zero. In the case of MLXIPL+HAVCR1, this was also true for TG levels. Interestingly, 
for PCSK9+TMEM57 the LDL levels significantly increased when one allele of each 
SNP was present, but decreased when there was homozygosity for at least one of 
two SNPs (3 or 4 risk alleles) (see Fig. 36). 
 
 
Figure 36. SNP co-occurrence effect on lipid levels for the 4 gene pairs and 1 triplet from the gene 
interactions of my co-RNAi screen that are mapped close to SNPs on the Exome Chip used for the 
Bioimage cohort  
(A) The lipid levels (HDL, LDL, TG) in individuals where both SNPs are present (2 SNPs) (or 3 SNPs for 
LDLR_MLXIPL_HAVCR1) versus individuals carrying 1 of the two SNPs (1 SNP) or no SNP, for the four 
gene pairs and one triplet that were interactors in my co-RNAi screen and are mapped close to SNPs 
of the Exome Chip used for genotyping in the Bioimage study.  (B) The lipid levels (residuals) for HDL, 
LDL and TG (y axis) are plotted against the total number of LDL-increasing alleles (x axis), in cases of 
SNP co-occurence (2, 3 or 4 risk alleles)) and non co-occurence (0 or 1 risk alleles), for the same gene 
pairs. For the triplet LDLR_MLXIPL_HAVCR1, SNP co-occurrence: 3, 4, 5 or 6 risk alleles, while non co-
occurrence: 2 risk alleles. The gene mapped closest to each SNP is shown above the SNP ID. 
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4 DISCUSSION 
In the present study, a combinatorial RNAi screening approach was used to explore 
gene interaction networks underlying human cholesterol regulation, with respect to 
CVD. The identification through GWA studies of genes associated with lipids and CVD 
has only to a minor extent explained the genetic architecture of common disorders 
such as dyslipidemias and CVD. A probable reason for this is that common disorders 
are assumed to arise from a complex interplay between many genes (Farhan and 
Hegele 2013); therefore genes need to be studied in combination, rather than in 
isolation. Considering that a deregulation in cholesterol homeostasis, is a well 
established major risk factor for CVD (Brown and Goldstein 1974, 1986), I envisaged 
that by studying the genetic networks behind cholesterol regulation I could shed 
more light on the genetic architecture of CVD.  
With a view to investigating the underlying network connectivity of genes associated 
with the disease, I tested for interactions those genes that had been associated in 
GWA studies with lipid traits, CAD and/ or MI. Additionally, the genes that were 
selected to be tested were already shown to have a functional effect on cholesterol 
regulation (Blattmann et al. 2013). Interestingly however, most of the effector genes 
identified by Blattmann et al. only showed moderate effects on LDL uptake upon 
their depletion via RNAi. This finding further supports the notion that the combined 
action of two -or more- genes, rather than that of individual genes could account for 
the regulation of the complex cholesterol homeostasis (Pirucello and Kathiresan 
2010).  
With an aim to enrich the query set with genes carrying low-frequency and rare 
variants, that are poorly captured by GWA studies, the gene selection was made 
from a juxtaposition of the functional profiling data (Blattmann et al. 2013) with 
genotyping data from a recent Exome Chip of 75k individuals (Peloso et al. 2014), 
which were tested for associations with blood lipid traits.  
With respect to reducing the gene combinations, I followed a focused screening 
design with a set of 30 genes, which were tested for pairwise interactions. Solid-
phase reverse transfection in siRNA-spotted microarrays was employed together 
with a cell-based functional assay to test the effect of combinatorial gene depletion 
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on the uptake of LDL-cholesterol from cells. Using high-content automated 
microscopy and computational analysis, 35 gene-gene interactions were identified 
(at FDR of 1%) out of 435 pairwise gene combinations (excluding reciprocals).  
Following up the identified gene interactions, a number of secondary experiments 
were performed. First, correlation of the gene knockdown level with the functional 
effect was investigated. Secondly, the effect of the double knockdowns of 
interacting gene pairs on LDLR mRNA and protein levels, as well as on SREBF1a and 
SREBF2 mRNA levels was assessed. Moreover, a gene-gene interaction model 
network was constructed based on results obtained, by overlapping them with 
available information from STRING database. 
The sub-network of the three genes; HAVCR1-LDLR-MLXIPL was prioritized for more 
detailed studies. Preliminary results with these candidates suggest a previously not 
described function for HAVCR1 and MLXIPL in LDL uptake and a collaborative role of 
these two genes with LDLR in cholesterol homeostasis.  
In parallel, 19 variants of a prominent interactor identified by the co-RNAi screen, 
HAVCR1 were tested for their effect on LDL uptake upon overexpression of their 
GFP-tagged constructs. 15 of those variants were rare (MAF<5%). This was done with 
two aims; (1) to show the significance of rare variants in complex traits and (2) to 
further evidence a key role of HAVCR1 in cholesterol homeostasis, suggested from 
the findings of the co-RNAi screen. 
Finally, in an effort to place the identified genetic interactions in a disease context, a 
cohort of >4,000 individuals in high risk for CVD (Bioimage study (Muntendam et al. 
2010)) was tested for SNP-SNP interactions, among the lead SNPs of the genes 
investigated with the co-RNAi screen. This was performed in collaboration with 
Heiko Runz (Merck Research Laboratories, US) and the analysis was done by Gulum 
Kosova.  
In this section discussed in detail are: the model system (4.1) and the functional 
assays (4.2) used in the present study, as well as the candidate gene selection 
strategy (4.3). Moreover, the screening approach (4.4) and the gene interaction 
analysis (4.5) are discussed. In addition, the results of the co-RNAi screen are 
evaluated (4.6), and hypotheses for mechanistic interpretation of the selected sub-
network LDLR-MLXIPL-HAVCR1 are provided (4.7). Next, the effect of overexpression 
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of HAVCR1 mutations is discussed (4.8), and finally, the co-occurrence of SNPs of the 
tested candidate genes is examined (4.9). 
 
4.1 THE USE OF HELA CELL LINE AS A MODEL FOR CHOLESTEROL HOMEOSTASIS 
Using a cell line to model human disease can be considered as reductionism. An in 
vitro disease model system allows studying the tissue of interest in isolation from the 
rest of the body, thus removing effects resulting from the organic, systemic or 
organismal level. Therefore, the effect on cholesterol regulation that is observed 
upon the depletion of a gene product in a cell line might not be the same in an 
animal model, where the cholesterol regulating system of the whole organism is 
present. Furthermore, the identification of genes that affect cholesterol homeostasis 
in vitro does not necessarily guarantee that these genes will explain the disease risk 
in humans. However, the co-RNAi screen that was performed in this study was 
different from other in vitro RNAi screens, because it had the advantage of testing 
genes, which had already been associated with the disease in GWA and genotyping 
studies. For this reason, the chances that genetic interactions identified with this 
screen will be causally related to the disease, are much higher than for other 
completely unbiased RNAi screens. Furthermore, the study of Blattmann et al. 
(Blattmann et al. 2013) has already demonstrated the potential of the in vitro 
approach to identify cholesterol-regulating genes within GWAS loci.  
In this study, HeLa Kyoto cells were used, an epithelial cell line which derived from 
cervical cancer. HeLa cells have been widely and successfully used in research of 
many diseases unrelated to cancer, such as AIDS and poliomyelitis etc. These cells 
have many characteristics that make them the cell line of choice; they are easy to 
culture, their doubling time is less than that of other cancer cells, they grow in 
monolayers and they are adherent. HeLa Kyoto is a strongly adherent version of this 
cell line. These features make them very suitable for high-throughput microscopy.  
Furthermore, these cells are very well characterized, as they have been recently 
sequenced (Landry et al. 2013). 
Nonetheless, the suitability of HeLa cells for the study of cholesterol regulation, 
instead of a liver cell line, can be viewed as controversial by some researchers. 
Importantly however, it has been demonstrated that although the liver plays a 
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central role in cholesterol metabolism, the extrahepatic tissues are responsible for 
more than 80% of the total sterol synthesis (Dietschy et al. 1993). Moreover, 
extrahepatic tissues are responsible for the clearance of about 30% of the LDL 
cholesterol. For these reasons, HeLa cells are considered to be a satisfactory model 
system for cholesterol homeostasis modeling. What is more, LDLR expression levels 
in Hela Kyoto cells are comparable to other liver-derived cell lines, such as Huh7 and 
HepG2 (not shown here), which are generally used to study cholesterol homeostasis. 
In addition, most hepatic cell lines are not suitable for automated high-throughput 
microscopy experiments, due to reasons such as aggregate formation and variable 
cell morphology. Besides, non-hepatic cell lines (such as fibroblasts, aortic 
endothelial, or alveolar epithelial cells) have been extensively used in cholesterol 
studies and our current knowledge of cellular cholesterol trafficking derives mainly 
from such studies (Ikonen 2008). 
One possible downside of the use of HeLa cells for the co-RNAi screen is that out of 
the 30 genes tested, seven genes were not detected in the transciptome, six out of 
those were neither detected in the proteome. However, five of the respective 
proteins (HAVCR1, NCAN, SEZ6L, CXCL12, MYBPHL) were not detected in neither of 
ten other cell lines (including the liver-derived cell line HepG2) tested in a 
comparative proteomic analysis (Geiger et al. 2012). An off-target effect for these 
genes is ruled out, since more than one siRNA targeting each of those showed an 
effect in Blattmann et al. (Blattmann et al. 2013). Hence, it is likely that these five 
genes are expressed under detection levels in tissue culture cells.  
 
4.2 ASSESSING FUNCTIONAL ASSAYS 
In order to identify genetic interactions, a phenotypic trait has to be evaluated. 
Binary phenotypic readouts were assessed in early genetic interaction studies, such 
as cellular fitness. However, analysis of quantitative phenotypes is much more 
informative, as it allows the detection of more subtle interactions and furthermore 
their classification into positive and negative ones.  
In the present study, the uptake of fluorescently labeled LDL (DiI-LDL) from cells was 
used as phenotypic readout, which can be quantified. The phenotypic readout was 
obtained through performance of the LDL-uptake assay, a well established cellular 
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assay (Gilbert et al. 2009; Pitas et al. 1981), that has been previously applied in high-
throughput screens by our group (Bartz et al. 2009; Blattmann et al. 2013). Thus, the 
LDL-uptake assay was suitable for high-throughput screening as well as for 
systematic functional analysis of perturbed human cells. 
The aforementioned assay measures the ability of cells to endocytose LDL 
cholesterol, thus clearing it from the bloodstream. Therefore, LDL uptake is a key 
process to achieve balanced cholesterol levels in the circulation, and subsequently 
avoid atherosclerosis and CAD. Hence, the LDL-uptake assay closely reflects the role 
of the cells in regulating extracellular lipid levels and this is why it was selected in the 
present study. 
 
4.3 EVALUATION OF CANDIDATE GENE SELECTION STRATEGY 
The approach followed for candidate gene selection for the co-RNAi screen turned 
out to be very efficient resulting in many hits. The gene set was carefully selected to 
contain both known cholesterol regulators as well as genes not previously 
functionally related to cholesterol homeostasis, and completely uncharacterized 
genes. Specifically, of the 30 candidate genes, 8 were already linked to cholesterol 
regulation (LDLR, LDLRAP1, PCSK9, MYLIP, HMGCR, LPL, APOB, APOE), and 2 
additional (MLXIPL, PAFAH1B1) were linked to lipid homeostasis by GO (Gene 
Ontology) annotation. The remaining 20 genes had not been previously linked to 
lipid homeostasis. Moreover, for 5 of those (CELSR2, FAM174A, MYBPHL, SIK3, 
TMEM57) no functional information was available in the literature (see Tbl. S5).  
Interestingly, genes with a well-defined cholesterol regulatory function, such as 
SREBP, SCAP, INSIG and LXR were entirely absent from GWAS, and therefore from 
the co-RNAi screen as well. The lack of GWAS-identified disease-associated SNPs in 
these genes might be either due to the highly detrimental effect of those SNPs, 
which are therefore removed by purifying selection, or due to their low frequency 
that renders them unlikely to be detected by GWAS. On the other hand, genes 
regulating cholesterol removal (such as ABCA1, ABCG5, ABCG8) or storage (such as 
LCAT) were reported in GWAS but did not show a significant effect on LDL uptake or 
cholesterol levels upon depletion (Blattmann et al. 2013), therefore were not 
included in the co-RNAi screen. 
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It has commonly been assumed that strong epistatic interactions are detected 
between genes with small main effects (Phillips 2008), although contrasting theories 
support that interactions are more likely to occur between alleles with more severe 
effects (Crow 1990). With this consideration in mind, I selected for the interaction 
screen both genes with a small individual effect (such as CELSR2) and genes with a 
stronger effect (such as LDLR) on LDL uptake and/or total cholesterol levels 
(Blattmann et al. 2013).  
Nonetheless, not all genes with a single phenotypic effect in Blattmann et al. were 
selected for the co-RNAi screen. Ideally, one could select all the 55 genes that were 
effectors in the aforementioned study. This would though result in 3025 pairwise 
combinations to be tested, as compared to 900 that correspond to 30 candidate 
genes. However, it needs to be pointed out that the current gene selection was not 
meant to be exhaustive for the gene interactions that affect cholesterol regulation, 
but rather highly enriched in gene interactions that could be then followed up by 
more experiments. 
Moreover, it should be noted that the candidate genes from Blattmann et al. 
originate from GWA studies, which are only powered to detect common variants. 
With an aim to more efficiently address the missing heritability problem (see section 
1.1.3.2.1), genes with rare variants associated to lipid traits were also included in the 
screen. Therefore, the results of the Blattmann et al. were juxtaposed to those of a 
genotyping study for lipid traits (Peloso et al. 2014). In this study, a cohort of 
>70,000 individuals was genotyped for LDL-c, HDL-c and TG (Peloso et al. 2014). 
Specifically, the genotyping was performed with the Illumina HumanExome array, 
which was built to contain coding sequence variants discovered from the exome 
sequencing of ~12,000 individuals. In this way, low-frequency and rare variants were 
associated with lipid traits.  
All 30 candidate genes selected for the interaction screen contain or are located 
adjacent to SNPs identified by GWAS to be associated with blood lipid levels (LDL, 
HDL, TG, TC), CAD and/ or MI (Blattmann et al. 2013). Namely, these genes are 
residing in loci associated with cardiovascular disease risk, either directly or 
indirectly -through association with causal risk factors for the disease. As a 
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consequence, interactions detected among these genes would be immediately 
associated with cardiovascular disease risk.  
What is more, 23 of these genes (see Tbl. S2) contain rare variants which showed a 
significant association with lipid traits in the aforedescribed genotyping study 
(Peloso et al. 2014). The analyzed cohort consisted at large of participants of 
cardiovascular disease studies, in which affected individuals presented with 
atherosclerosis, MI and/or CAD. Hence, the genes investigated in the co-RNAi screen 
performed in the present study have a direct relation with CVD. 
 
4.4 EVALUATION OF THE CO-RNAI APPROACH 
The concept of studying gene-gene interactions via the systematic co-depletion of 
genes and the analysis of a quantitative phenotype has already been implemented 
on metazoan cells, including C. elegans (Lehner et al. 2006; Tischler et al. 2006), 
Drosophila cells (Billmann et al. 2016; Horn et al. 2011), mouse (Roguev et al. 2013) 
and human cell lines (Barr and Bakal 2015; Laufer et al. 2013; Wang et al. 2014). 
Using co-RNAi, multiple genes can be targeted for depletion at the same time, thus 
enabling the observation of phenotypic outcomes that arise from the combined 
contribution of functionally connected genes. This is a powerful approach to reveal 
functional relationships between previously unrelated genes, as well as to yield 
important information concerning the biological pathways in which the genes take 
part. Moreover, by constructing the genetic interaction profile of a gene, that is the 
total of genetic interactions in which it participates, the function of a previously 
uncharacterized gene can be inferred. 
One aspect of the co-RNAi approach that needs to be taken into account is that we 
frequently obtain only partial depletion, rather than complete abolishment of the 
gene product through RNAi-mediated knockdowns. The inhibition of gene 
expression induced by RNAi depends on the knockdown efficiency of the siRNA used, 
the stability of the gene product, as well as regulation of gene expression by 
feedback mechanisms. Intermediate gene expression levels lead to the emersion of 
partial phenotypes (hypomorphs) that would not be observed otherwise. This has 
both drawbacks and benefits; one drawback is that the outcome of the simultaneous 
complete depletion of the two gene products cannot be observed. This would show 
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the effect of the complete absence of function of both genes. On the other hand, 
however, the incomplete knockdowns result in substantially reduced gene 
expression levels but sufficient for their viability, which is crucial in the case of 
essential genes. In addition, partial phenotypes have been shown to frequently yield 
biologically meaningful genetic interactions (Schuldiner et al. 2005). Moreover, the 
intermediate expression levels achieved through RNAi result in phenotypes very 
closely resembling those of patients carrying partial loss-of-function mutations in the 
respective genes. Thus, the RNAi-mediated reduction of gene expression, which can 
be tuned, can lead to different levels of residual gene activity, which is 
physiologically relevant and therefore its effects can be very informative.   
 
4.5 EVALUATION OF THE GENETIC INTERACTION ANALYSIS 
The statistical analysis of genetic interactions is challenging in the aspects of their 
definition, detection and interpretation. A genetic interaction is considered as an 
unpredictable phenotype that emerges from the combination of two or more alleles. 
However, different mathematical definitions have been provided, as it is not 
straightforward to predict in which way individual alleles combine to produce a 
phenotype (Mani et al. 2008).  
In this study, one of the most commonly used approaches was used, deviation from 
additivity. This approach is based on the original definition of statistical epistasis by 
Fisher in 1918, in which the effect on a quantitative phenotype of two alleles at 
different loci deviates from additivity in a statistical model (Cordell 2002; Fisher 
1918). Under an additive model, each allele is assumed to have an additive 
contribution to the phenotype, in such a way that the phenotype of the double 
mutant equals the sum of the two mutants, in the case of no genetic interaction. In 
this context, in order to detect genetic interactions in the present study, the 
observed double knockdown phenotype was compared to the expected one, which 
would equal the sum of the two single ones.  
Different statistical models and computational methods have been employed for the 
detection of genetic interactions. For the modeling of quantitative traits, a popular 
choice is linear regression (Gilbert-Diamond and Moore 2011). Here, I applied linear 
regression to model the ability of cells to endocytose cholesterol, which is a 
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quantitative phenotype. In linear regression analysis, the relationship between a 
continuous dependent (͞outcome͟) variable (Y) and one (simple linear regression) or 
more (multiple linear regression) continuous independent (͞predictor͟) variables (X1, 
X2, etc.) is modeled. Here, multiple linear regression was used to model the amount 
of fluorescently-labeled cholesterol uptake (Y), as a function of two single 
knockdown phenotypes (X1, X2). In this model, which corresponds to an additive 
model, the expected outcome phenotype for a pair of non-interacting genes is the 
sum of the two single-gene effects (main effects).  
In the current combinatorial RNAi screen two different approaches were followed to 
estimate the main effects of single siRNAs. In the first one, the main effect of a query 
siRNA was estimated from the combinations of the siRNA with the nontargeting 
control partner siRNA (NEG9), whereas in the second approach the main effects 
were estimated from all double RNAi measurements that included the query siRNA. 
The first approach is used when among the investigated gene siRNAs there are many 
with measurable knockdown effects, whereas the second one is used when the 
majority of them show negligible effects (Horn et al. 2011; Laufer et al. 2014). Since 
most of the siRNAs did not have a strong phenotypic effect, both approaches were 
applicable in this case.  
Genetic interactions can be easily modeled with linear regression, using a standard 
desktop computer and a statistical package, such as the package ͞MASS͟ of the R 
software environment, which was used here. Moreover, the mathematical theory 
behind linear regression analysis of interactions is very well characterized.   
Once a model for genetic interactions has been established, the fitted model, as well 
as the detected interactions, need to be interpreted. That is to say, etiological 
inferences need to be made from the computational model, in order to deduce what 
is the biological relevance of the interactions detected. More specifically, it should 
be clarified how two genes combine to associate with a trait or a disease. At this 
point, it is critical to stress that the genetic interactions tested for with this analysis 
are statistical interactions and not physical interactions (Cordell 2009; Phillips 1998, 
2008). In other words, the fact that two genes have an unexpected combinatorial 
effect on an observed phenotype does not necessarily mean that the corresponding 
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gene products physically interact. The exact nature of the interactions has to be 
further investigated.   
 
4.6 RESULTS OF THE CO-RNAI SCREEN 
The simultaneous co-depletion of two different gene products with RNAi showed 
both expected as well as unexpected results. For instance, the majority of siRNAs 
had a down-regulating effect on LDL uptake when co-transfected with LDLR siRNA, 
which was similar to the effect of LDLR single knockdown, demonstrating that the 
effect of LDLR was dominant over the other gene (see Fig. 14). This result is in 
accordance with the essential role of LDLR on LDL-uptake, since in absence of 
functional LDL receptors at the plasma membrane, LDL cannot be efficiently 
endocytosed (Goldstein et al. 1985). Only in two cases the co-knockdown of LDLR 
with a second gene did not result in a decreased LDL uptake; that of HMGCR and 
PVRL2.  
HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) encodes for the rate-limiting 
enzyme in cholesterol biosynthesis pathway. Therefore, a knockdown of HMGCR 
would decrease cellular cholesterol synthesis and promote the uptake of cholesterol 
from the cell to compensate for low cellular cholesterol levels. This is in agreement 
with the results of my screen, where knockdown of HMGCR together with the 
negative control siRNA, or in combination with most other genes upregulated LDL 
uptake. The upregulating effect of HMGCR knockdown is counteracted by the 
downregulating effect of LDLR knockdown, and this results to a neutral effect, as 
expected. 
PVRL2 (Poliovirus receptor-Related protein 2), on the other hand, encodes for a 
membrane glycoprotein, which serves as a plasma membrane component of 
adherence junctions and has no described connection to cholesterol homeostasis. Its 
single knockdown had no significant effect on LDL uptake, but neither did however 
the co-knockdown with LDLR. This gene pair was identified as a positive interaction, 
as it alleviated the inhibitory effect of LDLR depletion on LDL uptake. As the function 
of this gene is at large uncharacterized, I cannot generate hypothesis to explain this 
unpredictable result.  
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Unexpectedly, the depletion of LDLRAP1 resulted to up-regulation of LDL uptake, 
which is in agreement with the previous study (Blattmann et al. 2013) but in contrast 
to existing literature on LDLRAP1. LDLRAP1 (alias; ARH) encodes for a known adaptor 
protein for LDLR, which promotes the internalization of the LDLR-LDL complex in 
hepatocytes, via clustering LDLRs to clathrin-coated pits (Garuti et al. 2005; He et al. 
2002; Sirinian et al. 2005). In addition, it has been shown that mutations in this gene 
lead to autosomal recessive hypercholesterolemia (ARH) (see section 1.3.2.3) due to 
defective internalization of the receptor-ligand complex (Cohen et al. 2003; Garcia 
2001). Therefore, it is expected that LDLRAP1 depletion would lead to down-
regulation of LDL uptake. One possibly explanation for the unexpected result might 
be that LDLR endocytosis in HeLa cells might be regulated differently. For example, it 
has been shown that in hepatocytes LDLRs are dispersed on the plasma membrane, 
whereas in fibroblasts they are clustered in coated pits (He et al. 2002). Moreover, 
DAB2, the alternative adaptor protein for LDLR, is expression at higher levels in HeLa 
cells than in hepatocytes (Maurer and Cooper 2006). Therefore, DAB2 could be 
substituting LDLRAP1 in the absence of the latter, and a co-depletion of both 
LDLRAP1 and DAB2 is probably required to give an effect on LDL uptake in non-
hepatic cells (Eden et al. 2007). 
The co-depletion of MYLIP with most other genes resulted to an up-regulation of LDL 
uptake, as expected. MYLIP (alias; IDOL: Inducible Degrader of the LDLR) encodes for 
an E3 ubiquitin ligase that promotes LDLR degradation, via its ubiquitination (Zelcer 
2009; Zhang et al. 2011). Therefore, depletion of MYLIP would lead to decrease LDLR 
degradation, therefore increased LDLR concentration at the plasma membrane and 
consequently increased LDL uptake. The up-regulating effect is reversed upon co-
depletion with LDLR, as expected, showing the dominance of LDLR effect over 
MYLIP.  
Unexpectedly, the knockdown of PCSK9 does not have an upregulating effect on LDL 
uptake, and its combinatorial knockdown with the other 29 genes has both 
upregulating and downregulating effect. PCSK9 (Proprotein Convertase 
Subtilisin/Kexin type 9) encodes for a protease which promotes the degradation of 
LDLR in lysosomes, after its internalization (Zhang et al. 2007). Consequently, 
depletion of PCSK9 would be expected to result in decreased LDLR degradation, and 
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subsequently increased LDL uptake. A possible reason for this contradiction to the 
literature results might be the use of a non-hepatic cell-line. PCSK9 has been shown 
to promote LDLR degradation in hepatocytes, however the role of the gene in our 
model system had not been studied so far.    
4.6.1 IDENTIFIED GENE-GENE INTERACTIONS  
The reliability of the screening approach and the appropriateness of the statistical 
model applied for the analysis of the co-RNAi screen data were corroborated by the 
identification of a well-known interaction pair; LDLR+LDLRAP1, which indicates that 
biologically meaningful interactions can be derived with this approach. The 
interaction between LDLR and LDLRAP1 (LDL Receptor Adaptor Protein) represents a 
well established genetic and physical interaction, as LDLRAP1 is known to interact 
with LDLR to achieve efficient endocytosis of LDLR (Garcia 2001; He et al. 2002) (see 
section 1.3.2.3).  
The primary analysis approach (control-based) of the interaction screen revealed 35 
interactions among 24 (APOB, APOE, BCAM, CELSR2, CXCL12, HAVCR1, HMGCR, 
LDLR, LDLRAP1, LPL, MLXIPL, MYBPHL, MYLIP, NCAN, PAFAH1B1, PCSK9, PVRL2, 
SEZ6L, SIK3, SORT1, TMEM57, TOMM40 and ZNF259) of the 30 genes tested, at p-
value<10-2. Seven of the candidate genes tested (BAZ1B, BCL7B, CBLC, FAM174A, 
PAFAH1B2, TM6SF2 and WDR12) did not participate in any interaction. Among the 
24 ͞interactors͟ (genes participating in interactions), were all 9 genes that had been 
previously linked to cholesterol regulation (see Table S5). The remaining 15 genes 
had no previously described cholesterol-regulatory function, except for the 
Blattmann et al. study, which showed ane effect of their depletion on LDL uptake 
and/or cholesterol levels (Blattmann et al. 2013). 
Of the 35 identified interactions, approximately one-third (11) resulted in an 
upregulation of LDL uptake (positive interaction effect), and two-thirds (24) 
downregulated LDL uptake (negative interaction effect) (see Tbl. 4). This finding is 
interesting, considering that the candidate gene set was equally enriched in genes 
with an individual positive (8 genes) or negative (8 genes) effect on LDL-uptake assay 
in Blattmann et al. (see Table S1). The prevalence of negative interactions among the 
screen hits is easily explained, taking into account the fact that these genes derive 
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from GWA studies and are associated to disease either directly (CAD/MI) or 
indirectly (lipid traits). It is therefore expected that depletion of the function of these 
genes would lead to decreased uptake of LDL-cholesterol from the cells, which 
results in increased circulating LDL levels, a risk factor for CAD/MI.   
The alternative analysis approach (sample-based) revealed significantly fewer 
interactions; only 2 gene-gene interactions were identified at the same threshold 
with the primary analysis (p-value<10-2), and 7 at a lower threshold (p-value<5x10-2). 
There was a 100% overlap between the hits of the two methods, at the same 
thresholds (see 3.1.7). However, the LDLR+LDLRAP1 interaction, as well as many 
other interactions that were later confirmed with secondary experiments were 
missed out with this analysis. Therefore, the first analysis approach was considered 
as more appropriate for the existing dataset.  
 
4.6.2 GENE INTERACTION VALIDATION 
In order to correlate the phenotypic effects with the knockdown efficiency, as well as 
to assess the effect of the detected interactions on the expression levels of LDLR and 
SREBP, the 32 double knockdowns that were identified as gene-gene interactions, 
along with the respective single knockdowns, were repeated with forward, liquid-
phase transfection, in a multiwell-plate format that allowed for these experiments. 
Surprisingly, for many genes (13 out of 23 taking part in interactions) more 
penetrant gene knockdowns were observed than in the screen. As in many cases the 
single knockdown phenotypes were stronger upon forward transfection, the double 
knockdowns were not able to further potentiate the effect of the singles, and 
therefore the interaction could not be detected (see Fig. S1a). 
For this reason, the siRNA concentrations had to be adjusted for those genes 
showing a more penetrant knockdown in forward transfection, in order to achieve 
the same single knockdown phenotypes as in the screen, and consequently replicate 
the initially detected interactions (see Fig. S1b).  
There might be various reasons why siRNA-mediated knockdowns were shown to be 
more penetrant in forward, liquid-phase than in reverse, solid-phase transfection. 
First, a key difference between forward and reverse transfection is the condition of 
cells at the time of transfection. In solid phase transfection, the cells are transfected 
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at the moment that they are plated, as opposed to liquid-phase transfection, 
whereby the cells are transfected one day after they are plated. Consequently, in the 
two approaches the cells are in different condition at the time of the transfection. In 
addition, in reverse transfection the cells share the same growth medium in a 
spotted array, therefore secreted signals from cells on one spot might affect the 
phenotype of cells at a different spot.  
After adjusting the siRNA concentrations, 20 out of 35 gene interactions were 
reproduced with liquid-phase transfection (see Tbl. 4 and Fig. 17). These 20 hits had 
a statistically significant interaction effect, which had the same direction as in the 
screen (up- or down-regulating of LDL uptake). Of the 20 replicated interactions, 
nearly one-third (6) had a positive effect on LDL update (positive robust Z score), 
while nearly two-thirds (14) had a negative effect on LDL update (negative robust Z 
score). Of those 20 interactions, one-quarter (5) were positive (positive interaction 
effect), while three-quarters (15) were negative (negative interaction effect) (see 
Tbl. 4 and Fig. 17). In addition, one more interaction that did not initially score as 
statistically significant, but seemed interesting to us (see section 3.3) was 
independently confirmed (LDLR+HAVCR1). Among the replicated gene interactions, 
the prevalence of negative interactions was obvious. As was aforementioned, this 
finding is rather expected due to the association of the tested genes with disease, a 
risk factor for which is the decreased clearance of circulating LDL by the cells.  
 
4.6.3 CORRELATION OF KNOCKDOWN EFFICIENCY WITH PHENOTYPIC EFFECT 
The model system that was utilized here for the study of genetic interactions is very 
complex and dynamic, as evidenced by several observations. First, the effect of many 
siRNAs that demonstrated higher knockdown efficiency (such as BCAM, PAFAH1B1, 
SIK3 in Tbl. 5) was milder than that of siRNAs resulting to lower knockdown (such as 
MLXIPL, TMEM57 and HMGCR in Tbl. 5). Taking into account that all siRNAs were 
transfected for 48 hours, different kinetics of gene expression and transcript 
processing might be causing this effect. Namely, the products of the genes tested 
could have dissimilar half-lives, and the period required for the attainment of new 
mRNA levels after siRNA-mediated degradation is related to those. Within a high-
throughput RNAi screen it is not feasible to achieve knockdowns at different time 
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points, because the functional assay is performed at the same time for a microarray 
spotted with many different siRNAs. However, for some genes longer knockdown 
periods might be required to achieve product depletion, which exceed that 
preceding the phenotypic readout. Therefore, measurements at different intervals 
might be needed in order to properly evaluate the efficiency of the siRNAs.  
Secondly, it was noticed that reduced amount of siRNA resulted in substantial 
increase/decrease of the effect for some genes (see Fig. S1b), while for others the 
phenotype remain at large unaffected. Moreover, the phenotypic effect of some 
siRNAs differed between the screen and the liquid-phase transfections (e.g. 
CXCL12+PAFAH1B1 in Tbl. 4 and Tbl. 5). These findings demonstrate that the 
cholesterol-regulating model system is sensitive and adapts to perturbations in order 
to achieve balance. 
The latter can be understood if we consider that multiple intertwined feedback 
mechanisms control cholesterol homeostasis in the cell. An outstanding example of 
feedback process is the aforedescribed INSIG-SCAP-SREBP system (see 1.3.2.2). 
Decreased cholesterol levels results in activation of the system, which turns on the 
cholesterol biosynthetic pathway (Brown and Goldstein 1997). The same system 
increases the expression of LDLR, leading to increased cholesterol uptake from the 
cell. Once enough cholesterol has been synthesized, it functions to shut down the 
INSIG-SCAP-SREBP system, thus closing the feedback loop (Brown and Goldstein 
2009). This paradigm demonstrates the potential of the cellular cholesterol-
regulatory machinery to efficiently respond to external stimuli through complicated 
processes.  
 
4.6.4 DOUBLE KNOCKDOWNS DEMONSTRATE THE IRREPLACEABLE ROLE OF LDLR  
Importantly, it was observed that in most cases the combinatorial depletion of LDLR 
with a second gene could not further potentiate the down-regulating effect of LDLR 
single knockdown on either LDL uptake or LDLR expression levels. As was already 
mentioned (section 4.6), the majority of siRNAs had a similar effect on LDL uptake to 
that of LDLR single knockdown when co-transfected with LDLR siRNA (see Fig. 14). 
This was also true for two of the four interactions of LDLR that were identified by the 
co-RNA screen: LDLR+LDLRAP1 (Fig. S2.7) and LDLR+MLXIPL (Fig. S2.10). Only in two 
  96 
cases LDL-uptake was more inhibited upon double knockdown: LDLR+NCAN (Fig. 
S2.1) and LDLR+HAVCR1 (Fig. S2.21). However, the co-knockdown of LDLR with 
HAVCR1 could not further decrease LDLR mRNA (Figs. 21 and 22) or protein levels 
(Figs. 23 and 24). Neither could the co-knockdown with LDLRAP1 (see Figs. 21, 23, 
24). Nonetheless, co-depletion of LDLR with NCAN or MLXIPL resulted in lower LDLR 
transcript levels (Fig. 22). 
These findings demonstrate that the effect of LDLR on LDL uptake is dominant over 
most of the other genes tested. Upon LDLR depletion by siRNA, the amount of LDL 
receptors on the plasma membrane exceeds the lower threshold, and cannot be 
decreased more by co-knockdown with an siRNA targeting a second gene. This 
rationale is in accordance with the essential role of LDLR on LDL-uptake, since in 
absence of functional LDLRs at the plasma membrane, LDL cannot be efficiently 
endocytosed (Goldstein et al. 1985). Furthermore, the results from LDLR protein 
expression experiments again illustrate the epistatic effect of LDLR itself on its post-
transcriptional regulation. Hence, the unexpected effect of LDLR co-depletion with 
NCAN or MLXIPL on the transcriptional regulation of LDLR (Fig. 22) is considered very 
interesting and are discussed later (see sections 4.6.6 and 4.6.7). 
 
4.6.5 CONSTRUCTION OF A MODEL GENE INTERACTION NETWORK 
Aiming to uncover potential functional relationships among the identified interactors 
of the co-RNAi screen, a model gene-gene interaction network was constructed 
among all 30 genes tested in the screen, by overlapping the 21 validated gene 
interactions with known interactions from the STRING database. The overlap of the 
validated LDLR+LDLRAP1 gene interaction with an experimentally determined 
interaction from STRING showed that the screening approach employed can indeed 
identify interactions between cholesterol regulating genes (see section 4.6.1). The 
fact that only one out of eight experimentally determined interactions (pink lines in 
Fig. 29) from STRING was identified with the co-RNAi screen, could be due to the use 
of a single phenotypic readout for the identification of gene-gene interactions. 
Namely, only the effect on LDL uptake of combinatorial gene depletion was 
assessed, which means that any interactions implicated in cholesterol regulation but 
not implicitly in the endocytosis of LDL, would be probably missed out. Furthermore, 
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the interactions shown in STRING are not related to cholesterol metabolism, but to 
different cellular functions or processes. That is to say that the reported interactions 
were mapped under completely different experimental conditions and phenotypic 
readouts, and most likely concern other aspects of the cellular function. Moreover, 
false results from earlier work should also not be excluded. Therefore, an overlap is 
not necessarily expected. 
Noteworthy, in the constructed genetic interaction network most genes interact 
with only one or two genes, whereas a small number of genes have many 
interactions, such as HAVCR1, which interacted with 6 other genes, or LDLR and 
LDLRAP1 with 4 other genes each. This finding is consistent with the non-uniform 
topology of most cellular networks, where most of the nodes are sparsely connected 
having one or two links, whereas a few nodes are highly connected, having a very 
large number of links, and therefore serve as network ͞hubs͟ (Barabasi and Oltvai 
2004). Thus, the genes HAVCR1, LDLR and LDLRAP1 can be considered as ͞hubs͟ in 
the present network, which probably means that their role in the cholesterol-
regulatory pathways is quite central. Although the majority of genetically interacting 
genes belong to the same pathway or biological process, network ͞hubs͟ usually 
interact with many functionally diverse genes and tend to be pleiotropic (Costanzo 
et al. 2010). This means that each of these three aforementioned ͞hub͟- genes is 
likely to take part in a number of distinct pathways/ processes affecting LDL 
endocytosis. 
Noteworthy, the genetic interaction profile of a gene, namely the total of genetic 
interactions in which a gene participates, can give important information for the 
function of the gene, since genes taking part in the same pathway usually have 
similar interaction profiles (Costanzo et al. 2011). For example, I could hypothesize 
that HAVCR1 might take part in the same pathway as LDLRAP1, since their 
interaction profiles are similar -they both interact with BCAM, LDLR and SORT1, as 
well as with each other. 
 
4.6.6 HYPOTHESES FOR MECHANISMS OF GENETIC INTERACTIONS 
With regards to building hypotheses on the mechanisms of the identified gene 
interactions, a number of secondary experiments were performed. Asking if the 
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interacting genes exert their effects via modulation of LDLR transcription and/or 
translation, the effect of the 21 validated interactions on LDLR mRNA and protein 
levels was measured. In addition, to determine whether the gene interactions 
regulate cholesterol homeostasis through the INSIG-SCAP-SREBP system via affecting 
SREBF transcription, the effect of the 21 gene-gene interactions on SREBF mRNA was 
also tested. 
The INSIG-SCAP-SREBP system, which regulates cholesterol homeostasis at a 
transcriptional level, has already been described (see section 1.3.2.2). The SREBF 
family in human consists of SREBF-1a, SREBF-1c and SREBF2, of which SREBF-1a and 
SREBF2 upregulate cholesterol synthesis (Goldstein and Brown 2015). Therefore, the 
effect on both SREBF1 and SREBF2 mRNA levels was measured.  
In the following part a few interesting interactions are discussed in detail. First I 
discuss three interactions (LDLR+LDLRAP1, LDLR+NCAN and SORT1+LDLRAP1) of the 
͞hub͟ genes of the identified network; LDLR and LDLRAP1.  
The pivotal role of LDLR and the accessory role of LDLRAP1 in cholesterol uptake 
were already described (section 1.3.2.3). Co-depletion of LDLR with LDLRAP1 
resulted in reduced LDL-uptake, at levels similar to those of single LDLR knockdown 
(Fig. S2.7). Hence, the interaction identified between the two genes is epistatic, and 
was reflected also at the post-transcriptional level of LDLR expression (Fig. 24). 
Moreover, the double knockdown increased SREBF2 mRNA levels (Fig. 25 and 27). 
This finding is expected taking into account that decreased endocytosis of LDL 
caused by the co-depletion of LDLR and LDLRAP1 results in reduced cellular 
cholesterol levels, which would need to be compensated for. An activation of the 
SCAP/SREBP system would increase LDLR expression as well as cholesterol synthesis, 
thus restoring LDL endocytosis and replenishing the cholesterol pool (Goldstein et al. 
2006). Normally, the SCAP/SREBP pathway could be turned on by simply 
transporting the available SCAP/SREBP complexes from the ER to the Golgi and 
cleaving SREBPs. However, upon high demand for cholesterol, an increase in SREBF2 
synthesis would be required, as observed here. 
NCAN (Neurocan) is located on 19p13.11 locus, which is associated with Tc levels. 
The co-depletion of NCAN with LDLR further potentiated the inhibitory effect of LDLR 
depletion on LDL uptake (Fig. S2.1). Additionally, the combinatorial knockdown of 
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the two genes further reduced LDLR mRNA levels (Fig. 22). Moreover, it alleviated 
the diminishing effect of the two single knockdowns on SREBF2 mRNA (Fig. 27). 
These findings suggest that the interaction of NCAN with LDLR might down-regulate 
LDLR transcription, via inhibition of SREBF2 transcription, thus leading to reduced 
LDL uptake. NCAN encodes for a surface proteoglycan, which may be involved in 
neuronal adhesion and neurite growth during development, via binding to neural cell 
adhesion molecules (Rauch, Feng, and Zhou 2001). Hence, one could alternatively 
hypothesize that NCAN depletion might interfere with the adhesion of the cells, thus 
indirectly affecting various other unrelated processes, including LDL endocytosis.   
SORT1 resides at the genomic locus 1p13, which has the strongest association to 
LDL-cholesterol, and is associated with CVD as well. Here, the co-depletion of SORT1 
and LDLRAP1 further potentiated the inhibitory effect of SORT1 depletion on LDL 
uptake (Fig. S2.6). SORT1 encodes for a transmembrane receptor of many ligands, 
including lipoprotein lipase (LPL), a triglyceride hydrolase (Nielsen et al. 1999). The 
main function of sortilin is the binding of ligands in the Golgi or at the plasma 
membrane and their trafficking to the lysosome. Loss-of-function studies in LDLR-/- 
mice demonstrated that sortilin binds LDL at the cell surface, contributing to the 
non-LDLR-mediated uptake of LDL, and mediates its lysosomal degradation (Strong 
et al. 2012).  
Taking the above into account, the combined effect of SORT1 and LDLRAP1 on LDL 
endocytosis can be explained, since SORT1 takes part in non-LDLR-mediated uptake 
of LDL (Patel et al. 2015), whereas LDLRAP1 is involved in LDLR-mediated uptake of 
LDL (Garuti et al. 2005; Maurer and Cooper 2006), which are two parallel and 
convergent pathways (see Fig. 9). In addition, the co-knockdown of SORT1 and 
LDLRAP1 resulted in the reduction of both SREBF1 (Fig. 26) and SREBF2 mRNA (Fig. 
27). This suggests that co-depletion of the two gene products might downregulate 
LDL uptake by inhibiting LDLR synthesis, via reduction of SREBF1 and SREBF2 
transcription.  
Sortilin has been also implicated in atherosclerosis, though existing reports are quite 
contradictory (Mortensen et al. 2014; Patel et al. 2015). Hence, SORT1 appears to 
have a key role in LDL metabolism and CAD (Tall and Ai 2011), and the clarification of 
its synergistic contribution with LDLRAP1 to both of them is needed. 
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Secondly, two more interesting interactions are now discussed; PCSK9+TMEM57, 
NCAN+TOMM40. PCSK9 resides at the locus 1p36.11, whereas TMEM57 at 1p32.3. 
PCSK9 (proprotein convertase subtilisin/kexin type 9) encodes for a degrader of 
LDLR, while it also decreases the recycling of LDLR to the plasma membrane (see 
section 1.3.2.3). TMEM57 is a largely uncharacterized gene. The combinatorial 
knockdown of PCSK9 with TMEM57 strongly upregulated LDL uptake, inverting the 
effects of both single depletions (Fig. S2.20). This finding suggests that TMEM57 
might also affect the recycling of LDLR. Furthermore, the double knockdown of the 
two gene products reversed the inhibitory effect of both single knockdowns on 
SREBF1 transcription (Fig. 26), while it also alleviated the diminishing effect of both 
singles on SREBF2 mRNA (Fig. 27). Based on these results, I could hypothesize that 
the interaction between PCSK9 and TMEM57 might increase LDL uptake by affecting 
SCAP/SREBF-mediated LDLR synthesis.  
TOMM40 resides at the locus 19q13.32 and NCAN at the locus 19p13.11. NCAN was 
previously described. TOMM40 (Translocase Of Outer Mitochondrial Membrane 40) 
encodes for the channel-forming subunit of the translocase of the mitochondrial 
outer membrane (TOM) complex, which imports protein precursors into 
mitochondria. The combined depletion of NCAN and TOMM40 decreased LDL uptake 
(see Fig. S2.4) as well as LDLR mRNA levels (Fig. 22). In addition, it decreased SREBF2 
mRNA levels, having a similar effect to that of both single knockdowns (Fig. 27). 
These results suggest that the interaction of the two genes might reduce LDL uptake 
through down-regulation of LDLR transcription, induced via inhibition of SREBF2 
transcription. Based on the function of TOMM40, I could hypothesize that its 
interaction with NCAN might affect the trafficking of LDLR through mitochondria, 
subsequently disturbing its recycling back to the plasma membrane.  
The correlation of LDL-uptake with LDLR mRNA and protein as well as SREBF1 and 
SREBF2 mRNA levels for all 21 validated gene interactions is shown in Tbl. S18. For 
those that are not discussed here, the results were complicated and inconclusive. 
Therefore, further investigations are required for the elucidation of the underlying 
mechanisms. 
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4.6.7 THE GENE INTERACTION SUB-NETWORK: LDLR-MLXIPL-HAVCR1 
A very interesting sub-network of the gene interaction model network, which was 
selected for follow up, is that of LDLR-MLXIPL-HAVCR1. In this network, each gene 
has a combinatorial effect with the other two on LDL internalization. Specifically, the 
combinatorial knockdown of LDLR with MLXIPL (Fig. S2.10) or with HAVCR1 (Fig. 
S2.21) is potentiating the negative effect of LDLR knockdown on LDL uptake. 
Conversely, the combinatorial knockdown of HAVCR1 with MLXIPL (Fig. S2.5) is 
reversing the positive effects of the two single knockdowns, leading to a down-
regulation of LDL uptake. In order to construct hypotheses on the mechanistic 
interpretation of these interactions, one needs to take into account what has already 
been reported concerning the function of these genes.  
LDLR is a well-described gene that encodes for the receptor of LDL, and is 
responsible for its endocytosis, as was already described (see section 1.3.2.3). 
MLXIPL (MLX Interacting Protein Like) resides on locus 7q11.23, which is strongly 
associated with plasma triglycerides. MLXIPL, (also known as ChREBP: Carbohydrate 
Responsive Element Binding Protein) encodes for a transcription factor that converts 
excess hepatic carbohydrates to lipids (Cha and Repa 2007; Stoeckman et al. 2004). 
The mechanism of action of MLXIPL is similar to that of SREBP, the main difference 
being that MLXIPL is sensitive to glucose, whereas SREBP is sensitive to cholesterol. 
Specifically, upon increase of glucose levels MLXIPL upregulates the transcription of 
genes associated with glycolysis, lipogenesis and fatty acid synthesis (Park et al. 
2014). Noteworthy, the depletion of MLXIPL alone resulted in a 0.25 fold decrease in 
SREBF2 mRNA, whereas the combinatorial depletion with LDLR resulted in a slight 
increase of SREBF2 mRNA (Fig. 27 and 25). Taking the above into account, I 
hypothesize that MLXIPL might function as a activator of SREBF2 transcription in the 
presence of LDLR, while this effect is abolished upon LDLR depletion. Namely, when 
there is sufficient amount of LDL receptors on the plasma membrane, and 
subsequently adequate LDL-c is internalized, MLXIPL might function as an ͞on͟ 
switch for the SCAP-SREBP system. On the contrary, upon depletion of LDLR, MLXIPL 
might block SREBF2 transcription, thus allowing for the deactivation of SCAP-SREBP.  
MLXIPL was shown here to exert a combinatorial effect with LDLR on LDLR mRNA, 
further decreasing its levels (Fig. 22). However, MLXIPL depletion resulted in 
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increased LDL uptake (Fig. S2.10), which correlated with higher LDLR protein levels 
(Fig. 23). To explain these apparently contrasting results one has to take into account 
that mRNA and protein levels do not necessarily correlate. Various factors, including 
post-transcriptional modifications and protein half-lives could account for 
discrepancies between the two. The above findings could lead to the hypothesis that 
MLXIPL might function as a transcription factor of LDLR. Together with the 
aforedescribed results on SREBF2 mRNA, I could hypothesize that MLXIPL might 
participate in the regulation of LDLR transcription via controlling the SREBF2 
component of the SCAP-SREBF pathway. 
The genetic interaction identified by the screen between LDLR and MLXIPL, together 
with the secondary findings is very interesting, because MLXIPL has been 
demonstrated to protect against atherosclerosis (Sarrazy et al. 2015). In particular, it 
was shown that MLXIPL deletion in LDLR-/- mice resulted in faster atherosclerosis 
progression (Sarrazy et al. 2015).  
HAVCR1 (Hepatitis A Virus Cellular Receptor) -also known as TIM1 (T-Cell 
Immunoglobulin Mucin Receptor 1) or KIM1 (Kidney Injury Molecule 1)- resides at 
locus 5q33.3, which is strongly associated with plasma LDL and Tc levels. HAVCR1 
encodes for a receptor for hepatitis A virus and other viruses (s.a. Ebola virus), as 
well as for T-cells. Interestingly, it has been demonstrated that HAVCR1 can bind and 
internalize oxidized -and possibly also native- LDL, though the molecular mechanism 
has not been clarified (Ichimura et al. 2008). Hence, the synergistic effect of HAVCR1 
with LDLR on LDL uptake identified by co-RNAi (Fig. S2.21) could lead to the 
hypothesis that HAVCR1 might act as an alternative receptor for LDL, with lower 
affinity for LDL than LDLR.  
With a view to investigating this hypothesis, I performed some follow-up 
experiments for LDLR and HAVCR1. In order to examine if HAVCR1 could function as 
an alternative receptor for LDL, the effect of co-depletion of HAVCR1 and LDLR on 
LDL binding was compared to that of single depletion of HAVCR1. No significant 
difference was observed (Fig. 31). Furthermore, the effect of overexpression of GFP-
tagged wtHAVCR1 on LDL uptake in LDLR-depleted cells was compared to its effect in 
control cells. However, the overexpression of wtHAVCR1 could not rescue the effect 
of LDLR depletion on LDL uptake (Fig. 32). These findings contradict the initial 
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hypothesis that HAVCR1 might act as an alternative receptor for LDL, in the absence 
of LDLR. HAVCR1 might rather act as a chaperone for LDLR, thus promoting LDL 
uptake, as its combinatorial depletion with LDLR further inhibited LDL uptake (Fig. 
S2.21). 
Besides, HAVCR1 has also signaling functions, which are mediated via the tyrosine 
kinase phosphorylation motif located on its cytoplasmic tail (Fig. 37) (Tietjen et al. 
2014).   Therefore, an alternative hypothesis could be that HAVCR1 functions as a 
signaling factor in the LDL internalization pathway.  
Moeover, HAVCR1 demonstrated a synergistic effect with LDLR on LDLR mRNA (Fig. 
22) and protein (Fig. 24), which could suggest that HAVCR1 might affect the 
transcriptional and translational regulation of LDLR.  
Furthermore, HAVCR1 was reported to co-localize and interact in endosomes and 
lysosomes with NPC1 (Kuroda et al. 2015), the role of which in transporting 
cholesterol from late-endosomes and lysosomes has already been described (see 
section 1.3.2.3). Hence, HAVCR1 could take part in the endolysosomal trafficking of 
LDLR. Specifically, the mechanism of action of HAVCR1 might rather involve later 
steps of the LDL endocytosis pathway, occurring for example in the endo-lysosomal 
compartment.  
Elucidation of the role of HAVCR1 in LDL endocytosis and/or trafficking through 
testing the above hypotheses could moreover give insight into the contribution of 
this gene to atherosclerosis development, since HAVCR1 has been reported to 
attenuate atherosclerosis (Hosseini et al. 2015). 
 
 
 
 
 
 
 
Figure 37. Schematic representation of HAVCR1 protein structure.  
Glycosylation sites were predicted using NetOglyc and NetNglyc. 
(Adapted by permission from Macmillan Publishers Ltd: Nature Rev. Immun. Kuchroo et 
al., copyright 2003) 
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4.7 HAVCR1 RARE VARIANTS 
HAVCR1 was considered as a very interesting interactor in my co-RNAis screen, since 
its co-depletion with LDLR potentiated the effect of LDLR depletion on LDL uptake, 
and it also interacted with a number of other genes. Therefore, its role in LDL 
endocytosis was further examined, by testing the effect of variants of the protein. In 
particular, 19 variants were extracted from the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/), which contains data from patients with 
extreme lipid traits and/ or atherosclerosis, as well as healthy individuals. Of the 19 
variants, 15 are rare (MAF<5%) and four are common (MAF>5%). Surprisingly, 
overexpression of 18 out of 19 tested variants of HAVCR1 in HeLa Kyoto cells had a 
significant inhibitory effect on LDL uptake (Fig. 33, 34). Of those variants, most are 
localized in the coding sequence of the extracellular domain of the protein; 
therefore they could affect PtdSer binding. Two variants (K317E, A343E) are localized 
in the cytoplasmic part, and could affect signal transduction. One variant (Y297C) is 
localized on the transmembrane part of the protein.  
Interestingly, four variants that were predicted as benign by Polyphen-2 (V156I, 
L179P, T207A and M158T) had a significant inhibitory effect as well, while on the 
other hand, a variant that was predicted as probably damaging (V138I) had no 
significant effect.  
The finding that almost all tested variants had an effect on LDL uptake could be due 
to factors not directly related to the uptake of LDL. Noteworthy, five of the variants 
that significantly decreased LDL uptake (V69G, D99H, N114S, A343E, S100G) had a 
toxic effect on the cells overall, decreasing the total cell number more than 50%, as 
compared to cells treated with the wild-type protein. Hence, these variants might 
interfere with more basic cell functions, such as cell growth, division or survival. 
However, the remaining ten variants with a significant effect on LDL uptake were not 
toxic for the cells. Therefore, the inhibition of LDL uptake caused by these variants is 
probably not attributed to decreased cell viability but rather directly related to 
endocytosis. These findings strongly suggest a role for HAVCR1 in LDL uptake, which 
is disturbed by these mutations. 
Nonetheless, it should be determined if the effect of HAVCR1 variants is specific to 
the endocytosis of LDL or is a rather general effect on clathrin-mediated endocytosis. 
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For this, their effect should be further tested on the internalization of other ligands, 
such as transferrin or EGFR (epidermal growth factor receptor).   
 
4.8 SNP CO-OCCURENCE 
The genes that were tested in the co-RNAi screen are located in close proximity to 
lead SNPs of loci identified in GWA studies as associated with lipid traits and/ or 
CAD/MI. The identification of interactions among these genes implies the existence 
of synergistic combinations among the SNPs, nearby which the genes under study 
are mapped. Moreover, as many studies have shown that the co-occurrence of SNPs 
can predict the risk of getting diseases, a question that arises is whether the co-
occurrence of SNPs in genes identified to interact will be associated with increased 
CVD risk. 
In order to investigate SNP-SNP interactions and co-occurence, the total 144 lead 
SNPs for each of the 30 genes that were tested in the co-RNAi screen were tested for 
pairwise interactions in a cohort of 4893 individuals with subclinical atherosclerosis 
(Bioimage study) (Muntendam et al. 2010), in collaboration with Heiko Runz (Merck 
Research Laboratories, US). For the (70) SNPs that were present on the exome chip 
used for genotyping in the Bioimage study, as well as for the proxies of those not 
present, single-variant LDL association test was performed by Gulum Kosova, based 
on the allele-frequency of the LDL-raising allele.  
None of the SNP pairs tested showed a statistically significant interaction; one 
reason for this might be the relatively low size of the study sample. Specifically, the 
detection of epistatic effects requires measurements taken from very large 
population sizes, in order to obtain sufficient statistical power (Carlborg and Haley 
2004; Phillips 2008). Therefore, in order to bring non-significant detected SNP 
interactions to statistical significance, larger sample sizes probably need to be 
tested. 
Nonetheless, 36 SNP pairs showed a significant additive effect (see Tbl. S13). 
Namely, for these 36 pairs it was shown that plasma LDL increased proportionally to 
the number of LDL-increasing alleles. Interestingly, 3 SNP pairs (LPL + CELSR2, APOB 
+ HMGCR, LDLR+NCAN) that showed an additive effect, corresponded to genes that 
were identified as interactors for LDL-uptake in the co-RNAi screen (see Fig. 35). 
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These findings corroborate a synergistic effect for these genes in cholesterol 
regulation. 
Next, SNP co-occurrence was investigated for those interactors of the co-RNAi 
screen, which were mapped close to SNPs that were present on the Exome Chip, or 
that had proxies that were present on it (PCSK9+TMEM57, LDLR+MLXIPL, 
LDLR+HAVCR1, MLXIPL+HAVCR1), as well as for the triplet LDLR+MLXIPL+HAVCR1. In 
individuals showing co-occurrence of the corresponding SNPs, the LDL levels 
increased proportionally to the number of risk alleles. In the case of 
MLXIPL+HAVCR1, this was also true for TG levels. Interestingly, for PCSK9+TMEM57 
the LDL levels were significantly higher in the case of heterozygosity for both risk 
alleles (2 risk alleles), as compared to homozygosity for at least one of two risk 
alleles (3 or 4 risk alleles) (see Fig. 36).  
Overall, the SNP interaction/ co-occurence analysis demonstrated that lipid levels, 
and especially those of LDL strongly correlate with the total number of risk alleles 
present. Given the fact that elevated LDL levels increase the risk for CVD, the amount 
of lipid-increasing alleles also correlates with the disease risk.  
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5 IMPLICATIONS FOR FURTHER RESEARCH 
This study investigated genetic interactions underlying cholesterol homeostasis in 
human, and specifically LDL-cholesterol endocytosis. This was done in an effort to 
uncover gene networks that control complex polygenic diseases that arise from a 
deregulation in lipid metabolism, most importantly cardiovascular disease. With this 
study, genetic interactions were identified between previously unrelated genes, 
including also genes without a previously described role in cholesterol metabolism. 
For many of the identified interactions, hypotheses were constructed for the 
mechanistic interpretation of the synergistic effect of the genes on LDL endocytosis, 
based on corroborating effects on LDLR expression, as well as on the transcription of 
SREBF, the transcription factor of LDLR.  
However, the exact mechanisms of genetic interactions still need to be elucidated. 
Further experiments are needed to define if any physical interactions exist between 
the products of interacting genes, or between transcription factors and promoter 
sites. For instance, a potential protein-protein interaction between LDLR and 
HAVCR1 needs to be examined, in order to test the hypothesis of an assisting role for 
HAVCR1 in LDLR-mediated endocytosis. Moreover, potential interaction between 
MLXIPL transcription factor and LDLR or HAVCR1 should be examined, to test the 
hypothesis of a role for MLXIPL in the expression of the two genes. Furthermore, the 
effect of the detected gene interactions on different steps in the pathway of LDL 
endocytosis could be explored, such as the transport of LDLR back to the plasma 
membrane and the glycosylation of LDLR, which is required for its stable expression 
at the cell surface. In addition, the effect of gene interactions on the efficiency of the 
cell transport machinery, from the membrane to the endocytic compartments and 
from those back to the plasma membrane could be tested. Specifically, effects on 
COPII-mediated vesicle formation and its components -such as Sec23, Sec24 and 
Sar1- as well as on recycling endosomes and their components -such Rab11- could 
be tested.  
In parallel to the in vitro experiments, this study attempted to uncover SNP-SNP 
interactions in patients, between SNPs within or in close proximity to genes that 
were identified to interact. For this, a cohort of nearly 5000 individuals with 
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subclinical atherosclerosis was genotyped and single-variant association analysis was 
performed for lipid traits. Statistically significant additive effects were detected 
between SNPs, but none of the SNP-SNP interactions reached statistical significance. 
To bring these interactions to statistical significance, two possible approaches could 
be considered; one is to repeat the analysis in a much larger sample that would 
increase the chances for epistasis detection. The second approach includes the 
correlation of the clinical findings with in vitro experiments, whereby two 
supposedly interacting SNPs could be simultaneously introduced, and their 
synergistic effect on cholesterol homeostasis could be monitored. In the future, in 
vivo experiments in animal models could be also considered, to model the effect of 
SNP-SNP interactions on cholesterol regulation and atherosclerosis development.    
All the approaches and experiments outlined above will increase the data to be 
assessed for the elucidation of genetic interaction mechanisms. The results of the 
present study lay the basis for more advanced investigations. A potential approach 
to a better understanding of the system could be integration of the generated data 
into a testable and predictive model. In this way, a better understanding of the 
complex nature of lipid traits and cardiovascular disease could be achieved. 
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6 MATERIALS 
6.1 EUKARYOTIC CELL LINES 
Cell line Tissue Supplier 
HeLa Kyoto Human cervical carcinoma S. Narumiya, Kyoto  
University, Japan (gift to  
J. Ellenberg, EMBL HD) 
HuH7   Human hepatocellular 
carcinoma 
Japanese Collection of Research 
Bioresources JCRB (#JCRB0403) 
(Nakabayashi et al., 1982) 
HEK293 Human embryonic kidney ATCC: CRL-1573  
Kai Simons, Dresden 
Sk-Hep1 Human ascites/ Liver 
adenocarcinoma 
ATCC: HTB-52 
Martin Beck Lab, EMBL 
HLE Human hepatoma Martin Beck Lab, EMBL 
HLF Human lung fibroblasts Martin Beck Lab, EMBL 
6.2 CELL CULTURE MEDIA 
Medium  Composition Supplier 
Fetal bovine serum (FBS)   PAA #A15-101 
L-glutamin  Sigma Aldrich #G7513 
Penicillin 10,000U-Streptomycin 10 
mg/mL (Pen-Strep) 
 Sigma #P0781 
DMEM (Dulbecco’s Modified Eagle 
Medium)  
With: Low Glucose (1g/L), L-
Glutamine, Sodium Pyruvate,  
Phenol Red  
GIBCO #31885-023 
Supplemented medium DMEM 1g/L glucose 
10% (v/v) FCS 
1% (v/v) L-glutamin 
Self produced 
Supplemented medium, with 
antibiotics 
DMEM 1g/L glucose 
10% (v/v) FCS 
1% (v/v) L-glutamin 
1% (v/v) P/S 
Self produced 
Starving medium DMEM 1g/L glucose 
1% (v/v) L-glutamin 
0.2% (v/v) BSA  
Self produced 
OptiMEM |Reduced Serum 
Medium 
 GIBCO #31985070 
0.05% Trypsin-EDTA   GIBCO #25300054 
Freezing medium DMEM 1g/L glucose 
1% (v/v) L-glutamin 
20% (v/v) FCS 
10% (v/v) DMSO 
Self produced 
Imaging Medium 30 mM Hepes 
115 mM NaCl 
1.2 mM CaCl2 
1.2 mM MgCl2 
1.2 mM K2HPO4 
2 g/l D-glucose 
Medium was adjusted to pH 7.4 
EMBL media kitchen 
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6.3 BUFFERS AND SOLUTIONS 
Buffer Composition Supplier 
1M HEPES (4-(2-hydroxyethyl-)piperazin-
1-ethansultonic acid) 
23.8% (w/v) HEPES (Biomol 
#05288.100) in ddH2O 
adjusted to pH 7.25, 
autoclaved 
Media kitchen 
MgCl2 0.5M MgCl2 in ddH2O Self produced 
MOPS (1x) running buffer NuPAGE® MOPS SDS running buffer 
(20x) 
Diluted to 1x in ddH2O  
Self produced 
PFA 3% fixation buffer 3% (v/v) PFA in PBS Pepperkok lab 
PBS (Phosphate buffer saline) 137 mM NaCl 
2.7 mM KCl 
1.4 mM KH2PO4 
4.8 mM NA2HPO4/Na2CO3 
Adjusted to pH 7.4, autoclaved 
Media kitchen 
Quenching buffer 30 mM glycine Pepperkok lab 
Methanol/Acetone permeabilization 
buffer 
50% Methanol 
50% Ethanol 
stored at -20
o
 C 
Self produced 
Saponin permeabilization buffer 0.1% (v/v) saponin in PBS Self produced 
Triton X-100 permeabilization buffer 0.1% (v/v) Triton X-100 in PBS Self produced 
Western blot blocking buffer 0.1% (v/v) Tween-20 
5% (w/v) milk powder  
in PBS 
Self produced 
Tris-HCl 0.5M  Trizma-base 6.06g 
Adjusted to pH 6.8 with HCl 
ddH2O to 100 ml 
Self produced 
Western blot sample buffer: SDS-loading 
buffer (2x) 
80 mM Tris-HCl 
10% Glycerol 
4.5% SDS 
130 mM DTT 
0.005% Bromoph. Blue 
Diluted in ddH2O to 10 ml 
Self produced 
Western blot (mild) stripping buffer for 
reprobing 
15 g glycine 
1 g SDS 
10 ml Tween20 
Add ddH2O to 1L 
Adjust pH to 2.2 
Bring volume up to 1 L with 
ultrapure water 
Self produced 
Western blot (harsh) stripping buffer for 
reprobing 
20 ml SDS 10% 
12.5 ml Tris HCl 0.5M pH 6.8  
67.5 ml ultra pure water 
0.8 ml ß-mercaptoethanol  
Self produced 
Western blot transfer buffer 25mM Trizma Base 
190mM Glycine  
20% MeOH  
for proteins > 80kDa add 0.5% SDS  
Dilute in ddH2O to 1 L 
Self produced 
Western blot wash buffer (PBS-T) 1% (v/v) Tween-20 in PBS 
 
Self produced 
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6.4 REAGENTS 
 
 
 
Reagent Manufacturer 
Ampicillin  Applichem #A0839.0025 
Benzonase nuclease, purity >90% Novagen Ϯϱ U /μl #70746 
Bovine serum albumin (BSA) Sigma #A7979 
Bromphenol blue Sodium Salt Applichem #A1120 
DiI-LDL Invitrogen #L3482 
Dimethylsulfoxide (DMSO) Merck Milipore #102952 
DRAQ5 Biostatus #DR50200 
Drying pearls orange Aldrich #94098 
1.4 Dithiothreitol (DTT) Sigma Aldrich #D0632-1G 
Ethanol Merck Millipore #100983 
Filipin III Sigma #F4767 
Gelatine Sigma #69391 
Gelatine from pig skin, Oregon Green®  488 
conjugate 
Molecular Probes #G13186 
Glycerol 85% pro analysis Merck #104094 
Glycerol 99.0-101.0% Sigma #15523-1L-R 
Glycine: GR for analysis Merck Millipore #56-40-6 
Hoechst, 1mg/ml Molecular Probes #H33342 
(2-Hydroxypropyl)-β-cyclodextrin  (HPCD) powder Sigma #C0926 
Hydrochloric acid  Merck Millipore #100317 
Lipofectamine 2000 Invitrogen #11668-019 
Magnesium chloride hexahydrate  Merck #1058331000 
β-mercaptoethanol  Sigma #M1511 
Methanol  Merck Millipore #106009 
Milk powder Reform, Granovita GmbH 
NuPAGE® MOPS SDS Running Buffer (20x)  Novex #NP0001 
Mowiol® 4-88  Calbiochem #475904 
Nonidet® P40 ( NP-40) Applichem #A1694 
Oligofectamine Invitrogen #12252011 
PageRuler Plus Prestained Protein Ladder Thermoscientific #26619 
Paraformaldehyde (PFA) 16% Solution EM Grade Electron Microscopy Science #15710 
Paraformaldehyde (PFA) powder EM grade Polysciences #00380-250 
Poly-L-lysine hydrobromide  Sigma #P6282  
Ponceau S  Applichem #A1405 
RNAse H 120U (2U/ml) Invitrogen #18021-071 
Saponin  Sigma Aldrich #47036 
Sodium Dodecyl Sulfate (SDS) 20% (w/v)  BioRad #161-0418 
Sodium hydroxide Merck Millipore #109137 
Sucrose  Affymetrix, USB # 21938 
SYBR Green  Applied Biosystems #4309155 
Triton-X-100  Sigma #T9284 
Trizma-base Sigma #T1503  
Tween-20  Sigma #P7949 
Water HPLC grade Sigma Aldrich #V270733 
Western Blotting Substrate, Pierce®  ECL Plus Thermo Scientific #32132 
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6.5 PLASMIDS AND OLIGONUCLEOTIDES 
6.5.1 PLASMIDS  
Plasmid ORF Tag ORF [bp] Total [bp] Supplier 
EX-EGFP-M03 eGFP C-eGFP  7033 GeneCopoieia 
EX-A0821-M03 LDLR C-eGFP 2583 8931 GeneCopoieia 
EX-Z7459-M03 SORT1 C-eGFP 2496 8844 GeneCopoieia 
EX-Z7374-M03 DAB2 C-eGFP 2313 8673 GeneCopoieia 
EX-H9327-M03 SEZ6L C-eGFP   GeneCopoieia 
EX-Z9616-M03 CXCL12 C-eGFP 423 6783 GeneCopoieia 
EX-Z0263-M03 HAVCR1 C-eGFP 1095 7443 GeneCopoieia 
EX-Z0263-M03 HAVCR1-W47R C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-V69I C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-V69G C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-D99H C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-S100G C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-R110C C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-N114S C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-V138I C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-T149A C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-V156I C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-T174M C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-L179P C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-T207A C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-E223stop C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-D264N C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-Y297C C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-K317E C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-A343E C-eGFP 1095 7443 Heiko Runz lab. 
EX-Z0263-M03 HAVCR1-M158T C-eGFP 1095 7443 Heiko Runz lab. 
6.5.2 PRIMER OLIGONUCLEOTIDES 
Gene Fwd primer 5΄->3΄ Rev pƌiŵeƌ 5΄->3΄ 
ACTB CCACGAAACTACCTTCAACTCC CTCGTCATACTCCTGCTTGCT 
BCAM GTGCGCTTGTCTGTACCC ATATAATGGTCGTGGGTTCC 
BCL7B CCCGAGAACCTAATGGCTTT CGGAACTCTGGTTGCTGTTT 
CELSR2 ATGACACGCTCATCTGGAGT AGGACCTTTCTTCTCAAAGCCC 
GAPDH CATGAGAAGTATGACAACAGCCT AGTCCTTCCACGATACCAAAGT 
HMGCR CCATCCCTGGGAAGTCATAG AGGATGGCTATGCATCGTG 
HRPT1 TGAGGATTTGGAAAGGGTGTT CAGAGGGCTACAATGTGATGG 
HSPC3 ATGGAAGAGAGCAAGGCAAA AATGCAGCAAGGTGAAGACA 
LDLR CGATGAAGTTGGCTGCGTTA GTTGCAGACTTTGTCCAGGG 
LDLRAP1 GTCGCCACGGGGAATTAT TTGTCGTGCATCTTGTCTG 
LPL GTGGCTACCTGTCATTTCAA GCACCCAACTCTCATACATTC 
MLXIPL CAGCAACAAGACCGAGAACC GCACTGAGTGTGCTCACGA 
PAFAH1B1 GTGTCTGCCTCAAGGGATAA ACGTACCCATTCTCTGTGTC 
PCSK9 GTGAAGATGAGTGGCGACC GTAATCCGCTCCAGGTTCCA 
PVRL2 CCTGATACCTGTGACCCTCT CCGAGGTACCAGTTGTCATC 
RPS18 TGTGGTGTTGAGGAAAGCA CTTCAGTCGCTCCAGGTCTT 
SDHA TGGTGCTGGTTGTCTCATTA ACCTTTCGCCTTGACTGTT 
SIK3 GGAGCAGGCAGGTACTGCTAT CTTCACCCTCATCACTGTCCAA 
SORT1 ATGGCTATTGGTCCTGAGAA TTCTTCGCAAAATCTGATGA 
SREBF1 CAGCATAGGGTGGGTCAAAT GAGCCGTGCGATCTGGA 
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6.5.3 SIRNA OLIGONUCLEOTIDES 
Gene 
Symbol 
siRNA ID Sense siRNA Sequence 5΄->3΄ AŶtiseŶse siRNA SeƋueŶce 5΄->3΄ 
APOB s1476 GCAAGUACCUGAGAACGGAtt UCCGUUCUCAGGUACUUGCtg 
APOE s1496 CUAGUUUAAUAAAGAUUCAtt UGAAUCUUUAUUAAACUAGgg 
BAZ1B s17209 CCUUCGUAGUGAUCUCAUUtt AAUGAGAUCACUACGAAGGaa 
BCAM s8338 CGACCAUUAUAUGCUGGAAtt UUCCAGCAUAUAAUGGUCGtg 
BCL7B s228480 AGACAUUGGAGGGAAGGGAtt UCCCUUCCCUCCAAUGUCUct 
CBLC s24223 GGGAGGCCGUGAGUAUCUAtt UAGAUACUCACGGCCUCCCag 
CELSR2 s4526 GACCCAGACUGCAACAAGAtt UCUUGUUGCAGUCUGGGUCaa 
CXCL12 s445518 CCAUGGAGGCACUAACAAAtt UUUGUUAGUGCCUCCAUGGca 
FAM174A s445532 CCGCGCCUAUGGUCCCUCUtt AGAGGGACCAUAGGCGCGGug 
HAVCR1 s230290 CGACUGUUCUGACGACAAUtt AUUGUCGUCAGAACAGUCGtt 
HMGCR s143 GGUUCGCAGUGAUAAAGGAtt UCCUUUAUCACUGCGAACCct 
LDLR s224006 CAGCGAAGAUGCGAAGAUAtt UAUCUUCGCAUCUUCGCUGgg 
LDLRAP1 s25120 CCAACCAGCUCAUUGAGAAtt UUCUCAAUGAGCUGGUUGGtg 
LPL s702 GCAACAAUCUGGGCUAUGAtt UCAUAGCCCAGAUUGUUGCag 
MLXIPL s27387 GCAAGCUGGUGUCUCCCAAtt UUGGGAGACACCAGCUUGCca 
MYBPHL s50998 UGAACCUACUAAUCCCAUUtt AAUGGGAUUAGUAGGUUCAct 
MYLIP s26522 GACUUUAGCCCAAUUAAUAtt UAUUAAUUGGGCUAAAGUCat 
NCAN s3648 GGCCUUCUGUAAACAGGAAtt UUCCUGUUUACAGAAGGCCat 
PAFAH1B1 s445574 GGAGGGACAUACCACUAUAtt UAUAGUGGUAUGUCCCUCCUU 
PAFAH1B2 s10001 GGAACAAAUAACCACGAAAtt UUUCGUGGUUAUUUGUUCCta 
PCSK9 s48694 GGAACAAAUAACCACGAAAtt atCCUUGUUUAUUGGUGCUUU  
PVRL2 s445582 GCAUUUCACCAUUCAAACAtt UGUUUGAAUGGUGAAAUGCcc 
SEZ6L s24052 GGCUAGAGCGCAGCGGGAAtt UUCCCGCUGCGCUCUAGCCuc 
SIK3 s445595 GCCUGAAAAUGGAUACCAAtt UUGGUAUCCAUUUUCAGGCag 
SORT1 s224557 GAAUGGUCGAGACUAUGUUtt AACAUAGUCUCGACCAUUCtg 
TM6SF2 s28703 GCUUCUUCGUGUGCAAUCUtt AGAUUGCACACGAAGAAGCag 
TMEM57 s30473 GCUUCGGAAAUAUAAGGAAtt UUCCUUAUAUUUCCGAAGCtc 
TOMM40 s20449 CACGCAACAUACUACCACAtt UGUGGUAGUAUGUUGCGUGca 
WDR12 s31441 GACUGGAUCAGUUCAAUUAtt UAAUUGAACUGAUCCAGUCat 
ZNF259 s445636 GCUCUUUCUGUAGGUUAUUtt AAUAACCUACAGAAAGAGCag 
INCENP s7424 AGUCCUUUAUUAAGCGCAAtt UUGCGCUUAAUAAAGGACUtc 
NPC1 s237198 CCAAUUGUGAUAGCAAUAUtt AUAUUGCUAUCACAAUUGGtc 
neg9 s444246 UACGACCGGUCUAUCGUAGtt CUACGAUAGACCGGUCGUAtt 
neg1 s813 UAACGACGCGACGACGUAAtt UUACGUCGUCGCGUCGUUAtt 
6.6 ANTIBODIES 
6.6.1 WESTERN BLOT ANTIBODIES 
6.6.1.1 PRIMARY WESTERN BLOT ANTIBODIES 
 
 
SREBF2 ATGGGCAGCAGAGTTCCTTC CGACAGTAGCAGGTCACAGG 
TMEM57 GAGGGATCCGCTCAGAAATGG GGCTTCCTGCTCAGCTTTTAG 
TOMM40 ATTCAGATGGAGGGTGTCAAG ATTGTGCTGAGGGCTACTGT 
Protein Host Supplier Cat. No. Clone Dilution 
a-Tubulin mouse Neomarkers  #MS581 monoclonal 1:10000 
LDLR rabbit BioVision 3839-100 polyclonal 1:1000 
LDLRAP1/ARH rabbit ProteinTech 13213-1-AP polyclonal 1:1000 
  114 
6.6.1.2 SECONDARY WESTERN BLOT ANTIBODIES 
 
6.6.1.3 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES 
 
6.6.1.4 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES 
6.7 KITS 
6.8 EQUIPMENT 
6.8.1 MICROSCOPES 
 
6.8.2 OTHER LABORATORY EQUIPMENT 
Protein/Label Host Supplier Cat. No. Clone Dilution 
HRP-anti-rabbit goat Sigma A0545 polyclonal 1:16000 
HRP-anti-mouse rabbit Sigma A9044 polyclonal 1:8000 
HRP-anti-goat mouse Sigma A9452 monoclonal 1:10000 
Protein/Label Host Supplier Cat. No. Clone IF Fixation Dilution 
BCAM mouse R n D systems MAB148-SP monoclonal  1:500 
BCAM rabbit Sigma HPA005654 polyclonal  1:50 
CXCL12 mouse R n D systems MAB350-SP monoclonal  1:250 
HAVCR1/TIM1 goat R n D systems MAB1750 monoclonal PFA/MeOH 1:250 
LDLR rabbit Fitzerald 20R-LR002 polyclonal PFA 1:100 
LDLRAP1/ARH rabbit ProteinTech 13213-1-AP polyclonal  1:1000 
MLXIPL/CHREBP goat SantaCruz (P-13): sc-
21189 
polyclonal  1:200 
PAFAH1B1/LIS1 mouse Sigma Aldrich L7391 monoclonal  1:5000 
SORT1/NTR3 rabbit Sigma HPA006889 polyclonal  1:100 
TOMM40 rabbit Sigma HPA036232 polyclonal  1:50 
Protein/Label Host Supplier Cat. No. Clone Dilution 
AlexaFluor 488-mouse goat Molecular Probes #A11001 polyclonal 1:200 
AlexaFluor 488-rabbit goat Molecular Probes #A11008 polyclonal 1:400 
AlexaFluor 488-goat donkey Molecular Probes #A11055 polyclonal 1:400 
Kit Supplier Cat.No. 
Western blot   
Invitrap Spin Universal RNA Mini Kit Stratec Molecular #1060100300 
Superscript III, First-Strand Synthesis Supermix for RT-qPCR Invitrogen #11752-050 
Microscope Manufacturer 
Automated widefield microscope Scan^R Olympus 
Axiovert 200 widefield microscope Zeiss 
  
Device/Model Manufacturer 
VersArray ChipWriter Pro System BioRad 
Liquidator 96 manual pipetting system 360 Rainin Mettler-Toledo 
MiVac Quattro concentrator, GeneVac SPScientific 
  115 
6.8.3 EQUIPMENT FOR CELL CULTURE AND MICROSCOPY 
 
Equipment Supplier/ Cat. No. 
Cell counting chamber Superior Marienfeld #0610610 
Cell culture dish 10 cm Nunc #150350 
6-well cell culture plate  Nunc #140675 
12-well cell culture plate  Falcon #353225 
24-well cell culture plate  Falcon #353226 
96-well glass bottom plate Zellkontakt #21315241 
96-well black bottom plate Nunc #137101 
96-well deep well plate Greiner #780270 
96-well conical bottom microwell plate Nunc #277143 
384-well glass bottom plate BD Falcon #353962 
384-well low volume plate Nunc #264360 
384-well deep well plate Eppendorf #0030 521.145 
Cell freezing container Nalgene #5100-0001 
Cell scrapers Corning® #3010 
Chemiluminescent films Amersham HyperfimTM ECL #28906835 
Chemiluminescent films Kodak 
Coverslips 11 mm diameter Menzel-Gläser #CB00110RA1 
Coverslips 15 mm diameter Menzel-Gläser #CB00150RA1 
Cryotubes Nunc #363401 
Immobilon
®
 PVDF membrane Merck Millipore #ISEQ00010 
LabTek 1 well Nunc #155361 
MicroAmp
®
 Fast Optical 96-well Reaction Plate 
with Barcode 
Applied Biosystems #4346906 
MicroAmp
®
 Optical 384-well Reaction Plate with 
Barcode 
Applied Biosystems #4326270 
MicroAmp
®
 Optical Adhesive Film MicroAmp #4311971 
NuPAGE
®
 4-12% Bis-Tris Gel 1.0mm x10 well NOVEX #NP0321BOX  
NuPAGE
®
 4-12% Bis-Tris Gel 1.0mm x12 well NOVEX #NP0322BOX 
Cell culture incubator Binder 
Centrifuge 5417R eppendorf 
Centrifuge 5804R eppendorf 
Kodak RP X-OMAT Processor M6B Kodak  
Large bench centrifuge Multifuge 3s Heraeus 
Magnetic stirring hotplate MR3001 K Heidolph 
Mastercycler gradient eppendorf 
Microcentrifuge 5417R eppendorf 
Mini-PROTEAN
® 
II Cell Gel System Bio-Rad #1599 
Nanodrop 8000 Spectrophotometer PeqLab 
pH Meter #MP225 Mettler-Toledo 
PowerPac Power Supply BioRad 
QuaŶtStudio™ 6 Flex Real-Time PCR System Applied Biosystems 
Scale SBA 51 Scaltec 
Scale TE124S-OCE Sartorius 
Scanner Perfection V750 Pro Epson 
Sonificator Hielscher Ultrasound 
Technology 
StepOne
TM 
Real-Time PCR System #4376357 Applied Biosystems  
Thermomixer C eppendorf 
Tube shaker eppendorf 
Vortex Genie2 Scientific Industries 
Water bath GFLR 
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NuPAGE
®
 4-12% Bis-Tris Gel 1.0mm x15 well NOVEX #NP0323BOX 
Object Slides frosted end Menzel-Gläser #ISO 8037/I 
Parafilm
® BEMIS® #PM996 
Sterile filter 0.45 μm Millipore Stericup DuraporeTM #SCHVU05RE 
Tips for Liquidator Steinbrenner #SL-LT-L200 
Whatmann Paper Whatman® #3030917 
Water reservoir Thermo Fisher #370906 
X-Ray cassette KISKER #IEC 60406 
Combitips advanced eppendorf #0030089774 
6.9 SOFTWARE 
Software Developer 
Adobe Acrobat X Pro Adobe systems Inc., San Jose, USA 
Adobe Acrobat Reader DC Adobe systems Inc., San Jose, USA 
Adobe Illustrator CS6 Adobe systems Inc., San Jose, USA 
Adobe Photoshop CS6 Adobe systems Inc., San Jose, USA 
ApE 2-A plasmid Editor M. Wayne Davis, biologylabs, Utah 
AxioVision Carl Zeiss 
CellProfiler Broad Institute, Cambridge, USA 
EndNote X6 Thomson Reuters, New York, USA 
FiJi Schindelin J. et al. 
HTM (High Throughput Microscopy) Explorer  Tischer C., ALMF, EMBL 
ImageJ 1.46r Rasband W., NIH, Bethesda, USA 
Mendeley Desktop 1.16.1 Elsevier 
Microsoft Office 2011 Microsoft Corporation, Redmond, USA 
QuantStudio
TM
 Real-Time PCR Software Applied Biosystems, USA 
R 3.2.2 GUI 1.66 The R Foundation for Statistical Computing, 
Vienna, Austria 
RStudio RStudio Team (2015) 
Scan^R Olympus, Hamburg, Germany 
StepOne Software v2.3 Applied Biosystems, USA 
  
6.10 WEBTOOLS AND RESOURCES 
Tool Usage Website 
BLAST/BLAT Align sequence to genome/ 
oligonucleotide design 
http://www.ensembl.org/Multi/Tools/Blast 
Bluegecko Information on siRNAs and 
genome-wide screens 
https://bluegecko.embl.de (EMBL intranet only) 
BLOCK-iT RNAi 
Designer 
siRNA design https://rnaidesigner.thermofisher.com/rnaiexpr
ess 
Confetti; a multi-
enzyme map of the 
HeLa proteome 
Information on protein 
expression in HeLa cell line 
https://proteomics.swmed.edu/confetti/ 
Exome Variant 
Server 
Rare variant database http://evs.gs.washington.edu/EVS/ 
GeneOntology Information on gene 
function/ classification 
http://www.geneontology.org/ 
Life Technologies 
Fluorescence 
Spectra Viewer 
Fluorescence Spectra 
Viewer 
https://www.thermofisher.com/de/de/home/lif
e-science/cell-analysis/labeling-
chemistry/fluorescence-spectraviewer.html 
PhenoScanner SNPs database-
Cardiovascular 
Epidemiology 
http://www.phenoscanner.medschl.cam.ac.uk/
phenoscanner 
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Primer-BLAST NCBI PCR primers design https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
Primer 3 PCR primers design http://bioinfo.ut.ee/primer3-0.4.0/primer3/ 
PrimerBank PCR primer database https://pga.mgh.harvard.edu/primerbank/ 
qPrimerDepot PCR primer database https://primerdepot.nci.nih.gov/ 
Reverse 
Complement 
Oligonuclotide sequence 
transformation 
http://www.bioinformatics.org/sms/rev_comp.
html 
Sigma Aldrich 
OligoEvaluator 
Sequence Analysis Tool http://www.oligoevaluator.com/OligoCalcServle
t 
SNPcheck PCR primers design https://secure.ngrl.org.uk/SNPCheck/snpcheck.
htm 
STRING Functional proteins 
associations network 
http://string-db.org/ 
UCSC In-silico PCR PCR primers design http://rohsdb.cmb.usc.edu/GBshape/cgi-
bin/hgPcr 
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7 METHODS 
7.1 CELL BIOLOGY 
7.1.1 CELL CULTURE 
HeLa Kyoto cells were cultured in 10 cm petri dishes (Nunc) with supplemented, low 
glucose  (1g/L) DMEM growth medium (GIBCO) at 37°C, 5% CO2 and saturated 
humidity. The cells were passaged every two or three days, once they reached 
approximately 80% confluence, until passage 24, after which the cells were 
discarded and fresh cells were thawed (see 7.1.1.2). For passaging, the cells were 
first washed once with trypsin-EDTA (GIBCO) and then incubated shortly at 37°C with 
1 mL trypsin to detach from the plastic dish. Once detached, the cells were 
suspended in 9 mL supplemented DMEM medium and part of the cell suspension 
was transferred to a new dish and complemented with medium. For transfection 
experiments, cells were diluted [1:2] one day prior to plating (see 7.1.2). For the co-
RNAi screen, penicillin 100μg/ml- streptomycin/0.2% (w/v) (Sigma) was added to the 
medium throughout all the experiments.        
7.1.1.1 PLATING CELLS 
Depending on the type and the duration of the experiment, a certain amount of cells 
was plated on LabTeks or multi-well plates (see Tbl. 10), after counting with a 
Hemocytometer (Superior Marienfeld). For experiments performed using multi-well 
plates in which the cells would be finally imaged, cells were plated on top of glass 
coverslips placed inside the plate wells.  
 
Table 10. Amounts of cells used in different cell culture plates and times of transfection 
 
 
 
 
Dish format DMEM volume 
per well 
Cell No  Transfection duration 
(siRNA/ cDNA) 
Total experimental time 
from plating to end point 
1-well LabTek 1.5 mL 6x10
4
 48 h 48 h 
6-well plate 2 mL 3x10
4 
48 h 72 h 
12-well plate 1 mL 1.5x10
4 
48 h 72 h 
12-well plate 1 mL 4x10
4 
24 h 48 h 
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7.1.1.2 FREEZING AND THAWING CELLS 
The cells were frozen and stored in liquid nitrogen to keep stocks for future use, 
after being tested for mycoplasma. For this purpose, cells were diluted [1:2]  (see 
7.1.1) in a 10 cm dish one day prior to freezing, to reach about 80% confluency. The 
cells were trypsinised (see 7.1.1) and suspended in supplemented medium, and the 
suspension was centrifuged for 5 minutes at 1,000 rpm. After sedimentation of the 
cells, the medium was removed, and the cells were suspended in 2 mL freezing 
medium. Aliquots of 1 mL cell suspension were transferred into labeled cryotubes 
(Nunc) and stored at -80°C in a freezing container which allowed for slow freezing of 
the cells. Within the next days, the cells were transferred to the liquid nitrogen tank.  
To thaw cells, cryotubes were removed from the liquid nitrogen and quickly thawed 
by holding shortly (1-2 minutes) in the 37°C waterbath. After thawing, the cells were 
transferred into a Falcon tube, where they were suspended in supplemented DMEM, 
before centrifuging for 5 minutes at 1,000 rpm. The supernatant was aspirated, and 
the sedimented cells were suspended in supplemented DMEM and transferred into a 
10 cm dish. 
7.1.2 TRANSFECTION 
In order to increase or inhibit the expression of a gene of interest, nucleic acids were 
introduced into cells by transfecting them with cDNA or siRNA, respectively. Two 
different transfection protocols were used, described as forward or liquid-phase 
transfection and reverse or solid-phase transfection.  
7.1.2.1  FORWARD (LIQUID-PHASE) TRANSFECTION  
The conventional transfection protocol employed is referred to as ͞forward 
transfection͟, whereby cells are seeded one day prior to transfection. For both cDNA 
and siRNA transfection experiments, two different mixtures were first prepared. The 
first mixture contained the nucleic acid -cDNA or siRNA- diluted in OptiMEM 
(GIBCO), whereas the second mixture contained the transfection reagent diluted in 
OptiMEM. The two mixtures were mixed after incubation at room temperature (RT) 
for 5 minutes, and incubated for another 20 minutes to allow for the formation of 
the transfection complexes. The transfection mixture was then added drop-wise to 
the cells. For cDNA transfection, the transfection mixture was added to cells grown 
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in supplemented DMEM medium. For siRNA transfection, the cell medium was 
aspirated, the cells were washed once with serum-free growth medium, and then 
serum-free DMEM medium was added to the cells before the addition of the 
transfection mixture. The medium of siRNA-transfected cells was replaced after 4 h 
incubation with supplemented DMEM medium. The amounts of transfection reagent 
and nucleic acid differed depending on the method and format used. Typically used 
amounts are shown in Tables 11 and 12, however these amounts were subject to 
changes if transfection efficiency was not satisfactory. 
 
Table 11. Typical amounts of siRNA and transfection reagents used 
Format Experiment siRNA mix (1) Transfection 
reagent mix (2) 
Final Mix (1+2) 
6-well plate 48h siRNA 
knockdown 
ϯϬ pŵol ;ϭ μL of 30 μMͿ 
siRNA iŶ ϮϬϬ μL OptiMEM 
Ϯ μL Lipofectamine 
in 200 μL OptiMEM 
ϰϬϯ μL into 800 μL 
serum-free DMEM 
12-well plate 48h siRNA 
knockdown 
ϭϱ pŵol ;Ϭ.ϱ μL of 30 μMͿ 
siRNA iŶ ϭϬϬ μL OptiMEM 
ϭ μL Lipofectamine 
in 100μL OptiMEM 
ϮϬϭ.ϱ μL into 400 μL 
serum-free DMEM 
 
 
 
Table 12. Typical amounts of cDNA and transfection reagents used 
Format Experiment cDNA mix (1) Transfection  
reagent mix (2) 
Final Mix (1+2) 
12-well plate 48h siRNA 
knockdown 
ϭ.Ϯϱμg cDNA in 
125μL OptiMEM 
ϯμL LipofeĐtaŵiŶe   
iŶ ϭϮϱμL OptiMEM 
ϮϱϯμL iŶto ϭŵL  
supplemented DMEM 
 
7.1.2.2 REVERSE (SOLID-PHASE) TRANSFECTION  
For high-throughput knockdown experiments, reverse transfection was used, 
whereby freshly passaged cells -passaged 24 h before- were added to transfection 
complexes in pre-spotted microarrays; ͞LabTeks͟ (see Tbl. 10).  
7.1.2.2.1 LABTEK SPOTTING 
For reverse transfection experiments, glass-bottomed chambered cell culture slides 
(1-well LabTeks) coated with siRNAs for solid phase reverse-transfection of cells 
were produced as described (Erfle et al. 2007, 2008). In detail, the transfection 
mixtures were prepared as follows.  
First, 0.2 g gelatin (Sigma) was dissolved in 100 ml ddH2O at 56°C for 20 minutes in a 
prewarmed waterbath. The gelatin solution was sterilized by filtration with a 0.45 
μm pore filter after cooling down. Besides the normal gelatin solution, a 0.2% 
Oregon Green gelatin solution (Molecular Probes) was prepared by dissolving 5 mg 
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Oregon Green gelatin in 2.5 mL ddH2O as previously described. At the same time, 
1.37 g sucrose (Affymetrix) was dissolved in 10 mL OptiMEM.  
Second, four numbered 96-well conical bottom plates containing 15 pmol Silencer 
Select siRNA (ThermoFisher) (5 μL of a 3μM solutioŶ) per well were prepared and 
centrifuged at 500 rpm for 1 minute. Additionally, the transfection mix was prepared 
by mixing 1.662 mL of the sucrose /OptiMEM solution with 0.969 mL ddH2O and 
0.969 mL Lipofectamine (Invitrogen). The transfection mix and the gelatin solution 
were distributed into two 96-well conical bottom plates, by transferring 32 μL and 50 
μL per well, respectively, and the two plates were centrifuged. The gelatin solution 
was then distributed into four numbered 96-well plates, by transferring 10 μL per 
well and the plates were centrifuged. The normal gelatin was replaced with Oregon 
Green gelatin in those wells of the four gelatin plates that would be used for the 
transfection control siRNA spotting.  
Third, 7 μL from the transfection mix plate were transferred to each of the four 
siRNA plates with the Liquidator and mixed by pipetting. The plates were then 
incubated at RT for 20 minutes to allow for the formation of the transfection 
complexes. Afterwards, 7 μL of the four gelatin plates were transferred to the 
corresponding siRNA/transfection-mix-containing plates with the Liquidator and 
mixed by pipetting and the plates were centrifuged shortly.  
Fourth, 16 μL from the four siRNA transfection cocktail-containing plates were 
transferred to a low-volume 384-well plate with the Liquidator, and the plate was 
centrifuged shortly. For better spotting results, LabTeks were washed before 
spotting with ddH2O, then ethanol and then again ddH2O. Finally, the 384-well plate 
was used to spot LabTeks using a ChipWriter Compact Robot (Bio-Rad) with solid 
pins (Point Technologies) resulting in a spot volume of ~4 nL (containing ~5 ng siRNA) 
and a spot diameter of ~400 μm and a spot-to-spot distance of 900 μm, mirroring 
one 384-well plate per chamber. siRNA arrays were printed in 12 replicates and 
dried for 10 minutes in a SpeedVac pre-warmed to 37°C. The LabTeks were then 
stored in sealed plastic boxes containing drying pearls (Aldrich).  
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7.1.2.2.1.1 DETERMINING THE OPTIMAL SIRNA CONCENTRATION FOR THE DOUBLE 
KNOCKDOWNS 
In order to determine the optimal siRNA concentration to be used for the double 
knockdowns, two conditions were examined in a pilot experiment. For this purpose, 
siRNAs targeting two genes with a known role in cholesterol uptake were used 
(LDLR, DAB2), as well as a negative control siRNA (NEG9) and a transfection control 
siRNA (INCENP).  
In detail, LabTeks were spotted with the following combinations of siRNAs; 
Neg9+Neg9, LDLR+LDLR, DAB2+DAB2, LDLR+NEG9, DAB2+NEG9, LDLR+DAB2, 
INCENP+INCENP using either 15pmol of each siRNA (30pmol siRNA in total) or 
7.5pmol of each siRNA (15pmol siRNA in total) per LabTek spot. The LDL uptake was 
performed on the spotted LabTeks as described (see 7.1.6.1) and the knockdown 
effect of different siRNA concentrations on LDL uptake was evaluated. The 
experimental settings are shown schematically in Table 13.  
 
Table 13. siRNA amount used in the pilot experiment to determine optimal concentrations for 
double knockdowns 
 
7.1.2.2.1.2 SPOTTING OF LABTEKS FOR THE COMBINATORIAL RNAI SCREEN 
For the combinatorial RNAi screen, LabTeks coated with siRNAs were produced as 
described previously (see 7.1.2.2.1). For the spotting of two siRNAs per LabTek spot, 
the four 96-well conical bottom plates contained 15 pmol of each of the two Silencer 
Select siRNAs (2 x 2.5 μL of a 6μM solutioŶ=30 pmol total siRNA) per well. 
Previously validated siRNAs against three genes were selected as controls: INCENP, 
siRNA combination Amount of each siRNA Total siRNA amount 
Neg9+Neg9 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
LDLR+LDLR 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
LDLR+LDLR 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
DAB2+DAB2 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
DAB2+DAB2 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
LDLR+NEG9 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
LDLR+NEG9 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
DAB2+NEG9 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
DAB2+NEG9 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
LDLR+DAB2 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
LDLR+DAB2 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
INCENP+INCENP 15pmol (2.5μL of 6μΜ) 30pmol (5 μL of 3μM) 
INCENP+INCENP 7.5pmol (2.5μL of 3μΜ) 15pmol (5 μL of 1.5μM) 
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inducing multinucleated arrested cells that served to monitor siRNA transfection 
efficiency (Neumann et al. 2006); LDLR, reducing DiI-LDL uptake to ~25% and 
perinuclear Filipin signal to ~60%; NPC1, increasing perinuclear Filipin signal to 
~150% (Bartz et al. 2009).  
The total 30x30 (900 including the reciprocal interactions) pairwise combinations to 
be tested in the combinatorial RNAi screen including all the controls were printed on 
5 different LabTeks. On each LabTek, the single knockdowns (siRNA(X)+Neg9) were 
spotted 2 times-with the exception of LDLR+Neg9, that was spotted 10 times, while 
the double knockdowns (siRNA(X)+siRNA(Y)) were spotted 1 time. Of the 384 spots 
printed on the LabTeks, 56 spots contained control siRNAs; 8 spots contained 
INCENP-siRNA (s7424) to control for transfection efficiency, 8 spots contained the 
non-silencing control siRNA; Neg1 (s229174), 8 spots contained the non-silencing 
control siRNA; Neg9 (s444246), 8 spots contained siRNA targeting LDLR (s224006) as 
a positive control for LDL-uptake, 8 spots contained siRNA targeting NPC1 (s237198) 
as a positive control for free cholesterol (FC), 8 spots contained both Neg9 and LDLR 
siRNA, as a positive control for the double knockdowns in LDL-uptake assay and 8 
spots contained both Neg9 and NPC1 siRNA, as a positive control for the double 
knockdowns in FC. 
 
7.1.3 IMMUNOSTAINING 
For immunofluorescence experiments, cells were seeded at a concentration of 1x104 
cells/mL in 12-well dishes containing a glass coverslip in each well. After washing 
once with PBS, cells were fixed with either paraformaldehyde (PFA) or methanol, 
depending on the protein and the antibody. For PFA fixation, cells were incubated 
for 20 minutes at RT in 3% PFA and then for 5 minutes with quenching buffer. For 
methanol fixation, cells were incubated with methanol at -20°C for 4 minutes. 
Following fixation, cells were washed three times for 3 minutes with PBS at RT. For 
intracellular protein labeling, cells needed to be permeabilized with either Triton-X-
100 buffer for 5 minutes at RT, or saponin permeabilization buffer for 10 minutes at 
RT. Cells were then washed three times with PBS. For the staining, the antibody was 
diluted in PBS or in saponin buffer in case of cells permeabilized with saponin. The 
cells were incubated with the primary antibody, then washed three times with PBS 
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and then incubated with the secondary antibody. Subsequently, cells were washed 
with PBS and their nuclei were stained with Hoechst (diluted 1:5,000) for 5 minutes 
at RT. After washing once more with PBS, coverslips were mounted on glass slides 
using Mowiol. The glass slides were dried overnight at RT or at 37° C for at least 30 
minutes prior imaging.  
   
7.1.4 MICROSCOPY-DETECTION OF FLUORESCENT MOLECULES IN THE CELL 
7.1.4.1 WIDE-FIELD MICROSCOPY 
Immunostained cells were imaged with a Zeiss Axiovert 200, inverted, wide-field 
microscope. The light source was an HBO lamp and the fluorescence filters used 
were the following; Dapi/Hoechst (Excitation(Ex): 365/12, Emission (Em): LP397), 
FITC (Ex: 450-490, Em: 515-565), Cy3 (Ex: 545/25, Em: 605/70). The images were 
acquired with a Zeiss EC Plan-NEO FLUOAR 40x/NA 1.3 Oil or a Zeiss Plan-
APOCHROMAT 63x/NA 1.4 Oil objective, using the AxioVision software.  
 
7.1.4.2 HIGH-THROUGHPUT MICROSCOPY 
For high-throughput microscopy the automated wide-field Olympus Scan^R 
microscope was used. The light source was a MT20 Xenon lamp and typically an 
Olympus UPlanSApo 20x/ NA 0.75 objective was used. The fluorescence filters used 
were the following; Dapi/Hoechst (Ex: 350/50, Em: 447/60), Cy3 (Ex: 545/25, Em: 
605/70), Cy5 (Ex: 640/30, Em: 690/50) and GFP (Ex: 470/40, Em: 525/50). A software 
autofocus was based on the nuclear (Dapi/Hoechst) staining. It consisted of a coarse 
autofocus (± 13μm, 18 steps) and a fine autofocus (± 2 μm, 15 steps). The starting 
position of each coverslip/ LabTek, as well as the spot distance (for LabTeks) was set, 
and the imaging was then performed in an automated manner. In order to find the 
first spot on a LabTek, the fluorescence signal from the Oregon Green gelatin was 
used (see 7.1.2.2.1), which was only contained in spots with the transfection control 
siRNA -including the upper left (A1) spot of the LabTek. Usually 100 images were 
obtained per coverslip, or 1 image per spot of a LabTek. The imaging settings were 
stored in an experiment descriptor .xml file, which could be re-used in the following 
imaging set. 
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7.1.5 ENDOCYTOSIS ASSAYS 
7.1.5.1 LDL UPTAKE ASSAY 
To analyse the ability of cells to endocytose low-density lipoprotein (LDL), the LDL-
uptake assay was employed (Bartz et al. 2009; Gilbert et al. 2009; Pitas et al. 1981). 
Cells were seeded in appropriate format and usually transfected with siRNAs for 48 h 
before performing the assay. Cells were depleted from sterols in two sequential 
steps, before the assay (see section 7.1.6). They were subsequently washed with ice-
cold imaging medium (IM)/0.2% BSA for 2 minutes and then labeled with 1.25μg/mL 
DiI-LDL (Invitrogen) for 30 minutes at 4 °C. The endocytosis of DiI-LDL was then 
stimulated for 20 minutes at 37 °C and then cells were washed with IM/0.2% BSA for 
2 minutes at 4 °C. To remove membrane-bound DiI-LDL, cells were washed for 
exactly 1 minute with IM at pH 3.5, and then again with IM/0.2% BSA for 2 minutes 
at 4 °C. Fixation of cells in 3% PFA for 20 minutes followed and after washing with 
PBS, cells were counterstained for cytoplasm and nucleus with DRAQ5 and Hoechst, 
for 5 minutes at RT, respectively. Finally, cells were washed with PBS and either 
imaged directly in the case of LabTeks, or mounted with Mowiol onto glass slides, in 
the case of coverslips. 
 
7.1.5.2 LDL BINDING ASSAY 
To test for the ability of siRNA-treated versus non-treated cells to bind LDL, a similar 
cellular assay to the LDL-uptake assay was performed. The difference in the LDL-
binding assay was that the cells were only let to bind LDL for 30 minutes at 4° C, with 
no LDL-internalization step following. Immediately after the binding step, cells were 
washed 3 times with IM-BSA and then fixed with PFA. 
 
7.1.6 STEROL-DEPLETION PROTOCOLS 
Cells were depleted from sterols prior to the LDL-uptake (or LDL-binding) assay, in 
two steps. For this purpose, 28 h after the transfection (20 h before the assay) the 
cells were washed once with serum-free DMEM medium and then serum-free 
DMEM medium containing 0.2% BSA was added to the cells. Additionally, 45 minutes 
before the assay, 1% (w/v) HPCD was given to the cells to extract cholesterol for the 
medium. 
  126 
7.2 MOLECULAR BIOLOGY 
7.2.1 RNA EXTRACTION AND REVERSE TRANSCRIPTION 
In order to measure gene expression on mRNA level, total RNA needs to be 
extracted from cultured cells. For this purpose, 30000 HeLa Kyoto cells/ well were 
seeded in 6-well plates three days before the extraction. 24 hours after seeding, cells 
were transfected with siRNAs and 48 hours after the transfection RNA was extracted 
using the Invitrap Spin Universal RNA Mini Kit (Stratec), according to manufacturer’s 
instructions. The concentration of the extracted RNA was quantified by measuring its 
absorbance at 260 nm using the Nanodrop 8000 Spectrophotometer. Samples were 
either directly used for reverse transcription or stored at -20° C until usage. Similarly, 
the RNA purity was assessed by measuring the absorbance ratio A260/A280 nm. 
Total extracted RNA was then reverse-tƌaŶsĐƌiďed iŶto ĐDNA usiŶg the SupeƌSĐƌipt™ 
III First-Strand Synthesis SuperMix for RT-qPCR (Invitrogen). According to 
manufacturer’s instructions, 500 ng RNA were used as template for a 10 μl total 
volume reaction. cDNA samples were wither directly used for quantitative real-time 
polymerase chain reaction (RT-qPCR) or stored at -20° C until usage. Before usage, 
cDNA samples were diluted 1:10 with RNAse-free water. 
 
7.2.2 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QRT-PCR) 
RT-qPCR was performed using SYBR Green fluorescent dye (Applied Biosystems). The 
-relative or absolute- quantity of the amplified DNA is thereby calculated by 
measuring the SYBR Green fluorescence at the end of each amplification cycle. In 
each well of a MicroAmp® optical 96-well reaction plate (Applied Biosystems), 2 μl of 
the previously synthesized cDNA were added, as well as 18 μl of a mix consisting of 
11 μl SYBR Green, 1.1 μl forward and 1.1 μl reverse primer (10 μΜ) and 6.6 μl 
ddH2O, to a total volume of 20 μl. For each gene target, different mixes were 
prepared. All reactions were performed in triplicates within the same plate. The 
plate was sealed with a MicroAmp® Optical Adhesive Film and centrifuged at 1000 
rpm for 2 minutes. 
RT-qPCR experiments were performed at the GeneCore Facility at EMBL using the 
StepOneTM Real-Time PCR System (Applied Biosystems). The experimental setup 
used was as follows: experiment type ͞Quantitation-Comparative CT (ΔΔCT)͟, reagent 
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type ͞SYBR® Green Reagents͟, ramp speed ͞Standard (~2 hours to complete a run)͟ 
and the following program was run: (1) hot start polymerase activation at 95 °C for 
10 minutes, (2) 40 cycles of dissociation at 95 °C for 15 seconds and elongation at 60 
°C for 1 minute, (3) primer melt curve at 95 °C for 15 seconds, 60 °C for 1 minute, a 
gradient of  +0.3 °C to 95 °C and finally 95 °C for 15 seconds. Upon completion of the 
run, RT-qPCR data were analyzed with the StepOne Software v2.3 (Applied 
Biosystems) using the comparative CT method. 
 
7.2.3 HIGH-THROUGHPUT QRT-PCR 
For measuring the expression of multiple genes in multiple samples simultaneously 
on the same plate, MicroAmp® Optical 384-well Reaction Plates (Applied Biosystems) 
were used and the RT-ƋPCR ǁas ƌuŶ oŶ a QuaŶtStudio™ ϲ Flex Real-Time PCR 
System (Applied Biosystems). For the generation of the 384-well plates, four 
MicroAmp® Optical 96-well reaction plates were produced and combined with a 
Liquidator into one MicroAmp® Optical 384-well Reaction Plate. In each of the four 
96-well plates, 2 μl of the synthesized cDNA were pipetted, as well as 8 μl of a mix 
consisting of SYBR Green, forward (10 μΜ) and reverse primer (10 μΜ) and ddH2O. 
For one well mix, 2.2 μl ddH2O, 0.55 μl FW primer (10μM), 0.55 μl RV primer (10μM) 
and 5.5 μl Sybr Green 1 were combined, and different mixes were prepared for each 
gene target. Thus, the total reaction volume per well was 10 μl. The four 96-well 
plates were combined onto the 384-well plate using a Liquidator. The 384-well plate 
was then centrifuged, and the RT-qPCR reaction was run using the same settings as 
in the StepOneTM Real-Time PCR System. The RT-qPCR was analyzed using the 
QuantStudio® Real-Time PCR Software v1.3. 
 
7.2.4 PRIMER VALIDATION FOR QRT-PCR 
Primer pair oligonucleotides were custom designed for the qRT-PCR experiments 
(see section 7.4.5.2). Before use, primer pairs were evaluated for their binding to the 
target gene, using cDNA synthesized from total RNA extracted from untreated cells. 
Four serial dilutions of cDNA were prepared by diluting with a serial factor {1:10}; 
1:1, 1:10, 1:100, 1:1000, which were used as standards to construct a standard 
curve, in order to estimate the PCR amplification efficiency of each primer. Thus, the 
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concentration of the ͞standards͟ was indicated as 1, 0.1, 0.01 and 0.001. Aside the 
͞standards͟, two ͞negatives͟ were used; a no template control (NTC) which omits 
the cDNA and serves as a control for extraneous nucleic acid contamination, and a 
no reverse transcriptase control (NRT), which serves as a control for DNA 
contamination in the RNA preparation. All standards and negatives were used in 
duplicate wells, to assess variation in Cq (quantitation cycle). The slope of the 
standard curve and the binding efficiency were evaluated, and primers were rejected 
when they didn’t give efficient results; slope range between -3.58 and -3.10 and 
efficiency between 90% and 110% were considered acceptable. 
 
7.2.5 SELECTION OF REFERENCE GENE FOR QRT-PCR EXPERIMENTS 
In order to compare mRNA transcription through qRT-PCR in different samples or 
tissues, the appropriate reference gene (aka ͞housekeeping gene͟) needs to be 
selected, for normalization purposes. Five candidate reference genes were tested; 
GAPDH (Glyceraldehyde 3-Phosphate Dehydrogenase), HRPT1 (Hypoxanthine 
Phosphoribosyltransferase 1), RPS18 (Ribosomal Protein S18), SDHA (Succinate 
Dehydrogenase Complex Flavoprotein Subunit A) and HSPC3 (Small Heat-Shock 
Protein 3) for their expression stability under different experimental settings, which 
was evaluated using qRT-PCR.  
For this purpose, total RNA was extracted from HeLa Kyoto cells, untransfected or 
transfected and cDNA was synthesized from the extracted RNA. Primer sequences 
for HRPT1, RPS18, SDHA and HSPC3 were taken from Krainova et al. (Krainova et al. 
2013). All primer sequences are shown in section 6.5.2.  
 
7.2.6 NUCLEID ACIDS HANDLING 
Small interfering RNAs (siRNAs) were delivered lyophilized in tubes or plates in a 
concentration of 5nM, and were reconstituted by resuspending in nuclease-free H2O 
to a final concentration of 30μM. siRNAs were then used at this concentration in 
liquid-phase transfections, or were further diluted in nuclease-free H2O to 3μM for 
the reverse transfections. Plates and tubes with siRNAs were stored at -20 °C. 
Lyophilized oligonucleotide primers were reconstituted by resuspending in ddH2O to 
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100 μM stock solutions, which were stored at -20 °C. For qRT-PCR primer 100 μM 
stock solutions were diluted to 10 μM working solutions with ddH2O. 
 
7.3 BIOCHEMISTRY 
7.3.1 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
To assess the amount of a protein of interest in cells, cells were grown in 6-well 
plates and after washing once with PBS they were lysed in 200μL sample buffer on 
ice. After transferring to a 1.5 mL eppendorf tube, cell lysates were boiled at 95 °C 
for 5 minutes. After brief spinning and cooling down of the samples, 1% (v/v) 
benzonase as well as 1% (v/v) MgCl2 were added to the each tube and let to degrade 
DNA at RT for 10-20 minutes. Afterwards, samples were boiled for 5 minutes at 95 °C 
to ensure complete protein denaturation, and either stored at -20 °C or were used 
directly after cooling down. For SDS-PAGE, 18 μL of the samples were loaded on 
precast 12-well 4%-12% NuPAGE Bis-Tris gels (Invitrogen), and run using MOPS 
buffer at 100-140 V. To determine the molecular weight of the proteins, 4 μL protein 
ladder was loaded onto the first well of the gel. 
 
7.3.2 WESTERN BLOT 
After separating with SDS-PAGE, proteins were transferred to a PVDF membrane, 
where they would later be detected using specific antibodies. Initially, a PVDF 
membrane piece was activated in methanol for 10 minutes. Whatmann papers and 
Western blot sponges were also soaked in cold transfer buffer. The cassette was 
assembled using in the following order from the white to the black back of the 
cassette; sponge, two Whatmann papers, SDS-PAGE gel, PVDF membrane, two 
Whatmann papers, sponge. The cassette was then placed in the blotting chamber, 
which was filled with cold transfer buffer and an ice pack and a magnetic stirrer. The 
transfer of the proteins from the gel to the PVDF membrane was then performed in 
the cold-room for 1 h at 400mA.  
After the transfer, the PVDF membrane was immersed into blocking buffer and 
placed on a shaker for at least 1 h at RT. The membrane was then incubated with the 
primary antibody in blocking buffer shaking overnight in the cold room. Next day, 
the membrane was washed with PBS-T for 1-2 h at RT, before incubation with the 
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secondary antibody diluted in blocking buffer, which was performed at RT for 1 h on 
a shaker. After washing three times for 10 minutes with PBS-T, a chemiluminescence 
reaction was performed to detect the protein signal, using the Pierce® ECL Plus 
Western Blotting Substrate. For this, Substrate A and Substrate B were mixed at a 
40:1 ratio and incubated on a membrane for 5 minutes at RT. After the 
chemiluminescence reaction, the blot was placed between two plastic foils inside of 
a developing X-ray cassette and the signal was detected in the darkroom by exposing 
the membrane to a photographic film (Kodak). The films were developed in a Kodak 
developing machine and scanned using an Epson scanner, in order to be quantified 
with ImageJ. 
 
7.3.3 STRIPPING OF WESTERN BLOT MEMBRANES 
In order to reprobe a membrane with a different antibody, the blotted PVDF 
membrane was stripped to remove the bound antibodies, with a mild stripping 
buffer made according to Abcam protocol. The membrane was washed 3 times for 
10 minutes in fresh stripping buffer, then 2 times for 10 minutes in PBS, and finally 2 
times for 5 minutes in PBS-T. After placing in blocking buffer for at least 1 h, 
membrane was ready for incubation with the primary antibody. 
 
7.4  COMPUTATIONAL BIOLOGY 
7.4.1 IMAGE ANALYSIS 
7.4.1.1 IMAGEJ 
Images acquired with the Axiovert microscope were imported in ImageJ and 
inspected visually for fluorescence intensity. 
Images acquired with the Scan^R widefield microscope from Olympus were initially 
visually inspected using ImageJ, in order to exclude from the analysis any out-of-
focus images or otherwise non-analyzable.  
 
7.4.1.2 CELLPROFILER 
7.4.1.2.1 LDL-UPTAKE ASSAY ANALYSIS 
To quantify images from the LDL-uptake assay, images were analyzed with 
CellProfiler v2.1.1, using a pipeline developed with the help of Volker Hilsenstein at 
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ALMF, EMBL Heidelberg. For this purpose, the images were first converted from 12-
bit images to 16-bit, using the TransferTool (V. Hilsenstein). In the CellProfiler 
pipeline (see Tbl. 14), image sets that consisted of three channels (Dapi for Hoechst, 
Cy3 for DiI-LDL and Cy5 for DRAQ5) were first loaded  (LoadImages) and pixel 
intensity values were rescaled between 0 and 0.0624856 (Rescale Intensity). The 
intensity rescaling was done to convert 12-bit images saved in 16-bit format to the 
correct range; the value of 0.0624856 is equivalent to 212divided by 216. Then, image 
quality was measured using the Cy3 channel that reflected the DiI-LDL signal 
(MeasureImageQuality). Here, the image blur was measured and blur metrics were 
calculated with special algorithms (eg. PowerLogLogSlope). Afterwards, the image 
intensity of the DiI-LDL channel was measured (MeasureImageIntensity), by 
measuring pixel intensity. In the next step, the nuclei of the cells were identified, 
using the Dapi/Hoechst signal (IdentifyPrimaryObjects), after setting a threshold 
range for the fluorescence intensity, as well the diameter range of the nuclei. Then, 
the whole cell area as well as the cell boundaries were identified using the DRAQ5 
fluorescence signal, by digitally expanding the nuclei identified with the previous 
module, after setting a threshold and a threshold correction factor 
(IdentifySecondaryObjects). The cytoplasm was expanded by 15 pixels in the next 
module, in order to perform the background subtraction (ExpandOrShrinkObjects). In 
the next module, a mask is created from the DiI-LDL channel, by inverting the mask 
found in the previous module from the cytoplasm, in order to measure the image 
background intensity (MaskImage), which is measured in the next module 
(MeasureImageIntensity). Afterwards, the background fluorescence intensity is 
subtracted from the DiI-LDL intensity (ImageMath). Then, cells touching the image 
borders are discarded (IdentifySecondaryObjects). In the next two steps, a threshold 
is applied to find saturated pixels in the image, and a binary imaged is generated 
(ApplyThreshold) and the intensity of saturated pixels in the binary image is 
measured, to define the number of saturated pixels per cell 
(MeasureObjectIntensity). Next, cells with more than a specified number of 
saturated pixels (typically 10) in the DiI-LDL channel are discarded (FilterObjects). 
The DiI-LDL signal is afterwards enhanced over the cellular background signal 
(EnhanceOrSuppressFeatures), and the fluorescence signal parameters of identified 
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DiI-LDL dots are measured (MeasuredObjectIntensity). Then, DiI-LDL dots outside of 
cells are excluded (Crop) and dots within cells are finally identified 
(IdentifyPrimaryObjects), after setting a threshold. Next, a mask is created that 
consists of the dots that were previously identified (MaskImage), and the size and 
shape features of the identified dots are measured (MeasureObjectSizeShape), as 
well as the fluorescence intensity of the dots within whole cells from the background 
corrected DiI-LDL image and the enhanced signal image (MeasureObjectIntensity). In 
the following two modules, a binary image is generated out of the identified DiI-LDL 
dots (ConvertObjectsToImage) and dots are assigned to the cells which they belong 
to (RelateObjects). In the next three modules, the mean total intensity of DiI-LDL for 
one cell (CalculateMath), the total area of DiI-LDL dots in one cell (CalculateMath) 
and the ratio of the DiI-LDL dots intensity to the total intensity (CalculateMath) are 
calculated. In the following 16 modules, images are generated which visualize the 
outlines of the segmented objects on a black image and the fluorescence intensity 
data are shown on the objects and the images are saved as .tif files (OverlayOutlines, 
DisplayDataOnImage, SaveImages). Finally, the results are exported and saved as 
.csv files (ExportToSpreadSheet). 
 
Table 14. LDL-uptake assay pipeline 
1. LoadImages 
2. Rescale Intensity 
3. Rescale Intensity 
4. MeasureImageQuality 
5. MeasureImageIntensity 
6. IdentifyPrimaryObjects 
7. IdentifySecondaryObjects 
8. ExpandOrShrinkObjects 
9. MaskImage 
10. MeasureImageIntensity 
11. ImageMath 
12. IdentifySecondaryObjects 
13. ApplyThreshold 
14. MeasureObjectIntensity 
15. FilterObjects 
16. EnhanceOrSuppressFeatures 
17. MeasureObjectIntensity 
18. Crop 
19. IdentifyPrimaryObjects 
20. MaskImage 
21. MeasureObjectSizeShape 
22. MeasureObjectIntensity 
23. ConvertObjectsToImage 
24. RelateObjects 
25. CalculateMath 
26. CalculateMath 
27. CalculateMath 
28. OverlayOutlines 
29. OverlayOutlines 
30. OverlayOutlines 
31. OverlayOutlines 
32. DisplayDataOnImage 
33. DisplayDataOnImage 
34. DisplayDataOnImage 
35. DisplayDataOnImage 
36. DisplayDataOnImage 
37. SaveImages 
38. SaveImages 
39. SaveImages 
40. SaveImages 
41. SaveImages 
42. SaveImages 
43. SaveImages 
44. ExportToSpreadSheet 
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Figure 38. Cellprofiler pipeline for quantitative image analysis of LDL-uptake assay. 
Shown are representative images from the LDL-uptake assay (left column) acquired 
with the Scan^R software of the Olympus widefield microscope with the 20x 
objective and the segmentation of cellular structures (right column) performed 
through a Cellprofiler pipeline.  
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7.4.1.2.2 GFP-TAGGED VARIANT OVEREXPRESSION ANALYSIS 
In order to quantify the effect on LDL uptake of the overexpression of GFP-tagged 
HAVCR1 variants, two CellProfiler pipelines were sequentially used, after the initial 
visual inspection and filtering of images with ImageJ. In the first pipeline, the GFP 
threshold for transfected cells was determined, that would be used in the second 
pipeline, which calculated the effect of the cDNA transfection on LDL uptake.  
In the first pipeline (Tbl. 15), only the images from untransfected cells were loaded 
(LoadImages), and the fluorescence intensity was rescaled in the Cytoplasm, DAPI 
and GFP channels (RescaleIntensity). The image quality on the DAPI channel was 
measured (MeasureImageQuality) and the cell nuclei (IdentifyPrimaryObjects) and 
cytoplasm (IdentifySecondaryObjects) were identified as described previously (see 
7.4.1.2.1). Then, the cells were digitally expanded by 15 pixels 
(ExpandOrShrinkObjects) and the expanded cytoplasms were identified 
(IdentifySecondaryObjects). A mask was created by applying on the GFP image the 
inverted signal of the cell cytoplasm (MaskImage) and the GFP intensity of the cells 
was measured (MeasureImageIntensity). Afterwards, the GFP signal of the cells was 
normalized to the backround of the GFP image (ImageMath) and the cell GFP 
intensity was measured (MeasureObjectIntensity). Finally, the results were exported 
on a .csv spreadsheet (ExportToSpreadSheet). The pipeline modules are shown 
below. 
Table 15. Pipeline for the identification of the GFP threshold 
1. LoadImages  
2. RescaleIntensity  
3. RescaleIntensity  
4. RescaleIntensity  
5. MeasureImageQuality  
6. IdentifyPrimaryObjects  
7. IdentifySecondaryObjects  
8. ExpandOrShrinkObjects  
9. IdentifySecondaryObjects  
10. MaskImage  
11. MeasureImageIntensity  
12. ImageMath  
13. MeasureObjectIntensity  
14. ExportToSpreadSheet 
 
After exporting the results, the GFP intensity of the 95th percentile of the 
untransfected cells was calculated with Excel; 4*PERCENTILE(array,0.97) using the 
measurement; Mean_UnfilteredCytoplasm_Intensity_MeanIntensity_GFPbgCorr. 
This number was then used in the second pipeline.  
In the second pipeline (Tbl. 16), all the other images -excluding the ones from 
untransfected cells- were loaded as described previously, and the intensities in all 
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four channels (DAPI, cytoplasm, DiI-LDL, GFP) were rescaled. Then, steps 5-11 were 
performed as described before, and the dimensions of the enlarged cytoplasms were 
measured (MeasureObjectSizeShape). In the next step, the cells were filtered based 
on their size (FilterObjects), to exclude very small cells that could be apoptotic. 
Subsequently, a mask was created on the LDL channel and the GFP channel to 
measure the fluorescence background (MaskImage), and the background intensities 
were measured (MeasureImageIntensity). Next, the LDL background and GFP 
background were subtracted from the corresponding images (ImageMath). 
Afterwards, a threshold was applied to find saturated pixels in the LDL image 
(ApplyThreshold) and the number of saturated pixels was measured 
(MeasureObjectIntensity). In the following step, the cells with more that 10 
saturated pixels in LDL channel were filtered out, and the GFP threshold from the 
previous pipeline was applied to filter transfected cells (FilterObjects). The DiI-LDL 
signal was afterwards enhanced over the cellular background signal 
(EnhanceOrSuppressFeatures), and the fluorescence signal parameters of identified 
DiI-LDL dots are measured (MeasuredObjectIntensity). Then, DiI-LDL dots outside of 
cells are excluded (Crop) and dots within cells are finally identified, after setting a 
threshold (IdentifyPrimaryObjects). Next, a mask is created that consists of the dots 
that were previously identified (MaskImage), and the size and shape features of the 
identified dots are measured (ObjectSizeShape), as well as the fluorescence intensity 
of the dots within whole cells from the background corrected DiI-LDL image and the 
enhanced signal image (MeasureObjectIntensity). In the following two modules, a 
binary image is generated out of the identified DiI-LDL dots (ConvertObjectsToImage) 
and dots are assigned to the cells which they belong to (RelateObjects). In the next 
three modules, the mean total intensity of DiI-LDL for one cell (CalculateMath), the 
total area of DiI-LDL dots in one cell (CalculateMath) and the ratio of the DiI-LDL dots 
intensity to the total intensity (CalculateMath) are calculated. In the following 16 
modules, images are generated which visualize the outlines of the segmented 
objects on a black image and the fluorescence intensity data are shown on the 
objects and the images are saved as .tif files (OverlayOutlines, DisplayDataOnImage, 
SaveImages). Finally, the results are exported and saved as .csv files 
(ExportToSpreadSheet). 
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Table 16. Pipeline for the analysis of Variant Overexpression effect on LDL uptake 
1. LoadImages 
2. RescaleIntensity  
3. RescaleIntensity  
4. RescaleIntensity  
5. RescaleIntensity  
6. MeasureImageQuality  
7. MeasureImageIntensity 
8. IdentifyPrimaryObjects 
9. IdentifySecondaryObjects 
10. ExpandOrShrinkObjects 
11. IdentifySecondaryObjects 
12. MeasureObjectSizeShape 
13. FilterObjects 
14. MaskImage 
15. MaskImage 
16. MeasureImageIntensity 
17. ImageMath 
18. ImageMath  
19. ApplyThreshold 
20. MeasureObjectIntensity 
21. FilterObjects 
22. OverlayOutlines 
23. EnhanceOrSuppressFeatures 
24. MeasureObjectIntensity 
25. Crop 
26. IdentifyPrimaryObjects 
27. MaskImage 
28. MeasureObjectSizeShape 
29. MeasureObjectIntensity 
30. ConvertObjectsToImage 
31. RelateObjects 
32. CalculateMath 
33. CalculateMath 
34. CalculateMath  
35. OverlayOutlines 
36. OverlayOutlines  
37. GrayToColor 
38. OverlayOutlines  
39. OverlayOutlines  
40. OverlayOutlines  
41. DisplayDataOnImage  
42. DisplayDataOnImage  
43. DisplayDataOnImage  
44. DisplayDataOnImage  
45. DisplayDataOnImage  
46. SaveImages  
47. SaveImages  
48. SaveImages  
49. SaveImages  
50. SaveImages  
51. SaveImages  
52. SaveImages  
53. SaveImages  
54. SaveImages  
55. ExportToSpreadSheet 
 
7.4.1.3 HTM (HIGH-THROUGHPUT-MICROSCOPY) TOOL 
The image data generated from CellProfiler software were imported into HTM 
Explorer, an R-based software developed by C. Tischer from EMBL Heidelberg, for 
visual inspection, quality control and statistical analysis. Thresholds were set for the 
cell number range (5 to 150 cells per image), as well as for the quality (using the 
PowerLogLogSlope measurement from CellProfiler) and for the background of the 
DiI-LDL image. Finally, the data were normalized to the negative control and the 
measurements are saved. 
 
7.4.2 ANALYSIS OF SCREENING RESULTS 
Screening results were analysed using R Studio, R version 3.2.2. In the R code 
created by the author of this manuscript, the HTM output files of all the LabTeks 
analyzed in the screen were read one after the other, and the intensities were 
normalized to the negative control (Neg9). To achieve this, for each plate, the mean 
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robust z score per image, as well as the mean median absolute deviation, MAD of 
the image were calculated. In detail, the robust z score of an image was calculated 
by subtracting from the fluorescence signal (mean intensity of DiI-LDL dots per cell) 
from an siRNA treatment (͞treated͟), the median fluorescence signal of all the 
negative control siRNAs across the same plate (͞median(controls)͟) and dividing by 
the MAD of these controls (͞mad(controls)͟);  
 ݎ𝑜ܾݑݏݐ𝑍ݏܿ𝑜ݎ𝑒 = ௧௥௘𝑎௧௘ௗ−௠௘ௗ𝑖𝑎௡ሺ𝐶௧௥௟௦ሻ௠𝑎ௗሺ𝐶௧௥௟௦ሻ  .  
 
Then, a median robust z score per treatment was calculated for each treatment, by 
taking the median of robust z scores of same treatments across different biological 
replicates. The R script is shown below with some basic descriptions of the code.  
 
####### 
# Scipt written by Anthi Trasta 
#Combinatorial RNAi screen with LDL-uptake assay 
# Calculation of robust Z scores for each treatment, by normalizing to controls 
 
# Preparations 
rm(list=ls()) ### clear R-memory 
library(xlsx) ### load xlsx package  
setwd(͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis/HTM_ImageTables͟)  
### set data path for MacOSX  
flnms<-list.files(path=͟.͟) 
flNr<-length(flNms) 
Tblall<-data.frame 
 
# Import data and make calculations 
for (i in 1:flNr){  
Tbl<-read.csv(flNms[i]) ###read table and save into vector named Tbl  
trueTbl<-subset(Tbl,Tbl$HTM_qcImages==TRUE)&(Tbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean!=͟NA͟))  
### select rows that correspond to images which passed the quality control and where the  
### measurement to be analyzed is not NA  
trueTbl<-subset(trueTbl,select=c(͞Metadata_gene_sorted͟,͟Mean_Cytoplasm_Math_DiITotalIntensityDotsbyMean͟)) 
###select columns to be analyzed  
trueTbl$Metadata_gene_sorted<-as.factor(trueTbl$Metadata_gene_sorted) ###set treatment as factor  
trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean<-
as.numeric(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean) ###set measurement as numeric  
medianTbl<-
aggregate(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean,by=list(trueTbl$Metadata_gene_sorted), 
FUN=͟median͟,na.rm=TRUE) ###calculate median of each treatment and save in a table named medianTbl 
names(medianTbl)<-c(͞treatment͟,͟medianDiIintensity͟) ###name columns of medianTbl 
medianCtrl<-medianTbl$medianDiIintensity[medianTbl$treatment==͟XWNeg9__NA͟] 
###calculate median of controls of the plate  
MADTbl<-
aggregate(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean,by=list(trueTbl$Metadata_gene_sorted), 
FUN=͟mad͟,na.rm=TRUE) )  
###calculate median absolute deviation of each treatment and save in a table named MADTbl 
names(MADTbl)<-c(͞treatment͟,͟MADofDiIintensity͟) ###name columns of MADTbl 
MADctrl<-MADtbl$MADofDiIintensity[MADtbl$treatment==͟XWNeg9__NA͟] ###calculate MAD of controls of the plate  
trueTbl$robustZscore=(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean-medianCtrl)/MADctrl  
###calculate robust z score per treatment  
Tblall<-rbind(Tblall,trueTbl) ###each time this for-loop is run, the table generated is merged with a combined table, which 
###in the end consists of all the rows of all the tables generated 
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}  
robustZscoreTbl<-aggregate(Tblall$robustZscore,by=list(Tblall$Metadata_gene_sorted),FUN=͟median͟,na.rm=TRUE) 
###calculate robust Z score per treatment  
names(robustZscoreTbl)<-c("treatment","robustZscore") ###name columns of robustZscoreTbl 
madRobZscoreTbl<- aggregate(Tblall$robustZscore,by=list(Tblall$Metadata_gene_sorted), FUN=͟mad͟,na.rm=TRUE) 
###calculate mad of each robust Z score  
names(madRobZscoreTbl)<-c("treatment","madRobZscore")  ###name columns of madRobZscoreTbl 
robustZscoreTbl<-merge(robustZscoreTbl,madRobZscoreTbl,by=c("treatment")) ###merge the two tables  
names(robustZscoreTbl)<-c(͞treatment͟,͟ robustZscore͟,͟ madRobZscore͟) 
 
#Save Results 
wb<-createWorkbook() ###create new workbook 
Sheet1<-createSheet(wb,sheetName=͟Tblall͟) ###create new sheet in the workbook 
addDataFrame(x=Tblall,sheet=Sheet1,row.names=F) ###save Tblall in Sheet1  
Sheet2<-createSheet(wb,sheetName=͟robustZscoreTbl͟) ###create new sheet in the workbook  
addDataFrame(x=robustZscoreTbl,sheet=Sheet2,row.names=F) ###save robustZscoreTbl in Sheet2 
saveWorkbook(wb,͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis/Tblall.xlsx͟) ###save workbook as excel file  
write.csv(Tblall,͟/Volumes/t2pepperkok/Anthi/ScreenAnalysis/Tblall.csv͟,row.names=T)  
### save Tblall as .csv file to be used in next script  
write.csv(robustZscoreTbl,͟/Volumes/t2pepperkok/Anthi/ScreenAnalysis/robustZscoreTbl.csv͟,row.names=T)  
###save robustZscoreTbl as .csv file to be used in next script  
 
In an alternative approach, the robust Z scores were calculated by subtracting from 
the fluorescence signal (mean intensity of DiI-LDL dots per cell) of an siRNA 
treatment (͞treated͟), the median fluorescence signal of all treatments (after 
excluding the transfection controls; Incenp, and the positive controls; Ldlr and Npc1) 
across the same plate (͞median(All)͟) and dividing by the MAD of all treatments 
(͞mad(All)͟); 
 
 ݎ𝑜ܾݑݏݐ𝑍ݏܿ𝑜ݎ𝑒 = ௧௥௘𝑎௧௘ௗ−௠௘ௗ𝑖𝑎௡ሺ𝐴௟௟ሻ௠𝑎ௗሺ𝐴௟௟ሻ    (Birmingham et al. 2009; Malo et al. 2006).  
 
Then, a median robust Z score per treatment was calculated for each treatment, by 
taking the median of robust Z scores of same treatments across different biological 
replicates. The R scipt is shown below with some basic descriptions of the code. 
 
####### 
# Scipt written by Anthi Trasta 
#Combinatorial RNAi screen with LDL-uptake assay 
# Calculation of robust Z scores for each treatment, by normalizing to all treatments 
 
# The preparations are same as in previous script 
 
# Import data and make calculations 
for(i in 1:flNr){  
      Tbl<-read.csv(flNms[i]) ### read file and save to vector Tbl 
      trueTbl<-subset(Tbl,(Tbl$HTM_qcImages==TRUE) &(Tbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean!="NA"))  
      ### select rows that correspond to images which passed the quality control and where the  
      ### measurement to be analyzed is not NA  
      trueTbl<-subset(trueTbl,select=c("Metadata_gene_sorted","Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean", 
     "Mean_Cytoplasm_Math_Area_Endos_Mean","Mean_Dots_Intensity_IntegratedIntensity_MaskedLDLTopHat")) 
      ###select columns to be analyzed 
      trueTbl$Metadata_gene_sorted<-as.factor(trueTbl$Metadata_gene_sorted) ###set treatment as factor  
      trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean<-   
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      as.numeric(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean) ###set measurement as numeric 
      ###########  calculate medians  ######### 
      medianTbl<-trueTbl 
      medianTbl<-subset(medianTbl,(medianTbl$Metadata_gene_sorted!="INCENP__NA")&     
      (medianTbl$Metadata_gene_sorted!="LDLR__NA")&(medianTbl$Metadata_gene_sorted!="LDLR__NEG9")& 
      (medianTbl$Metadata_gene_sorted!="NPC1__NA")&(medianTbl$Metadata_gene_sorted!="NEG9__NPC1")) 
      medianTbl$Metadata_gene_sorted<-"any" ###remove treatment names, for calculation of median 
      medianAll<-aggregate(medianTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean, 
      by=list(medianTbl$Metadata_gene_sorted),FUN="mean",na.rm=TRUE) ###calculated medians of treatments 
      medianAll<-medianAll$x ###calculate median of all treatments 
      ###########  calculate mad  ######### 
      MADTbl<-trueTbl 
      MADTbl<-subset(MADTbl,(MADTbl$Metadata_gene_sorted!="INCENP__NA")& 
     (MADTbl$Metadata_gene_sorted!="LDLR__NA")&(MADTbl$Metadata_gene_sorted!="LDLR__NEG9")& 
     (MADTbl$Metadata_gene_sorted!="NPC1__NA")&(MADTbl$Metadata_gene_sorted!="NEG9__NPC1")) 
  MADTbl$Metadata_gene_sorted<-"any" ###remove names of treatments 
   MADAll<-aggregate(MADTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean,      
   by=list(MADTbl$Metadata_gene_sorted),FUN="mad",na.rm=TRUE) ###calculate medians of treatments 
  MADAll<-MADAll$x ###calculated mad of all treatments 
  #########  calculate Z score  ####### 
  trueTbl$minusMedianAll=(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean-medianAll) 
 trueTbl$robustZscore=(trueTbl$Mean_Cytoplasm_Math_DiITotalIntensityDots_byMean-medianAll)/MADAll 
 write.csv(trueTbl, file = paste("/Users/anthi/ PhD/Experiments/2016/ScreenAnalysis /",flNms[i]),row.names=FALSE) 
 Tblall<-rbind(Tblall,trueTbl)  ### merge each file (Tbl) to a new one (Tblall)  
 } 
 robustZscoreTbl<-aggregate(Tblall$robustZscore,by=list(Tblall$Metadata_gene_sorted),FUN=͟median͟,na.rm=TRUE)  
###calculate robust Z score per treatment  
 names(robustZscoreTbl)<-c("treatment","robustZscore") ###name columns of robustZscoreTbl 
 madRobZscoreTbl<- aggregate(Tblall$robustZscore,by=list(Tblall$Metadata_gene_sorted), FUN=͟mad͟,na.rm=TRUE) 
 ###calculate mad of each robust Z score  
 names(madRobZscoreTbl)<-c("treatment","madRobZscore")  ###name columns of madRobZscoreTbl 
 robustZscoreTbl<-merge(robustZscoreTbl,madRobZscoreTbl,by=c("treatment")) ###merge the two tables  
 names(robustZscoreTbl)<-c(͞treatment͟,͟ robustZscore͟,͟ madRobZscore͟) 
 
### Save Results; this part is same as in previous script 
 
7.4.3 INTERACTION ANALYSIS 
7.4.3.1 PRIMARY APPROACH; CONTROL-BASED NORMALIZATION 
To test for gene-gene interactions among the results of the combinatorial RNAi 
screen, the effect on LDL uptake of the combined transfection with two siRNAs 
targeting two different genes A and B was compared to the additive effect of the 
two single transfections. In single transfections the respective siRNAs were co-
transfected together with the negative control siRNA. For this, a robust linear model 
was fitted using R, where the additive effect of two single knockdowns A and B 
{(GeneA+control)+(GeneB+control)} was regressed to the respective double 
knockdown effect (GeneA+GeneB), assuming the negative control as an intercept, to 
derive a common effect estimate for each combination (Cordell 2002). Thus, the 
interaction effect wAB between two genes A and B was calculated from the 
difference between the main effects mA and mB of the two single knockdowns and 
the effect of the double knockdown yAB (wAB= mA+mB-yAB-y0), with y0 being the 
baseline value, which is given from the negative control siRNA effect. A p-value was 
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then calculated from the t-value of the linear regression model using the following 
equation; pVal=2-2*pnorm(abs(tVal)). To correct for multiple comparison, the p-value 
was adjusted using the false discovery rate (fdr) method (Benjamini and Hochberg 
1995), and the significance threshold for gene interactions was set at pValuefdr<10
-2. 
The R script for the interaction calling is shown below, with descriptions of the steps. 
 
####### 
# Script written by Anthi Trasta with the help of Bernd Klaus from Huber group 
#Combinatorial RNAi screen with LDL-uptake assay  
#Interaction calling  
 
#Preparations  
rm(list=ls()) ### clear R-memory 
library(xlsx) ### load xlsx package  
library(MASS) ### load MASS package for rlm function  
library(dplyr) ###load dplyr package  
setwd(͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis͟) ### set data path for MacOSX  
 
#Import data 
Tblall<-read.csv ### read Tblall.csv file generated from previous R-script  
robustZscoreTbl<-read.csv ### read robustZscoreTbl generated from previous R-script  
 
#Split treatments into two gene names 
for (i in 1:nrow(robustZscoreTbl){  
geneName<-unlist(strsplit(as.character(robustZscoreTbl$treatment[i],͟__͟))  
robustZscoreTbl$Gene1[i]=geneName[1] ###create new column with gene1 name 
 robustZscoreTbl$Gene2[i]=geneName[2] ###create new column with gene2 name  
}  
 
#Prepare for rlm fitting 
robustZscoreTbl$treatment<-as.character(robustZscoreTbl$treatment) 
robustZscoreTbl$treatment[robustZscoreTbl$Gene1=="XWNeg9"]<-"NEG9__NEG9" 
#rename treatment XWNeg9__NA into NEG9__NEG9 
robustZscoreTbl$Gene1[robustZscoreTbl$treatment=="NEG9__NEG9"]<-"NEG9" 
robustZscoreTbl$Gene2[robustZscoreTbl$treatment=="NEG9__NEG9"]<-"NEG9" 
robustZscoreTbl<-subset(robustZscoreTbl,(robustZscoreTbl$Gene2!="NA"))  
### exclude all controls; INCENP, NPC1, NEG1, LDLR, etc  
geneTbl<-read.csv(͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis/geneNames.csv͟) ###read table with names of 30 genes  
geneTbl2<-read.csv(͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis/geneNamesPlusNEG.csv͟) 
###read table containing the names of the 30 genes plus NEG9  
for (i in 1:nrow(Tblall)){ 
geneName<-unlist(strsplit(as.character(Tblall$Metadata_gene_sorted[i]),"__"))  #Separate gene names in table Tblall 
Tblall$Gene1[i]=geneName[1] ### create new col in Tblall with gene1 
Tblall$Gene2[i]=geneName[2] ### create new col in Tblall with gene2 
Tblall$treatment[i]<-paste(Tblall$Gene1[i],"__",Tblall$Gene2[i]) 
} 
 
#Fit robust  linear model  
rlmTbl<-data.frame() 
for(i in 1:nrow(geneTbl)) { 
testGene1<-geneTbl$gene[i] 
for(j in 1:nrow(geneTbl)){ 
testGene2<-geneTbl$gene[j]  
if (testGene1!=testGene2){ 
### create new data frame, with only those combinations from "Tblall" that contain the two testGenes; 
###Gene1__NEG9,Gene2__NEG9, Gene1__Gene2 and XWNeg9_NA 
### the "testTbl" is overwritten in each run of the loop 
testTbl<subset(Tblall,(Gene1=="XWNeg9")|((Gene1==testGene1)&(Gene2=="NEG9"))| 
((Gene1==testGene2)&(Gene2=="NEG9"))| 
((Gene1==testGene1)&(Gene2==testGene2))| 
((Gene1=="NEG9")&(Gene2==testGene1))| 
((Gene1=="NEG9")&(Gene2==testGene2))| 
((Gene1==testGene2)&(Gene2==testGene1)))   
for(k in 1:nrow(testTbl)){ 
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if (testTbl$Gene1[k]=="NEG9"){ 
          testTbl$Gene1[k]<-testTbl$Gene2[k] 
testTbl$Gene2[k]<-"NEG9" 
        } 
      }  
      combi<-(((testTbl$Gene1==testGene1)&(testTbl$Gene2==testGene2))| 
  ((testTbl$Gene1==testGene2)&(testTbl$Gene2==testGene1)))  
              ### combi: testGene1_testGene2, testGene2_testGene1 
              single1<-((testTbl$Gene1==testGene1)&(testTbl$Gene2=="NEG9")|combi) 
              ### single1: testGene1_NEG9, testGene1_testGene2, testGene2_testGene1 
      single2<-((testTbl$Gene1==testGene2)&(testTbl$Gene2=="NEG9")|combi) 
              ### single2: testGene2_NEG9, testGene1_testGene2, testGene2_testGene1 
      rlmfit<-rlm(robustZscore~single1+single2+combi,data=testTbl)  
      rs <- summary(rlmfit)$sigma  
      rlmfit.df<-as.data.frame(coef(summary(rlmfit))) 
      rlmfit.df$Gene1<-paste(testGene1) 
      rlmfit.df$Gene2<-paste(testGene2) 
      rlmTbl<-rbind(rlmTbl,rlmfit.df) 
}  
} 
} 
names(rlmfit.df)[2]<-"Std.Error" 
names(rlmTbl)[3]<-"tvalue" ###name the 2
nd
 and 3
rd
 column of table rlmTbl 
wb<-createWorkbook() ###create new workbook to save results 
rlmsheet<-createSheet(wb, sheetName="rlm") ###create new sheet in the workbook 
addDataFrame(x=rlmTbl,sheet=rlmsheet, row.names=F) ###add results of robust linear model to new sheet 
rlmTbl$coefficient=rownames(rlmTbl) ###create new column in rlmTbl, "coefficient", copying the column "rownames" 
rlmTblcombi<-subset(rlmTbl,grepl("combiTRUE",rlmTbl$coefficient)) 
### create new Table: "rlmTblcombi", with only those rows from rlm Tblall that contain "combiTRUE" which corresponds to the 
###value of the combined treatment 
rlmTblcombi<-within(rlmTblcombi, rm("coefficient")) ### remove column "coefficient" from rlmTblcombi 
for (i in 1:nrow(rlmTblcombi)){ 
  for (j in 2:nrow(rlmTblcombi)){ 
    if (rlmTblcombi$Gene1[i]==rlmTblcombi$Gene2[j]){ 
      if (rlmTblcombi$Gene2[i]==rlmTblcombi$Gene1[j]){ 
        rlmTblcombi$Gene1[j]<-rlmTblcombi$Gene1[i] 
        rlmTblcombi$Gene2[j]<-rlmTblcombi$Gene2[i] 
      } 
    } 
  } ### rename Gene2_Gene1 to Gene1_Gene2 
  rlmTblcombi$treatment[i]<-paste(rlmTblcombi$Gene1[i],"__",rlmTblcombi$Gene2[i])  
  ### create new column "treatment" with Gene1__Gene2 
} 
rlmTblcombi<-rlmTblcombi[!duplicated(rlmTblcombi$treatment), ] ###remove duplicated rows from table rlmTblcombi 
rlmTblcombi$pvalue<-(2-2*pnorm(abs(rlmTblcombi$tvalue))) ###calculate p-values 
rlmTblcombi$pVal_fdr<-p.adjust(rlmTblcombi$pvalue,method="fdr") ###apply fdr correction to p-values 
rlmTblcombi$pVal_fdr<-as.numeric(rlmTblcombi$pVal_fdr) 
 
#Calculate hits of robust linear model  
 
#Preparations 
CombiTbl<-data.frame(treatment=character())  #Create new data frame with all the gene combinations 
CombiTblall<-data.frame(treatment=character()) 
for (i in 1:nrow(geneTbl2)){ 
for (j in 1:nrow(geneTbl2)){ 
CombiTbl<-data.frame(paste(geneTbl2$gene[i],"__",geneTbl2$gene[j])) 
CombiTblall<-rbind(CombiTblall,CombiTbl) 
} 
} 
names(CombiTblall)<-c("treatment") 
for (i in 1:nrow(CombiTblall)){ 
geneName<-unlist(strsplit(as.character(CombiTblall$treatment[i])," __ "))  #Separate gene names in table CombiTblall 
CombiTblall$Gene1[i]=geneName[1] ### create new col in Tblall with gene1 
CombiTblall$Gene2[i]=geneName[2] ### create new col in Tblall with gene2 
CombiTblall$treatment[i]<-paste(CombiTblall$Gene1[i],"__",CombiTblall$Gene2[i]) 
}  
 
#Calculation of hits 
rlmTblfdrsign1star<-subset(rlmTblcombi,rlmTblcombi$pVal_fdr<0.05) 
rlmTblfdrsign2stars<-subset(rlmTblcombi,rlmTblcombi$pVal_fdr<0.01) 
rlmTblfdrsign3stars<-subset(rlmTblcombi,rlmTblcombi$pVal_fdr<0.001) 
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rlmTblfdrsign4stars<-subset(rlmTblcombi,rlmTblcombi$pVal_fdr<0.0001) ###Create four new tables that contain the ͞hits͟ 
###Define significance as follows: * =pValfdr<0.05, **= pValfdr<0.01, *** =pValfdr<0.001, ###****=pValfdr<0.0001  
rlmTblfdrsign1star[,"robustZscore"] <- NA 
rlmTblfdrsign1star[,"madRobZscore"] <- NA 
for (l in 1:nrow(rlmTblfdrsign1star)){ 
  for (k in 1:nrow(CombiTblall)){ 
    if ((CombiTblall$treatment[k]==rlmTblfdrsign1star$treatment[l])){ 
      rlmTblfdrsign1star$robustZscore[l]<-CombiTblall$robustZscore[k] 
      rlmTblfdrsign1star$madRobZscore[l]<-CombiTblall$madRobZscore[k] 
    }   
  } 
} 
###add robustZscore and madRobZscore values to hits table, from CombiTblall rlmTblfdrsign2stars[,"robustZscore"] <- NA 
rlmTblfdrsign2stars[,"madRobZscore"] <- NA 
for (l in 1:nrow(rlmTblfdrsign2stars)){ 
  for (k in 1:nrow(CombiTblall)){ 
    if ((CombiTblall$treatment[k]==rlmTblfdrsign2stars$treatment[l])){ 
      rlmTblfdrsign2stars$robustZscore[l]<-CombiTblall$robustZscore[k] 
      rlmTblfdrsign2stars$madRobZscore[l]<-CombiTblall$madRobZscore[k] 
    }   
  } 
} 
rlmTblfdrsign3stars[,"robustZscore"] <- NA 
rlmTblfdrsign3stars[,"madRobZscore"] <- NA 
for (l in 1:nrow(rlmTblfdrsign3stars)){ 
  for (k in 1:nrow(CombiTblall)){ 
    if ((CombiTblall$treatment[k]==rlmTblfdrsign3stars$treatment[l])){ 
      rlmTblfdrsign3stars$robustZscore[l]<-CombiTblall$robustZscore[k] 
      rlmTblfdrsign3stars$madRobZscore[l]<-CombiTblall$madRobZscore[k] 
    }   
  } 
} 
 
rlmTblfdrsign4stars[,"robustZscore"] <- NA 
rlmTblfdrsign4stars[,"madRobZscore"] <- NA 
for (l in 1:nrow(rlmTblfdrsign4stars)){ 
  for (k in 1:nrow(CombiTblall)){ 
    if ((CombiTblall$treatment[k]==rlmTblfdrsign4stars$treatment[l])){ 
      rlmTblfdrsign4stars$robustZscore[l]<-CombiTblall$robustZscore[k] 
      rlmTblfdrsign4stars$madRobZscore[l]<-CombiTblall$madRobZscore[k] 
    }   
  } 
} 
 
#Save results 
rsignfdrsheet1<-createSheet(wb, sheetName="rsignfdrTbl1star") 
addDataFrame(x=rlmTblfdrsign1star,sheet=rsignfdrsheet1, row.names=F) 
rsignfdrsheet2<-createSheet(wb, sheetName="rsignfdrTbl2stars") 
addDataFrame(x=rlmTblfdrsign2stars,sheet=rsignfdrsheet2, row.names=F) 
rsignfdrsheet3<-createSheet(wb, sheetName="rsignfdrTbl3stars") 
addDataFrame(x=rlmTblfdrsign3stars,sheet=rsignfdrsheet3, row.names=F) 
rsignfdrsheet4<-createSheet(wb, sheetName="rsignfdrTbl4stars") 
addDataFrame(x=rlmTblfdrsign4stars,sheet=rsignfdrsheet4, row.names=F) 
saveWorkbook(wb,͞/Volumes/t2pepperkok/Anthi/ScreenAnalysis/Interactions.xlsx") 
 
 
 
7.4.3.2 ALTERNATIVE APPROACH; SAMPLE-BASED NORMALIZATION 
An alternative statistical method was used, to analyze the co-RNAi screen data for 
genetic interactions. In this approach, the effect on LDL uptake of the combined 
transfection with two siRNAs targeting two different genes A and B was compared to 
the additive effect of the two single transfections, which were considered the 
combination of the respective siRNA with any other siRNA. For this, a robust linear 
  143 
model was fitted using R, where the additive effect of two single knockdowns A and 
B {(GeneA+any)+(GeneB+any)} was regressed to the respective double knockdown 
effect (GeneA+GeneB), assuming the negative control as an intercept, to derive a 
common effect estimate for each combination (Cordell 2002). Thus, the interaction 
effect wAB between two genes A and B was calculated from the difference between 
the main effects mA and mB of the two single knockdowns and the effect of the 
double knockdown yAB (wAB= mA+mB-yAB-y0), with y0 being the baseline value, which 
is given from the median effect of any other treatment. A p-value was then 
calculated and adjusted using the false discovery rate (fdr) method, as before. The R 
script for the interaction calling is shown below, with descriptions of the steps. 
 
####### 
# Script written by Anthi Trasta with the help of Bernd Klaus from Huber group 
#Combinatorial RNAi screen with LDL-uptake assay  
#Interaction calling  
 
###The parts; Preparations, Import data, Split treatment names and Prepare for rlm fitting are the same as in previous code 
 
###Fit robust linear model 
rlmTbl<-data.frame() 
for(i in 1:nrow(geneTbl)) { 
testGene1<-geneTbl$gene[i] 
for(j in 1:nrow(geneTbl)){ 
      testGene2<-geneTbl$gene[j]  
      if (testGene1!=testGene2){ 
      ### create new data frame, with only those combinations from "Tblall" that contain the two testGenes   
      ### combinations: Gene1__any,Gene2__any, Gene1__Gene2 and [any treatment] as control  
      ### the "testTbl" is overwritten in each run of the loop 
      controlTbl<-subset(Tblall,((Tblall$Metadata_gene_sorted!="INCENP__NA")& 
      (Tblall$Metadata_gene_sorted!="NPC1__NA")&(Tblall$Metadata_gene_sorted!="NEG9__NPC1"))) 
      controlTbl$Metadata_gene_sorted<-"any" 
      controlTbl$Gene1<-"any" 
      controlTbl$Gene2<-"any" 
      single1Tbl<-subset(Tblall,((Gene1==testGene1)|(Gene2==testGene1))) 
              for(k in 1:nrow(single1Tbl)){ 
            single1Tbl$Gene2[k]<-"any" 
            single1Tbl$Gene1[k]<-testGene1 
            single1Tbl$Metadata_gene_sorted<-paste(single1Tbl$Gene1,"__",single1Tbl$Gene2) 
      }       
      single2Tbl<-subset(Tblall,((Gene1==testGene2)|(Gene2==testGene2))) 
      for(k in 1:nrow(single2Tbl)){ 
            single2Tbl$Gene2[k]<-"any" 
            single2Tbl$Gene1[k]<-testGene2 
            single2Tbl$Metadata_gene_sorted<-paste(single2Tbl$Gene1,"__",single2Tbl$Gene2) 
      }  
     doublesTbl<-subset(Tblall,((Gene1==testGene2)&(Gene2==testGene1))|((Gene1==testGene1)&(Gene2==testGene2))) 
     for(k in 1:nrow(doublesTbl)){ 
           doublesTbl$Gene1[k]<-testGene1 
           doublesTbl$Gene2[k]<-testGene2 
           doublesTbl$Metadata_gene_sorted<-paste(doublesTbl$Gene1,"__",doublesTbl$Gene2) 
     } 
    testTbl<-rbind(controlTbl,single1Tbl,single2Tbl,doublesTbl) 
combi<-((testTbl$Gene1==testGene1)&(testTbl$Gene2==testGene2)) ### combi: testGene1_testGene2 
single1<-((testTbl$Gene1==testGene1)&(testTbl$Gene2=="any")|combi) ### single1: testGene1_any 
single2<-((testTbl$Gene1==testGene2)&(testTbl$Gene2=="any")|combi) ### single2: testGene2_any 
rlmfit<-rlm(robustZscore~single1+single2+combi,data=testTbl)  
rs <- summary(rlmfit)$sigma  
rlmfit.df<-as.data.frame(coef(summary(rlmfit))) 
names(rlmfit.df)[2]<-"Std.Error" 
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rlmfit.df$Gene1<-paste(testGene1) 
rlmfit.df$Gene2<-paste(testGene2) 
fsheet<-createSheet(wb2, sheetName=paste(testGene1,"__",testGene2)) 
addDataFrame(x=rlmfit.df,sheet=fsheet, row.names=F) 
rlmTbl<-rbind(rlmTbl,rlmfit.df) 
}  
      } 
} 
names(rlmTbl)[3]<-"tvalue" ###name the 3rd column of rlm Tbl 
rlmTbl$coefficient=rownames(rlmTbl) ###create new column in lmTbl, "coefficient", copying the column "rownames"  
 
###The rest of the code is the same as in previous one 
 
 
7.4.4 PLOTTING OF SCREEN HITS 
7.4.4.1 BARPLOTS 
### This R-code chunk continues from the previous one 
rlmTblfdrsign2stars<-rlmTblfdrsign2stars[with(rlmTblfdrsign2stars, 
order(-rlmTblfdrsign2stars$Value,rlmTblfdrsign2stars$treatment)),] ###order hits according to interaction effect 
 
pdf("/Volumes/t2pepperkok/Anthi/ScreenAnalysis/barplot_interactions_2stars.pdf")   par(mar=c(8,7,2,2))   
bp<-barplot(height=rlmTblfdrsign4stars$Value,              
    space=c(0,1),              
    main="Gene Interactions pVal(fdr)<10^-4",              
    axes=F,              
    ylim=c(-4,4),              
   xpd=F )  
axis(side=2,       
         pos=1,       
         las=1,        
         at=c(-4,-3,-2,-1,0,1,2,3,4))  
axis(side=1,       
at=bp,       
labels=F)  
text(x=seq_along(rlmTblfdrsign4stars$treatment),       
par("usr")[3]-0.2,       
adj=c(0.9,2.4),       
srt=45,xpd=T,       
labels=rlmTblfdrsign4stars$treatment,       
cex=0.7)  
arrows(bp,rlmTblfdrsign4stars$Value+rlmTblfdrsign4stars$Std.Error,        bp,rlmTblfdrsign4stars$Value-
rlmTblfdrsign4stars$Std.Error,         
angle=90,         
code=3,         
length=0.05)   
abline(h=c(0))  
mtext("treatment",side=1,line=6) mtext("Estimated value of robust linear model",side=2,line=5)  
 
dev.off() 
 
 
7.4.4.2 CORRELATION HEATMAP 
### This R-code chunk continues from the previous one 
CombiTblalln<-data.frame(grep("NEG9",CombiTblall$treatment,value=T,invert=T)) 
CombiTblalln<-subset(CombiTblall,(CombiTblall$Gene1!="NEG9")&(CombiTblall$Gene2!="NEG9")) 
 
pdf("/Volumes/t2pepperkok/Anthi/ScreenAnalysis/CorrelationHeatmap.pdf")   
rgb.palette <- colorRampPalette(c("green", "white","magenta"), space = "rgb") 
par(mar=c(8,6,2,2)) 
 
#Build the horizontal and vertical axis information 
hor <- c(geneTbl$gene) 
ver <- c(geneTbl$gene) 
 
#Build the fake correlation matrix, see matrix{base} 
Nrow<-length(unique(as.factor(CombiTblalln$Gene1))) 
Ncol<-length(unique(as.factor(CombiTblalln$Gene2))) 
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CorHeatDat<-CombiTblalln$robustZscore 
cor <- matrix(data=CorHeatDat, nrow=Nrow, ncol=Ncol, dimnames = list(hor, ver)) 
 
#Build the plot 
levelplot(cor,  
          main="Candidate LDL-effector genes array correlation matrix",  
          xlab="Gene 1",  
          ylab="Gene 2",  
          scales=list(x=list(rot=90)), 
          col.regions=rgb.palette(150),  
          cuts=100,  
          at=seq(-max(abs(CombiTblalln$robustZscore)),max(abs(CombiTblalln$robustZscore)),0.1)) 
dev.off() 
 
7.4.5 QRT-PCR ANALYSIS 
qRT-PCR results were analyzed using the comparative CT method. For this, baseline 
fluorescence was set in the StepOne Software, to subtract the background signal 
owed to the reaction medium. This baseline threshold was set to 0.1 CT and was kept 
constant throughout all the qRT-PCR reactions performed, for comparison reasons. 
Next, the threshold cycle (CT) value was determined, which reflects the cycle number 
at which the fluorescence signal generated from a reaction crosses the threshold. 
The difference (ΔCT) between the CT value of a target gene and the CT value of a 
housekeeping gene (typically GAPDH) was calculated. Subsequently, the difference 
(ΔΔCT) between the ΔCT from a treated well and a non-treated well was calculated 
and the fold change corresponded to 2-ΔΔCT. The statistical significance of the 
treatment fold change compared to the untreated was calculated by using a two-
tailed Student’s t-test in Microsoft Excel (TTEST (array1, array2, 2, 3)). 
 
7.4.6 WESTERN BLOTTING ANALYSIS 
Scanned western blots were analyzed with ImageJ to quantify protein band 
intensities. For the quantifications, films were selected where bands were not 
saturated. As a first step in the protein quantification, the intensity of bands was 
normalized to background intensity, and then the intensity of protein bands of 
interest was normalized to that of a-tubulin bands on the same gel. 
 
7.4.7 PROTEIN/ MRNA INTERACTION ANALYSIS 
To test for interactions at the level of LDLR or SREBF1/2 mRNA, or LDLR protein, the 
results of qPCR or western blotting experiments, respectively were used. For qPCR, 
results derived from three to four biological replicas, and from three replicas for 
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western blots. The exact same experimental conditions (48h knockdown, cell 
starvation) were used, as before performing the LDL-uptake assay. Specifically, for 
ƋPCR expeƌiŵeŶts, the ΔCt ǀalues (see section 7.4.5) were used to fit a linear model, 
whereas for Western blot experiments, the ratio LDLR/a-tubulin (see 7.4.6), without 
normalization was used. The effect of the combined transfection with two siRNAs 
targeting two different genes A and B was compared to the additive effect of the 
two single transfections. In single transfections the respective siRNAs were co-
transfected together with the negative control siRNA. For this, a robust linear model 
was fitted using R, where the additive effect of two single knockdowns A and B 
{(GeneA+control)+(GeneB+control)} was regressed to the respective double 
knockdown effect (GeneA+GeneB), assuming the negative control as an intercept, to 
derive a common effect estimate for each combination (Cordell 2002). A p-value was 
then calculated from the t-value of the linear regression model using the following 
equation; pVal=2-2*pnorm(abs(tVal)). To correct for multiple comparison, the p-value 
was adjusted using the false discovery rate (fdr) method (Benjamini and Hochberg 
1995), and the significance threshold for gene interactions was set at pValuefdr<10
-1. 
The R script for the interaction calling is shown below, with descriptions of the steps. 
 
####### 
# Script written by Anthi Trasta  
rm(list=ls())           ### clear R-memory 
 
#Preparations  
 
library(xlsx)           ### load xlsx package 
library(MASS)       ### load MASS package for rlm function 
setwd("/Users/anthi/Desktop/Interaction_calc")  
 
#Import data 
Tbl<-read.csv("Table.csv") ### read file and save to vector Tbl 
 
#Split treatments into two gene names 
for (i in 1:nrow(Tbl)){ 
  geneName<-unlist(strsplit(as.character(Tbl$treatment[i]),"__"))   
   
  Tbl$Gene1[i]=geneName[1] ### create new col in Tblall with gene1 
  Tbl$Gene2[i]=geneName[2] ### create new col in Tblall with gene2 
   
} 
 
#Prepare for rlm fitting 
###Change the two test genes every time this chunk is ran, to test for all gene pairs 
testGene1<-"HAVCR1" 
testGene2<-"LDLR" 
rlmTbl<-data.frame() 
testTbl<-subset(Tbl,(Gene1=="NEG9")|((Gene1==testGene1)&(Gene2=="NEG9"))|((Gene1==testGene2)&(Gene2=="NEG9"))| 
                  ((Gene1==testGene1)&(Gene2==testGene2))|((Gene1==testGene2)&(Gene2==testGene1)))   
combi<-
(((testTbl$Gene1==testGene1)&(testTbl$Gene2==testGene2))|((testTbl$Gene1==testGene2)&(testTbl$Gene2==testGene1)))  
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single1<-((testTbl$Gene1==testGene1)&(testTbl$Gene2=="NEG9")|combi) 
single2<-((testTbl$Gene1==testGene2)&(testTbl$Gene2=="NEG9")|combi) 
 
#Fit robust  linear model  
rlmfit<-rlm(DDCt~single1+single2+combi,data=testTbl)  
rs <- summary(rlmfit)$sigma  
rlmfit.df<-as.data.frame(coef(summary(rlmfit))) 
names(rlmfit.df)[2]<-"Std.Error" #name column 2 of generated table 
rlmfit.df$Gene1<-paste(testGene1) 
rlmfit.df$Gene2<-paste(testGene2) 
rlmTbl<-rbind(rlmTbl,rlmfit.df) 
names(rlmTbl)[3]<-"tvalue" #name column 3 of generated table 
rlmTbl$pvalue<-(2-2*pnorm(abs(rlmTbl$tvalue))) #calculate p-values 
 
#Save data 
wb<-createWorkbook() 
sheet1<-createSheet(wb, sheetName="HAVCR1_LDLR") 
addDataFrame(x=rlmTbl,sheet=sheet1, row.names=F) 
saveWorkbook(wb, "/Users/anthi/Desktop/qRT-PCR/LDLR_mRNA_interaction_calc/linear_model.xlsx") 
 
7.4.8 NUCLEIC ACID DESIGN 
7.4.8.1 QRT-PCR PRIMER DESIGN 
Primers for qRT-PCR were custom designed to target the genes studied and met 
certain requirements, according to which the parameters of the primer design tool 
(NCBI Primer-Blast) were set; First, the primers need to span an exon-exon junction 
to avoid amplification of genomic DNA. For this purpose, two neighboring exons 
were selected that were present in most protein coding transcripts of the gene, 
using the Ensembl genome browser. The sequences of the two exons were extracted 
from Ensembl and jointly pasted into NCBI Primer-Blast Tool. The range for the 
design of the forward primer was set within the sequence of the first exon, while the 
range for the design of the reverse primer was set within the sequence of the second 
exon. Second, the PCR product size was set between 60 and 150 bp for efficient 
amplification. Third, the primer melting temperature was set between 57°C and 
63°C, with the ideal Tm being 60°C, and the maximum Tm between the two primers 
targeting the same gene was set as 3°C. Fourth, the primer GC content was set 
around 50-60% to ensure maximum product stability. Last, the primer length was set 
between 18 and 23 nucleotides.  In order to examine the retrieved primers from 
NCBI Primer-Blast for specific targeting, the primers were mapped against the 
human reference genome (Human GRCh38) using the Ensembl BLAST/BLAT Tool. 
Specifically, each primer sequence was pasted into BLAST, and a search was 
performed against the DNA database, selecting the option ͞Genomic sequence͟, and 
with the search tool BLASTN, with sensitivity for Short sequences. Primers binding to 
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other genomic locations with high identity and statistical significance were not 
selected. Next, selected primers were evaluated for secondary structure formation 
and dimerization probability using the OligoEvaluator Tool from Sigma-Aldrich. 
Primers with high probability to form secondary structures were rejected. Finally, 
the selected primers that passed the aforementioned quality control criteria were 
ordered from Sigma Aldrich. 
 
7.4.8.2 SIRNA DESIGN 
7.4.8.2.1 MAPPING SIRNAS TO THE REFERENCE GENOME 
Most of the siRNAs used in this study were extracted from Blattmann et al. 
(Blattmann et al. 2013), and few were selected using Bluegecko Tool (J.K. Hériché). 
All siRNAs were initially mapped to the reference genome (Ensembl 66 release 
GRCh38) with Bluegecko. With this tool the number of targeted protein-coding 
transcripts was evaluated and unspecific siRNAs that target other human mRNAs 
were identified. Moreover, the siRNAs were evaluated for mismatches to the 
reference sequence of the respective target gene or for targeting transcripts not 
anymore considered as protein coding. 
 
7.4.8.2.2 CELLBASE 
All the plates and microscope images from the interaction screen performed in this 
study were uploaded and stored in Cellbase. Cellbase is an EMBL internal database, 
developed and maintained by S. Sauer. Thus, all the images from spotted positions 
across a LabTek could be easily explored and evaluated. 
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8 ABBREVIATIONS 
 
CAD   Coronary Artery Disease 
CDCV   Common Disease, Common Variant 
cDNA   complementary DNA 
CDRV   Common Disease, Rare Variant 
Co-RNAi  combinatorial RNA interference 
Cq   quantitation cycle 
Ct, CT   threshold cycle 
Ctrl   Control 
CVAS   Common Variant Association Study  
CVD   Cardiovascular Disease 
DAPI   4,6-Diamino-2-Phenylindole 
DiI   Di-alkyl-Indocarbocyanine dye 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO   Dimethylsulfoxide 
DRAQ5   Deep Red Anthraquinone 5 EDTA    
Em   Emission 
ESP   Exome Sequencing Project 
EVS   Exome Variant Server 
Ex   Excitation 
FC   Free Cholesterol 
FH   Familial Hypercholesterolemia 
FW   Forward 
GAPDH  Glyceraldehyde 3-Phosphate Dehydrogenase  
GFP   Green Fluorescent Protein 
GI   Genetic Interaction 
GWAS   Genome Wide Association Study 
HDL   High-Density Lipoprotein 
HDL-C   HDL-cholesterol 
HPCD   Hydroxypropylcyclodextrin 
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IM   Imaging Medium 
LD   Linkage Disequilibrium 
LDL   Low-Density Lipoprotein 
LDL-C   LDL-cholesterol 
LDLR   Low-Density Lipoprotein Receptor 
MAD   Median Absolute Deviation 
MAF   Minor Allele Frequency  
MI   Myocardial Infarction 
MOPS   (3-(N-morpholino) propanesulfonic acid 
mRNA   messenger RNA 
OR   Odds Ratio 
PBS   Phosphate Buffer Saline 
PBS-T   Phosphate Buffer Saline-Tween 
PCR   Polymerase Chain Reaction 
PFA   Paraformaldehyde 
PVDF   Polyvinylidene Fluoride 
RNAi   RNA-mediated interference 
RNA-Seq   RNA Sequencing 
RT   Room Temperature 
RT-qPCR  quantitative Real-Time Polymerase Chain Reaction 
RV   Reverse 
RVAS   Rare Variant Association Study 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
siRNA   small interfering RNA 
SNP   Single Nucleotide Polymorphism 
TG   Triglycerides 
TC   Total Cholesterol 
ΔCT   threshold cycle difference  
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9 APPENDIX 
9.1 SUPPLEMENTARY TABLES 
 
Table S1. Exome-Chip results from 2/12/2013 (Peloso et al. 2014) 
Shown in this table are the number of individuals genotyped for each of four lipid traits (LDL, HDL, TG 
and TC), and the number of variants identified at a genome-wide significance level to be associated 
with these traits, as well as the number of the corresponding genes. Moreover, the number of genes 
that were also tested in Blattmann et al. (͞of these in GWAS-RNAi͟), and the percentage of overlap 
between genes identified in Exome Chip and the ones from Blattmann et al. (͞% overlap͟) are shown. 
 
 
  LDL HDL TG TC 
No. of individuals genotyped 73.652 75.995 75.273 76.948 
No. of variants with p<10-7 159 242 182 207 
No. genes with variants p<10-7  61 87 56 68 
 of these in GWAS-RNAi 28 28 25 35 
 % overlap 0,26 0,18 0,23 0,27 
No. genes with missense  p<10-7 33 55 29 37 
 of these in GWAS-RNAi 13 18 13 22 
 % overlap 0,28 0,23 0,33 0,44 
 152 
Table S2. Exome-Chip results from 2/12/2013 (Peloso et al. 2014) and comparison of data to Blattmann et al., by Heiko Runz. 
Juxtaposition of the Exome Chip results with the Blattmann et al results. In the left part of the table are shown are the number of variants (total and missense) from the Exome Chip associated at a genome-wide 
significance level with each of four lipid traits (LDL, HDL, TG and TC). In the right part of the table are shown the number of siRNAs tested per gene in the Blattmann et al. study (͞siRNAs͟), and the number of siRNAs 
that had an effect on LDL uptake (͞LDL͟) or free cholesterol (͞FC͟). Moreover, it is shown if the gene was tested in a secondary assay (͞sec.assay?͟), y= tested, n=not tested, if the filipin assay results were validated 
in Huh7 cells (͞FC val.͟), or in if it had an effect on LDLR mRNA (͞LDLR͟), if the overexpression of GFP-tagged protein of the gene (͞GFP-͞), or of its cDNA had an effect (͞cDNA͟). SiRNAs that showed an effect below 
or above thresholds are indicated with blue (decreased) or red (increased). 
 
 Gene 
Exome Chip (2-12-13; 75K individuals) Blattmann et al., 2013 
LDL HDL TG TC RNAi effector? Secondary assay effector? cDNA effector? 
total  miss. total  miss. total  .miss. total  miss. siRNAs LDL 
uptake 
FC sec. assay? FC val. LDLR GFP-
cDNA? 
cDNA 
effect? APOE 2 1 2 1 2 1 2 1 5 1 3 y 2 NA NA NA 
BAZ1B 0 0 2 0 3 0 0 0 6 0 3 y 2 0 y 2 
BCAM 2 2 0 0 1 1 2 2 6 0 3 n NA NA NA NA 
BCL7B 0 0 1 0 1 0 0 0 5 1 4 y 0 -2 NA NA 
CBLC 1 1 0 0 0 0 1 1 4 2 2 y 0 NA NA NA 
CELSR2 4 1 2 0 0 0 4 1 6 0 1 n NA NA NA NA 
HAVCR1 0 0 0 0 0 0 1 1 6 0 4 y 2 NA y 2 
LDLR 3 0 0 0 0 0 3 0 7 -4 -2 y -2 -2 y 2 
LPL 0 0 8 3 8 3 0 0 6 -1 1 y NA 0 y 0 
MLXIPL 0 0 2 2 2 2 0 0 5 0 2 y 2 2 y 0 
MYBPHL 2 2 0 0 0 0 1 1 5 1 3 y 0 NA y 2 
NCAN 1 1 0 0 1 1 1 1 5 1 4 y 2 NA y 2 
PCSK9 3 3 0 0 0 0 3 3 3 0 3 n NA NA y NA 
PVRL2 1 0 0 0 0 0 1 0 4 1 1 n NA NA NA NA 
SIK3 0 0 1 0 3 0 2 0 5 0 1 y NA 0 y 2 
TM6SF2 1 1 0 0 1 1 1 1 5 -1 3 y 2 2 y 0 
TMEM57 1 0 0 0 0 0 1 0 5 1 3 y 2 0 y 2 
TOMM40 2 0 2 0 2 0 2 0 5 -1 3 y -2 NA y 0 
APOB 9 8 4 3 5 4 7 6 3 0 3 y 0   NA  NA  
HMGCR 3 0 0 0 0 0 3 0 3 0 1 y NA 0 NA NA 
ZNF259 1 0 3 1 3 1 3 1 4 0 1 n NA NA NA NA 
CXCL12 0 0 0 0 0 0 0 0 5 1 3 y 0 1 y -1 
SORT1 0 0 0 0 0 0 0 0 4 -1 -1 y -1 0 y 1 
FAM174A 0 0 0 0 0 0 0 0 5 -1 2 y 0 -2 y 2 
PAFAH1B1 0 0 0 0 0 0 0 0 5 -3 -2 y -2 -2 y 0 
WDR12 0 0 0 0 0 0 0 0 0 0 -2 y 0 -2 y 2 
SEZ6L 0 0 0 0 0 0 0 0 5 -1 -1 y -1 2 y 1 
LDLRAP1 0 0 0 0 0 0 0 0 5 0 3 y 1 4 NA NA 
MYLIP 1 1 0 0 0 0 0 0 NA NA NA NA NA NA y NA 
PAFAH1B2 0 0 1 1 3 2 2 1 NA NA NA NA NA NA NA NA 
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Table S3. Overview of genes analyzed and the GWAS that showed association to blood lipid levels 
and/or CAD/MI. 
 
  
Locus 1p13.3 1p32.3 1p36.11 2p24-p23 2q33 5q13.3-q14 5q21 5q23 6p22.3-23 7q11. 23 8p21.3 10q11.1 11q23.3 17q13.3 19p12 19p13. 2 19q13. 2 22q12.1 
Genes 
CELSR2/ 
MYBPHL/ 
SORT1 
PCSK9 
LDLRAP1/ 
TMEM57 
APOB WDR12 HMGCR FAM174A HAVCR1 MYLIP 
BAZ1B/ 
BCL7B/ 
MLXIPL 
LPL CXCL12 
SIK3/ 
ZNF259/ 
PAFAH1B2 
PAFAH1B1 
NCAN/ 
TM6SF2 
LDLR 
APOE/ 
BCAM/ 
CBLC/ 
PVRL2/ 
TOMM40 
SEZ6L 
Lead trait LDL LDL TC LDL/TG CAD/MI TC CAD/MI TC TG TG TG CAD/MI TG HDL TC LDL LDL/TG CAD/MI 
studies with association 28 21 6 29 4 13 2 8 5 28 37 9 28 4 8 24 41 4 
Allen 2016 
                                x   
Angelakopoulou 2012 
      x                         x x 
Asselberg et al. 2012 x x   x   x       x x   x   x x     
Aulchenko et al. 2009 x   x x   x       x x   x   x x x   
Barber et al. 2010   x     x           x       x         
Below 2016 x                   x   x   x       
Benn 2008           x                         
Braun et al. 2012 x                       x       x   
Brautbar et al. 2011                         x           
Burkhardt et al. 2008           x                     x   
C4D et al. 2012 x x   x x           x x       x     
Calandra et al. 2011 x     x   x     x                   
Chambers et al. 2011                   x     x           
Chasman et al. 2008       x                 x       x   
Chasman et al. 2009a                   x x               
Chasman et al. 2009b       x                             
Chasman et al. 2012   x             x             x x   
Comuzzie et al. 2012                         x           
Coram et al. 2013   x   x             x         x x   
Dichgans et al. 2013 x       x           x   x     x     
Elbers et al. 2012   x                           x x   
Willer GLGC 2013 x x x x   x     x x x   x x x x x   
Grallert et al. 2012                         x           
Guo et al. 2011                   x                 
Heid et al. 2008                     x               
Hopewell et al. 2013                                 x   
Johansen et al. 2011                     x   x           
Kamatani et al. 2010                   x x               
Kathiresan et al. 2008a x     x   x   x   x x   x   x x x   
Kathiresan et al. 2008b   x   x   x                     x   
Kathiresan et al. 2009 x x     x         x x x       x     
Katoh et al. 2004                         x           
Keller et al. 2013                     x               
Kettunen et al. 2012   x               x     x       x   
Kim et al. 2011                   x x   x       x   
Ko et al. 2014                     x   x           
Kooner et al. 2008                   x x   x           
Kraja et al. 2011                     x   x       x   
Kristiansson et al. 2012                   x             x   
Kurano 2016                     x   x       x   
Lee 2013                       x             
Lettre et al. 2011   x x   x   x   x     x x   x   x   x 
Lu et al. 2010                     x         x x   
Makela et al. 2014       x                             
Mehta et al. 2011                       x             
Middelberg et al. 2011       x             x   x     x x   
MIGC 2009   x                                 
Musunuru et al. 2010 x                                   
Musunuru et al. 2012 x x   x   x       x x   x     x x   
Nakayama et al. 2011 x                 x                 
Nikpay et al. 2015   x x   x               x       x x   
Pan et al. 2009                   x                 
Parihar 2014       x           x x               
Rasmussen et al. 2012                                 x   
Reilly et al. 2013 x                   x   x       x   
Reynolds et al. 2010                   x                 
Ridker et al. 2009                     x   x       x   
Ronald et al. 2009                                 x   
Sabatti ei al. 2009 x     x                   x   x x   
Saleheen et al. 2010                         x           
Samani et al. 2007 x           x       x x           x 
Sandhu et al. 2008 x     x                         x   
Saxena et al. 2007       x             x           x   
Schunkert et al. 2011 x x     x             x x     x     
Service et al. 2014                     x               
Seshadri et al. 2010                                 x   
Shen et al. 2010       x                             
Smith et al. 2010                                 x   
Surakka 2015   x x x       x x   x       x x x   
Song et al. 2013 x                                   
Talmud et al. 2009                   x     x           
Tan et al. 2012                     x   x           
Teslovich et al. 2010 x x x x   x   x x x x   x     x x   
Tukainen et al. 2012 x x x x   x         x         x x   
Uebi et al. 2012                         x           
Vrablik et al. 2008                   x                 
Wakil 2016                       x             
Wallace et al. 2008 x     x           x x   x     x x   
Wang et al. 2008                   x                 
Waterworth et al. 2010 x x x x   x   x x x x   x     x x   
Weissglas-Volkov et al. 2013                   x                 
Willer et al. 2008 x x   x       x   x x   x   x x x   
WTCC 2007             x                   x x 
Wu et al. 2013       x       x   x x           x   
Zhang et al. 2011               x         x           
Zhou et al. 2011                     x   x   x   x   
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Table S4. The 30 genes selected for the co-RNAi screen and rationale for selection 
Shown are the genes that were screened for gene-gene interactions in the co-RNAi screen, and the 
reason why they were selected. If the gene was a hit (+) in both studies, no other reason is provided. 
If the gene was a hit only in one of the two studies, the reason for selection is given in the column 
͞other͟.  
 
  Gene Ensemble ID 
Reason for selection 
Blattmann 
et al. hit 
Exome chip 
hit  
Other 
1 APOB ENSG00000084674 + + 
 2 APOE ENSG00000130203 + +   
3 BAZ1B ENSG00000009954 + +   
4 BCAM ENSG00000187244 + +   
5 BCL7B ENSG00000106635 + +   
6 CBLC ENSG00000142273 + +   
7 CELSR2 ENSG00000143126 + +   
8 CXCL12 ENSG00000107562 + - one of the strongest hits in Blattmann et al. 
9 FAM174A ENSG00000174132 +  -  
10 HAVCR1 ENSG00000113249 + +   
11 HMGCR ENSG00000113161 + +   
12 LDLR ENSG00000130164 + +   
13 LDLRAP1 ENSG00000157978 + - 
1) required for efficient endocytosis of LDLR 
2) mutations are responsible for autosomal 
recessive hypercholesterolemia 
14 LPL ENSG00000175445 + +   
15 MLXIPL ENSG00000009950 + +   
16 MYBPHL ENSG00000221986 + +   
17 MYLIP ENSG00000007944   + degrader of LDLR 
18 NCAN ENSG00000130287 + +  
19 PAFAH1B1 ENSG00000007168 + - 
potential significant role in cholesterol 
regulation, based on P. Blattmann results 
20 PAFAH1B2 ENSG00000168092 - + forms complex together with PAFAH1B1 
21 PCSK9 ENSG00000169174 + +  
22 PVRL2 ENSG00000130202 + +  
23 SEZ6L ENSG00000100095 + - one of the strongest hits in Blattmann et al. 
24 SIK3 ENSG00000160584 + + 
 
25 SORT1 ENSG00000134243 + - 
1)potential role in atherosclerosis  2)one of 
the strongest hits in Blattmann et al. 
26 TM6SF2 ENSG00000213996 + +  
27 TMEM57 ENSG00000204178 + +  
28 TOMM40 ENSG00000130204 + +  
29 WDR12 ENSG00000138442 + - one of the strongest hits in Blattmann et al. 
30 ZNF259 ENSG00000109917 + +   
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Table S5. Genes analyzed in the co-RNA screen and a priori knowledge on molecular function and association with cholesterol regulation and/or lipid homeostasis.  
Genes tested in the co-RNAi screen are listed with HGNC Symbol and Ensembl Gene ID. Previously link of the genes to lipid metabolism using GO annotation (cellular lipid metabolism, cellular response to cholesterol, 
cholesterol, lipid, lipoprotein, triglyceride, high-density, low-density, very-low-density), or to monogenic lipid disorders (Teslovich, Musunuru, and Smith 2010) was checked. Genefunction adapted from www.genecards.org 
is shown. 
 
  Gene Ensembl ID 
Linked to lipid 
homeostasis (GO) 
Linked to cholesterol 
regulation 
Described function 
1 APOB ENSG00000084674 + + apolipoprotein B, major constituent of chylomicrons, LDL and VLDL 
2 APOE ENSG00000130203 + + 
apolipoprotein E, mediates binding, internalization and catabolism of lipoprotein particles, ligand of LDLR, promotes 
reverse cholesterol transport 
3 BAZ1B ENSG00000009954 - - atypical protein kinase, transcription regulator 
4 BCAM ENSG00000187244 - - Lutheran blood group glycoprotein 
5 BCL7B ENSG00000106635 - - regulates positively apoptosis, role in Wnt signaling pathway 
6 CBLC ENSG00000142273 - - E3 ubiquitin ligase, regulator of EGFR signaling 
7 CELSR2 ENSG00000143126 - - cadherin 
8 CXCL12 ENSG00000107562 - - chemokine ligand, stimulates migration of monocytes and T-lymphocytes, protective role after MI 
9 FAM174A ENSG00000174132 - - nothing known 
10 HAVCR1 ENSG00000113249 - - membrane receptor for HAV and TIMD4, involved in allergy, kidney injury and repair 
11 HMGCR ENSG00000113161 + + rate-limiting enzyme for cholesterol synthesis 
12 LDLR ENSG00000130164 + + binds LDL and transports it into cells by endocytosis 
13 LDLRAP1 ENSG00000157978 + + clathrin-associated adapter protein required for efficient endocytosis of LDLR in polarized cells 
14 LPL ENSG00000175445 + + lipoprotein lipase, hydrolyses TGs of chylomicrons and VLDL 
15 MLXIPL ENSG00000009950 + - transcriptional repressor 
16 MYBPHL ENSG00000221986 - - nothing known 
17 MYLIP ENSG00000007944 + + E3 ubiquitin ligase, induces proteasomal degradation of LDLR, VLDLR, and LRP8 
18 NCAN ENSG00000130287 - - may regulate neuronal adhesion and neurite growth 
19 PAFAH1B1 ENSG00000007168 + - activates Rho GTPases, required for actin polymerization, may enhance dynein-mediated microtubule sliding  
20 PAFAH1B2 ENSG00000168092 - - Inactivates platelet-activating factor 
21 PCSK9 ENSG00000169174 + + binds to LDLR,VLDLR,LRP1 and LRP8 and promotes their degradation in lysosomes 
22 PVRL2 ENSG00000130202 - - receptor for herpes virus 
23 SEZ6L ENSG00000100095 - - may contribute to ER functions in neurons 
24 SIK3 ENSG00000160584 - - nothing known 
25 SORT1 ENSG00000134243 + + sorting receptor in Golgi, transports proteins from Golgi to lysosomes 
26 TM6SF2 ENSG00000213996 - - regulates liver fat metabolism, influencing TG secretion and hepatic lipid droplet content 
27 TMEM57 ENSG00000204178 - - nothing known 
28 TOMM40 ENSG00000130204 - - channel-forming protein essential for import of protein precursors into mitochondria 
29 WDR12 ENSG00000138442 - - component of the PeBoW complex, which is required for maturation of 28S and 5.8S rRNAs and formation of 60S ribosome 
30 ZNF259 ENSG00000109917 - - signaling molecule, induces neuron differentiation and stimulates axonal growth and formation of growth cone 
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Table S6. Selection of siRNAs for the co-RNAi screen (Adapted from Blattmann et al. 2013) 
Genes tested in the co-RNAi screen are listed with HGNC Symbol and Ensembl Gene ID. The siRNA ID, and the new siRNA ID, if it has 
been changed are shown, as well as Bluegecko ID and number of targeted transcripts. The effect on LDL uptake (͞DiI_TotInt͟) and Filipin 
assay (͞Fp_TotInt͟) in the two screens of Blattmann et al., and the total effect above threshold are shown. Rationale for siRNA selection 
is provided for the selected siRNA, which is in bold script.  
*siRNA shows one or two mismatch(es) against intended gene 
**siRNA targets multiple genes because of overlapping transcripts or homology and was exluded from further analysis 
***gene targeted is not an established protein-coding gene 
 
Gene information siRNA information 
first screen of 
Blattmann et al. 
(GWAS1) 
second screen of 
Blattmann et al. 
(GWAS2) 
effect 
above 
threshold 
Rationale for siRNA 
selection 
  
Gene 
Name ENSG 
siRNA 
ID 
new  
siRNA 
ID Bluegecko ID 
targeted  
transcripts DiI_TotInt Fp_TotInt DiI_TotInt Fp_TotInt DiI Fp   
1 APOB ENSG00000084674 
s1475   MCO_0062883  1/2 0.16 1.44     0 0   
s1476   MCO_0062852   1/2 0.18 3.36     0 1 strongest effect on Fp 
s1477   MCO_0062817     1/2 0.35 2.21     0 1   
2 APOE ENSG00000130203 
s1495   MCO_0062875 4/4 0.1 2.03 0.45 0.71 0 1   
s1496   MCO_0062909 1/4 0.65 2.23 1.07 1.58 1 1 effect on DiI 
s194291   MCO_0062832 1/4 0.17 0.16     0 0   
s445491   - ?     0.68 0.3 0 0   
s445492   MCO_0067615 1/4     0.58 0.6 0 0   
3 BAZ1B ENSG00000009954 
s17208   MCO_0060780 2/2 -0.42 -0.76     0 0   
s17209   MCO_0061566 2/2 0.13 3.15 0.65 0.52 0 1 strongest effect on Fp 
s17210   MCO_0063016 2/2 -0.2 0.88     0 0   
s445497   MCO_0067585 2/2     0.91 1.7 0 1   
s445498   MCO_0067546 2/2     0.69 0.16 0 0   
s445499   MCO_0067539 2/2     0.67 1.39 0 1   
4 BCAM ENSG00000187244 
s445500   MCO_0067670 1/3     0.06 0.54 0 0   
s445501   MCO_0067651 1/3     0.78 0.05 0 0   
s8336   MCO_0063049 3/3 0.03 0.19     0 0   
s8337   MCO_0063024 3/3 0.28 -0.88     0 0   
s8338   MCO_0062977 3/3 0.66 1.53 1 0.91 0 0 strongest score on Fp 
5 BCL7B ENSG00000106635 
s17733   MCO_0063008 2/2** 0.13 1.86 0.42 0.48 0 1   
s17734   MCO_0062911 2/2 0.56 0.18     0 0   
s228480   MCO_0063061 2/2 0.4 4.16 1.1 1.66 1 1 effect on DiI 
s445504   MCO_0067676 2/2     -0.24 -0.1 0 0   
s445505   MCO_0067579 2/2     0.3 1.89 0 1   
6 CBLC ENSG00000142273 
s24223   MCO_0061739 2/2     1.15 1.13 1 1 
strongest effect on DiI+ 
effect on Fp 
s24224   MCO_0061772 2/2     1.15 0.2 1 0   
s445508   MCO_0067516 2/2     0.28 2.65 0 1   
s445509   MCO_0067473 2/2     0.12 -0.38 0 0   
7 CELSR2 ENSG00000143126 
s445512   MCO_0067521 1/1     0.5 0.89 0 0   
s445513   MCO_0067513 1/1     0.12 -0.89 0 0   
s4525   MCO_0062967 1/1 0.41 -0.02     0 0   
s4526   MCO_0062980 1/1** 0.66 0.78 0.87 1.7 0 1 effect on Fp 
s4527   MCO_0062952 1/1 0.1 1.09 0.61 -0.24 0 0   
8 CXCL12 ENSG00000107562 
s12644   MCO_0063000 6/6 0.49 3.35 0.31 1.31 0 1   
s12645   MCO_0062869 5/6 -0.11 0.29     0 0   
s226988   MCO_0062979 5/6** 0.8 2.21 0.68 0.67 0 1   
s445518   MCO_0067610 2/6     1.34 0.64 1 0 effect on DiI 
s445519   MCO_0067544 2/6     -0.21 -1.98 0 -1   
9 FAM174A ENSG00000174132 
s226341   MCO_0062830 1/1 -0.12 1.5     0 0   
s226342   MCO_0062895 1/1 0.2 -1.6 0.71 -0.69 0 -1   
s445532   MCO_0067632 1/1     -1.69 1.57 -1 1  effect on DiI 
s445533   MCO_0067578 1/1     0.44 1.21 0 1   
s51157   MCO_0059172 1/1 0.59 1.5 0.57 0.21 0 0   
10 HAVCR1 ENSG00000113249 
s230290   MCO_0063002 6/6 0.37 3.7 0.33 3.49 0 1 strongest effect on Fp 
s230291   MCO_0062934 3/6 0.44 1.75 0.12 1.15 0 1   
s25632   MCO_0063054 6/6 0.26 -0.15     0 0   
s445544   MCO_0067639 5/6     0.41 1.04 0 0   
s445545   MCO_0067620 5/6     0.22 0.27 0 0   
11 HMGCR ENSG00000113161 
s141   MCO_0063040 5/7 0.62 0.86     0 0   
s142   MCO_0062915   3/7 0.40 0.81     0 0   
s143   MCO_0062814  3/7 0.67 1.93     0 1  effect on Fp 
12 LDLR ENSG00000130164 
s224006   MCO_0062803 8/9 -1.47 -4.11 -1.12 -1.34 -1 -1 strongest effect on DiI 
s224007   MCO_0067566 8/9     -1.13 -1.83 -1 -1   
s224008   MCO_0062858 8/9* 0.22 0.94     0 0   
s237197   MCO_0062790 9/9 -0.32 -0.1     0 0   
s445552 s445551 MCO_0067650 7/9     0.59 -0.51 0 0   
s445553 s445550 MCO_0067662 7/9     0.56 1.08 0 1   
s6   MCO_0062944 7/9 -0.81 -0.78     -1 0   
13 LDLRAP1 ENSG00000157978 
s25118   MCO_0063012 1/1 -0.15 0.77     0 0   
s25119   MCO_0062955 1/1 0.23 1.13 0.29 1.08 0 1   
s25120   MCO_0062881 1/1 0.36 2.57 0.49 0.53 0 1 strongest effect on Fp 
s445550 s445553 MCO_0067563 1/1     0.02 -0.28 0 0   
s445551 s445552 MCO_0067624 1/1     -0.11 -0.72 0 0   
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14 LPL ENSG00000175445 
s445556   MCO_0067630 3/4     0.42 0.08 0 0   
s445557   MCO_0067531 3/4     0.89 1.22 0 1   
s445558   MCO_0067471 1/4     1.01 0.13 0 0   
s701   MCO_0062983 4/4 0.08 -0.13     0 0   
s702   MCO_0062910 1/4 -0.86 -0.81 -0.09 0.33 -1 0  effect on DiI 
s703   MCO_0062882 2/4 0.17 1.02     0 0   
15 MLXIPL ENSG00000009950 
s27386   MCO_0062920 7/8** 0.43 2.8 0.89 0.5 0 1 rejected 
s27387   MCO_0062796 7/8 0.02 1.99 0.62 0.94 0 1 
second strongest effect on 
Fp 
s27388   MCO_0062931 6/8 -0.2 1.69     0 0   
s445563   MCO_0067533 6/8     0.11 -0.12 0 0   
s445564   MCO_0067505 6/8     0.99 0.17 0 0   
16 MYBPHL ENSG00000221986 
s445565   MCO_0067649 1/1     0.26 0.14 0 0   
s445566   MCO_0067638 1/1     0.91 0.92 0 0   
s50998   MCO_0062849 1/1 0.35 3.74 0.25 1.68 0 1   
s50999   MCO_0062788 1/1 0.46 3.13 1.06 0.55 1 1  effect on DiI 
s51000   MCO_0062878 1/1** 0.19 0.89     0 0   
17 NCAN ENSG00000130287 
s3648   MCO_0062916 2/4 0.64 3.15 1.09 1.08 1 1  effect on DiI 
s3649   MCO_0063025 2/4 0.15 0.93     0 0   
s3650   MCO_0062843 1/4 -0.35 4.74 0.28 0.27 0 1   
s445567 s445568 MCO_0067483 1/4     0.74 -1.1 0 -1   
s445568   -       -0.01 1.87 0 1   
18 PAFAH1B1 ENSG00000007168 
s445573   MCO_0067597 2/5     -0.44 0.86 0 0   
s445574   MCO_0067515 2/5     -1.2 -0.52 -1 0 strongest effect on DiI 
s9996   MCO_0054981 3/5 -0.2 -3.57 -0.26 0.05 0 -1   
s9997   MCO_0054982 4/5 -0.26 -1.35 0 -0.9 0 -1   
s9998   MCO_0061379 4/5 -0.61 -0.28 -0.59 0.22 -1 0   
19 PCSK9 ENSG00000169174 
s48694   MCO_0062856 1/3 0.16 2.74     0 1 strongest effect on Fp 
s48695   MCO_0062860 1/3 0.57 2.74     0 1   
s48696   MCO_0062996 3/3 -0.22 2.22     0 1   
20 PVRL2 ENSG00000130202 
s11606   MCO_0067547 3/5**     0.35 1.24 0 1   
s11607   MCO_0067518 3/5     0.26 0.49 0 0   
s445581   MCO_0067527 1/5     0.27 0.07 0 0   
s445582   MCO_0067511 1/5     1.17 -0.23 1 0  effect on DiI 
21 SEZ6L ENSG00000100095 
s225966   MCO_0062899 7/8 0.5 1.81 0.47 0.21 0 1   
s24051   MCO_0063022 7/8 0.41 1.44     0 0   
s24052   MCO_0062976 6/8 -0.49 -1.8 -1.03 -0.34 -1 -1  effect on DiI 
s445592   MCO_0067507 7/8     0.43 -1.57 0 -1   
s445593   MCO_0067506 8/8*     0.02 -0.72 0 0   
22 SIK3 ENSG00000160584 
s225956   MCO_0063064 4/5 0.43 0.97     0 0   
s225957   MCO_0063023 4/5 0.58 0.54 0.41 0.3 0 0   
s225958   MCO_0062890 5/5 0.7 1.08 0.79 -0.33 0 0   
s445594   MCO_0067596 5/5     0.52 0.99 0 0   
s445595   MCO_0067522 5/5     0.67 1.55 0 1  effect on Fp 
23 SORT1 ENSG00000134243 
s224557   MCO_0063053 2/2 -0.56 -2.81 -0.1 -0.38 -1 -1  effect on DiI 
s224558   MCO_0062806 2/2 0.29 1.37 0.49 0.67 0 0   
s445600   MCO_0067608 2/2     0.25 0.85 0 0   
s445601   MCO_0067591 1/2     0.52 0.5 0 0   
24 TM6SF2 ENSG00000213996 
s28703   MCO_0062906 1/1 -1.07 -1.23 -0.15 0.92 -1 -1 effect on DiI 
s28704   MCO_0062810 1/1 0.37 3.71 0.3 2.35 0 1   
s28705   MCO_0062958 1/1 -0.19 0.8     0 0   
s445610   MCO_0067588 1/1     0.13 0.63 0 0   
s445611   MCO_0067465 1/1     0.41 1.18 0 1   
25 TMEM57 ENSG00000204178 
s30473   MCO_0062918 3/3 0.81 2.6 0.4 1.19 1 1 effect on DiI 
s30474   MCO_0062877 1/3 0.35 0.27     0 0   
s30475   MCO_0062819 3/3 0.63 2.06 0.66 0.95 0 1   
s445612   MCO_0067625 3/3     -0.24 -3.03 0 -1   
s445613   MCO_0067508 3/3     0.46 0.81 0 0   
26 TOMM40 ENSG00000130204 
s20448   MCO_0062829 4/6 0.33 1.07     0 0   
s20449   MCO_0062926 4/6 -0.42 -1.63 -1.25 -2.16 -1 -1 effect on DiI 
s20450   MCO_0062835 4/6 0.62 2.51 0.77 2.17 0 1   
s445614   MCO_0067652 4/6     -0.15 1.66 0 1   
s445615   MCO_0067486 4/6     0.53 -0.15 0 0   
27 WDR12 ENSG00000138442 
s31440   MCO_0060407 1/1 -0.09 -1.08 0.18 0.17 0 0   
s31441   MCO_0060426 1/1 0.28 -1.65 0.5 -1.85 0 -1 effect on Fp 
s31442   MCO_0063042 1/1 0.74 -0.99     0 0   
s445627   MCO_0067592 1/1     0.42 0.24 0 0   
s445628   MCO_0067497 1/1     0.96 0.28 0 0   
28 ZNF259 ENSG00000109917 
s16972   MCO_0067555 3/3     0.16 0.35 0 0   
s16973   MCO_0067619 3/3**     0.44 -0.46 0 0   
s445635   MCO_0067478 3/3     0.17 0.8 0 0   
s445636   MCO_0067467 3/3     1.04 1.55 0 1 effect on Fp 
29 MYLIP ENSG00000007944 
s26522   MCO_0061841 2/2             targets all transcripts 
s26523   MCO_0061848 2/2               
s26521   MCO_0063512 1/2               
30 PAFAH1B2 ENSG00000168092 
s9999   MCO_0067567 4/5***               
s10001   MCO_0067590 5/5             targets all transcripts 
s10000   MCO_0067623 2/5               
sPafah1b2_1   MCO_0078010 2/5               
sPafah1b2_2   MCP_0078011 3/5               
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Table S7. Amounts of siRNA used for ͞single͟ knockdowns in the validation experiments and gene knockdown 
efficiency, measured with qRT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S8. Amounts of siRNA used for ͞double͟ knockdowns in the validation experiments and gene knockdown efficiency, 
measured with qRT-PCR. 
 
 
siRNA treatment gene kd pmol of each siRNA  % kd efficiency 
HAVCR1 + LDLR HAVCR1 15 n.d. 
 LDLR 7.5 58.2 
HAVCR1 + LDLRAP1 HAVCR1 15 n.d. 
 LDLRAP1 30 91.7 
HAVCR1 + BCAM HAVCR1 15 n.d. 
 BCAM 30 94.7 
HAVCR1 + MLXIPL HAVCR1 15 n.d. 
 MLXIPL 7.5 18.7 
HAVCR1 + SEZ6L HAVCR1 30 n.d. 
 SEZ6L 30 n.d. 
HAVCR1 + SORT1 HAVCR1 30 n.d. 
 SORT1 30 93.2 
BCAM + LDLRAP1 BCAM 30 94.3 
 LDLRAP1 30 89.9 
LDLR + MLXIPL LDLR 30 83.4 
 MLXIPL 30 39.3 
LDLR + LDLRAP1 LDLR 30 75.6 
 LDLRAP1 30 87.2 
LDLRAP1 + SORT1 LDLRAP1 30 89.8 
 SORT1 30 91.9 
MLXIPL + TOMM40 MLXIPL 30 20.1 
 TOMM40 7.5 90.4 
CXCL12 + PAFAH1B1 CXCL12 30 n.d. 
 PAFAH1B1 7.5 90.2 
SORT1 + TOMM40 SORT1 7.5 52.7 
 TOMM40 7.5 90.8 
NCAN + TOMM40 NCAN 30 n.d. 
 TOMM40 7.5 91.7 
NCAN + SEZ6L NCAN 30 n.d. 
 SEZ6L 15 n.d. 
NCAN + LDLR NCAN 30 n.d. 
 LDLR 7.5 72.7 
PAFAH1B1 + SIK3 PAFAH1B1 7.5 77.1 
 SIK3 30 77.9 
MYBPHL + SIK3 MYBPHL 30 n.d. 
 SIK3 30 78.6 
PCSK9 + TMEM57 PCSK9 30 74.7 
 TMEM57 30 51.9 
CELSR2 + LPL CELSR2 30 86.7 
 LPL 30 92.5 
APOB + HMGCR APOB 30 n.d. 
 HMGCR 30 74.9 
 
 
 
 
 
 
siRNA treatment gene kd pmol of each siRNA  % kd efficiency 
HAVCR1 + control HAVCR1 30 n.d. 
  15 n.d. 
LDLR + control LDLR 30 76.8 
  7.5 58.6 
LDLRAP1 + control LDLRAP1 30 92.9 
MLXIPL + control MLXIPL 30 35.6 
  7.5 44.2 
BCAM + control BCAM 30 95.7 
SEZ6L + control SEZ6L 30 n.d. 
  15 n.d. 
SORT1 + control SORT1 30 93.9 
  7.5 91.7 
TOMM40 + control TOMM40 7.5 88.6 
CXCL12 + control CXCL12 30 n.d. 
PAFAH1B1 + control PAFAH1B1 7.5 95.3 
NCAN + control NCAN 30 n.d. 
SIK3 + control SIK3 30 78.9 
MYBPHL + control MYBPHL 30 n.d. 
PCSK9 + control PCSK9 15 85.1 
TMEM57 + control TMEM57 30 44.8 
CELSR2 + control CELSR2 30 85 
LPL + control LPL 30 96.7 
APOB + control APOB 30 n.d. 
HMGCR + control HMGCR 30 67.4 
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Table S9. siRNA quantities used for the validation of the co-RNAi screen hits 
Shown are the siRNA quantities used in the liquid-phase transfections in 6-well plates (for details see 7.1.1) for the validation of 
the screen hits. Because the forward transfections (in liquid-phase format) were more efficient than the reverse transfections 
(in the co-RNAi screen), the siRNA quantities needed to be adjusted, so that the same phenotypes could be achieved as the 
ones observed in the screen.  
 
  Treatment siRNAA siRNAA (pmol) siRNAB siRNAB (pmol) 
1 LDLR+ NCAN LDLR 7.5 NCAN 30 
2 CXCL12+ PAFAH1B1  CXCL12 30 PAFAH1B1 7.5 
3 NCAN + SEZ6L NCAN 30 SEZ6L 15 
4 NCAN + TOMM40  NCAN 30 TOMM40 7.5 
5 HAVCR1 + MLXIPL HAVCR1 15 MLXIPL 7.5 
6 LDLRAP1 + SORT1 LDLRAP1 30 SORT1 30 
7 LDLR + LDLRAP1 LDLR 30 LDLRAP1 30 
8 CELSR2 + LPL  CELSR2 15 LPL 15 
9 MLXIPL + TOMM40  MLXIPL 30 TOMM40 7.5 
10 LDLR + MLXIPL LDLR 30 MLXIPL 30 
11 HAVCR1+ SEZ6L HAVCR1 30 SEZ6L 30 
12 HAVCR1 + LDLRAP1 HAVCR1 15 LDLRAP1 30 
13 BCAM + LDLRAP1 BCAM 30 LDLRAP1 30 
14 HAVCR1 + SORT1 HAVCR1 30 SORT1 30 
15 BCAM + HAVCR1  BCAM 30 HAVCR1 15 
16 MYBPHL + SIK3 MYBPHL 30 SIK3 30 
17 APOB + HMGCR APOB 30 HMGCR 30 
18 SORT1 + TOMM40  SORT1 7.5 TOMM40 7.5 
19 PAFAH1B1+ SIK3 PAFAH1B1 7.5 SIK3 30 
20 PCSK9 + TMEM57  PCSK9 15 TMEM57 15 
21 HAVCR1+LDLR HAVCR1 15 LDLR 7.5 
 
 
Table  S10. siRNA quantities used for the evaluation of gene interactions at the LDLR mRNA level 
Shown are the quantities of siRNA used in the qRT-PCR experiments for the measurement of the effect on LDLR mRNA levels of 
the gene interactions identified in the screen. These quantities are essentially the exactly same quantities used in the validation 
experiments (see Tables S8, S9). (A-D) correspond to (A-D) of Figure 21. 
 
A        B 
       
 C        D 
 
 
Treatment siRNAA siRNAA  
(pmol) 
siRNAB siRNAB  
(pmol) 
mock - - - - 
control NEG9 30 - - 
HAVCR1 HAVCR1 15 NEG9 15 
LDLR LDLR 7.5 NEG9 7.5 
LDLRAP1 LDLRAP1 30 NEG9 30 
MLXIPL MLXIPL 7.5 NEG9 7.5 
BCAM BCAM 30 NEG9 30 
NCAN NCAN 30 NEG9 30 
HAVCR1+BCAM HAVCR1 15 BCAM 30 
HAVCR1+MLXIPL HAVCR1 15 MLXIPL 7.5 
HAVCR1+LDLRAP1 HAVCR1 15 LDLRAP1 30 
HAVCR1+LDLR HAVCR1 15 LDLR 7.5 
BCAM+LDLRAP1 BCAM 30 LDLRAP1 30 
LDLR+NCAN LDLR 7.5 NCAN 30 
Treatment siRNAA siRNAA  
(pmol) 
siRNAB siRNAB  
(pmol) 
mock - - - - 
control NEG9 30 - - 
SORT1 SORT1 30 NEG9 30 
SEZ6L SEZ6L 30 NEG9 30 
LDLRAP1 LDLRAP1 30 NEG9 30 
LDLR LDLR 30 NEG9 30 
HAVCR1 HAVCR1 30 NEG9 30 
MLXIPL MLXIPL 30 NEG9 30 
TOMM40 TOMM40 7.5 NEG9 7.5 
LDLR+MLXIPL LDLR 30 MLXIPL 30 
LDLR+LDLRAP1 LDLR 30 LDLRAP1 30 
HAVCR1+SEZ6L HAVCR1 30 SEZ6L 30 
HAVCR1+SORT1 HAVCR1 30 SORT1 30 
LDLRAP1+SORT1 LDLRAP1 30 SORT1 30 
MLXIPL+TOMM40 MLXIPL 30 TOMM40 7.5 
Treatment siRNAA siRNAA  
(pmol) 
siRNAB siRNAB  
(pmol) 
mock - - - - 
control NEG9 30 - - 
SEZ6L SEZ6L 15 NEG9 15 
NCAN NCAN 30 NEG9 30 
PCSK9 PCSK9 15 NEG9 15 
TMEM57 TMEM57 15 NEG9 15 
CELSR2 CELSR2 15 NEG9 15 
LPL LPL 15 NEG9 15 
APOB APOB 30 NEG9 30 
HMGCR HMGCR 30 NEG9 30 
NCAN+SEZ6L NCAN 30 SEZ6L 15 
PCSK9+TMEM57 PCSK9 15 TMEM57 15 
CELSR2+LPL CELSR2 15 LPL 15 
APOB+HMGCR APOB 30 HMGCR 30 
Treatment siRNAA siRNAA  
(pmol) 
siRNAB siRNAB  
(pmol) 
mock - - - - 
control NEG9 30 - - 
SORT1 SORT1 7.5 NEG9 7.5 
NCAN NCAN 30 NEG9 30 
TOMM40 TOMM40 7.5 NEG9 7.5 
CXCL12 CXCL12 30 NEG9 30 
PAFAH1B1 PAFAH1B1 7.5 NEG9 7.5 
SIK3 SIK3 30 NEG9 30 
MYBPHL MYBPHL 30 NEG9 30 
SORT1+TOMM40 SORT1 7.5 TOMM40 7.5 
NCAN+TOMM40 NCAN 30 TOMM40 7.5 
MYBPHL+SIK3 MYBPHL 30 SIK3 30 
PAFAH1B1+SIK3 PAFAH1B1 7.5 SIK3 30 
CXCL12+PAFAH1B1 CXCL12 30 PAFAH1B1 7.5 
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Table S11. Results of qRT-PCR experiments for LDLR mRNA expression used for interaction calling. 
Shoǁn are the ΔCt ǀalues of LDLR expression, where ΔCt=Ct(LDLR)-Ct(GAPDH), for four biological replicas. The four ΔCt values 
were used to fit a linear regression model, where the double knockdown was compared with the additive effect of the two 
single knockdowns, considering NEG9 as control. 
 
TREATMENT siRNA quantities ŵRNA expressioŶ LDLR ΔCt 
Double knockdown siRNA1 pmol1 
siRNA1 
siRNA 2 pmol2 
siRNA2 
Exp. 1 Exp. 2 Exp. 3 Exp. 4 
NEG9[30] NEG9 30 NEG9 30 6.17 6.96 7.09 6.41 
HAVCR1[15]+NEG9 HAVCR1 15 NEG9 30 5.94 6.15 5.88 5.75 
LDLR[7.5]+NEG9 LDLR 7.5 NEG9 30 7.46 8.46 8.14 7.66 
LDLRAP1[30]+NEG9 LDLRAP1 30 NEG9 30 6.98 6.98 5.55 6.34 
MLXIPL[7.5]+NEG9 MLXIPL 7.5 NEG9 30 5.42 6.57 6.13 6.79 
BCAM[30]+NEG9 BCAM 30 NEG9 30 7.19 7.65 6.34 6.44 
HAVCR1[15]+LDLR[7.5] HAVCR1 15 LDLR 7.5 6.74 8.57 8.07 8.17 
HAVCR1[15]+LDLRAP1[30] HAVCR1 15 LDLRAP1 30 4.98 5.66 5.66 
 
HAVCR1[15]+BCAM[30] HAVCR1 15 BCAM 30 6.54 7.56 7.80 
 
HAVCR1[15]+MLXIPL[7.5] HAVCR1 15 MLXIPL 7.5 5.98 5.09 5.28 6.84 
BCAM[30]+LDLRAP1[30] BCAM 30 LDLRAP1 30 6.34 6.67 6.30 6.68 
SEZ6L[30]+NEG9 SEZ6L 30 NEG9 30 6.63 6.64 6.62 6.87 
SORT1[30]+NEG9 SORT1 30 NEG9 30 6.18 7.12 6.68 6.53 
LDLR[30]+NEG9 LDLR 30 NEG9 30 8.36 7.36 8.46 8.47 
HAVCR1[30]+NEG9 HAVCR1 30 NEG9 30 5.12 5.36 5.28 6.69 
MLXIPL[30]+NEG9 MLXIPL 30 NEG9 30 6.47 6.58 6.06 8.28 
LDLR[30]+MLXIPL[30] LDLR 30 MLXIPL 30 8.57 9.45 9.00 9.54 
LDLR[30]+LDLRAP1[30] LDLR 30 LDLRAP1 30 7.97 9.11 8.23 9.15 
HAVCR1[30]+SEZ6L[30] HAVCR1 30 SEZ6L 30 5.70 6.83 6.18 6.21 
HAVCR1[30]+SORT1[30] HAVCR1 30 SORT1 30 5.34 6.05 5.94 6.54 
LDLRAP1[30]+SORT1[30] LDLRAP1 30 SORT1 30 7.47 
 
6.36 5.94 
TOMM40[7.5]+NEG9 TOMM40 7.5 NEG9 30 6.45 8.15 7.05 6.46 
MLXIPL[30]+TOMM40[7.5] MLXIPL 30 TOMM40 7.5 5.58 8.90 7.18 7.02 
CXCL12[30]+NEG9 CXCL12 30 NEG9 30 6.11 
 
5.90 6.21 
PAFAH1B1[7.5]+NEG9 PAFAH1B1 7.5 NEG9 30 7.08 8.20 6.62 6.35 
SORT1[7.5]+NEG9 SORT1 7.5 NEG9 30 6.24 8.32 6.39 7.31 
NCAN[30]+NEG9 NCAN 30 NEG9 30 5.96 6.22 6.39 6.80 
CXCL12[30]+PAFAH1B1[7.5] CXCL12 30 PAFAH1B1 7.5 6.81 7.16 6.65 7.70 
SORT1[7.5]+TOMM40[7.5] SORT1 7.5 TOMM40 7.5 6.76 8.64 7.08 7.79 
NCAN[30]+TOMM40[7.5] NCAN 30 TOMM40 7.5 7.33 7.88 7.54 8.31 
SEZ6L[15]+NEG9 SEZ6L 15 NEG9 30 6.72 6.86 6.61 7.32 
NCAN[30]+SEZ6L[15] NCAN 30 SEZ6L 15 7.36 7.61 6.93 6.34 
LDLR[7.5]+NCAN[30] LDLR 7.5 NCAN 30 8.15 9.14 8.87 7.72 
SIK3[30]+NEG9 SIK3 30 NEG9 30 5.94 7.15 6.50 6.49 
PAFAH1B1[7.5]+SIK3[30] PAFAH1B1 7.5 SIK3 30 7.32 6.58 6.40 5.44 
MYBPHL[30]+NEG9 MYBPHL 30 NEG9 30 6.25 6.92 5.77 6.03 
MYBPHL[30]+SIK3[30] MYBPHL 30 SIK3 30 5.89 6.06 6.10 6.35 
PCSK9[15]+NEG9 PCSK9 15 NEG9 30 8.31 6.14 6.15 7.54 
TMEM57[15]+NEG9 TMEM57 15 NEG9 30 7.76 8.28 5.83 5.32 
PCSK9[15]+TMEM57[15] PCSK9 15 TMEM57 15 6.23 8.92 5.86 5.66 
CELSR2[15]+NEG9 CELSR2 30 NEG9 30 6.82 9.16 6.18 5.59 
LPL[15]+NEG9 LPL 30 NEG9 30 7.17 
 
6.62 6.10 
CELSR2[15]+LPL[15] CELSR2 30 LPL 30 6.41 
 
6.64 5.99 
APOB[30]+NEG9 APOB 30 NEG9 30 6.57 10.78 5.82 5.29 
HMGCR[30]+NEG9 HMGCR 30 NEG9 30 6.73 9.49 5.70 5.04 
APOB[30]+HMGCR[30] APOB 30 HMGCR 30 8.31 8.35 5.62 4.88 
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Table S12. Results of Western Blot experiments for LDLR protein used for interaction calling. 
Shown are the LDLR/a-tubulin protein values without normalization to negative control siRNA, from three biological replicates 
used to fit a linear regression model, where the double knockdown was compared with the additive effect of the two single 
knockdowns, considering NEG9 as control. 
 
 
blot#2 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 1.31 1.50 1.67 
HAVCR1[30] HAVCR1 30 NEG9 30  1.15 1.62 
SORT1[30] SORT1 30 NEG9 30 1.01 0.21 0.17 
SEZ6L[30] SEZ6L 30 NEG9 30 0.80 0.43 0.42 
LDLRAP1[30] LDLRAP1 30 NEG9 30 0.90 1.20 1.34 
BCAM[30] BCAM 30 NEG9 30 0.87 0.93 0.55 
LDLRAP1[30]+BCAM[30] LDLRAP1 30 BCAM 30 0.92 0.95 1.02 
LDLRAP1[30]+SORT1[30] LDLRAP1 30 SORT1 30 1.04 0.29 0.15 
HAVCR1[30]+SORT1[30] HAVCR1 30 SORT1 30 0.67 0.78 0.30 
HAVCR1[30]+SEZ6L[30] HAVCR1 30 SEZ6L 30 0.53 1.17 0.90 
 
blot#3 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 1.18 2.11 2.08 
LDLR[30] LDLR 30 NEG9 30 0.14 0.07 0.25 
MLXIPL[30] MLXIPL 30 NEG9 30 1.48 1.68 1.74 
LDLRAP1[30] LDLRAP1 30 NEG9 30 1.28 1.10 2.39 
TOMM40[7.5] TOMM40 7.5 NEG9 30 1.00 0.30 0.24 
SORT1[7.5] SORT1 7.5 NEG9 30 1.48 0.95 1.52 
SORT1[7.5]+TOMM40[7.5] SORT1 7.5 TOMM40 7.5 0.37 0.33 0.36 
MLXIPL[30]+TOMM40[7.5] MLXIPL 30 TOMM40 7.5 0.70 0.51 0.59 
LDLR[30]+LDLRAP1[30] LDLR 30 LDLRAP1 30 0.25 0.01 0.06 
LDLR[30]+MLXIPL[30] LDLR 30 MLXIPL 30 0.67 0.01 0.03 
  
blot#4 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 2.26 1.41 0.85 
CXCL12[30] CXCL12 30 NEG9 30 0.86 0.90 0.75 
PAFAH1B1[7.5] PAFAH1B1 7.5 NEG9 30 0.42 0.54 0.51 
SIK3[30] SIK3 30 NEG9 30 1.14 0.75 1.14 
MYBPHL[30] MYBPHL 30 NEG9 30 1.36 1.37 1.82 
MYBPHL[30]+SIK3[30] MYBPHL 30 SIK3 30 0.95 0.82 1.51 
PAFAH1B1[7.5]+SIK3[30] PAFAH1B1 7.5 SIK3 30 0.25 0.30 0.55 
CXCL12[30]+PAFAH1B1[7.5] CXCL12 30 PAFAH1B1 7.5 0.14 0.44 0.30 
blot#1 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 1.60 2.84 0.71 
HAVCR1[15] HAVCR1 15 NEG9 30 2.19 1.53 2.10 
LDLR[7.5] LDLR 7.5 NEG9 30 0.12 0.18 0.06 
LDLRAP1[30] LDLRAP1 30 NEG9 30 1.49 0.89 0.95 
MLXIPL[30] MLXIPL 30 NEG9 30 1.25 1.22 1.72 
BCAM[30] BCAM 30 NEG9 30 0.72 1.48 0.66 
HAVCR1[15]+BCAM[30] HAVCR1 15 BCAM 30 0.72 1.37 0.93 
HAVCR1[15]+MLXIPL[30] HAVCR1 15 MLXIPL 30 0.80 0.85 1.04 
HAVCR1[15]+LDLRAP1[30] HAVCR1 15 LDLRAP1 30 0.97 0.47 0.80 
HAVCR1[15]+LDLR[7.5] HAVCR1 15 LDLR 7.5 0.31 0.08 0.03 
blot#5 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 1.60 0.89 1.52 
NCAN[30] NCAN 30 NEG9 30 1.17 0.67 2.83 
TOMM40[7.5] TOMM40 7.5 NEG9 30 0.21 0.38 0.28 
LDLR[7.5] LDLR 7.5 NEG9 30 0.03 0.21 0.10 
SEZ6L[15] SEZ6L 15 NEG9 30 0.53 1.11 1.16 
NCAN[30]+SEZ6L[15] NCAN 30 SEZ6L 15 0.38 1.33 0.70 
NCAN[30]+LDLR[7.5] NCAN 30 LDLR 7.5 0.01 0.20 0.02 
NCAN[30]+TOMM40[7.5] NCAN 30 TOMM40 7.5 0.11 1.03 0.13 
blot#6 siRNA quantities LDLR/a-tubulin 
Treatment siRNA1 pmol1 siRNA2 pmol2 Exp.1 Exp.2 Exp.3 
NEG9[30] NEG9 30 NEG9 30 0.62 1.90 1.18 
CELSR2[15] CELSR2 15 NEG9 30 1.03 1.38 0.71 
LPL[15] LPL 15 NEG9 30 0.44 0.29 0.48 
APOB[30] APOB 30 NEG9 30 1.00 0.68 0.57 
HMGCR[30] HMGCR 30 NEG9 30 1.15 0.96 1.59 
TMEM57[15] TMEM57 15 NEG9 30 1.34 1.43 0.92 
PCSK9[15] PCSK9 15 NEG9 30 1.14 0.47 0.62 
PCSK9[15]+TMEM57[15] PCSK9 15 TMEM57 15 0.91 0.66 1.08 
APOB[30]+HMGCR[30] APOB 30 HMGCR 30 0.76 0.58 1.29 
CELSR2[15]+LPL[15] CELSR2 15 LPL 15 0.42 0.13 0.61 
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Table S13. Regulation of LDLR transcription and translation upon single and double knockdown of the genes that were 
identified by the screen as interacting. 
Significant effect calculated with Student’s t-test in Microsoft Excel (TTEST (array1, array2, 2, 3)) is shown in bold. *<0.05, 
**<0.01, ***<0.001 
 
 
Treatment mRNA protein 
 log2 (fold change)  LDLR/a-tubulin  
 Exp. 1 Exp. 2 Exp. 3 Exp. 4 median mRNA 
regulation 
Exp.1 Exp.2 Exp.3 mean protein 
regulation HAVCR1[15]+NEG9 0.23 0.81 1.22 0.66 0.74 * 1.40 0.50 2.90 1.60  
LDLR[7.5]+NEG9 -1.29 -1.50 -1.04 -1.25 -1.27 ** 0.10 0.10 0.10 0.10 * 
LDLRAP1[30]+NEG9 -0.81 -0.03 0.75 0.07 0.02  0.90 0.30 1.30 0.83  
MLXIPL[7.5]+NEG9 0.75 0.39 0.97 -0.38 0.57  0.80 0.40 2.40 1.20  
BCAM[30]+NEG9 -1.02 -0.69 0.75 -0.03 -0.36  0.50 0.50 0.90 0.63 * 
HAVCR1[15]+LDLR[7.5] -0.57 -1.62 -0.97 -1.76 -1.29 * 0.20 0.00 0.00 0.07  
HAVCR1[15]+LDLRAP1[30] 1.19 1.29 1.43  1.29 * 0.60 0.20 1.10 0.63  
HAVCR1[15]+BCAM[30] -0.37 -0.60 -0.71  -0.60  0.50 0.50 1.30 0.77  
HAVCR1[15]+MLXIPL[7.5] 0.19 1.87 1.81 -0.42 1.00  0.50 0.30 1.50 0.77  
BCAM[30]+LDLRAP1[30] -0.17 0.29 0.79 -0.26 0.06  0.70 0.60 0.60 0.63 * 
SEZ6L[30]+NEG9 -0.46 0.31 -0.32 -0.46 -0.39  0.60 0.30 0.30 0.40 ** 
SORT1[30]+NEG9 -0.01 -0.16 -0.38 -0.12 -0.14  0.80 0.10 0.10 0.33 * 
LDLR[30]+NEG9 -2.19 -0.40 -2.16 -2.06 -2.11 ** 0.10 0.00 0.10 0.07 * 
HAVCR1[30]+NEG9 1.05 1.60 1.02 -0.28 1.03   0.80 0.10 0.45  
MLXIPL[30]+NEG9 -0.30 0.38 0.24 -1.86 -0.03  1.30 0.80 0.80 0.97  
LDLR[30]+MLXIPL[30] -2.40 -2.49 -2.70 -3.13 -2.60 *** 0.60 0.00 0.00 0.20 * 
LDLR[30]+LDLRAP1[30] -1.80 -2.15 -1.93 -2.74 -2.04 ** 0.20 0.00 0.00 0.07 * 
HAVCR1[30]+SEZ6L[30] 0.47 0.13 0.12 0.21 0.17  0.40 0.80 0.50 0.57 * 
HAVCR1[30]+SORT1[30] 0.83 0.91 0.22 -0.13 0.52  0.50 0.50 0.20 0.40 ** 
LDLRAP1[30]+SORT1[30] -1.30  -0.06 0.47 -0.06  0.80 0.20 0.10 0.37 * 
TOMM40[7.5]+NEG9 -0.28 -1.19 -1.02 -0.04 -0.65  0.80 0.10 0.10 0.33 * 
MLXIPL[30]+TOMM40[7.5] 0.58 -1.94 -1.02 -0.61 -0.81  0.60 0.20 0.30 0.37 * 
CXCL12[30]+NEG9 0.06  1.19 0.21 0.21  0.40 0.60 0.90 0.63  
PAFAH1B1[7.5]+NEG9 -0.91 -1.24 0.47 0.06 -0.42  0.20 0.40 0.60 0.40  
SORT1[7.5]+NEG9 -0.07 -1.36 -0.36 -0.89 -0.63  1.20 0.40 0.70 0.77  
NCAN[30]+NEG9 0.21 0.74 -0.22 -0.38 -0.01  0.70 0.80 1.90 1.13  
CXCL12[30]+PAFAH1B1[7.5] -0.64 -0.20 0.44 -1.28 -0.42  0.10 0.30 0.40 0.27 * 
SORT1[7.5]+TOMM40[7.5] -0.59 -1.68 -1.05 -1.37 -1.21  0.30 0.20 0.20 0.23 * 
NCAN[30]+TOMM40[7.5] -1.16 -0.92 -1.38 -1.89 -1.27 * 0.10 1.20 0.10 0.47 * 
SEZ6L[15]+NEG9 -0.55 0.10 0.49 -0.91 -0.23  0.30 1.30 0.80 0.80  
NCAN[30]+SEZ6L[15] -1.19 -0.65 0.16 0.08 -0.29  0.20 1.50 0.50 0.73  
LDLR[7.5]+NCAN[30] -1.98 -2.18 -1.78 -1.31 -1.88 ** 0.00 0.20 0.00 0.07 * 
SIK3[30]+NEG9 0.23 -0.20 0.59 -0.08 0.08  0.50 0.50 1.30 0.77  
PAFAH1B1[7.5]+SIK3[30] -1.15 0.38 0.70 0.97 0.54  0.10 0.20 0.60 0.30  
MYBPHL[30]+NEG9 -0.08 0.03 1.33 0.38 0.21  0.60 1.00 2.10 1.23  
MYBPHL[30]+SIK3[30] 0.28 0.90 0.99 0.07 0.59  0.40 0.60 1.80 0.93  
PCSK9[15]+NEG9 -2.14 0.81 0.94 -1.12 -0.15  1.80 0.20 0.50 0.83  
TMEM57[15]+NEG9 -1.06 0.45 1.27 0.34 0.39  2.20 0.80 0.80 1.27  
PCSK9[15]+TMEM57[15] 0.47 -0.19 1.23 0.00 0.24  1.50 0.30 0.90 0.90  
CELSR2[15]+NEG9 -0.11 -0.43 0.91 0.07 -0.02  1.70 0.70 0.60 1.00  
LPL[15]+NEG9 -0.47  0.48 -0.44 -0.44  0.70 0.20 0.40 0.43  
CELSR2[15]+LPL[15] 0.29  0.46 -0.33 0.29  0.70 0.10 0.50 0.43  
APOB[30]+NEG9 0.14 -2.06 1.27 0.37 0.25  1.60 0.40 0.50 0.83  
HMGCR[30]+NEG9 -0.02 -0.76 1.40 0.62 0.30  1.80 0.50 1.30 1.20  
APOB[30]+HMGCR[30] -1.60 0.37 1.47 0.78 0.57  1.20 0.30 1.10 0.87  
 
 
Table S14. Results of qRT-PCR experiments for SREBF1 and SREBF2 mRNA expression used for interaction calling. 
Shoǁn are the ΔCt ǀalues of SREBF1 and SREBF2 expression, where ΔCt=Ct(SREBF)-Ct(GAPDH), for four biological replicas. The 
four ΔCt values were used to fit a linear regression model, where the double knockdown was compared with the additive effect 
of the two single knockdowns, considering NEG9 as control. 
 
     mRNA expression ΔCt 
     SREBF1 SREBF2 
Treatment siRNA1 pmol 
siRNA1 
siRNA2 pmol 
siRNA2 
Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 3 
NEG9[30] NEG9 30 NEG9 30 7.81 6.79 6.81 5.82 5.72 5.73 
HAVCR1[15]+NEG9 HAVCR1 15 NEG9 30 7.83 6.61 6.76 7.04 6.56 5.78 
LDLR[7.5]+NEG9 LDLR 7.5 NEG9 30 7.81 6.69 7.43 6.25 5.61 6.52 
LDLRAP1[30]+NEG9 LDLRAP1 30 NEG9 30 7.39 6.91 6.53 6.08 5.92 5.40 
MLXIPL[7.5]+NEG9 MLXIPL 7.5 NEG9 30 7.25 7.16 7.57 5.62 5.53 5.82 
BCAM[30]+NEG9 BCAM 30 NEG9 30 8.15 9.11 7.85 6.40 6.94 6.30 
HAVCR1[15]+LDLR[7.5] HAVCR1 15 LDLR 7.5 8.05 6.12 7.05 7.20 5.50 6.08 
HAVCR1[15]+LDLRAP1[30] HAVCR1 15 LDLRAP1 30 8.05 6.26 7.06 6.75 6.14 6.26 
HAVCR1[15]+BCAM[30] HAVCR1 15 BCAM 30 8.07 7.62 8.12 6.56 7.14 7.14 
HAVCR1[15]+MLXIPL[7.5] HAVCR1 15 MLXIPL 7.5 6.19 7.52 6.52 6.49 6.40 6.47 
BCAM[30]+LDLRAP1[30] BCAM 30 LDLRAP1 30 7.33 7.17 7.77 6.06 6.59 7.00 
SEZ6L[30]+NEG9 SEZ6L 30 NEG9 30 8.46 6.54 0.74 7.07 5.75 0.86 
SORT1[30]+NEG9 SORT1 30 NEG9 30 4.70 7.04 1.11 3.23 5.57 0.98 
LDLR[30]+NEG9 LDLR 30 NEG9 30 7.37 6.95  4.91 5.79  
HAVCR1[30]+NEG9 HAVCR1 30 NEG9 30 6.41 7.27 6.49 6.60 7.66 5.75 
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MLXIPL[30]+NEG9 MLXIPL 30 NEG9 30 7.28 1.16 9.31 4.93 5.47 7.66 
LDLR[30]+MLXIPL[30] LDLR 30 MLXIPL 30 8.60 7.10 6.91 4.72 5.57 6.00 
LDLR[30]+LDLRAP1[30] LDLR 30 LDLRAP1 30 6.66 8.03 7.36 5.59 6.12 5.60 
HAVCR1[30]+SEZ6L[30] HAVCR1 30 SEZ6L 30 6.83 7.13 5.41 5.29 7.15 5.29 
HAVCR1[30]+SORT1[30] HAVCR1 30 SORT1 30 5.96 5.88 6.73 4.91 5.63 4.80 
LDLRAP1[30]+SORT1[30] LDLRAP1 30 SORT1 30 8.30  7.32 6.39 5.71 6.10 
TOMM40[7.5]+NEG9 TOMM40 7.5 NEG9 30 8.68 7.43 7.40 7.45 7.13 6.52 
MLXIPL[30]+TOMM40[7.5] MLXIPL 30 TOMM40 7.5 7.70 9.74 7.53 6.90 8.02 6.27 
CXCL12[30]+NEG9 CXCL12 30 NEG9 30 6.83 4.16 7.78 6.24 5.77 5.94 
PAFAH1B1[7.5]+NEG9 PAFAH1B1 7.5 NEG9 30 6.19 6.50 6.83 5.71 6.26 5.84 
SORT1[7.5]+NEG9 SORT1 7.5 NEG9 30 6.49 6.85 7.24 6.28 14.72 5.78 
NCAN[30]+NEG9 NCAN 30 NEG9 30 7.81 7.59 8.35 7.50 6.35 6.52 
CXCL12[30]+PAFAH1B1[7.5] CXCL12 30 PAFAH1B1 7.5 6.48 6.91 8.05 5.06 6.07 6.13 
SORT1[7.5]+TOMM40[7.5] SORT1 7.5 TOMM40 7.5 6.88 7.94 7.92 6.36 6.69 6.52 
NCAN[30]+TOMM40[7.5] NCAN 30 TOMM40 7.5 7.60 7.68 8.78 5.78 6.95 6.70 
SEZ6L[15]+NEG9 SEZ6L 15 NEG9 30 7.71 7.83 7.37 5.74 7.39 6.17 
NCAN[30]+SEZ6L[15] NCAN 30 SEZ6L 15 7.70 7.94 8.25 6.92 6.37 6.08 
LDLR[7.5]+NCAN[30] LDLR 7.5 NCAN 30 7.70 7.60 7.77 5.72 5.99 6.26 
SIK3[30]+NEG9 SIK3 30 NEG9 30 8.11 7.65 7.97 5.88 6.56 7.61 
PAFAH1B1[7.5]+SIK3[30] PAFAH1B1 7.5 SIK3 30 9.35 8.05 8.37 8.80 7.56 7.38 
MYBPHL[30]+NEG9 MYBPHL 30 NEG9 30 6.47 6.61 7.19 5.18 5.39 6.15 
MYBPHL[30]+SIK3[30] MYBPHL 30 SIK3 30 7.04 7.36 7.26 6.84 6.89 6.63 
PCSK9[15]+NEG9 PCSK9 15 NEG9 30  7.78 7.21 7.75 6.01 6.29 
TMEM57[15]+NEG9 TMEM57 15 NEG9 30 7.31 7.80 7.89 6.16 6.80 6.87 
PCSK9[15]+TMEM57[15] PCSK9 15 TMEM57 15 6.74 6.49 6.78 5.55 5.85 6.16 
CELSR2[15]+NEG9 CELSR2 30 NEG9 30 7.61 6.88 7.51 5.83 5.83 5.98 
LPL[15]+NEG9 LPL 30 NEG9 30 9.18 5.39 8.38 6.75  6.33 
CELSR2[15]+LPL[15] CELSR2 30 LPL 30 7.36 n.d. 7.67 6.29 8.95 6.78 
APOB[30]+NEG9 APOB 30 NEG9 30 5.98 8.31 6.23 4.62 8.33 5.85 
HMGCR[30]+NEG9[30] HMGCR 30 NEG9 30 7.81 7.51 7.40 4.73 6.43 6.72 
APOB[30]+HMGCR[30] APOB 30 HMGCR 30 7.13 8.66 7.36 4.31 6.56 5.90 
 
 
Table S15. Regulation of SREBF1 and SREBF2 transcription upon single and double knockdown of the genes that were 
identified by the screen as interacting. 
Significant effect calculated with Student’s t-test in Microsoft Excel (TTEST (array1, array2, 2, 3)) is shown in bold. *<0.1, 
**<0.01, ***<0.001. 
 
 SREBF1 
 
SREBF2 
  log2 (fold change) 
 
 log2 (fold change) 
 
 
Treatment Exp.1 Exp.2 Exp.3 mean mRNA 
regulation 
Exp.1 Exp.2 Exp.3 mean mRNA 
regulation HAVCR1[15]+NEG9 -0.02 0.18 0.05 0.07  -1.21 -0.84 -0.05 -0.70  
LDLR[7.5]+NEG9 0.00 0.11 -0.63 -0.17  -0.42 0.12 -0.79 -0.36  
LDLRAP1[30]+NEG9 0.42 -0.12 0.28 0.19  -0.25 -0.20 0.33 -0.04  
MLXIPL[7.5]+NEG9 0.58 -0.36 -0.77 -0.18    0.19 -0.09 0.05  
BCAM[30]+NEG9 -0.34 -2.31 -1.05 -1.23 * -0.16 -1.22 -0.57 -0.65 * 
HAVCR1[15]+LDLR[7.5] -0.66 0.68 -0.25 -0.08  -1.12 0.22 -0.35 -0.42  
HAVCR1[15]+LDLRAP1[30] -0.80 0.53 -0.26 -0.18  -1.13 -0.42 -0.53 -0.69 * 
HAVCR1[15]+BCAM[30] 0.08 -0.83 -1.32 -0.69  -0.16 -1.42 -1.41 -0.99 * 
HAVCR1[15]+MLXIPL[7.5]   -0.72 0.28 -0.22  0.71 -0.67 -0.74 -0.24 *** 
BCAM[30]+LDLRAP1[30] 0.72 -0.38 -0.96 -0.20  0.69 -0.86 -1.27 -0.48 * 
SEZ6L[30]+NEG9 -0.39 0.25 -0.43 -0.19  -0.51 -0.03 -0.22 -0.26  
SORT1[30]+NEG9   -0.24 0.15 -0.04    0.15 -0.03 0.06  
LDLR[30]+NEG9 -0.04 -0.16   -0.10    -0.07   -0.07  
HAVCR1[30]+NEG9   -0.48 0.66 0.09  0.47 -1.94 0.11 -0.45  
MLXIPL[30]+NEG9 -2.59   -2.17 -2.38  -1.70   -1.80 -1.75  
LDLR[30]+MLXIPL[30] -1.22 -0.30 0.27 -0.42  0.19 0.15 0.29 0.21  
LDLR[30]+LDLRAP1[30] -0.24 -1.23 -0.17 -0.55  1.00 -0.40 0.69 0.43  
HAVCR1[30]+SEZ6L[30] 0.45 -0.33   0.06  -0.35 -1.43 0.57 -0.40  
HAVCR1[30]+SORT1[30]   0.92 0.42 0.67  -0.19 0.09 1.06 0.32  
LDLRAP1[30]+SORT1[30] -1.65   -0.14 -0.89  -0.79 0.01 0.19 -0.20  
TOMM40[7.5]+NEG9 -1.85 -0.64 -0.25 -0.91  -2.16 -1.41 -0.66 -1.41 * 
MLXIPL[30]+TOMM40[7.5] -1.74 -2.95 -0.38 -1.69  -1.99 -2.30 -0.41 -1.57  
CXCL12[30]+NEG9     -0.98 -0.98  0.15 -0.05 -0.21 -0.04  
PAFAH1B1[7.5]+NEG9   0.30 -0.03 0.14    -0.54 -0.11 -0.33  
SORT1[7.5]+NEG9   -0.05 -0.43 -0.24  0.63   -0.05 0.29  
NCAN[30]+NEG9 -0.98 -0.79 -1.54 -1.10  -1.26 -0.63 -0.79 -0.89  
CXCL12[30]+PAFAH1B1[7.5] -0.28 -0.11 -1.24 -0.55  0.66 -0.35 -0.40 -0.03  
SORT1[7.5]+TOMM40[7.5] -0.39 -1.15 -1.12 -0.89  -0.09 -0.97 -0.79 -0.61 ** 
NCAN[30]+TOMM40[7.5] 0.22 -0.88 -1.97 -0.88    -1.23 -0.97 -1.10 * 
SEZ6L[15]+NEG9 -1.24 -1.03 -0.57 -0.95  -0.68 -1.67 -0.44 -0.93  
NCAN[30]+SEZ6L[15] -0.81 -1.15 -1.45 -1.14  -0.56 -0.65 -0.35 -0.52  
LDLR[7.5]+NCAN[30] -0.10 -0.81 -0.97 -0.63  0.05 -0.27 -0.53 -0.25  
SIK3[30]+NEG9 -0.40 -0.85 -1.17 -0.81  -0.14 -0.84 -1.88 -0.95  
PAFAH1B1[7.5]+SIK3[30] -1.66 -1.25 -1.56 -1.49 * -1.88 -1.84 -1.65 -1.79 * 
MYBPHL[30]+NEG9   0.19 -0.39 -0.10  0.54 0.33 -0.42 0.15  
MYBPHL[30]+SIK3[30]   -0.56 -0.46 -0.51 * -0.96 -1.17 -0.90 -1.01 ** 
PCSK9[15]+NEG9   -0.99 -0.40 -0.70    -0.29 -0.56 -0.43  
TMEM57[15]+NEG9 -0.83 -1.01 -1.08 -0.97  -0.97 -1.08 -1.14 -1.06 * 
PCSK9[15]+TMEM57[15] 0.31 0.31 0.03 0.21    -0.13 -0.43 -0.28  
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CELSR2[15]+NEG9   -0.09 -0.70 -0.39    -0.11 -0.25 -0.18  
LPL[15]+NEG9 -1.87   -1.58 -1.72  -0.60   -0.60 -0.60  
CELSR2[15]+LPL[15] -0.31   -0.86 -0.59  0.44   -1.05 -0.30  
APOB[30]+NEG9 1.07   0.57 0.82  0.61   -0.12 0.25  
HMGCR[30]+NEG9[30] -0.77 -1.12 -0.60 -0.83    -1.29 -0.99 -1.14  
APOB[30]+HMGCR[30] -0.09 -2.27 -0.55 -0.97  0.92 -1.42 -0.17 -0.22  
 
 
Table S16. Effect of the gene interactions on LDLR mRNA and protein levels. 
Interaction effects on LDLR mRNA and protein of the 21 validated gene interactions, calculated by fitting a linear model on the 
Dct values of 4 biological replicates and the LDLR/a-tubulin protein values of 3 biological replicates, whereby the effect of single 
knockdowns was compared to that of doubles. The standard error, as well as the p-value of the interaction are shown. The 
significant interactions (pVal<10
-1
) are highlighted in bold. 
 
  LDLR mRNA LDLR protein 
Gene1 Gene2 Interaction Effect Std.Error pvalue Interaction Effect Std.Error pvalue 
HAVCR
1 
LDLR 0.91 0.45 0.04 -0.44 0.24 0.07 
HAVCR1 LDLRAP
1 
-0.43 0.43 0.32 -0.70 0.54 0.19 
HAVCR1 BCAM -0.43 0.43 0.32 -0.29 0.66 0.66 
HAVCR1 MLXIPL 0.10 0.52 0.86 0.51 0.26 0.05 
BCAM LDLRAP
1 
-0.27 0.58 0.64 0.38 0.41 0.36 
LDLR MLXIPL 1.00 0.52 0.05 0.42 0.32 0.19 
LDLR LDLRAP
1 
0.65 0.57 0.26 0.30 0.38 0.43 
HAVCR
1 
SEZ6L 0.78 0.47 0.10 0.32 0.22 0.14 
HAVCR1 SORT1 0.53 0.48 0.27 0.67 0.22 0.00 
LDLRAP
1 
SORT1 0.15 0.65 0.82 0.59 0.23 0.01 
TOMM4
0 
MLXIPL 0.13 0.93 0.89 0.50 0.48 0.30 
CXCL12 PAFAH1
B1 
0.77 0.61 0.20 0.38 0.22 0.09 
SORT1 TOMM4
0 
0.23 0.94 0.81 0.27 0.31 0.38 
NCAN TOMM
40 
1.16 0.51 0.02 -0.03 0.56 0.96 
SEZ6L NCAN 0.55 0.43 0.20 0.25 0.58 0.66 
LDLR NCAN 0.86 0.49 0.08 0.27 0.24 0.26 
MYBPH
L 
SIK3 0.08 0.53 0.88 -0.05 0.62 0.94 
PAFAH1
B1 
SIK3 -0.31 0.70 0.66 0.13 0.46 0.78 
PCSK9 TMEM5
7 
-0.31 0.70 0.66 0.09 0.48 0.85 
CELSR2 LPL -0.13 0.66 0.85 0.08 0.56 0.89 
APOB HMGCR 0.45 1.62 0.78 -0.88 0.52 0.09 
 
 
Table S17. Effect of the gene interactions on SREBF1 and SREBF2 mRNA levels. 
Shown are the interaction effects of the 21 validated gene interactions on SREBF1 and SREBF2  mRNA, as calculated by fitting a 
linear model on the DCt values of 4 biological replicates, to compare the effect of the single knockdowns to that of the doubles. 
The standard error of the estimated interaction effect, as well as the p-value of the interaction are shown. The significant ones 
(pVal<10
-1
) are highlighted in bold. 
 
  SREBF1 mRNA SREBF2 mRNA 
Gene1 Gene2 Interaction Effect Std.Error pvalue Interaction Effect Std.Error pvalue 
HAVCR1 LDLR -0.18 0.92 0.85 -1.08 0.28 0.00 
HAVCR1 LDLRAP1 0.22 0.85 0.80 -0.85 0.85 0.32 
HAVCR1 BCAM -0.27 0.88 0.76 -0.35 0.42 0.40 
HAVCR1 MLXIPL -0.20 0.74 0.79 -0.15 0.22 0.51 
BCAM LDLRAP1 -0.73 0.65 0.26 -0.03 0.22 0.90 
LDLR MLXIPL -0.81 1.29 0.53 -0.01 0.39 0.99 
LDLR LDLRAP1 0.38 0.76 0.61 -0.76 0.45 0.09 
HAVCR1 SEZ6L 0.69 1.06 0.51 -0.32 0.16 0.05 
HAVCR1 SORT1 2.48 1.49 0.09 -1.19 0.48 0.01 
LDLRAP1 SORT1 3.93 1.32 0.00 1.00 1.25 0.42 
TOMM40 MLXIPL -0.71 1.35 0.60 2.75 0.65 0.00 
CXCL12 PAFAH1B1 -0.46 0.91 0.61 -0.57 1.28 0.66 
SORT1 TOMM40 -0.07 0.90 0.94 -0.39 0.37 0.29 
NCAN TOMM40 -0.57 0.76 0.46 -0.88 0.38 0.02 
SEZ6L NCAN -0.53 0.46 0.25 -1.11 0.38 0.00 
LDLR NCAN -0.42 0.57 0.46 -0.63 0.51 0.22 
MYBPHL SIK3 -0.45 0.50 0.37 -1.07 0.36 0.00 
PAFAH1B1 SIK3 0.83 0.52 0.11 0.60 0.29 0.04 
PCSK9 TMEM57 -1.47 0.45 0.00 0.84 0.63 0.19 
CELSR2 LPL -1.35 0.77 0.08 -0.15 0.50 0.76 
APOB HMGCR 0.71 0.44 0.10 -0.77 0.56 0.17 
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Table S18. Correlation of LDLR mRNA and protein, as well as SREBF1 and SREBF2 mRNA with functional effect on LDL uptake. 
Shown is the effect on LDL uptake, LDLR mRNA and protein, as well as SREBF1 and SREBF2 mRNA, upon double knockdowns of the genes which were identified by the screen as interacting. Interaction effects are 
highlighted with pink (increased) or green (decreased). 
 
  
    LDL uptake LDLR mRNA LDLR protein SREBF1 mRNA SREBF2 mRNA correlation anti-correlation 
  
Treatment Robust Z 
score 
log2 (fold 
change) 
log2(LDLR/a-
tubulin) 
log2 (fold 
change) 
log2 (fold 
change)     
1 LDLR+ NCAN -1.23 -1.88 -3.91 -0.63 -0.25 LDL-LDLR mRNA-SREBF2 mRNA   
2 CXCL12+ PAFAH1B1  1.32 -0.42 -1.91 -0.55 -0.03   LDL-LDLR protein 
3 NCAN + SEZ6L -0.08 -0.29 -0.45 -1.14 -0.52     
4 NCAN + TOMM40  -1.49 -1.27 -1.10 -0.88 -1.10 LDL-LDLR mRNA-SREBF2 mRNA   
5 HAVCR1 + MLXIPL -0.12 1.00 -0.38 -0.22 -0.24     
6 LDLRAP1 + SORT1 -1.09 -0.06 -1.45 -0.89 -0.20 LDL-SREBF1 mRNA-SREBF2 
mRNA 
  
7 LDLR + LDLRAP1 -2.49 -2.04 -3.91 -0.55 0.43 LDL-LDLR protein LDL-SREBF2 
mRNA 8 CELSR2 + LPL  -0.11 0.29 -1.21 -0.59 -1.28 LDL-SREBF1 mRNA   
9 MLXIPL + TOMM40  -1.94 -0.81 -1.45 -1.69 -1.57 LDL-LDLR protein   
10 LDLR + MLXIPL -2.26 -2.60 -2.32 -0.42 0.21 LDL-LDLR mRNA LDL-SREBF2 
mRNA 11 HAVCR1+ SEZ6L -0.67 0.17 -0.82 0.06 -0.40     
12 HAVCR1 + LDLRAP1 0.39 1.29 -0.66 -0.18 -0.69     
13 BCAM + LDLRAP1 -0.05 0.06 -0.66 -0.20 -0.48 LDL-LDLR protein   
14 HAVCR1 + SORT1 -0.63 0.52 -1.32 0.67 0.32   LDL-SREBF1 
mRNA 15 BCAM + HAVCR1  -0.51 -0.60 -0.38 -0.69 -0.99     
16 MYBPHL + SIK3 2.30 0.59 -0.10 -0.51 -1.01   LDL-SREBF2 
mRNA 17 APOB + HMGCR 3.33 0.57 -0.21 -0.97 0.25     
18 SORT1 + TOMM40  -2.48 -1.21 -2.10 -0.89 -0.61 LDL-SREBF2 mRNA   
19 PAFAH1B1+ SIK3 3.30 0.54 -1.74 -1.49 -1.79     
20 PCSK9 + TMEM57  3.21 0.24 -0.15 0.21 -0.28 LDL-SREBF1 mRNA LDL-SREBF2 
mRNA 
21 HAVCR1+LDLR -2.24 -1.29 -3.91 -0.08 -0.42 LDL-LDLR mRNA-LDLR protein   
 
 
 
 
 
Table S19. Results of the co-RNAi screen. 
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Treatment siRNA1 siRNA2 robustZscore mad 
APOB__APOB APOB APOB -0.84 0.49 
APOB__APOE APOB APOE 0.29 1.00 
APOB__BAZ1B APOB BAZ1B 0.41 0.78 
APOB__BCAM APOB BCAM -0.07 0.82 
APOB__BCL7B APOB BCL7B 0.10 0.82 
APOB__CBLC APOB CBLC -0.09 1.24 
APOB__CELSR2 APOB CELSR2 0.83 0.79 
APOB__CXCL12 APOB CXCL12 -0.05 2.02 
APOB__FAM174A APOB FAM174A -1.40 0.97 
APOB__HAVCR1 APOB HAVCR1 -0.04 1.08 
APOB__HMGCR APOB HMGCR 2.80 1.53 
APOB__LDLR APOB LDLR -1.68 0.96 
APOB__LDLRAP1 APOB LDLRAP1 0.30 0.86 
APOB__LPL APOB LPL -0.86 0.69 
APOB__MLXIPL APOB MLXIPL -0.46 0.68 
APOB__MYBPHL APOB MYBPHL 0.58 0.62 
APOB__MYLIP APOB MYLIP 0.38 1.23 
APOB__NCAN APOB NCAN -0.30 0.97 
APOB__NEG9 APOB NEG9 -0.10 1.10 
APOB__PAFAH1B1 APOB PAFAH1B1 -0.13 1.54 
APOB__PAFAH1B2 APOB PAFAH1B2 -0.27 0.94 
APOB__PCSK9 APOB PCSK9 -0.74 1.49 
APOB__PVRL2 APOB PVRL2 0.03 0.78 
APOB__SEZ6L APOB SEZ6L -0.61 0.50 
APOB__SIK3 APOB SIK3 2.16 1.31 
APOB__SORT1 APOB SORT1 -0.29 0.44 
APOB__TM6SF2 APOB TM6SF2 -0.32 1.33 
APOB__TMEM57 APOB TMEM57 -0.27 0.98 
APOB__TOMM40 APOB TOMM40 -1.26 0.74 
APOB__WDR12 APOB WDR12 0.10 1.78 
APOB__ZNF259 APOB ZNF259 0.01 0.78 
APOE__APOE APOE APOE -0.26 0.62 
APOE__BAZ1B APOE BAZ1B 0.99 1.43 
APOE__BCAM APOE BCAM 0.28 1.17 
APOE__BCL7B APOE BCL7B -0.14 0.78 
APOE__CBLC APOE CBLC 0.52 0.56 
APOE__CELSR2 APOE CELSR2 0.23 1.05 
APOE__CXCL12 APOE CXCL12 1.75 1.77 
APOE__FAM174A APOE FAM174A -0.20 0.67 
APOE__HAVCR1 APOE HAVCR1 -0.15 1.48 
APOE__HMGCR APOE HMGCR 0.96 0.71 
APOE__LDLR APOE LDLR -1.07 0.91 
APOE__LDLRAP1 APOE LDLRAP1 0.47 0.95 
APOE__LPL APOE LPL -0.10 1.02 
APOE__MLXIPL APOE MLXIPL 0.35 0.46 
APOE__MYBPHL APOE MYBPHL 0.55 1.77 
APOE__MYLIP APOE MYLIP 0.39 0.69 
APOE__NCAN APOE NCAN 1.57 1.72 
APOE__NEG9 APOE NEG9 0.40 1.29 
APOE__PAFAH1B1 APOE PAFAH1B1 -1.04 1.23 
APOE__PAFAH1B2 APOE PAFAH1B2 0.53 0.95 
APOE__PCSK9 APOE PCSK9 -0.09 1.58 
APOE__PVRL2 APOE PVRL2 1.10 0.89 
APOE__SEZ6L APOE SEZ6L -1.00 0.74 
APOE__SIK3 APOE SIK3 0.93 0.87 
APOE__SORT1 APOE SORT1 0.36 0.73 
APOE__TM6SF2 APOE TM6SF2 -0.04 0.72 
APOE__TMEM57 APOE TMEM57 0.23 0.72 
APOE__TOMM40 APOE TOMM40 -0.62 0.11 
APOE__WDR12 APOE WDR12 0.27 0.68 
APOE__ZNF259 APOE ZNF259 0.11 1.53 
BAZ1B__BAZ1B BAZ1B BAZ1B -0.98 1.31 
BAZ1B__BCAM BAZ1B BCAM -0.63 0.57 
BAZ1B__BCL7B BAZ1B BCL7B 0.47 1.40 
BAZ1B__CBLC BAZ1B CBLC 0.31 0.69 
BAZ1B__CELSR2 BAZ1B CELSR2 0.39 0.44 
BAZ1B__CXCL12 BAZ1B CXCL12 0.41 1.58 
BAZ1B__FAM174A BAZ1B FAM174A -0.59 1.22 
BAZ1B__HAVCR1 BAZ1B HAVCR1 0.30 0.63 
BAZ1B__HMGCR BAZ1B HMGCR 1.00 1.39 
BAZ1B__LDLR BAZ1B LDLR -1.65 1.02 
BAZ1B__LDLRAP1 BAZ1B LDLRAP1 0.52 0.88 
BAZ1B__LPL BAZ1B LPL -0.69 0.97 
BAZ1B__MLXIPL BAZ1B MLXIPL 0.53 0.82 
BAZ1B__MYBPHL BAZ1B MYBPHL 0.22 1.21 
BAZ1B__MYLIP BAZ1B MYLIP 0.77 1.01 
BAZ1B__NCAN BAZ1B NCAN 1.26 2.15 
BAZ1B__NEG9 BAZ1B NEG9 0.42 1.65 
BAZ1B__PAFAH1B1 BAZ1B PAFAH1B1 -1.08 1.60 
BAZ1B__PAFAH1B2 BAZ1B PAFAH1B2 -0.31 0.64 
BAZ1B__PCSK9 BAZ1B PCSK9 0.25 0.92 
BAZ1B__PVRL2 BAZ1B PVRL2 -0.30 1.94 
BAZ1B__SEZ6L BAZ1B SEZ6L -0.30 0.36 
BAZ1B__SIK3 BAZ1B SIK3 0.12 0.58 
BAZ1B__SORT1 BAZ1B SORT1 -0.57 0.36 
BAZ1B__TM6SF2 BAZ1B TM6SF2 -0.66 0.43 
BAZ1B__TMEM57 BAZ1B TMEM57 1.35 1.51 
BAZ1B__TOMM40 BAZ1B TOMM40 -1.32 0.22 
BAZ1B__WDR12 BAZ1B WDR12 0.32 0.97 
BAZ1B__ZNF259 BAZ1B ZNF259 -0.13 0.94 
BCAM__BCAM BCAM BCAM -0.37 0.45 
BCAM__BCL7B BCAM BCL7B -0.43 0.59 
BCAM__CBLC BCAM CBLC -0.26 0.87 
BCAM__CELSR2 BCAM CELSR2 0.69 1.03 
BCAM__CXCL12 BCAM CXCL12 0.17 0.67 
BCAM__FAM174A BCAM FAM174A -0.49 1.25 
BCAM__HAVCR1 BCAM HAVCR1 -0.51 1.03 
 167 
BCAM__HMGCR BCAM HMGCR 1.27 1.19 
BCAM__LDLR BCAM LDLR -2.05 0.84 
BCAM__LDLRAP1 BCAM LDLRAP1 -0.40 0.88 
BCAM__LPL BCAM LPL -0.74 0.55 
BCAM__MLXIPL BCAM MLXIPL 0.44 0.66 
BCAM__MYBPHL BCAM MYBPHL -0.03 0.73 
BCAM__MYLIP BCAM MYLIP 0.63 0.72 
BCAM__NCAN BCAM NCAN 0.71 0.88 
BCAM__NEG9 BCAM NEG9 0.43 1.51 
BCAM__PAFAH1B1 BCAM PAFAH1B1 -0.34 0.94 
BCAM__PAFAH1B2 BCAM PAFAH1B2 -0.37 0.62 
BCAM__PCSK9 BCAM PCSK9 0.63 0.92 
BCAM__PVRL2 BCAM PVRL2 0.80 1.81 
BCAM__SEZ6L BCAM SEZ6L -0.41 1.44 
BCAM__SIK3 BCAM SIK3 -0.25 0.82 
BCAM__SORT1 BCAM SORT1 -0.44 0.84 
BCAM__TM6SF2 BCAM TM6SF2 -0.73 0.32 
BCAM__TMEM57 BCAM TMEM57 0.31 0.39 
BCAM__TOMM40 BCAM TOMM40 -0.78 0.16 
BCAM__WDR12 BCAM WDR12 -0.26 0.62 
BCAM__ZNF259 BCAM ZNF259 -0.07 0.61 
BCL7B__BCL7B BCL7B BCL7B 2.11 1.02 
BCL7B__CBLC BCL7B CBLC -0.64 0.56 
BCL7B__CELSR2 BCL7B CELSR2 1.41 1.59 
BCL7B__CXCL12 BCL7B CXCL12 0.04 0.69 
BCL7B__FAM174A BCL7B FAM174A -1.37 0.63 
BCL7B__HAVCR1 BCL7B HAVCR1 0.59 0.94 
BCL7B__HMGCR BCL7B HMGCR 0.94 0.45 
BCL7B__LDLR BCL7B LDLR -1.91 0.79 
BCL7B__LDLRAP1 BCL7B LDLRAP1 0.89 1.41 
BCL7B__LPL BCL7B LPL 0.23 1.08 
BCL7B__MLXIPL BCL7B MLXIPL -0.03 1.35 
BCL7B__MYBPHL BCL7B MYBPHL 0.46 1.05 
BCL7B__MYLIP BCL7B MYLIP 0.69 1.33 
BCL7B__NCAN BCL7B NCAN 0.20 0.85 
BCL7B__NEG9 BCL7B NEG9 0.29 1.23 
BCL7B__PAFAH1B1 BCL7B PAFAH1B1 0.02 0.66 
BCL7B__PAFAH1B2 BCL7B PAFAH1B2 0.57 1.33 
BCL7B__PCSK9 BCL7B PCSK9 -0.85 1.59 
BCL7B__PVRL2 BCL7B PVRL2 0.25 0.94 
BCL7B__SEZ6L BCL7B SEZ6L -0.87 0.66 
BCL7B__SIK3 BCL7B SIK3 1.53 1.72 
BCL7B__SORT1 BCL7B SORT1 -0.56 1.57 
BCL7B__TM6SF2 BCL7B TM6SF2 -0.55 0.75 
BCL7B__TMEM57 BCL7B TMEM57 0.26 1.45 
BCL7B__TOMM40 BCL7B TOMM40 -0.12 0.21 
BCL7B__WDR12 BCL7B WDR12 -0.47 0.71 
BCL7B__ZNF259 BCL7B ZNF259 -0.04 1.03 
CBLC__CBLC CBLC CBLC -0.13 0.79 
CBLC__CELSR2 CBLC CELSR2 0.67 1.70 
CBLC__CXCL12 CBLC CXCL12 0.36 0.58 
CBLC__FAM174A CBLC FAM174A -0.98 0.45 
CBLC__HAVCR1 CBLC HAVCR1 -0.14 0.74 
CBLC__HMGCR CBLC HMGCR 0.58 0.52 
CBLC__LDLR CBLC LDLR -1.60 1.21 
CBLC__LDLRAP1 CBLC LDLRAP1 0.57 1.12 
CBLC__LPL CBLC LPL -0.84 0.54 
CBLC__MLXIPL CBLC MLXIPL 0.41 0.58 
CBLC__MYBPHL CBLC MYBPHL 0.13 1.29 
CBLC__MYLIP CBLC MYLIP 0.69 1.73 
CBLC__NCAN CBLC NCAN 0.78 0.64 
CBLC__NEG9 CBLC NEG9 0.25 1.25 
CBLC__PAFAH1B1 CBLC PAFAH1B1 -0.57 1.34 
CBLC__PAFAH1B2 CBLC PAFAH1B2 0.70 1.05 
CBLC__PCSK9 CBLC PCSK9 -0.19 0.97 
CBLC__PVRL2 CBLC PVRL2 1.10 2.54 
CBLC__SEZ6L CBLC SEZ6L -0.97 0.65 
CBLC__SIK3 CBLC SIK3 1.04 0.99 
CBLC__SORT1 CBLC SORT1 -0.59 0.56 
CBLC__TM6SF2 CBLC TM6SF2 -0.07 1.06 
CBLC__TMEM57 CBLC TMEM57 -0.17 0.50 
CBLC__TOMM40 CBLC TOMM40 -0.54 0.73 
CBLC__WDR12 CBLC WDR12 0.63 1.13 
CBLC__ZNF259 CBLC ZNF259 -0.42 0.69 
CELSR2__CELSR2 CELSR2 CELSR2 -0.09 1.56 
CELSR2__CXCL12 CELSR2 CXCL12 0.86 0.73 
CELSR2__FAM174A CELSR2 FAM174A -1.11 1.46 
CELSR2__HAVCR1 CELSR2 HAVCR1 0.49 1.39 
CELSR2__HMGCR CELSR2 HMGCR 0.63 0.67 
CELSR2__LDLR CELSR2 LDLR -2.13 1.32 
CELSR2__LDLRAP1 CELSR2 LDLRAP1 1.04 1.22 
CELSR2__LPL CELSR2 LPL -1.40 0.58 
CELSR2__MLXIPL CELSR2 MLXIPL 0.49 0.99 
CELSR2__MYBPHL CELSR2 MYBPHL 1.28 1.89 
CELSR2__MYLIP CELSR2 MYLIP 0.49 0.31 
CELSR2__NCAN CELSR2 NCAN 0.89 1.28 
CELSR2__NEG9 CELSR2 NEG9 0.23 1.11 
CELSR2__PAFAH1B1 CELSR2 PAFAH1B1 0.29 1.18 
CELSR2__PAFAH1B2 CELSR2 PAFAH1B2 0.82 2.30 
CELSR2__PCSK9 CELSR2 PCSK9 -0.21 1.16 
CELSR2__PVRL2 CELSR2 PVRL2 1.50 1.10 
CELSR2__SEZ6L CELSR2 SEZ6L -0.97 0.69 
CELSR2__SIK3 CELSR2 SIK3 2.30 0.96 
CELSR2__SORT1 CELSR2 SORT1 -0.51 0.75 
CELSR2__TM6SF2 CELSR2 TM6SF2 -0.63 0.97 
CELSR2__TMEM57 CELSR2 TMEM57 0.42 1.16 
CELSR2__TOMM40 CELSR2 TOMM40 -0.05 0.74 
CELSR2__WDR12 CELSR2 WDR12 0.46 1.28 
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CELSR2__ZNF259 CELSR2 ZNF259 -0.61 1.39 
CXCL12__CXCL12 CXCL12 CXCL12 2.20 1.80 
CXCL12__FAM174A CXCL12 FAM174A -1.69 0.88 
CXCL12__HAVCR1 CXCL12 HAVCR1 -0.41 0.95 
CXCL12__HMGCR CXCL12 HMGCR 1.08 1.04 
CXCL12__LDLR CXCL12 LDLR -2.15 0.50 
CXCL12__LDLRAP1 CXCL12 LDLRAP1 1.37 1.46 
CXCL12__LPL CXCL12 LPL -1.01 1.16 
CXCL12__MLXIPL CXCL12 MLXIPL 0.71 1.55 
CXCL12__MYBPHL CXCL12 MYBPHL -0.41 0.64 
CXCL12__MYLIP CXCL12 MYLIP -0.06 0.74 
CXCL12__NCAN CXCL12 NCAN 1.83 1.14 
CXCL12__NEG9 CXCL12 NEG9 0.23 1.39 
CXCL12__PAFAH1B1 CXCL12 PAFAH1B1 -2.17 0.71 
CXCL12__PAFAH1B2 CXCL12 PAFAH1B2 -0.44 1.01 
CXCL12__PCSK9 CXCL12 PCSK9 0.82 1.40 
CXCL12__PVRL2 CXCL12 PVRL2 -0.20 1.28 
CXCL12__SEZ6L CXCL12 SEZ6L -0.78 1.46 
CXCL12__SIK3 CXCL12 SIK3 0.01 1.91 
CXCL12__SORT1 CXCL12 SORT1 -1.35 1.11 
CXCL12__TM6SF2 CXCL12 TM6SF2 -0.97 1.76 
CXCL12__TMEM57 CXCL12 TMEM57 0.86 2.16 
CXCL12__TOMM40 CXCL12 TOMM40 -1.54 0.80 
CXCL12__WDR12 CXCL12 WDR12 -0.04 0.98 
CXCL12__ZNF259 CXCL12 ZNF259 -0.69 0.85 
FAM174A__FAM174A FAM174A FAM174A -2.32 0.85 
FAM174A__HAVCR1 FAM174A HAVCR1 -1.04 1.26 
FAM174A__HMGCR FAM174A HMGCR 0.16 0.59 
FAM174A__LDLR FAM174A LDLR -2.17 0.41 
FAM174A__LDLRAP1 FAM174A LDLRAP1 -0.77 1.16 
FAM174A__LPL FAM174A LPL -1.87 0.74 
FAM174A__MLXIPL FAM174A MLXIPL 0.58 1.75 
FAM174A__MYBPHL FAM174A MYBPHL -0.91 1.51 
FAM174A__MYLIP FAM174A MYLIP -0.81 0.95 
FAM174A__NCAN FAM174A NCAN 0.08 1.43 
FAM174A__NEG9 FAM174A NEG9 -0.78 1.37 
FAM174A__PAFAH1B1 FAM174A PAFAH1B1 -0.60 1.39 
FAM174A__PAFAH1B2 FAM174A PAFAH1B2 -0.96 0.80 
FAM174A__PCSK9 FAM174A PCSK9 -0.53 1.00 
FAM174A__PVRL2 FAM174A PVRL2 -1.72 0.79 
FAM174A__SEZ6L FAM174A SEZ6L -0.63 1.55 
FAM174A__SIK3 FAM174A SIK3 0.19 0.99 
FAM174A__SORT1 FAM174A SORT1 -0.22 0.99 
FAM174A__TM6SF2 FAM174A TM6SF2 -1.20 1.08 
FAM174A__TMEM57 FAM174A TMEM57 -0.71 1.97 
FAM174A__TOMM40 FAM174A TOMM40 -1.23 1.41 
FAM174A__WDR12 FAM174A WDR12 -0.83 0.54 
FAM174A__ZNF259 FAM174A ZNF259 -0.96 1.05 
HAVCR1__HAVCR1 HAVCR1 HAVCR1 -0.67 1.52 
HAVCR1__HMGCR HAVCR1 HMGCR 0.28 1.38 
HAVCR1__LDLR HAVCR1 LDLR -2.18 0.49 
HAVCR1__LDLRAP1 HAVCR1 LDLRAP1 -0.56 0.84 
HAVCR1__LPL HAVCR1 LPL -1.65 0.59 
HAVCR1__MLXIPL HAVCR1 MLXIPL -0.63 1.35 
HAVCR1__MYBPHL HAVCR1 MYBPHL 0.59 1.31 
HAVCR1__MYLIP HAVCR1 MYLIP -0.13 0.65 
HAVCR1__NCAN HAVCR1 NCAN -0.51 1.07 
HAVCR1__NEG9 HAVCR1 NEG9 0.58 1.18 
HAVCR1__PAFAH1B1 HAVCR1 PAFAH1B1 -0.97 0.90 
HAVCR1__PAFAH1B2 HAVCR1 PAFAH1B2 0.13 0.30 
HAVCR1__PCSK9 HAVCR1 PCSK9 -0.67 1.93 
HAVCR1__PVRL2 HAVCR1 PVRL2 -0.70 1.75 
HAVCR1__SEZ6L HAVCR1 SEZ6L -1.19 0.86 
HAVCR1__SIK3 HAVCR1 SIK3 1.23 1.74 
HAVCR1__SORT1 HAVCR1 SORT1 -2.09 0.91 
HAVCR1__TM6SF2 HAVCR1 TM6SF2 -0.41 1.15 
HAVCR1__TMEM57 HAVCR1 TMEM57 -0.96 0.50 
HAVCR1__TOMM40 HAVCR1 TOMM40 -1.06 1.55 
HAVCR1__WDR12 HAVCR1 WDR12 -0.48 0.71 
HAVCR1__ZNF259 HAVCR1 ZNF259 -1.01 0.53 
HMGCR__HMGCR HMGCR HMGCR -0.63 0.80 
HMGCR__LDLR HMGCR LDLR -0.22 2.48 
HMGCR__LDLRAP1 HMGCR LDLRAP1 1.24 0.57 
HMGCR__LPL HMGCR LPL 0.11 0.43 
HMGCR__MLXIPL HMGCR MLXIPL 2.17 2.23 
HMGCR__MYBPHL HMGCR MYBPHL 1.74 0.51 
HMGCR__MYLIP HMGCR MYLIP -0.51 0.75 
HMGCR__NCAN HMGCR NCAN 1.38 1.22 
HMGCR__NEG9 HMGCR NEG9 0.71 1.11 
HMGCR__PAFAH1B1 HMGCR PAFAH1B1 1.45 1.74 
HMGCR__PAFAH1B2 HMGCR PAFAH1B2 0.00 0.90 
HMGCR__PCSK9 HMGCR PCSK9 0.44 0.80 
HMGCR__PVRL2 HMGCR PVRL2 1.24 1.14 
HMGCR__SEZ6L HMGCR SEZ6L 1.26 0.39 
HMGCR__SIK3 HMGCR SIK3 1.71 1.38 
HMGCR__SORT1 HMGCR SORT1 1.02 1.44 
HMGCR__TM6SF2 HMGCR TM6SF2 0.76 0.72 
HMGCR__TMEM57 HMGCR TMEM57 0.94 0.97 
HMGCR__TOMM40 HMGCR TOMM40 0.62 1.00 
HMGCR__WDR12 HMGCR WDR12 0.85 0.92 
HMGCR__ZNF259 HMGCR ZNF259 0.11 1.21 
LDLRAP1__LDLRAP1 LDLRAP1 LDLRAP1 0.86 0.98 
LDLRAP1__LPL LDLRAP1 LPL -0.81 0.96 
LDLRAP1__MLXIPL LDLRAP1 MLXIPL 1.50 1.94 
LDLRAP1__MYBPHL LDLRAP1 MYBPHL 0.90 2.03 
LDLRAP1__MYLIP LDLRAP1 MYLIP 0.68 1.88 
LDLRAP1__NCAN LDLRAP1 NCAN 1.85 2.37 
LDLRAP1__NEG9 LDLRAP1 NEG9 0.94 1.45 
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LDLRAP1__PAFAH1B1 LDLRAP1 PAFAH1B1 -0.73 0.94 
LDLRAP1__PAFAH1B2 LDLRAP1 PAFAH1B2 0.57 1.24 
LDLRAP1__PCSK9 LDLRAP1 PCSK9 0.43 1.92 
LDLRAP1__PVRL2 LDLRAP1 PVRL2 0.72 1.81 
LDLRAP1__SEZ6L LDLRAP1 SEZ6L -1.46 1.36 
LDLRAP1__SIK3 LDLRAP1 SIK3 1.51 1.00 
LDLRAP1__SORT1 LDLRAP1 SORT1 -1.11 0.77 
LDLRAP1__TM6SF2 LDLRAP1 TM6SF2 -0.57 0.49 
LDLRAP1__TMEM57 LDLRAP1 TMEM57 0.16 1.36 
LDLRAP1__TOMM40 LDLRAP1 TOMM40 -0.96 2.20 
LDLRAP1__WDR12 LDLRAP1 WDR12 0.20 1.03 
LDLRAP1__ZNF259 LDLRAP1 ZNF259 0.11 1.39 
LDLR__LDLR LDLR LDLR -1.39 1.17 
LDLR__LDLRAP1 LDLR LDLRAP1 -2.44 0.65 
LDLR__LPL LDLR LPL -2.05 0.65 
LDLR__MLXIPL LDLR MLXIPL -2.03 0.98 
LDLR__MYBPHL LDLR MYBPHL -1.54 1.87 
LDLR__MYLIP LDLR MYLIP -1.73 1.16 
LDLR__NCAN LDLR NCAN -1.86 0.69 
LDLR__NEG9 LDLR NEG9 -1.50 1.17 
LDLR__PAFAH1B1 LDLR PAFAH1B1 -1.24 1.74 
LDLR__PAFAH1B2 LDLR PAFAH1B2 -1.44 1.52 
LDLR__PCSK9 LDLR PCSK9 -1.84 0.97 
LDLR__PVRL2 LDLR PVRL2 0.08 3.67 
LDLR__SEZ6L LDLR SEZ6L -1.96 0.64 
LDLR__SIK3 LDLR SIK3 -1.61 0.94 
LDLR__SORT1 LDLR SORT1 -0.91 0.53 
LDLR__TM6SF2 LDLR TM6SF2 -1.07 1.76 
LDLR__TMEM57 LDLR TMEM57 -1.98 0.69 
LDLR__TOMM40 LDLR TOMM40 -2.18 1.50 
LDLR__WDR12 LDLR WDR12 -1.69 1.01 
LDLR__ZNF259 LDLR ZNF259 -1.45 1.11 
LPL__LPL LPL LPL -1.41 0.88 
LPL__MLXIPL LPL MLXIPL 0.36 0.76 
LPL__MYBPHL LPL MYBPHL -0.35 0.85 
LPL__MYLIP LPL MYLIP 0.53 1.00 
LPL__NCAN LPL NCAN 0.66 0.79 
LPL__NEG9 LPL NEG9 -0.29 1.12 
LPL__PAFAH1B1 LPL PAFAH1B1 -1.35 1.44 
LPL__PAFAH1B2 LPL PAFAH1B2 -0.86 1.08 
LPL__PCSK9 LPL PCSK9 -1.23 0.83 
LPL__PVRL2 LPL PVRL2 -0.43 1.24 
LPL__SEZ6L LPL SEZ6L -0.79 1.27 
LPL__SIK3 LPL SIK3 0.20 1.03 
LPL__SORT1 LPL SORT1 -1.08 1.50 
LPL__TM6SF2 LPL TM6SF2 -0.82 1.31 
LPL__TMEM57 LPL TMEM57 -0.68 0.88 
LPL__TOMM40 LPL TOMM40 -2.23 0.82 
LPL__WDR12 LPL WDR12 -0.73 1.02 
LPL__ZNF259 LPL ZNF259 -0.71 1.25 
MLXIPL__MLXIPL MLXIPL MLXIPL 1.54 0.79 
MLXIPL__MYBPHL MLXIPL MYBPHL -0.06 1.69 
MLXIPL__MYLIP MLXIPL MYLIP 1.30 1.13 
MLXIPL__NCAN MLXIPL NCAN 1.68 0.71 
MLXIPL__NEG9 MLXIPL NEG9 1.21 1.75 
MLXIPL__PAFAH1B1 MLXIPL PAFAH1B1 -0.54 0.81 
MLXIPL__PAFAH1B2 MLXIPL PAFAH1B2 0.32 1.30 
MLXIPL__PCSK9 MLXIPL PCSK9 1.87 1.03 
MLXIPL__PVRL2 MLXIPL PVRL2 2.20 1.93 
MLXIPL__SEZ6L MLXIPL SEZ6L -0.91 2.15 
MLXIPL__SIK3 MLXIPL SIK3 0.70 1.05 
MLXIPL__SORT1 MLXIPL SORT1 -0.14 0.75 
MLXIPL__TM6SF2 MLXIPL TM6SF2 -0.60 1.51 
MLXIPL__TMEM57 MLXIPL TMEM57 2.17 0.76 
MLXIPL__TOMM40 MLXIPL TOMM40 -2.14 1.24 
MLXIPL__WDR12 MLXIPL WDR12 -0.23 1.78 
MLXIPL__ZNF259 MLXIPL ZNF259 -0.95 1.18 
MYBPHL__MYBPHL MYBPHL MYBPHL 0.98 0.24 
MYBPHL__MYLIP MYBPHL MYLIP 0.72 0.90 
MYBPHL__NCAN MYBPHL NCAN 1.10 1.58 
MYBPHL__NEG9 MYBPHL NEG9 0.06 1.56 
MYBPHL__PAFAH1B1 MYBPHL PAFAH1B1 0.66 1.92 
MYBPHL__PAFAH1B2 MYBPHL PAFAH1B2 -0.60 0.91 
MYBPHL__PCSK9 MYBPHL PCSK9 -0.31 0.80 
MYBPHL__PVRL2 MYBPHL PVRL2 0.62 1.42 
MYBPHL__SEZ6L MYBPHL SEZ6L 0.73 1.44 
MYBPHL__SIK3 MYBPHL SIK3 2.17 1.49 
MYBPHL__SORT1 MYBPHL SORT1 1.08 2.25 
MYBPHL__TM6SF2 MYBPHL TM6SF2 0.02 0.74 
MYBPHL__TMEM57 MYBPHL TMEM57 0.25 0.92 
MYBPHL__TOMM40 MYBPHL TOMM40 0.21 0.90 
MYBPHL__WDR12 MYBPHL WDR12 0.92 1.02 
MYBPHL__ZNF259 MYBPHL ZNF259 1.25 1.43 
MYLIP__MYLIP MYLIP MYLIP 0.54 1.15 
MYLIP__NCAN MYLIP NCAN 0.82 1.24 
MYLIP__NEG9 MYLIP NEG9 0.38 1.53 
MYLIP__PAFAH1B1 MYLIP PAFAH1B1 -0.10 1.36 
MYLIP__PAFAH1B2 MYLIP PAFAH1B2 -0.17 1.32 
MYLIP__PCSK9 MYLIP PCSK9 1.07 2.68 
MYLIP__PVRL2 MYLIP PVRL2 0.06 0.95 
MYLIP__SEZ6L MYLIP SEZ6L 2.18 0.97 
MYLIP__SIK3 MYLIP SIK3 0.53 0.76 
MYLIP__SORT1 MYLIP SORT1 0.34 1.19 
MYLIP__TM6SF2 MYLIP TM6SF2 0.94 0.53 
MYLIP__TMEM57 MYLIP TMEM57 1.22 0.66 
MYLIP__TOMM40 MYLIP TOMM40 0.71 1.68 
MYLIP__WDR12 MYLIP WDR12 -0.31 0.29 
MYLIP__ZNF259 MYLIP ZNF259 0.39 1.17 
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NCAN__NCAN NCAN NCAN 1.42 0.59 
NCAN__NEG9 NCAN NEG9 1.04 1.76 
NCAN__PAFAH1B1 NCAN PAFAH1B1 -0.36 0.70 
NCAN__PAFAH1B2 NCAN PAFAH1B2 1.68 1.17 
NCAN__PCSK9 NCAN PCSK9 1.62 2.54 
NCAN__PVRL2 NCAN PVRL2 2.35 1.79 
NCAN__SEZ6L NCAN SEZ6L -0.59 1.10 
NCAN__SIK3 NCAN SIK3 1.49 1.43 
NCAN__SORT1 NCAN SORT1 -0.51 0.98 
NCAN__TM6SF2 NCAN TM6SF2 -0.22 0.58 
NCAN__TMEM57 NCAN TMEM57 0.96 2.45 
NCAN__TOMM40 NCAN TOMM40 -1.40 1.58 
NCAN__WDR12 NCAN WDR12 0.35 1.80 
NCAN__ZNF259 NCAN ZNF259 0.01 0.39 
NEG9__NEG9 NEG9 NEG9 0.00 1.00 
NEG9__NPC1 NEG9 NPC1 0.02 1.14 
NEG9__PAFAH1B1 NEG9 PAFAH1B1 -0.55 1.72 
NEG9__PAFAH1B2 NEG9 PAFAH1B2 0.07 1.21 
NEG9__PCSK9 NEG9 PCSK9 -0.01 1.39 
NEG9__PVRL2 NEG9 PVRL2 0.21 0.94 
NEG9__SEZ6L NEG9 SEZ6L -0.23 1.32 
NEG9__SIK3 NEG9 SIK3 0.48 1.75 
NEG9__SORT1 NEG9 SORT1 -0.39 0.98 
NEG9__TM6SF2 NEG9 TM6SF2 -0.11 1.32 
NEG9__TMEM57 NEG9 TMEM57 0.02 1.23 
NEG9__TOMM40 NEG9 TOMM40 -0.63 1.73 
NEG9__WDR12 NEG9 WDR12 -0.38 1.08 
NEG9__ZNF259 NEG9 ZNF259 -0.30 1.22 
PAFAH1B1__PAFAH1B1 PAFAH1B1 PAFAH1B1 -1.57 0.82 
PAFAH1B1__PAFAH1B2 PAFAH1B1 PAFAH1B2 -0.69 1.14 
PAFAH1B1__PCSK9 PAFAH1B1 PCSK9 -1.76 1.79 
PAFAH1B1__PVRL2 PAFAH1B1 PVRL2 1.41 1.75 
PAFAH1B1__SEZ6L PAFAH1B1 SEZ6L 0.28 0.18 
PAFAH1B1__SIK3 PAFAH1B1 SIK3 1.62 0.48 
PAFAH1B1__SORT1 PAFAH1B1 SORT1 0.70 2.60 
PAFAH1B1__TM6SF2 PAFAH1B1 TM6SF2 0.08 0.80 
PAFAH1B1__TMEM57 PAFAH1B1 TMEM57 0.08 1.54 
PAFAH1B1__TOMM40 PAFAH1B1 TOMM40 0.89 0.90 
PAFAH1B1__WDR12 PAFAH1B1 WDR12 0.41 2.05 
PAFAH1B1__ZNF259 PAFAH1B1 ZNF259 0.53 1.35 
PAFAH1B2__PAFAH1B2 PAFAH1B2 PAFAH1B2 0.13 1.36 
PAFAH1B2__PCSK9 PAFAH1B2 PCSK9 -0.50 0.84 
PAFAH1B2__PVRL2 PAFAH1B2 PVRL2 -0.76 0.72 
PAFAH1B2__SEZ6L PAFAH1B2 SEZ6L -0.36 0.81 
PAFAH1B2__SIK3 PAFAH1B2 SIK3 -0.20 1.87 
PAFAH1B2__SORT1 PAFAH1B2 SORT1 0.91 1.65 
PAFAH1B2__TM6SF2 PAFAH1B2 TM6SF2 0.19 1.12 
PAFAH1B2__TMEM57 PAFAH1B2 TMEM57 -0.30 0.62 
PAFAH1B2__TOMM40 PAFAH1B2 TOMM40 -0.62 1.22 
PAFAH1B2__WDR12 PAFAH1B2 WDR12 -0.13 0.72 
PAFAH1B2__ZNF259 PAFAH1B2 ZNF259 0.37 0.69 
PCSK9__PCSK9 PCSK9 PCSK9 -0.64 0.61 
PCSK9__PVRL2 PCSK9 PVRL2 0.32 0.97 
PCSK9__SEZ6L PCSK9 SEZ6L -1.52 1.15 
PCSK9__SIK3 PCSK9 SIK3 -0.42 0.87 
PCSK9__SORT1 PCSK9 SORT1 0.09 0.60 
PCSK9__TM6SF2 PCSK9 TM6SF2 -0.68 1.62 
PCSK9__TMEM57 PCSK9 TMEM57 1.46 0.81 
PCSK9__TOMM40 PCSK9 TOMM40 -1.66 0.47 
PCSK9__WDR12 PCSK9 WDR12 -0.26 0.79 
PCSK9__ZNF259 PCSK9 ZNF259 0.12 0.64 
PVRL2__PVRL2 PVRL2 PVRL2 0.67 0.79 
PVRL2__SEZ6L PVRL2 SEZ6L 0.36 0.38 
PVRL2__SIK3 PVRL2 SIK3 0.29 1.10 
PVRL2__SORT1 PVRL2 SORT1 1.36 1.71 
PVRL2__TM6SF2 PVRL2 TM6SF2 -0.38 1.22 
PVRL2__TMEM57 PVRL2 TMEM57 1.55 1.38 
PVRL2__TOMM40 PVRL2 TOMM40 0.43 1.27 
PVRL2__WDR12 PVRL2 WDR12 0.71 1.33 
PVRL2__ZNF259 PVRL2 ZNF259 1.12 0.85 
SEZ6L__SEZ6L SEZ6L SEZ6L -1.54 0.65 
SEZ6L__SIK3 SEZ6L SIK3 -0.02 0.76 
SEZ6L__SORT1 SEZ6L SORT1 -0.75 0.83 
SEZ6L__TM6SF2 SEZ6L TM6SF2 0.42 0.67 
SEZ6L__TMEM57 SEZ6L TMEM57 0.20 1.87 
SEZ6L__TOMM40 SEZ6L TOMM40 -0.19 1.00 
SEZ6L__WDR12 SEZ6L WDR12 -1.53 0.82 
SEZ6L__ZNF259 SEZ6L ZNF259 0.36 0.63 
SIK3__SIK3 SIK3 SIK3 2.35 1.24 
SIK3__SORT1 SIK3 SORT1 1.00 1.27 
SIK3__TM6SF2 SIK3 TM6SF2 -0.85 1.92 
SIK3__TMEM57 SIK3 TMEM57 1.38 0.19 
SIK3__TOMM40 SIK3 TOMM40 1.41 0.23 
SIK3__WDR12 SIK3 WDR12 0.66 1.35 
SIK3__ZNF259 SIK3 ZNF259 1.11 2.85 
SORT1__SORT1 SORT1 SORT1 0.16 0.14 
SORT1__TM6SF2 SORT1 TM6SF2 0.81 0.47 
SORT1__TMEM57 SORT1 TMEM57 0.79 0.74 
SORT1__TOMM40 SORT1 TOMM40 0.77 1.04 
SORT1__WDR12 SORT1 WDR12 -0.32 0.46 
SORT1__ZNF259 SORT1 ZNF259 0.35 0.50 
TM6SF2__TM6SF2 TM6SF2 TM6SF2 -0.13 0.46 
TM6SF2__TMEM57 TM6SF2 TMEM57 1.11 0.41 
TM6SF2__TOMM40 TM6SF2 TOMM40 0.42 1.53 
TM6SF2__WDR12 TM6SF2 WDR12 -0.90 0.73 
TM6SF2__ZNF259 TM6SF2 ZNF259 0.63 0.84 
TMEM57__TMEM57 TMEM57 TMEM57 1.53 0.29 
TMEM57__TOMM40 TMEM57 TOMM40 -0.83 1.86 
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Table S20. Results of the validation experiments for LDL uptake. 
 
  Robust Z score 
  Treatment Exp.1 Exp.2 Exp.3 Exp.4 
1 BCAM __ LDLRAP1 -0.97 -2.18 -1.16   
2 CXCL12__ PAFAH1B1  0.29 -1.97 -3.21   
3 HAVCR1 __ LDLRAP1 -1.97 0.53 -1.2   
4 HAVCR1 __ LPL -1.77 0.81 -0.12   
5 HAVCR1 __ MLXIPL -2.88 2.12 -0.34   
6 HAVCR1 __ NCAN 1.01 0.71 -0.27   
7 HAVCR1__ SEZ6L -0.96 1.22 -0.04 -1.74 
8 HAVCR1 __ SORT1 -1.25 1.51 -0.45 -1.56 
9 HAVCR1 __ TMEM57 0.18 -0.53 0.98   
10 LDLR__ LDLRAP1 -1.05 -0.17 0.11 -3.37 
11 LDLRAP1 __ LPL  2.6 -0.34 -1.2   
12 LDLRAP1 __ SEZ6L -0.74 -0.01 1.04   
13 MLXIPL __ SEZ6L  0.75 -0.73 -0.46   
14 MLXIPL __ TOMM40  -1.91 0.75 -1.29 -2.07 
15 PAFAH1B1 __ TOMM40 -0.66 -0.57 -0.35   
16 APOB __ HMGCR -0.52 -2.7 6.27   
17 APOE __ MLXIPL  -2.37 2.95 0.58   
18 BCAM __ HAVCR1  -3.88 0.11 0.9   
19 CELSR2 __ LPL  -0.35 -1.09 -0.06   
20 CELSR2 __ SIK3 4.48 -0.57 1.5   
21 HAVCR1 __ MYLIP -0.47 0.72 3.03   
22 HAVCR1 __ ZNF259 -2.07 0.99 -0.26 0.73 
23 HMGCR __ PAFAH1B1  -2.03 -5.24 3.38   
24 LDLR __ NCAN -2.37 0.52 -1.21   
25 LDLR __ MLXIPL -1.42 0.1 -0.88   
26 LDLR __ PVRL2 -1.05 -1.47 -0.94   
27 LDLRAP1 __ SORT1 -0.43 2.56 -1.7 -1.35 
28 MYBPHL __ SIK3 0.33 1.68 0.36   
29 MYLIP __ SEZ6L  2.28 -0.28 -1.47   
30 NCAN __ SEZ6L -0.48 0.01 -1.55   
31 NCAN __ TOMM40  -0.88 -0.06 -3.12   
32 PAFAH1B1 __ SIK3 -4.04 4.45 3.55   
33 PCSK9  __ TMEM57  1.95 2.02 -0.19   
34 PVRL2 __ SORT1  1.85 0.67 0.8   
35 SORT1  __ TOMM40  3.28 0.68 0.87   
TMEM57__WDR12 TMEM57 WDR12 1.20 1.41 
TMEM57__ZNF259 TMEM57 ZNF259 0.32 0.68 
TOMM40__TOMM40 TOMM40 TOMM40 0.72 1.11 
TOMM40__WDR12 TOMM40 WDR12 -0.18 1.96 
TOMM40__ZNF259 TOMM40 ZNF259 0.46 0.31 
WDR12__WDR12 WDR12 WDR12 -0.86 0.16 
WDR12__ZNF259 WDR12 ZNF259 -0.14 0.80 
ZNF259__ZNF259 ZNF259 ZNF259 -0.27 0.23 
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Table S21. The 144 SNPs that were tested for SNP co-occurrence in data from the Bioimage study.  
SNPs that were tested for SNP co-occurrence in data from the Bioimage study are listed. The 133 SNPs were extracted from the 
PhenoScanner of the University of Cambridge, with lipid-trait associations from the study of Willer et al. 2013. Associations for 
other traits (CAD, CHD, MI) were extracted from other studies and are highlighted in green. Shown are the chromosomal locus 
where the SNP is located (Locus), the Reference SNP cluster ID (rs ID), the SNP position on the chromosome (Position), the risk 
(A1) and the ancestral (A2) allele, the SNP function -if known- (Function), the reported gene (Gene), the associated trait (Trait), 
the p-value for the association (p-value), the number of individuals tested (N), the reported odds ratio or beta-coefficient 
associated with the strongest SNP risk allele  (beta) and the standard error of the beta-coefficient (sebeta). 
 
Locus SNP Pos A1  A2 Function Gene Trait p-value N beta Sebeta Reference 
1p13.3 
rs629301 109818306 G T UTR-3' CELSR2 LDL 5E-241 NA -0.167 0 Willer et al. 2013 
            TC 2E-170 155873 0.134 0.0047 Willer et al. 2013 
rs599839 109822166 A G nearGene-3' PSRC1 LDL 2.70E-268 170167 0.1601 0.0044 Willer et al. 2013 
            TC 1.40E-186 184335 0.1281 0.0042 Willer et al. 2013 
rs12740374 109817590 G T UTR-3' CELSR2 LDL 2.4e-272 172820 0.161 0.0044 Willer et al. 2013 
            TC 7.70E-187 187071 0.1278 0.0043 Willer et al. 2013 
rs660240 109817838 T C UTR-3' CELSR2 LDL 9.00E-265 173022 -0.1607 0.0044 Willer et al. 2013 
            TC 7.00E-182 187288 -0.1276 0.0043 Willer et al. 2013 
rs646776 109818530 T C nearGene-3 CELSR2 LDL 1.60E-272 173021 0.1602 0.0044 Willer et al. 2013 
            TC 4.80E-187 187288 0.1272 0.0042 Willer et al. 2013 
rs7528419 109817192 A G UTR-3'   LDL 1.50E-165 114743 0.1547 0.0054 Willer et al. 2013 
            TC 5.60E-110 128033 0.1189 0.0051 Willer et al. 2013 
rs602633 109821511 T G   CELSR2 LDL 1.50E-261 171593 -0.1591 0.0044 Willer et al. 2013 
            TC 2.10E-180 185817 -0.1268 0.0043 Willer et al. 2013 
rs4970833 109804646 A G intron CELSR2 LDL 7.00E-55 160040 0.0637 0.0039 Willer et al. 2013 
            TC 9.70E-38 171955 0.0503 0.0038 Willer et al. 2013 
rs6689614 109807099 A G synonymous CELSR2 LDL 7.80E-61 172988 0.0646 0.0038 Willer et al. 2013 
            TC 2.80E-41 187253 0.0507 0.0036 Willer et al. 2013 
rs4970834 109814880 T C intron CELSR2 LDL 2.00E-208 172825 0.1503 0.0047 Willer et al. 2013 
            TC 9.60E-143 187081 0.1188 0.0045 Willer et al. 2013 
rs611917 109815252 G A intron CELSR2 LDL 1.90E-151 159987 -0.111 0.0041 Willer et al. 2013 
            TC 5.60E-104 171876 -0.0881 0.0039 Willer et al. 2013 
rs3902354 109819296 C A   CELSR2 CHD 2.1E-11 184305 
-
0.06963 
0.0104 Nikpay et al. 2015 
            MI 0.00000014 167181 
-
0.06024 
0.01143 Nikpay et al. 2015 
rs672569 109827253 A G nearGene-5' CELSR2 LDL 2.10E-64 89876 -0.1431 0.0082 Willer et al. 2013 
1p32.3 
rs2479409 55504650 G A nearGene-5' PCSK9 LDL 3E-50 172970 -0.0642 0.0041 Willer et al. 2013 
            TC 2E-39 187226 -0.054 0.004 Willer et al. 2013 
rs11206510 55496039 C T intergenic PCSK9 LDL 2.40E-53 172812 -0.0831 0.005 Willer et al. 2013 
            TC 1.10E-41 187066 -0.069 0.0048 Willer et al. 2013 
rs11591147 55505647 G T nearGene-5' PCSK9 LDL 8.60E-143 77417 0.497 0.018 Willer et al. 2013 
            TC 8.80E-86 85729 0.3341 0.0173 Willer et al. 2013 
rs499883 55519174 A G     CHD 0.007 184305 0.02872 0.01066 Nikpay et al. 2015 
    A G     MI 0.034 167181 0.02497 0.01181 Nikpay et al. 2015 
rs505151 55529187 A G ncRNA PCSK9 LDL 4.2e-17 151827 -0.0866 0.01 Willer et al. 2013 
            TC 3.8e-10 164218 -0.0619 0.0096 Willer et al. 2013 
1p36.11 
rs12027135 25449242 A T intron TMEM57 TC 5E-12 NA     Willer et al. 2013 
            LDL 2E-14 NA     Willer et al. 2013 
2p24.1 
rs1367117 21263900 A G missense APOB LDL 9.48E-183 173007 0.1186 0.004 Willer et al. 2013 
            TC 2.48E-139 187252 0.0995 0.0038 Willer et al. 2013 
rs10199768 21244000 G T intron APOB LDL 5.00E-139 170875 -0.0971 0.0037 Willer et al. 2013 
            TC 2.80E-108 185137 -0.083 0.0036 Willer et al. 2013 
            TG 5.70E-21 175642 -0.0353 0.0035 Willer et al. 2013 
rs693 21232195 G A cds-synon APOB LDL 1.20E-131 157125 -0.0954 0.0038 Willer et al. 2013 
            TC 5.20E-102 168987 -0.0816 0.0037 Willer et al. 2013 
            TG 2.20E-30 160959 -0.0415 0.0034 Willer et al. 2013 
rs1801701 21228827 T C missense APOB LDL 2.3e-21 173030 0.0638 0.0064 Willer et al. 2013 
            TC 8.3e-15 187293 0.0497 0.0062 Willer et al. 2013 
rs1042034 21225281 T C missense APOB TG 4.10E-66 177771 0.0704 0.0039 Willer et al. 2013 
            HDL 2.90E-54 187071 -0.0659 0.004 Willer et al. 2013 
            LDL 7.40E-39 173002 0.0586 0.0043 Willer et al. 2013 
            TC 2.50E-25 187265 0.0448 0.0042 Willer et al. 2013 
rs12713956 21241505 G A intron APOB LDL 1.3e-28 173010 -0.0719 0.0062 Willer et al. 2013 
            TC 2.9e-28 187270 -0.0688 0.006 Willer et al. 2013 
rs11902417 21198900 A G intergenic APOB TG 6.70E-67 173384 -0.0694 0.0039 Willer et al. 2013 
            HDL 1.20E-47 182623 0.0605 0.004 Willer et al. 2013 
            LDL 2.10E-46 168630 -0.0628 0.0043 Willer et al. 2013 
            TC 4.90E-33 182782 -0.0506 0.0041 Willer et al. 2013 
rs515135 21286057 T C intergenic APOB LDL 1.10E-178 173029 -0.1394 0.0048 Willer et al. 2013 
            TC 6.40E-151 187291 -0.1238 0.0046 Willer et al. 2013 
rs6544366 21204025 G T intergenic APOB TG 5.40E-66 174737 0.0685 0.0039 Willer et al. 2013 
            HDL 1.80E-48 184086 -0.0606 0.004 Willer et al. 2013 
            LDLc 9.30E-46 170058 0.062 0.0043 Willer et al. 2013 
            TC 8.70E-32 184227 0.0492 0.0041 Willer et al. 2013 
rs6754295 21206183 G T intergenic APOB TG 2.00E-62 177784 -0.0657 0.0038 Willer et al. 2013 
            HDL 1.20E-49 187085 0.0609 0.0039 Willer et al. 2013 
            LDL 1.60E-47 173013 -0.0628 0.0042 Willer et al. 2013 
            TC 2.90E-33 187280 -0.0501 0.0041 Willer et al. 2013 
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rs7557067 21208211 A G intergenic APOB Tg 2.00E-62 177772 0.0659 0.0038 Willer et al. 2013 
            HDL 2.20E-49 187078 -0.0608 0.0039 Willer et al. 2013 
            LDL 2.50E-46 173006 0.062 0.0042 Willer et al. 2013 
            TC 1.20E-32 187265 0.0495 0.0041 Willer et al. 2013 
rs676210 21231524 A G missense MYLIP Tg 3.30E-71 177782 -0.0733 0.0039 Willer et al. 2013 
            HDL 2.30E-54 187081 0.066 0.004 Willer et al. 2013 
rs934197 21267461 A G non-coding    LDL 1.60E-74 84950 0.1049 0.0054 Willer et al. 2013 
            HDL 3.30E-05 
3.30E-
05 
-0.0228 0.0051 Willer et al. 2013 
rs673548 21237544 A G intron APOB TG 2.00E-68 163871 -0.0742 0.0041 Willer et al. 2013 
            HDL 2.10E-53 172585 0.0678 0.0042 Willer et al. 2013 
            LDL 2.70E-38 159959 -0.0606 0.0045 Willer et al. 2013 
rs754523 21311691 G A intergenic APOB LDL 6.00E-122 160051 0.0981 0.004 Willer et al. 2013 
            TC 2.60E-91 171993 0.0819 0.0039 Willer et al. 2013 
rs1713222 21271323 G A intergenic APOB LDL 2.60E-130 160080 0.1327 0.0053 Willer et al. 2013 
            TC 1.70E-113 172022 0.121 0.0051 Willer et al. 2013 
rs4635554 21389659 G T   APOB LDL 1.20E-75 156927 0.0783 0.0041 Willer et al. 2013 
            TC 5.10E-63 169635 0.0691 0.004 Willer et al. 2013 
rs312985 21378805 G A   APOB LDL 1.40E-118 158796 0.1106 0.0046 Willer et al. 2013 
            TC 7.80E-102 170715 0.0988 0.0045 Willer et al. 2013 
rs506585 21397182 A G   APOB LDL 3.90E-119 160084 0.1099 0.0046 Willer et al. 2013 
            TC 7.80E-102 172027 0.0983 0.0045 Willer et al. 2013 
rs503662 21414142 T C   APOB LDL 3.80E-83 173020 -0.0836 0.0042 Willer et al. 2013 
            TC 2.60E-70 187287 -0.0739 0.0041 Willer et al. 2013 
rs531819 21263639 G T intron APOB LDL 4.00E-141 173033 0.1343 0.0052 Willer et al. 2013 
            TC 6.50E-123 187299 0.1222 0.005 Willer et al. 2013 
rs17398765 21270751 A G   APOB LDL 3.50E-32 168107 -0.0916 0.0076 Willer et al. 2013 
            TC 9.90E-24 182233 -0.0734 0.0073 Willer et al. 2013 
2q33.2 
rs7582720 202881162 T C intron WDR12 LDL 0.000025 170099 -0.0249 0.0055 Willer et al. 2013 
            CHD 7.5E-18 184305 0.13342 0.0155 Nikpay et al. 2015 
            MI 1.7E-13 167181 0.12394 0.01681 Nikpay et al. 2015 
rs6725887     C intron WDR12 CHD 9.5E-18 184305 0.13288 0.01549 Nikpay et al. 2015 
            MI 2.6E-12 167181 0.11885 0.01699 Nikpay et al. 2015 
5q13.3 
rs12916 75360714 T C UTR-3' HMGCR TC 5E-74 182530 0.0684 0.0036 Willer et al. 2013 
            LDL 8E-78 NA 0.073 0 Willer et al. 2013 
rs3846662 74651084 G A intron HMGCR LDL 2.20E-69 NA     Willer et al. 2013 
            TC 6.90E-66 NA     Willer et al. 2013 
rs3846663 74655726 C T intron HMGCR LDL 1.10E-75 170020 -0.0722 0.0037 Willer et al. 2013 
            TC 2.90E-70 184190 -0.0665 0.0036 Willer et al. 2013 
rs12654264 74648603 A T intron HMGCR   3.90E-70 172958 -0.0687 0.0037 Willer et al. 2013 
              7.80E-65 187215 -0.0632 0.0036 Willer et al. 2013 
rs7703051 74625487 A C intergenic HMGCR LDL 1.40E-77 173015 0.0727 0.0037 Willer et al. 2013 
            TC 3.10E-72 187283 0.0672 0.0036 Willer et al. 2013 
rs10045497 74636484 A C intron HMGCR TC 2.10E-46 94595 0.0768 0.0052 Willer et al. 2013 
            LDL 2.30E-44 89888 0.0766 0.0053 Willer et al. 2013 
5q21 rs383830       intergenic FAM174A CAD 1.3E-5       WTTC 2007 
5q33.3 
rs6882076 156390297 C T nearGene-5' TIMD4 TC 5.35E-41 187270 0.0508 0.0037 Willer et al. 2013 
            TG 1.51E-15 177778 0.0286 0.0035 Willer et al. 2013 
            LDL 3.31E-31 173006 0.0456 0.0038 Willer et al. 2013 
            HDL 0.6852 187080 0.0015 0.0035 Willer et al. 2013 
rs1501908 156398169 G C intergenic HAVCR1 TC 4.9E-39 187107 -0.0494 0.0037 Willer et al. 2013 
            LDL 1.1E-28 172869 -0.0436 0.0038 Willer et al. 2013 
            TG 8.3E-15 177635 -0.0278 0.0035 Willer et al. 2013 
6p22.3 
rs3757354 16127176 C T nearGene-5'   LDL 2E-17 172987 -0.0382 0.0044 Willer et al. 2013 
          MYLIP TC 2E-15 187247 -0.0348 0.0042 Willer et al. 2013 
7q11.23 
rs17145738 72982874 C T nearGene-3' TBL2 TG 9.42E-99 175664 0.1149 0.0053 Willer et al. 2013 
            HDL 4.95E-13 184970 0.0408 0.0053 Willer et al. 2013 
            LDL 0.5431 170891 0.0039 0.0057 Willer et al. 2013 
            TC 0.008813 185161 0.0136 0.0055 Willer et al. 2013 
rs17145750 73612048 C T intron MLXIPL HDL 5E-13 NA     Willer et al. 2013 
rs2074755 72877166 T C intron BAZ1B TG 1.4E-98 174001 0.1092 0.0051 Willer et al. 2013 
            HDL 3.7E-12 183352 -0.0393 0.0052 Willer et al. 2013 
rs2286276 72987354 T C intron TBL2 TG 3.7e-70 163993 -0.067 0.0038 Willer et al. 2013 
            HDL 1.3e-06 172719 0.0208 0.0039 Willer et al. 2013 
rs2240466 72856269 G A UTR-3' BAZ1B TG 5.30E-90 170671 0.1051 0.0052 Willer et al. 2013 
            HDL 1.00E-11 178896 -0.0394 0.0053 Willer et al. 2013 
rs1178979 72856430 T A UTR-3' BAZ1B TG 2.00E-97 177782 0.0895 0.0042 Willer et al. 2013 
rs714052 72864869 A T intron BAZ1B TG 2.00E-99 177802 -0.1084 0.005 Willer et al. 2013 
            HDL 2.20E-12 187107 0.0394 0.0052 Willer et al. 2013 
rs3812316 73020337 C G missense MLXIPL TG 1.30E-31 79868 0.0912 0.0074 Willer et al. 2013 
            HDL 1.50E-04 84783 -0.0317 0.0077 Willer et al. 2013 
rs17145750 73026378 C T intron MLXIPL TG 1.00E-99 177797 0.1015 0.0047 Willer et al. 2013 
            HDL 5.70E-12 187102 -0.0358 0.0049 Willer et al. 2013 
rs12056034 72878645 A G intron BAZ1B TG 9.30E-100 177044 0.109 0.0051 Willer et al. 2013 
            HDL 1.30E-12 186350 -0.0399 0.0052 Willer et al. 2013 
rs799160 73060006 T C intergenic MLXIPL TG 5.50E-30 162118 0.0398 0.0036 Willer et al. 2013 
            HDL 2.90E-04 171614 -0.0133 0.0037 Willer et al. 2013 
rs11974409 72989390 A G intron TBL2 TG 1.40E-100 177786 0.0899 0.0042 Willer et al. 2013 
8p21.3 
rs12678919 19844222 G A intergenic LPL TG 1.82E-199 177749 0.1702 0.0056 Willer et al. 2013 
            HDL 1.38E-149 187049 0.1554 0.0057 Willer et al. 2013 
            LDL 0.5045 172984 0.008 0.0061 Willer et al. 2013 
            TC 0.7352 187233 0.0003 0.0059 Willer et al. 2013 
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rs17411031 19852310 C G intergenic LPL TG 7.30E-180 177569 0.1075 0.0037 Willer et al. 2013 
            HDL 3.90E-150 186853 -0.1047 0.0038 Willer et al. 2013 
rs17482753 19832646 G T intergenic LPL TG 5.80E-193 177737 0.1654 0.0055 Willer et al. 2013 
            HDL 2.80E-149 187036 -0.1538 0.0056 Willer et al. 2013 
rs3289 19823192 C T UTR-3'   HDL 6.40E-46 178804 -0.1695 0.0113 Willer et al. 2013 
            TG 3.70E-33 169504 0.1447 0.0111 Willer et al. 2013 
rs326 19819439 A G intron LPL TG 1.00E-63 96966 0.0869 0.005 Willer et al. 2013 
            HDL 2.00E-58 102961 -0.0889 0.0051 Willer et al. 2013 
rs10503669 19847690 A C   LPL TG 7.70E-190 177722 -0.1676 0.0056 Willer et al. 2013 
            HDL 4.10E-144 187021 0.1534 0.0057 Willer et al. 2013 
rs13702 19824492 T C UTR-3' LPL TG 6.60E-187 177749 0.1069 0.0037 Willer et al. 2013 
            HDL 1.30E-160 187044 -0.1058 0.0038 Willer et al. 2013 
rs325 19819328 C T intron LPL TG 9.40E-195 177748 -0.1676 0.0055 Willer et al. 2013 
            HDL 2.10E-148 187045 0.1552 0.0057 Willer et al. 2013 
rs10105606 19827848 A C intergenic LPL TG 5.10E-133 177734 -0.0876 0.0035 Willer et al. 2013 
            HDL 2.70E-105 187034 0.0833 0.0036 Willer et al. 2013 
rs2083637 19865175 G A intergenic LPL TG 2.10E-175 163987 -0.1084 0.0038 Willer et al. 2013 
            HDL 3.80E-143 172714 0.1051 0.0039 Willer et al. 2013 
rs10096633 19830921 C T intergenic LPL TG 3.40E-182 177749 0.1471 0.005 Willer et al. 2013 
            HDL 1.70E-144 187049 -0.1384 0.0051 Willer et al. 2013 
rs328 19819724 C G 
coding-
STOP-GAIN 
LPL TG 2.00E-179 160341 0.167 0.0058 Willer et al. 2013 
            HDL 3.20E-135 169631 -0.1541 0.0059 Willer et al. 2013 
rs3916027 19824868 G A nearGene-3'   TG 1.20E-179 177708 0.1072 0.0037 Willer et al. 2013 
            HDL 2.30E-154 187006 -0.1061 0.0038 Willer et al. 2013 
rs327 19819536 G T intron LPL TG 5.70E-174 177713 -0.1045 0.0037 Willer et al. 2013 
            HDL 4.60E-145 187014 0.1024 0.0038 Willer et al. 2013 
rs1581675 19858499 A T   LPL TG 7.40E-163 169466 -0.1054 0.0039 Willer et al. 2013 
            HDL 2.20E-133 177687 0.1026 0.004 Willer et al. 2013 
rs6993414 19902918 A G   LPL TG 3.30E-187 176745 0.1661 0.0056 Willer et al. 2013 
            HDL 5.00E-140 186043 -0.1514 0.0057 Willer et al. 2013 
rs2197089 19826373 G A intergenic LPL TG 7.60E-73 173751 0.0608 0.0034 Willer et al. 2013 
            HDL 9.60E-66 182963 -0.0612 0.0035 Willer et al. 2013 
rs6586891 19914598 A C intergenic LPL TG 9.20E-66 146609 -0.0656 0.0038 Willer et al. 2013 
            HDL 4.10E-61 154466 0.0675 0.0039 Willer et al. 2013 
rs331 19820405 A G intron LPL TG 1.10E-174 172997 -0.1089 0.0039 Willer et al. 2013 
            HDL 3.90E-150 182314 0.1105 0.004 Willer et al. 2013 
rs17091905 19849757 G A   LPL TG 2.00E-174 177742 -0.1481 0.0051 Willer et al. 2013 
            HDL 1.60E-137 187041 0.1377 0.0052 Willer et al. 2013 
rs264 19813180 A G intron LPL CAD 3E-7       Dichgans et al. 2013 
            TG 2.30E-84 172989 -0.0933 0.0048 Willer et al. 2013 
            HDL 8.0e-77 182301 0.0976 0.005 Willer et al. 2013 
rs264 19813180 A G intron LPL HDL 8.0e-77 182301 0.0976 0.005 Willer et al. 2013 
            TG 2.30E-84 172989 -0.0933 0.0048 Willer et al. 2013 
rs7016880 19876746 C G     TG 1.10E-184 177670 -0.165 0.0056 Willer et al. 2013 
            HDL 8.10E-144 186956 0.1534 0.0057 Willer et al. 2013 
rs9644568 19928582 A G   LPL TG 2.30E-129 177760 -0.1299 0.0053 Willer et al. 2013 
            HDL 4.10E-110 187059 0.1266 0.0054 Willer et al. 2013 
rs1059611 19824563 C T UTR-3 LPL TG 1.10E-190 177751 -0.1614 0.0053 Willer et al. 2013 
            HDL 1.10E-144 187052 0.1485 0.0055 Willer et al. 2013 
rs79236614 19860460 C G   LPL TG 1.10E-79 80066 0.1601 0.0082 Willer et al. 2013 
            HDL 4.70E-56 84992 -0.1444 0.0085 Willer et al. 2013 
rs17410962 19848080 G A   LPL TG 2.30E-172 176101 -0.1478 0.0051 Willer et al. 2013 
            HDL 8.30E-137 185404 0.1379 0.0052 Willer et al. 2013 
9p21.3 
rs501120         CXCL12 CHD 1.40E-11 184305 0.07861 0.01163 Nikpay et al. 2015 
            MI 4.10E-08 167181 0.07086 0.01292 Nikpay et al. 2015 
rs1333049 22125503 G     CXCL12 CHD 3.90E-93 184305 0.19322 0.00944 CARDIoGRAMplusC4D 
            MI 6.8E-6       Samani 2007 
10q11.21 
rs1746048   C   intergenic CXCL12 CAD 3E-10       Schunkert 2011 
            MI 7E-9       Kathiresan et al. 2009 
            CHD 6.50E-11 184305 0.07651 0.01171 Nikpay et al. 2015 
10q11.2 rs266089       intron CXCL12 MI 5.2e-18       Yamada 2011 
11q23.3 
rs964184       intron-3'UTR ZNF259 TG 7e-224 NA 0.0069 90991 Willer et al. 2013 
rs12286037 116652207 C T intron ZNF259 TG 5.30E-193 174655 -0.2151 0.0069 Willer et al. 2013 
            HDL 2.80E-47 184011 0.1052 0.007 Willer et al. 2013 
rs3741298 116657561 T C intron ZNF259 TG 2.50E-124 96989 -0.1473 0.0056 Willer et al. 2013 
            TC 7.70E-30 102894 -0.067 0.0058 Willer et al. 2013 
rs651821 116662579 C T 5' UTR ZNF259 Tg 3.00E-153 116795 0.2358 0.0084 Willer et al. 2013 
            TC 5.30E-28 126140 0.0978 0.0089 Willer et al. 2013 
            HDL 7.70E-26 126213 -0.1041 0.0088 Willer et al. 2013 
rs2075290 116653296 C T intron APOB TG 4.80E-244 177775 0.2278 0.0065 Willer et al. 2013 
            TC 3.80E-51 187268 0.1056 0.0069 Willer et al. 2013 
            HDL 1.30E-39 187082 -0.0947 0.0066 Willer et al. 2013 
rs1558861 116607437 C T intergenic MLXIPL TG 3.10E-161 103079 0.2368 0.0083 Willer et al. 2013 
            TC 1.20E-28 107665 0.1011 0.0088 Willer et al. 2013 
            HDL 9.00E-28 109540 -0.0964 0.0083 Willer et al. 2013 
rs4938303 116584987 C T intergenic ZNF259 TG 3.40E-166 177681 0.1071 0.0037 Willer et al. 2013 
            HDL 1.90E-31 186981 -0.0462 0.0038 Willer et al. 2013 
            TC 5.60E-25 187160 0.0414 0.0039 Willer et al. 2013 
rs28927680 116619073 G C UTR-3' ZNF259 TG 5.50E-78 101632 0.1802 0.0087 Willer et al. 2013 
            HDL 2.80E-18 107501 -0.0808 0.0087 Willer et al. 2013 
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            TC 4.80E-20 107532 0.0883 0.0092 Willer et al. 2013 
            LDL 1.20E-09 97617 0.0626 0.0097 Willer et al. 2013 
rs662799 116663707 A G intergenic APOA5 TG 1.60E-241 172713 -0.2474 0.0071 Willer et al. 2013 
            TC 2.50E-49 182202 -0.1113 0.0075 Willer et al. 2013 
            HDL 4.20E-37 182018 0.1001 0.0072 Willer et al. 2013 
            LDL 1.70E-22 168088 -0.0801 0.0078 Willer et al. 2013 
rs12272004 116603724 A C intergenic BUD13 TG 1.60E-179 162406 0.2021 0.0067 Willer et al. 2013 
            HDL 1.20E-45 171089 -0.102 0.007 Willer et al. 2013 
            TC 1.80E-36 170075 0.0925 0.0072 Willer et al. 2013 
            LDL 8.20E-19 158514 0.0679 0.0075 Willer et al. 2013 
rs6589566 116652423 A G intron ZNF259 TG 1.00E-239 177777 -0.226 0.0065 Willer et al. 2013 
            HDL 2.70E-38 187084 0.0931 0.0066 Willer et al. 2013 
            TC 8.20E-50 187270 -0.1042 0.0069 Willer et al. 2013 
            LDL 1.70E-23 173011 -0.0754 0.0071 Willer et al. 2013 
rs2000571 116585533 G A intergenic ZNF259 TG 1.40E-69 177725 -0.0763 0.0041 Willer et al. 2013 
            HDL 1.50E-10 187033 0.0291 0.0042 Willer et al. 2013 
            TC 2.60E-08 187215 -0.0251 0.0043 Willer et al. 2013 
rs486394 116526322 A C intergenic ZNF259 TG 2.80E-60 177648 -0.0665 0.0038 Willer et al. 2013 
            TC 2.70E-14 187138 -0.0307 0.004 Willer et al. 2013 
            HDL 2.10E-10 186954 0.0266 0.0038 Willer et al. 2013 
            LDL 3.20E-06 172883 -0.0198 0.0042 Willer et al. 2013 
rs2075292 116732512 G T intron SIK3 TG 6.40E-86 177762 0.1026 0.005 Willer et al. 2013 
            TC 4.10E-23 187249 0.0534 0.0053 Willer et al. 2013 
rs7124741 116752219 A T intron SIK3 TG 1.30E-85 177760 0.1048 0.0051 Willer et al. 2013 
            TC 8.60E-21 187253 0.0521 0.0055 Willer et al. 2013 
            LDL 9.10E-06 172995 0.031 0.0057 Willer et al. 2013 
rs17120139 116774201 A G intron SIK3 TG 3.20E-44 91013 0.1045 0.0074 Willer et al. 2013 
            TC 2.90E-14 94595 0.0629 0.0082 Willer et al. 2013 
            LDL 2.10E-05 89888 0.0367 0.0083 Willer et al. 2013 
rs3135506 116662407 C G coding APOA5 TG 1.10E-68 86746 0.1837 0.0096 Willer et al. 2013 
rs618923 116654159 A G intron ZNF259 TG 9.60E-30 155942 0.0488 0.0041 Willer et al. 2013 
            HDL 2.70E-21 165188 -0.0412 0.0042 Willer et al. 2013 
rs139961185 116807343 A G intron SIK3 CHD 2.20E-01 184305 0.07254 0.05942 Nikpay et al. 2015 
rs11216230 116884789 A G intron SIK3 CHD 6.30E-01 184305 
-
0.01722 
0.03592 
Nikpay et al. 2015 
            MI 8.70E-01 167181 -0.0068 0.04189 Nikpay et al. 2015 
17p13.3 rs9891572       intergenic PAFAH1B1 CAD 2.3E-7       Lettre 2011 
19p13.11 
rs10401969 19407718 C T intron NCAN TC 4.13E-77 185666 0.1369 0.007 Willer et al. 2013 
            TG 9.70E-70 176172 0.121 0.0065 Willer et al. 2013 
            LDLc 2.65E-54 171476 0.1184 0.0072 Willer et al. 2013 
            HDL 0.1022 185513 0.0128 0.0068 Willer et al. 2013 
rs2304130 19789528 A G intron NCAN TC 1.40E-46 170535 0.1039 0.0069 Willer et al. 2013 
            TG 5.40E-39 162508 0.085 0.0064 Willer et al. 2013 
            LDL 2.20E-32 158662 0.0885 0.0072 Willer et al. 2013 
rs17216525 19662220 C T intergenic NCAN TC 6.70E-62 185680 0.1133 0.0065 Willer et al. 2013 
            TG 1.00E-60 176188 0.1035 0.0061 Willer et al. 2013 
            LDL 3.40E-43 171492 0.096 0.0067 Willer et al. 2013 
rs16996148 19658472 G T intergenic NCAN TC 1.50E-62 183979 0.114 0.0065 Willer et al. 2013 
            TG 3.20E-60 174491 0.1031 0.0061 Willer et al. 2013 
            LDL 2.00E-45 169813 0.0986 0.0067 Willer et al. 2013 
19p13.2 
rs6511720 11202306 G T intron LDLR LDL 3.85E-262 170607 0.2209 0.0061 Willer et al. 2013 
            TC 5.43E-202 184763 0.1851 0.0059 Willer et al. 2013 
            LDL 3.85E-262 170607 0.2209 0.0061 Willer et al. 2013 
            HDL 6.32E-05 184617 0.0249 0.0057 Willer et al. 2013 
            TG 0.1043 175280 0.0084 0.0056 Willer et al. 2013 
rs688 11227602 C T cds-syn APOE LDLc 1.00E-43 166792 -0.054 0.0037 Willer et al. 2013 
            TC 1.60E-28 180878 -0.0416 0.0036 Willer et al. 2013 
rs2738459 11238473 A C intron LDLR LDLc 2.30E-19 88433 0.0532 0.0058 Willer et al. 2013 
            TC 2.10E-11 93067 0.0387 0.0057 Willer et al. 2013 
rs2228671 11210912 C T cds-syn LDLR LDL 1.70E-171 170510 0.1768 0.006 Willer et al. 2013 
            TC 4.30E-132 184667 0.1475 0.0058 Willer et al. 2013 
rs1122608 11163601 G T intron LDLR LDL 8.50E-57 159918 0.074 0.0045 Willer et al. 2013 
            TC 6.80E-41 173300 0.0599 0.0043 Willer et al. 2013 
rs11668477 11195030 A G intergenic LDLR LDL 3.80E-143 158659 0.1389 0.0052 Willer et al. 2013 
            TC 1.40E-107 170530 0.1144 0.005 Willer et al. 2013 
rs2738446 11227326 C G intron LDLR LDL 3.30E-29 88417 -0.0621 0.0053 Willer et al. 2013 
            TC 3.60E-19 93051 -0.0488 0.0052 Willer et al. 2013 
19q13.32 
rs4420638 45422946 G A nearGene-3' APOC1 LDL 2E-178 93103 -0.2251 0.0077 Willer et al. 2013 
    G       TC 1E-149 NA -0.197 0 Willer et al. 2013 
    G       HDL 2E-21       Willer et al. 2013 
rs157580 45395266 A G intron TOMM40 LDL 9.20E-119 139565 0.1078 0.0045 Willer et al. 2013 
            TC 3.20E-104 151145 0.0969 0.0043 Willer et al. 2013 
rs7412 45412079 C T missense APOE LDL 0.00E+00 82533 0.5898 0.0101 Willer et al. 2013 
            TC 1.60E-283 92046 0.3736 0.0096 Willer et al. 2013 
rs519113 45376284 G C intron PVRL2 LDL 1.60E-49 88346 -0.0971 0.0066 Willer et al. 2013 
            TC 2.70E-32 92971 -0.0922 0.0066 Willer et al. 2013 
rs439401 45414451 C T intergenic APOE TG 1.40E-66 152584 0.0659 0.0038 Willer et al. 2013 
rs2075650 45395619 A G intron TOMM40 LDL 1.70E-214 161076 -0.1767 0.0055 Willer et al. 2013 
            TC 8.90E-158 175566 -0.1432 0.0052 Willer et al. 2013 
rs769449 45410002 A G intron APOE LDL 4.90E-161 83660 0.2141 0.0076 Willer et al. 2013 
            TC 6.80E-103 93260 0.1589 0.0072 Willer et al. 2013 
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Table S22. The 36 SNP pairs that were identified as having an additive effect on LDL. 
Shown are the IDs of the SNPs in the Exome Chip (SNP1 and SNP2), the genes mapped close to the SNPs (Gene1 and Gene2), 
the beta-coefficient (Beta) and the p-value for the additive model. The SNP pairs that were hit in my co-RNAi screen are 
highlighted. (Data analysis performed by Gulum Kosova, unpublished) 
 
 SNP1 Gene1 SNP2 Gene2 Beta P-value 
1 exm62588 PCSK9 exm.rs12740374 CELSR2 0.13 4.62E-07 
2 exm62588 PCSK9 exm176096 APOB 0.11 5.19E-06 
3 exm62588 PCSK9 exm.rs3846662 HMGCR 0.09 1.83E-05 
4 exm62588 PCSK9 exm686341 LPL 0.17 4.90E-07 
5 exm62588 PCSK9 exm.rs6511720 LDLR 0.17 8.64E-08 
6 exm62588 PCSK9 exm.rs17216525 NCAN 0.18 3.60E-06 
7 exm62588 PCSK9 exm1479366 APOE 0.44 2.12E-32 
8 exm62588 PCSK9 exm.rs4420638 APOE 0.16 1.47E-08 
9 exm.rs12740374 CELSR2 exm176096 APOB 0.1 1.04E-08 
10 exm.rs12740374 CELSR2 exm.rs3846662 HMGCR 0.09 5.73E-08 
11 exm.rs12740374 CELSR2 exm686341 LPL 0.12 4.86E-09 
12 exm.rs12740374 CELSR2 exm.rs6511720 LDLR 0.13 8.95E-10 
13 exm.rs12740374 CELSR2 exm.rs17216525 NCAN 0.12 4.22E-08 
14 exm.rs12740374 CELSR2 exm1479366 APOE 0.22 1.12E-22 
15 exm.rs12740374 CELSR2 exm.rs4420638 APOE 0.13 1.14E-10 
16 exm176096 APOB exm.rs3846662 HMGCR 0.09 1.22E-07 
17 exm176096 APOB exm686341 LPL 0.11 6.33E-08 
18 exm176096 APOB exm.rs6511720 LDLR 0.11 1.58E-08 
19 exm176096 APOB exm.rs17216525 NCAN 0.11 3.95E-07 
20 exm176096 APOB exm1479366 APOE 0.18 4.30E-19 
21 exm176096 APOB exm.rs4420638 APOE 0.11 2.30E-09 
22 exm.rs3846662 HMGCR exm686341 LPL 0.09 2.84E-07 
23 exm.rs3846662 HMGCR exm.rs6511720 LDLR 0.1 6.26E-08 
24 exm.rs3846662 HMGCR exm.rs17216525 NCAN 0.09 1.66E-06 
25 exm.rs3846662 HMGCR exm1479366 APOE 0.16 4.92E-17 
26 exm.rs3846662 HMGCR exm.rs4420638 APOE 0.1 8.16E-09 
27 exm686341 LPL exm.rs6511720 LDLR 0.14 2.61E-09 
28 exm686341 LPL exm.rs17216525 NCAN 0.14 7.85E-08 
29 exm686341 LPL exm.rs6511720 LDLR 0.14 2.61E-09 
30 exm686341 LPL exm.rs4420638 APOE 0.14 3.84E-10 
31 exm.rs6511720 LDLR exm.rs17216525 NCAN 0.15 1.57E-08 
32 exm.rs6511720 LDLR exm1479366 APOE 0.27 1.04E-25 
33 exm.rs6511720 LDLR exm.rs4420638 APOE 0.14 5.55E-11 
34 exm.rs17216525 NCAN exm1479366 APOE 0.3 2.75E-25 
35 exm.rs17216525 NCAN exm.rs4420638 APOE 0.15 1.56E-09 
36 exm1479366 APOE exm.rs4420638 APOE 0.22 2.16E-23 
 
 
 
 
 
 
 
rs445925 45415640 G A nearGene-5' APOE LDL 0.00E+00 105162 0.3634 0.0081 Willer et al. 2013 
            TC 2.20E-166 118293 0.2212 0.0077 Willer et al. 2013 
rs8106922 45401666 A G intron APOE LDL 3.00E-22 139174 -0.0407 0.0041 Willer et al. 2013 
rs405509 45408836 T G nearGene-3' APOE LDL 2.80E-84 139202 0.0813 0.004 Willer et al. 2013 
            TC 1.60E-31 152735 0.0461 0.0039 Willer et al. 2013 
rs769450 45410444 G A intron APOE LDL 2.40E-11 84849 0.0368 0.0051 Willer et al. 2013 
            TC 4.90E-07 94482 0.0267 0.0049 Willer et al. 2013 
rs12721109 45447221 G A intron APOE LDL 3.00E-122 99409 -0.4462 0.0183 Willer et al. 2013 
            TC 8.80E-67 110455 -0.3234 0.0179 Willer et al. 2013 
rs10402271 45329214     intergenic BCAM LDL 2.60E-118 171428 0.0927 0.0038 Willer et al. 2013 
            TC 8.90E-74 185609 0.0702 0.0037 Willer et al. 2013 
rs4803750 45247627 A G intergenic APOE LDL 1.70E-162 164086 0.2189 0.0078 Willer et al. 2013 
            TC 7.90E-84 178198 0.1485 0.0075 Willer et al. 2013 
rs4605275 45338493 C T intergenic APOE LDL 2.80E-33 89503 0.0722 0.0061 Willer et al. 2013 
            TC 2.60E-20 94142 0.0547 0.006 Willer et al. 2013 
rs16979595 45477381 A G intron APOE TC 5.40E-09 185650 0.0296 0.005 Willer et al. 2013 
            LDL 4.90E-05 171472 0.02 0.0052 Willer et al. 2013 
            HDL 1.80E-04 185508 0.0188 0.0048 Willer et al. 2013 
rs769449 45410002 A G intron APOE LDL 4.90E-161 83660 0.2141 0.0076 Willer et al. 2013 
            TC 6.80E-103 93260 0.1589 0.0072 Willer et al. 2013 
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9.2 SUPPLEMENTARY FIGURES 
 
Figure S1. Comparison of the knockdown effect on LDL uptake between the reverse transfection 
(screen) and the liquid-phase transfection 
Shown is an example of the effect of gene knockdowns on LDL uptake, using the same siRNA amounts 
as in the screen (no siRNA adjustments) or smaller amounts of siRNAs than in the screen (adjusted 
siRNA concentration) (A), as well as an example of titration of an siRNA to determine the suitable 
amount to be used, in order to achieve the desirable phenotype. 
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Figure S2. Boxplot representation of the 21 gene-gene interactions that were replicated with liquid-
phase transfection. 
Shown are the 21 gene-gene interactions that were validated with liquid-phase transfection. The 
boxplots show the median intensity of internalized DiI-LDL, normalized to the control, for the two 
single knockdowns (transfected together with the control siRNA), as well as for the double 
knockdown, for each pair of genes. (n=3-4)  
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